

VISIT...

LANZAROTE
Caliente.COM



Review

Smoking, nicotine and neuropsychiatric disorders

Peter Dome^{a,*}, Judit Lazary^a, Miklos Peter Kalapos^b, Zoltan Rihmer^a^a Department of Clinical and Theoretical Mental Health, Kutvolgyi Clinical Center, Semmelweis University, Faculty of Medicine, Kutvolgyi ut 4, 1125 Budapest, Hungary^b Theoretical Biology Research Group, H-1029 Budapest, Dámvad utca 18, Hungary

ARTICLE INFO

Article history:

Received 16 June 2009

Received in revised form 23 July 2009

Accepted 30 July 2009

Keywords:

Nicotine

Nicotinic acetylcholine receptors

Smoking

Schizophrenia

Mood disorders

ADHD

Alzheimer's disease

Parkinson's disease

Suicide

ABSTRACT

Tobacco smoking is an extremely addictive and harmful form of nicotine (NIC) consumption, but unfortunately also the most prevalent. Although disproportionately high frequencies of smoking and its health consequences among psychiatric patients are widely known, the neurobiological background of this epidemiological association is still obscure. The diverse neuroactive effects of NIC and some other major tobacco smoke constituents in the central nervous system may underlie this association. This present paper summarizes the pharmacology of NIC and its receptors (nAChR) based on a systematic review of the literature. The role of the brain's reward system(s) in NIC addiction and the results of functional and structural neuroimaging studies on smoking-related states and behaviors (i.e. dependence, craving, withdrawal) are also discussed. In addition, the epidemiological, neurobiological, and genetic aspects of smoking in several specific neuropsychiatric disorders are reviewed and the clinical relevance of smoking in these disease states addressed.

© 2009 Elsevier Ltd. All rights reserved.

Contents

1. Basic pharmacology of nicotine and smoking	296
1.1. Pharmacology of nicotine	296
1.2. Pharmacology and health consequences of smoking	297
1.3. Gender differences in nicotine action	299
2. Nicotinic acetylcholine receptors (nAChRs)	299
2.1. Basic pharmacology of nAChRs	299
2.2. Neuroanatomical distribution of different nAChRs	300
2.3. Genetic variability in nAChRs genes and their associations with different aspects of nicotine addiction	301
2.4. Desensitization and upregulation of nAChRs	302
2.5. Non-synaptic transmission through nAChRs	303
3. Mechanisms of nicotine's actions in the reward pathway(s) and the relevance of dopamine in nicotine addiction	303
3.1. Nicotine and the mesocorticolimbic dopamine system	303
3.2. Nicotine and the habenular complex	304
3.3. Nicotine and insula	305
3.4. Relevance of dopamine in nicotine addiction	305
4. Results of structural and functional brain-imaging studies on the influence of nicotine/smoking on neural systems	305
4.1. Structural and morphological alterations of a smokers' brain	305
4.1.1. Gray matter alterations in smokers	305
4.1.2. White matter alterations in smokers	306
4.2. The effects of nicotine on brain activity	306
4.3. Functional brain-imaging studies on smoking abstinence and craving	307
4.4. Results of brain-imaging studies on nAChRs	307
4.5. Neuroimaging studies on smoking-related changes in the dopaminergic system	308

* Corresponding author. Tel.: +36 30 619 86 20; fax: +36 1 391 33 10.

E-mail address: dome_peter@yahoo.co.uk (P. Dome).

5.	Connections between smoking and mental disorders and/or suicidal behavior	308
5.1.	Epidemiology of smoking and nicotine dependence among smokers	308
5.2.	Epidemiology of smoking in psychiatric patients	309
5.3.	Smoking and suicide.	309
5.4.	Different forms of nicotine administration and the risk of mental disorders	310
6.	Schizophrenia.	310
6.1.	Epidemiology and consequences of smoking in schizophrenia.	310
6.2.	Self-medication theory	311
6.3.	The role of antipsychotics in smoking behavior	311
6.4.	Explanatory theories of elevated smoking rates among patients with schizophrenia.	312
6.5.	Alterations of the cholinergic system in schizophrenia	312
6.6.	Genetic evidence for the role of nAChRs in schizophrenia	313
6.7.	Antipsychotic treatment and the cholinergic system	313
6.8.	The role of the nicotinic system in sensory processing	314
6.9.	Nicotinic agents and AChE inhibitors as possible therapeutics for cognitive dysfunctions in schizophrenia.	314
7.	Affective disorders.	315
7.1.	Bipolar disorder	315
7.1.1.	Epidemiology.	315
7.1.2.	Smoking-related changes in clinical characteristics of bipolar disorder	315
7.1.3.	Relationships between the nicotinic system and bipolar disorder	316
7.2.	Major depression	316
7.2.1.	Epidemiology.	316
7.2.2.	Explaining theories of elevated smoking rates among patients with major depression	317
8.	Alzheimer disease (AD)	318
8.1.	Epidemiology	318
8.2.	Neuropathological findings and alterations of the cholinergic (nicotinic) system in AD	318
8.3.	Smoking effects on nAChR expression in AD.	320
8.4.	Effects of smoking or pure nicotine administration on AD pathology	320
8.5.	Smoking and cognitive decline.	320
8.6.	Nicotinic agents as possible therapeutics for cognitive decline in AD	321
8.7.	Genetic findings	321
9.	Attention-deficit/hyperactivity disorder	321
9.1.	Epidemiology	321
9.2.	Neurobiological explanations of frequent co-occurrence of ADHD and smoking.	322
9.3.	Nicotinic agents and AChE inhibitors as possible therapeutics for ADHD	322
10.	Parkinson's disease (PD)	323
10.1.	Epidemiology of smoking in PD.	323
10.2.	Regulation of the nigrostriatal pathway by nAChRs	323
10.3.	Neuropathological findings and alterations of the nicotinic system in PD	323
10.4.	Neuroprotective effects of nicotine and other tobacco smoke ingredients in PD	324
10.5.	Nicotinic agents and AChE inhibitors as possible therapeutics for PD: results of clinical and animal studies.	324
11.	Discussion	325
	Acknowledgements	325
	References	325

1. Basic pharmacology of nicotine and smoking

1.1. Pharmacology of nicotine

Nicotine (NIC) is an alkaloid present in tobacco leaves and in lower levels in other plants such as eggplant, tomato, potato, and green pepper, where it acts as a natural insecticide (Hukkanen et al., 2005; Doolittle et al., 1995; Gotti et al., 2006). NIC was first isolated from tobacco in 1828 by Posselt and Reimann (Henningfield and Zeller, 2006). Chemically, NIC is a weak base containing a pyridine and a pyrrolidine ring; each possesses a tertiary amine. The pK_a of the pyridine nitrogen is 3.04, whereas the pK_a of the pyrrolidine nitrogen is 7.84 at physiological temperature and ionic strength. With these characteristics, approximately 23% of NIC is nonionized at physiological pH and thus able to rapidly cross biological membranes (Brewer et al., 2004; Yildiz, 2004). The pH of the environment is a key regulatory factor in NIC traffic across biological membranes (Hukkanen et al., 2005). In an acidic environment NIC is in an ionized state and does not rapidly cross membranes. For example, because of the acidic pH of gastric juice there is little absorption of swallowed NIC (such as from NIC gum) in the stomach (Hukkanen et al., 2005; Metz et al., 2004). Smoke

from tobaccos used in pipes and cigars is more alkaline (pH = 6.5 or more), and as a result, NIC is mostly unionized and well absorbed from the mouth (Hukkanen et al., 2005; Metz et al., 2004). The acidic smoke (pH = 5.5–6) of tobacco used in cigarettes dramatically reduces the absorption of NIC from the mouth (because NIC is primarily ionized at this pH), so cigarette smokers need to inhale cigarette fumes into their lungs. There the alkaline fluid (pH = 7.4) of the human lung's inner surface can buffer the acidic fumes to a neutral pH on the extremely large surface of the alveoli, allowing NIC to be absorbed into the pulmonary circulation (the lungs may also act as a depot for NIC, as was demonstrated in some studies) (Hukkanen et al., 2005; Metz et al., 2004; Brewer et al., 2004; Yildiz, 2004).

In the blood (at physiological pH 7.4) NIC is about 69% ionized and 31% unionized and its binding to plasma proteins is less than 5% (Hukkanen et al., 2005). NIC can easily pass through the blood–brain barrier by passive diffusion and perhaps by carrier-mediated transport (but the exact mechanisms are not clear) (Wang et al., 2005; Lockman et al., 2005). Chronic NIC administration does not appear to influence the kinetics of NIC uptake into the brain (Lockman et al., 2005). The plasma half-life ($t_{1/2}$) of NIC is approximately 2 h. In the brain, the distributional $t_{1/2}$ of NIC is

10 min. Distributional $t_{1/2}$ describes the time that it takes a NIC dose to fall 50% from its peak level in the brain as the NIC is distributed to other body compartments with a high affinity for NIC (for example, the liver, spleen, kidney, lung) (Hukkanen et al., 2005; Baker et al., 2004b; Pogocki et al., 2007). When the half-life of NIC was determined by urine excretion data, it was much longer (≈ 11 h). This could be explained by the slow release of NIC from body tissues (Hukkanen et al., 2005).

NIC is extensively metabolized in the liver to six primary metabolites (nicotine glucuronide, nicotine N-oxide, nornicotine, nicotine isomethonium ion, cotinine, 2-hydroxynicotine). The predominant pathway during first-pass metabolism yields cotinine (in humans 70–80% of NIC is metabolized to cotinine), which may have some relevance in the diverse neurobiological effects of smoking as a ligand of nicotinic acetylcholine receptors (nAChRs) (Hukkanen et al., 2005; Yildiz, 2004; O'Leary et al., 2008). Furthermore, there are several other indications that cotinine is a pharmacologically active substance. It has (1) neuro- and/or cell-protective effects in cell-culture models; (2) attention enhancing effects; (3) antipsychotic-like effects (in prepulse inhibition paradigm); (4) dopamine-releasing effects in striatal tissue samples, etc. (Buccafusco, 2004; Terry et al., 2005a; Riveles et al., 2008; O'Leary et al., 2008). Several enzymes play a role in NIC metabolism in the liver, such as some members of the cytochrome P450 enzyme family (CYP2A6 > CYP2B6 >> CYP2D6 subtypes), flavin-containing monooxygenase 3, amine N-methyltransferase, aldehyde oxidase and UDP-glucuronosyltransferases (Hukkanen et al., 2005). Unmetabolized NIC excretion via the urine only accounts for about 5% of total elimination (Matta et al., 2007; Le Houezec, 2003; Balbani and Montovani, 2005). Animal studies suggest that to a minor extent NIC is metabolized in extrahepatic tissues, too (e.g. kidney, lung, brain) (Hukkanen et al., 2005; Le Houezec, 2003). The rate of NIC metabolism is influenced by a lot of factors, such as age, gender, meal consumption, race, hepatic or renal diseases, pregnancy, tobacco ingredients (e.g. menthol, which inhibits both CYP2A6 activity and also the glucuronidation of NIC), or medication status (e.g. contraceptive use) (for details see Hukkanen et al., 2005; Matta et al., 2007). Tobacco smoking per se influences NIC metabolism. The clearance of NIC is slower (thus the half-life of NIC tends to be longer) in smokers compared with non-smokers (Hukkanen et al., 2005; Matta et al., 2007; Benowitz and Jacob, 2000). This phenomenon may be explained by the effect of β -nicotyrine (a smoke ingredient with CYP2A6 inhibitory activity) as well as NIC-evoked CYP2A6 mRNA and protein down-regulation in the liver (Hukkanen et al., 2005).

1.2. Pharmacology and health consequences of smoking

The vast majority of tobacco users (98%) nowadays are cigarette smokers, in contrast to the last decades of the 19th century, when tobacco chewing and cigar smoking were the predominant forms of tobacco use (and industrial cigarette making was only in its infancy) (Mitrouska et al., 2007; Koob and Le Moal, 2006). In many respects (vide infra) cigarette smoking is a highly effective form of NIC intake (compared to, for example, different kinds of nicotine replacement therapy (NRT)). First, bioavailability of NIC in cigarette fumes (80–90%) is higher than in different formulations of NRT (NIC-containing gum/nasal spray/lozenge and most forms of patches) (Hukkanen et al., 2005). Second, most forms of NRT deliver NIC into the systemic circulation more slowly than smoking (Hukkanen et al., 2005). NIC is absorbed from smoke into the circulation relatively quickly because of the large alveolar surface and large blood perfusion of the pulmonary circulation (Brewer et al., 2004). During smoking, high levels of NIC reach the brain in 10–20 s after a puff, faster than with intravenous administration (Hukkanen et al., 2005). Third, maximal venous blood concentration of NIC during cigarette smoking could

reach a higher level than during the use of different forms of NRT (Hukkanen et al., 2005). Fourth, cigarette smokers can easily regulate their NIC intake by changing their smoking pattern (puff volume, number of puffs per cigarette, inter-puff interval, puff velocity, etc.) according to their NIC needs in contrast to users of other forms of NRT (i.e. patch or gum) (Hammond et al., 2006). This fact is highly significant because average smokers consume only 30% of the available tobacco in each cigarette; thus there is a large amount of “idle” NIC in every cigarette (Hammond et al., 2006). Routes of drug administration that enable a rapid drug entry into the brain increase the propensity of the given drug to induce addiction and are also associated with a greater feeling of euphoria. For example, smoked cocaine (‘crack’) is thought to be more addictive than snorted cocaine, and cocaine or heroin administered intravenously, rather than by snorting, results in greater self-reports of pleasure (Samaha et al., 2005; Samaha and Robinson, 2005). During smoking, NIC concentrations increase more rapidly and reach higher levels than with most forms of NRT (Hukkanen et al., 2005). Not surprisingly, therefore, NIC is highly addictive when inhaled from tobacco smoke, whereas NRT products (which deliver NIC slowly) are less likely to lead to addiction (Samaha et al., 2005; Samaha and Robinson, 2005). According to the above data those NRT forms which provide rapid NIC release (e.g. nasal spray, chewing gum) have greater potential to cause behavioral dependence compared to NRT forms that provide slower NIC release (e.g. NIC patch) (Hajek et al., 2007; West et al., 2000).

Tobacco contains approximately 2500 chemical compounds, while tobacco smoke consists of over 4000 compounds, so several compounds of smoke are generated by various mechanisms (combustion, pyrolysis, distillation) during the burning of tobacco (Baker, 1987; Newhouse et al., 2004a; Frishman et al., 2006). There is an exothermic combustion zone at the burning end of the cigarette, where the temperature is 700–950 °C. Below the combustion zone is the pyrolysis/distillation zone with a lower temperature (200–600 °C). Most smoke ingredients are generated in this area during endothermic reactions (Baker, 1987). The actual composition of cigarette smoke is influenced by many factors, such as characteristics of the cigarette paper and filter, column length of the tobacco rod, composition of the tobacco, etc. (Frishman et al., 2006). Tobacco smoke has two phases, the gaseous phase and the particulate phase. The gaseous and particulate phases comprise 95% and 5% of the smoke's weight (Zevin and Benowitz, 1999). The gaseous phase contains inter alia nitrogen oxide, carbon monoxide, carbon dioxide, ammonia, nitrites, alcohols, ketones (acetone, butanone), volatile sulfur-containing compounds (hydrogen sulfide), hydrocarbons, aldehydes (formaldehyde and acetaldehyde), free radicals and other oxidants (hydrogen peroxide, superoxide anion and peroxyxynitrite). According to recent results, hydrogen peroxide probably has a role in airway tumorigenesis (Frishman et al., 2006; Zevin and Benowitz, 1999; Khan et al., 2008; Swan and Lessov-Schlaggar, 2007; Hatzinikolaou et al., 2006; Pryor and Stone, 1993). The particulate phase contains alkaloids, water, and tar (Frishman et al., 2006; Zevin and Benowitz, 1999). NIC is the most abundant alkaloid in tobacco (accounting for 95% of the total alkaloid content) (Cai et al., 2003). Minor alkaloids are anatabine, anabasine, and nornicotine; some of them – like NIC – possess agonist activity on nAChRs. Other tobacco smoke ingredients, such as nitrosamines (i.e. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N-nitrososnornicotine (NNN) and N-nitrosodiethylamine (DEN)) and cembranoids are also ligands of nAChRs (Zevin and Benowitz, 1999; Ayers et al., 2005; Schuller, 2007; Ferchmin et al., 2005, 2009; Cai et al., 2003). Tar consists of polycyclic aromatic hydrocarbons (PAH), metallic ions, several radioactive compounds, and free radicals, as well (Frishman et al., 2006; Swan and Lessov-Schlaggar, 2007; Pryor and Stone, 1993). The internal

documents of tobacco companies – which were disclosed by law in 1998 – have revealed that many ingredients of tobacco were added by cigarette manufacturers to mask the odor, visibility, or irritation effects of environmental tobacco smoke (i.e. vanillin, bergamot oil), to enhance bronchodilation (i.e. theobromine, caffeine), and to regulate pH, which increases the bioavailability of NIC, and temper the harsh feeling of the smoke (i.e. levulinic acid, ammonia, sugars). Overall additives made up 10% of the total weight of the cigarette (Talhout et al., 2006; Rabinoff et al., 2007; Connolly et al., 2000; Keithly et al., 2005; Hammond et al., 2006; Henningfield et al., 2004).

Environmental tobacco smoke is a combination of sidestream smoke (85%) and exhaled mainstream smoke (15%) (Ambrose and Barua, 2004). Mainstream smoke (the inhaled part of smoke) is the smaller portion (45%) of total smoke compared with sidestream smoke (55%) (sidestream smoke is the smoke emitted from the burning end of a cigarette) (Phillips et al., 2003). Sidestream smoke has a greater concentration of some toxic components (i.e. carbon monoxide, benzene, ammonia, and many carcinogens) than mainstream smoke (Phillips et al., 2003; Ambrose and Barua, 2004; Brownson et al., 1997). Moreover, in sidestream smoke, the amount of NIC is twice as high as in the mainstream smoke (Brownson et al., 1997). These differences between compounds concentrations in sidestream and mainstream smoke are caused by the less complete combustion in those regions from which sidestream smoke derives (Brownson et al., 1997). The above facts suggest that sidestream and mainstream smoke have comparable carcinogenic and cardiovascular risk heightening effects (Swan and Lessov-Schlaggar, 2007). Because smoke is diluted in the environmental air, a non-smoker is typically exposed to less tobacco smoke than an active smoker. Nevertheless, epidemiological investigations have clearly demonstrated the health risks of passive smoking, too (Swan and Lessov-Schlaggar, 2007; Barnoya and Glantz, 2005; Brownson et al., 1997; Venn and Britton, 2007; Subramanian and Govindan, 2007).

An average cigarette contains 10–14 mg NIC, but only 1–1.5 mg of NIC is absorbed systemically from the inhaled smoke of one cigarette (Hukkanen et al., 2005). When a cigarette is smoked, a large amount of NIC ($\approx 35\%$) is destroyed by combustion and a similar amount of NIC is lost in non-inhaled smoke (Balbani and Montovani, 2005).

Many observations (see below) suggest that cigarette smoking is reinforced not only by NIC but also by nonnicotine chemical, behavioral and environmental factors, and NIC per se has merely a moderate addictive potential (Rose, 2006; Samaha et al., 2005; Samaha and Robinson, 2005; Talhout et al., 2007). For example, denicotinized cigarettes have been shown to reduce tobacco craving and some withdrawal symptoms during cessation and are comparable with NIC-containing cigarettes in terms of perceived reward (Dar and Frenk, 2004; Rose, 2006; Henningfield et al., 2005). Moreover, intravenous bolus injections of NIC elicit minimal feelings of reward, pure intravenous NIC self-administration has not been convincingly demonstrated among smokers, NIC has shown only a limited ability to induce self-administration in animals and conditioned place-preference (CPP) studies suggest that NIC has weak reinforcing effects. Finally NRT has limited efficacy as a cessation therapy and low addictive potential (Samaha et al., 2005; Samaha and Robinson, 2005; Talhout et al., 2007; Rose, 2006; Dar and Frenk, 2004; Henningfield et al., 2005; Le Foll and Goldberg, 2005). These findings have led to the hypothesis that, along with NIC, other addictive components are also present in tobacco smoke. Accordingly some cigarette tobacco ingredients (i.e. gamma-heptalactone, gamma-valerolactone, gamma-decalactone, delta-decalactone, gamma-dodecalactone, menthol, and β -nicotyrine) may decrease the metabolism of NIC via CYP2A6 inhibition, which could theoretically increase the addictive potential of NIC

sourced from tobacco smoke (Hukkanen et al., 2005; Rabinoff et al., 2007). Moreover, some other ingredients of tobacco smoke have intrinsic addictive properties. For example, several studies raised the possibility that acetaldehyde has addictive features. First, acetaldehyde activates dopaminergic cells in the ventral tegmental area (VTA), which is a feature of many (but not all) addictive agents (Melis et al., 2005; Foddai et al., 2004; Talhout et al., 2007). Second, self-administration and conditioned place-preference tests in animals have shown that acetaldehyde has reinforcing properties (Talhout et al., 2007). Third, it seems that acetaldehyde – as the first metabolite of ethanol, produced by alcohol dehydrogenase and catalase – could strongly mediate the addictive potential of ethanol (Melis et al., 2007; Foddai et al., 2004). This is supported by the findings of many investigations. For example, the administration of acetaldehyde-chelating agent D-penicillamine decreases spontaneous ethanol drinking and ethanol-induced locomotor stimulation and conditioned place-preference in rodents, ethanol-induced place-preference is also inhibited by alcohol dehydrogenase blocking agent 4-methyl-pyrazole (4-MP), 4-MP also decreases ethanol-evoked dopaminergic cell firing in VTA and dopamine level increase in nucleus accumbens (NAcc), and salsolinol – the condensation product of acetaldehyde and dopamine – also has intrinsic reinforcing properties (Foddai et al., 2004; Rodd et al., 2008; Matsuzawa et al., 2000; Melis et al., 2007; Font et al., 2006). Acetaldehyde is generated from sugars in tobacco during combustion, so it may have a role as a co-addictive agent in tobacco smoke (Talhout et al., 2006, 2007). This theory is further bolstered by acetaldehyde's ability to facilitate the reinforcing effects of NIC (in self-administration paradigm) (Talhout et al., 2007). NIC does not possess any monoamine oxidase (MAO) inhibitory activity, but tobacco smoke contains various compounds (i.e. farnesylacetone, 2-naphthylamine, harman, and norharman) with marked MAO inhibitory properties (Lewis et al., 2007; Castagnoli et al., 2002). MAO-A and MAO-B are key enzymes in the degradation of monoamine neurotransmitters, such as dopamine, serotonin, and norepinephrine (van Amsterdam et al., 2006; Lewis et al., 2007; Guillem et al., 2005). Among smokers the activities of both monoamine oxidase isoforms (MAO-A and MAO-B) are reduced in the brain and also in peripheral organs (van Amsterdam et al., 2006; Lewis et al., 2007; Fowler et al., 1996a,b; Leroy et al., 2009). A longitudinal study by Harro et al. (2004) showed that both high and low platelet MAO activity is a risk factor for the initiation of smoking; thus the decreased MAO activity among smokers may not (merely) be genetic in origin (Harro et al., 2004). The same conclusion was drawn by Fowler et al. (1996a) in their previous study, as they failed to find any difference in MAO-B brain activity between groups of non-smokers and former smokers (Fowler et al., 1996a). Other studies have also found that decreased MAO activity in smokers appeared to be reversible, since its activity slowly recovered following smoking cessation (van Amsterdam et al., 2006; Harro et al., 2004; Fowler et al., 1996a). Moreover, findings about the effects of genetic polymorphisms in genes for MAO-A and MAO-B on smoking habits are unclear (Lewis et al., 2007; Tochigi et al., 2007). In recent years, several studies have revealed that self-administration of NIC is significantly increased by MAO inhibitor pretreatment. Furthermore MAO inhibitors maintained the repeated NIC treatment-induced increased locomotor activity (as a form of behavioral sensitization) which is otherwise abolished following three periods of withdrawal (van Amsterdam et al., 2006; Lewis et al., 2007; Guillem et al., 2005; Villegier et al., 2003, 2007a,b). Moreover, treatment of rats with the non-selective monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of NIC (Wooters and Bardo, 2007). In addition, an NIC-induced increase of extracellular dopamine levels in the NAcc was enhanced by MAO inhibitor (tranylcypromine) pretreatment (addictive agents such as psychostimulants, NIC,

opiates, ethanol, and THC acutely increase the extracellular dopamine level in the NAcc, and this phenomenon is considered a possible neurochemical marker of their addictiveness) (Villegier et al., 2007b; Melis et al., 2005). Experiments by Villegier et al. (2007a,b) have shown that the α 1-adrenergic receptor antagonist prazosin decreases the enhancing effects of MAO inhibitors on NIC self-administration and also tempers the enhancing effect of MAO inhibitor pretreatment on NIC-induced elevation of dopamine concentration in the NAcc. Furthermore, they also showed that an increase in NIC self-administration evoked by MAO inhibition is a dopamine-1 (D1) receptor dependent process (Villegier et al., 2007a,b). Recently, the repeated co-administration of an MAO inhibitor and NIC (but neither repeated NIC nor repeated MAO inhibitor administration alone) was also demonstrated to evoke a similar neurochemical response (enhanced cortical norepinephrine and serotonin release induced by D-amphetamine or para-chloroamphetamine, respectively) to that found in the repeated administration of various other compounds (cocaine, ethanol, morphine, amphetamine) from different groups of addictive agents (for details see Lanteri et al., 2008, 2009). Because MAO inhibitors are present in tobacco smoke and act synergically with NIC to produce a feeling of reward and also to cause addiction, the inhibition of MAO enzymes (alone or with NIC replacement therapy) could be helpful in enhancing cessation rates. Double-blind studies examining the efficacy of MAO-A or MAO-B inhibitors as cessation agents have provided promising results (Lewis et al., 2007; Frishman et al., 2006; George and Weinberger, 2008).

Both human and animal studies have observed that NIC administration enhances the reinforcing effects of rewarding stimuli. Moreover NIC withdrawal is associated with brain reward threshold elevation; thus the strong addictive nature of NIC – which has a relatively moderate euphorogenic effect – can partially be explained by its capacity to increase the salience of rewarding stimuli in the environment (Markou, 2008; Barr et al., 2008c; Attwood et al., 2009).

Smoking is widely known to have a marked and diverse deleterious effect on health. Inter alia smoking is associated with chronic obstructive pulmonary disease, various types of malignancies, hypertension, unfavorable changes in the lipoprotein profile, signs of inflammation (i.e. elevated levels of white blood cells and inflammatory markers such as CRP, IL-6 and TNF- α), altered blood coagulation (by stimulating platelet aggregation and reducing fibrinolysis), elevated risk of diabetes mellitus, increased risk of infective disorders (i.e. severe forms of influenza, pneumococcal disease, tuberculosis and wound infections), and also decreased fertility and elevated risk of spontaneous abortion (Yildiz, 2004; Burns, 2001; Gleerup and Winther, 1996; Catanzaro et al., 2007; Halperin et al., 2008; Bowman et al., 2007; Benowitz, 2008; Steptoe and Ussher, 2006; Eliasson, 2003). NIC and other nAChRs agonists in cigarette smoke appear to have an essential role in the pathogenesis of cancer and arteriosclerosis, which were previously believed to be caused primarily by other components of tobacco smoke (i.e. PAHs and nitrosamines) (Bersch et al., 2009; Wong et al., 2007; Egleton et al., 2008; Schuller, 2007, 2008; Cucina et al., 2008; Lau et al., 2006; Catanzaro et al., 2007; Knaapen et al., 2007; Ramos and Moorthy, 2005; Baird et al., 2005). Furthermore, recent genome-wide association studies have identified single nucleotide polymorphisms (SNP) in 15q24–25 locus (containing the genes for α 3, α 5 and β 4 subunits of nAChRs), which are associated with the risk of lung cancer, arteriosclerosis, and NIC addiction (Thorgeirsson et al., 2008; Amos et al., 2008; Hung et al., 2008; Volkow et al., 2008). Although pure NIC may have damaging health effects, and NRT is frequently used longer than recommended, there is no doubt that long-term smoking is more harmful than long-term NIC administration alone (Etter, 2009; Hughes, 2008a).

1.3. Gender differences in nicotine action

A marked gender difference in smoking rates is reported from most parts of the world, because males are markedly over-represented among cigarette smokers (Pauly, 2008). Various human and animal studies have hinted that gender differences may play a role in the biological effects of NIC (Schnoll and Patterson, 2009; Pogun and Yazarbas, 2009; Pauly, 2008). The development of NIC dependence among females after first use of NIC is more rapid than among males (Pogun and Yazarbas, 2009). Moreover, females relapse more frequently following cue-induced drug craving (Pogun and Yazarbas, 2009; Pauly, 2008). Differences between the sexes have also been found in the extent of chronic NIC administration-evoked nAChR upregulation. In addition, among female rodents self-administration is acquired at lower NIC doses than among males, furthermore the anxiolytic effects of NIC are also more pronounced among females than among males (see in details in Pogun and Yazarbas, 2009). The reinforcing effect of NIC is probably lower among females than among males (Pogun and Yazarbas, 2009; Pauly, 2008). Although there are some discrepancies in the literature, the metabolism of NIC has been found to be higher among females than among males (Hukkanen et al., 2005; Pogun and Yazarbas, 2009). One of the most important practical consequence of the differences in NIC's effects between the sexes is that NIC replacement therapy (and probably bupropion) are less effective in females than males in promoting long-term smoking cessation (Schnoll and Patterson, 2009; Pogun and Yazarbas, 2009; Pauly, 2008).

2. Nicotinic acetylcholine receptors (nAChRs)

2.1. Basic pharmacology of nAChRs

Acetylcholine (ACh) is one of the most ubiquitous signaling molecules found in nature (Gotti and Clementi, 2004). It is a phylogenetically ancient molecule; both ACh and the acetylcholine synthesizing enzyme, choline acetyltransferase, are found in a wide range of life forms (i.e. bacteria, plants, fungi, lichens, invertebrates, vertebrates) (Gotti and Clementi, 2004; Horiuchi et al., 2003). NIC is an agonist of nicotinic acetylcholine receptors (nAChRs), which are members of the Cys-loop ligand-gated ion channel (LGIC) family and respond to ACh as their endogenous ligand (furthermore, in the last decade choline – the precursor of acetylcholine and also the product of acetylcholine degradation – has been shown to have some direct effects on some kinds of nAChRs) (Cassels et al., 2005; Bertrand and Gopalakrishnan, 2007; Hogg et al., 2005; Alkondon and Albuquerque, 2006). In addition to NIC, a great number of other ligands of nAChRs (i.e. epibatidine, cytisine, α -bungarotoxin, methyllycaconitine and α -conotoxin) are provided by natural sources (Daly, 2005; Hogg and Bertrand, 2004). LGICs – like ACh – are phylogenetically ancient structures. Recent studies have revealed their presence in prokaryote organisms (Hilf and Dutzler, 2008, 2009; Bocquet et al., 2007; Tasneem et al., 2005; Zouridakis et al., 2009). The family of Cys-loop LGICs also includes GABA-A, GABA-C, glycine, zinc activated ZAC and 5-HT₃ receptors (Jensen et al., 2005; Farber et al., 2004; Hogg et al., 2005). The Cys-loop family is a member of the LGIC superfamily which has two other families (P2X receptors for ATP and glutamate-activated cation channel receptors). The members of the superfamily differ from each other in their subunit number and the number of transmembrane domains in one subunit (Hogg et al., 2005). The members of the Cys-loop family are formed from a pentameric assembly of subunits, each of which has four transmembrane spanning regions (Jensen et al., 2005; Arias and Bhumireddy, 2005; Hogg et al., 2005). The subunits are localized around the central ion-conducting pore, and the receptors gate the

flux of either the cations Na^+ , K^+ , and Ca^{2+} (nAChRs and 5-HT₃R) or anions, such as Cl^- and HCO_3^- (GABA-A, GABA-C and glycine receptors) (Jensen et al., 2005; Arias and Bhunireddy, 2005). There are different molecular models (i.e. Monod–Wyman–Changeux or the “concerted two state model” and the “quaternary twist model”) based on biochemical and structural investigations that could explain the functional states (active, resting and desensitized states, which differ from each others in their affinity to agonists/antagonists and in the level of conductance of ion channels) of nAChRs and the molecular mechanisms of the gating process (for details, see Changeux and Taly, 2008; Jensen et al., 2005; Taly et al., 2006; Giniatullin et al., 2005; Wang and Sun, 2005; Quick and Lester, 2002).

To date, seventeen nAChR subunits have been cloned in vertebrate species. A much greater diversity of nicotinic receptor subunits have been found in some non-vertebrates, for example at least 27 kinds of nAChR subunits are known in rhabditid nematode *Caenorhabditis elegans* (Jensen et al., 2005; Jones et al., 2007; Millar and Gotti, 2009; Blaxter, 1998). The nAChR subunits have been divided into muscle types ($\alpha 1$, $\beta 1$, δ , γ and ϵ) and neuronal types ($\alpha 2$ – $\alpha 10$ and $\beta 2$ – $\beta 4$) (Jensen et al., 2005). Although the $\alpha 10$ subunit cannot form a functional homomeric receptor (see below), it can form a functional nAChR when co-expressed with the $\alpha 9$ subunit. Because the expression of the $\alpha 9$ subunit is limited mainly to extraneuronal tissues/organs (the olfactory epithelium, hair cells of the inner ear, lymphocytes, dorsal root ganglion cells, and epidermal basal cell and follicular central cell layers in the skin and pituitary gland), nAChRs containing $\alpha 9$ and $\alpha 10$ do not fall conveniently into the conventional classification of either muscle type or neuronal nAChRs (Jensen et al., 2005; Lips et al., 2005; Plazas et al., 2005; Baker et al., 2004a; Luebke et al., 2005; Millar and Gotti, 2009). The $\alpha 8$ subunit is expressed only in avian species (Jensen et al., 2005; Lips et al., 2005; Millar and Gotti, 2009).

The ligand (ACh) binding sites of the receptors comprise two parts (principal and complementary components) (Gotti et al., 2006a,b, 2007). In case of homopentameric (i.e. $\alpha 7$) receptors the same subunit carries – on its opposite sides – both the principal and the complementary components so at the interface between two identical subunits the complete ligand-binding site comes into existence (consequently homopentameric receptors have five identical ACh-binding sites per receptor molecule) (Gotti et al., 2006a,b, 2007). In case of heteropentameric receptors α ($\alpha 2$, $\alpha 3$, $\alpha 4$ or $\alpha 6$) subunits carry the principal components, and β subunits ($\beta 2$ or $\beta 4$) carry the complementary components of ligand-binding sites (consequently heteropentameric receptors have two identical ACh-binding sites per receptor molecule) (Gotti et al., 2006a,b, 2007). In this kind of formation of the ligand-binding site, the subunits are conventionally grouped into ligand-binding (α) subunits and structural (β , γ , ϵ , δ) subunits (Gotti et al., 2000). $\alpha 5$ and $\beta 3$ subunits are unique in this classification because they carry neither the principal nor the complementary component of the ACh-binding site; consequently, they are considered accessory subunits (Gotti et al., 2007; Kuryatov et al., 2008). The presence of $\alpha 5$ or $\beta 3$ subunits as a fifth subunit in heteromeric nAChRs are frequent in the brain (for example in $(\alpha 4\beta 2)_2\alpha 5$ or $(\alpha 6\beta 2)_2\beta 3$ receptors). The presence of these auxiliary subunits in the pentamer structure can change the neurochemical characteristics of the receptors (i.e. in regard to their Ca^{2+} permeability or sensitivity to activation by ACh). Furthermore, a recent investigation has revealed the absence of upregulation of $\alpha 4\beta 2\alpha 5$ receptors after chronic NIC administration in the rodent brain in contrast to the massive upregulation of simple $\alpha 4\beta 2$ receptors (Kuryatov et al., 2008; Mao et al., 2008; Gotti et al., 2006a,b, 2007; Tapia et al., 2007).

In addition to their classical ACh-binding site (the so-called orthosteric-binding site), both $\alpha 7$ and $\alpha 4\beta 2$ nAChRs have allosteric-binding sites for their positive and negative modulators.

For example, antihelminthic agent ivermectin, tyrosine kinase inhibitor genistein, 5-hydroxyindole, cholinesterase-inhibitor galantamine, or progesterone are allosteric modulators of $\alpha 7$ receptors, while progesterone, 17- β -estradiol, zinc and the thiazole analog LY-2087101 are allosteric modulators of $\alpha 4\beta 2$ receptors (Bertrand and Gopalakrishnan, 2007; Hogg et al., 2005; Dani and Bertrand, 2007). Some peptides (i.e. lynx-1, an endogenous brain protein closely related in structure to bungarotoxins isolated from snake venom; SLURP-1 secreted by keratinocytes; and β -amyloid, a key protein in the pathobiology of Alzheimer's disease) are widely known to also have allosteric modulatory properties on nAChRs (Changeux and Taly, 2008; Bertrand and Gopalakrishnan, 2007; Hogg et al., 2005; Gotti et al., 2006a,b; Miwa et al., 2006).

Neuronal nAChR are heteropentamers composed of α subunits ($\alpha 2$, $\alpha 3$, $\alpha 4$, $\alpha 5$, $\alpha 6$) and β subunits ($\beta 2$, $\beta 3$, $\beta 4$) or homopentamers of five α -subunits (e.g. $\alpha 7$, $\alpha 8$ or $\alpha 9$) or α heteropentamers (e.g. $\alpha 7/\alpha 8$ (in chicken) or $\alpha 9/\alpha 10$ (in mammals)). $\alpha\beta$ heteropentamers are α -bungarotoxin insensitive, while α homo- and heteropentamers are α -bungarotoxin sensitive receptors (Lips et al., 2005; Plazas et al., 2005; Lindstrom, 2003; Gotti et al., 2006a,b, 2007). Not only can the $\alpha 7$ subunit form a homopentameric nAChR, but, according to some convincing recent results (which may partially contradict the above classification), the $\alpha 7$ subunits may co-assemble with $\beta 2$ subunits to form a functional, naturally expressed heteromeric receptor (Liu et al., 2009; Son and Winzer-Serhan, 2008; Millar and Gotti, 2009).

The prevalent, naturally occurring stoichiometry of $\alpha\beta$ heteromer nAChRs in the brain is $(\alpha)_2(\beta)_3$, but the $(\alpha)_3(\beta)_2$ stoichiometry could also occur both naturally and under some experimental conditions (using in vitro models) (Jensen et al., 2005; Tapia et al., 2007; Gotti et al., 2007; Kuryatov et al., 2008). The relative proportions of α and β subunits within the pentamer may alter various biochemical properties of the receptors. For example, $(\alpha)_3(\beta)_2$ and $(\alpha)_2(\beta)_3$ differ from each other in their permeability to Ca^{2+} , their affinity to agonists, and the velocity of their desensitization (Tapia et al., 2007; Gotti et al., 2007; Kuryatov et al., 2008; Moroni and Bermudez, 2006; Millar and Gotti, 2009). The stoichiometry of heteromeric $\alpha 9/\alpha 10$ nAChR is $(\alpha 9)_2(\alpha 10)_3$ (Plazas et al., 2005). The $\alpha 9$ and $\alpha 9\alpha 10$ nAChRs are characterized by mixed muscarinic/nicotinic pharmacological profiles significantly different from those of other nAChRs. Furthermore, genes of $\alpha 9$ and $\alpha 10$ subunits represent a distant, distinct, and peculiar early divergent branch within the nAChR gene family (Jensen et al., 2005; Plazas et al., 2005; Verbitsky et al., 2000).

Ca^{2+} permeability of a given nAChR depends on its subunit composition. $\alpha 7$ – $\alpha 10$ subunits containing receptors have higher Ca^{2+} permeability compared to those nAChRs which are formed by $\alpha 2$ – $\alpha 6$ subunits together with $\beta 2$ – $\beta 4$ subunits (Fucile et al., 2006; Jensen et al., 2005).

Clearly, 12 different kinds of neuronal α and β subunits can combine in a great number of ways to homo- or heteropentamers, but in mammalian brain, two major subtypes of nAChRs are expressed: the $\alpha 4\beta 2^*$ heteropentamer receptors (with a high affinity for NIC) and the $\alpha 7$ homopentamer receptors (with low affinity for NIC) (Jensen et al., 2005; Tapia et al., 2007; Gotti et al., 2006a; Kulak et al., 2006). The $\alpha 4\beta 2^*$ subtype accounts for 90% of the brain's nAChRs with a high affinity for NIC (asterisk indicates that additional subunits such as $\alpha 5$ may be present in some of these AChRs) (Jensen et al., 2005; Tapia et al., 2007; Gotti et al., 2006a).

2.2. Neuroanatomical distribution of different nAChRs

The neuroanatomical distribution of different nAChRs is species dependent to some degree. Furthermore, relevant data are obtainable from studies using different methods (i.e. mRNA in

situ hybridization and/or immunoprecipitation and/or using subunit specific receptor ligands, etc.), thus only a brief survey of the issue is presented here (for a current review of the topic, see Millar and Gotti, 2009). The most abundant nAChR type ($\alpha 4\beta 2^*$ receptors) are present, inter alia, in the cortex, striatum, cerebellum, lateral geniculate nucleus, amygdala, superior colliculus, hippocampus, spinal cord, and thalamus. $\alpha 7$ receptors are expressed with high density in the cortex, hippocampus and limbic regions and with low density in the thalamus and basal ganglia. Receptors containing $\alpha 9$ - and $\alpha 10$ subunits are present in the dorsal root ganglia, the pars tuberalis of the pituitary gland and non-neuronal cells (see above), but not in the brain. $\alpha 3\beta 4^*$ receptors are mainly localized in the ganglions of the autonomic nervous system as well as in the adrenal medulla, medial habenula, pineal gland, dorsal medulla, cerebellum, interpeduncular nucleus, hippocampus and retina. $\alpha 3\beta 2^*$ receptors are expressed in different parts of the visual pathway, the cerebellum, and in monkey (but not rodent) striatum. $\alpha 6^*$ receptors (probably mainly in $\alpha 6\alpha 4\beta 2\beta 3$ and $\alpha 6\beta 2\beta 3$ subunit compositions) are distributed in the lateral geniculate nucleus, retina, locus coeruleus, VTA, striatum, reticular nucleus of the thalamus, and colliculus superior. Distribution of $\alpha 2^*$ receptors are limited, but are present in the retina, nucleus interpeduncularis, and cortex (in $\alpha 2\alpha 4\beta 2$ composition) (Jensen et al., 2005; Gotti et al., 2006a,b, 2007; Gaimarri et al., 2007; Quik et al., 2007; Millar and Gotti, 2009).

nAChRs are localized on cell bodies, axons, presynaptic terminals, postsynaptic densities and also on dendrites (Dani and Bertrand, 2007; Gahring and Rogers, 2006). Most nAChRs in the nervous system are at presynaptic localizations as autoreceptors in cholinergic, and as heteroreceptors in non-cholinergic (i.e. noradrenalinergic, dopaminergic, serotonergic, GABAergic, glutamatergic) synapses, where they serve to modulate the release of neurotransmitters (Amtage et al., 2004; Raiteri, 2006; Exley and Cragg, 2008; Quarta et al., 2007; Lendvai and Vizi, 2008).

Nicotinic receptors are also expressed in non-neuronal cells of the CNS (i.e. astrocytes or microglial cells) and in some cell types of non-nervous systems (i.e. different cell types of placenta, epithelial and endothelial cells of lung, lymphocytes and macrophages) (Gahring and Rogers, 2006; Lips et al., 2005; Gotti and Clementi, 2004; Lendvai and Vizi, 2008).

2.3. Genetic variability in nAChRs genes and their associations with different aspects of nicotine addiction

The genetic determination of smoking-related behaviors is supported by several twin-studies (Portugal and Gould, 2008). According to these results, the heritability of NIC dependence ranges from 31% to 75%, and of persistent smoking from 39% to 82% (Portugal and Gould, 2008). The roles of different nAChRs subunits in different aspects of addiction and in NIC-evoked behavioral changes are also under intensive investigation. The application of molecular genetic approaches (i.e. genome-wide linkage analysis, genome-wide association analysis, candidate gene screening, genetic animal models (knock-out rodent strains)) have shed light on many aspects of this topic (Portugal and Gould, 2008; Mineur and Picciotto, 2008; Fowler et al., 2008). Genome-wide linkage studies have identified a number of potential susceptibility loci (i.e. located on chromosomes 1, 2, 6, 9, 11, 14, 17, 18, 19, 21) for NIC dependence (Mineur and Picciotto, 2008). Genome-wide and candidate gene association studies have found several SNPs in various nicotinic acetylcholine receptor subunit genes associated with smoking behavior. Some SNPs (i.e. rs1044396, rs1044397, rs3787137) in the CHRNA4 gene (it codes for $\alpha 4$ subunit) are associated with smoking quantity or the risk of NIC dependence, while other SNPs in this gene (i.e. rs2236196, rs6122429) are associated with subjective responses to smoking (Portugal and

Gould, 2008). The association between polymorphisms in the CHRN2 gene (which codes for $\beta 2$ subunit) and smoking habits seems less robust than in the case of CHRNA4, but some SNPs of this gene have also been observed to affect smoking behavior (i.e. rs2072660 is associated with a reduced risk for smoking initiation, and rs2072658 and rs2072660 are associated with altered subjective feelings about the negative effects of smoking) (Portugal and Gould, 2008). Several studies have suggested that various SNPs in the nicotinic receptor gene cluster (that comprises CHRNA3, CHRNA5 and CHRN4 genes) on locus 15q25 and in another nicotinic receptor gene cluster (that comprises CHRNA6 and CHRN3 genes) on locus 8p11 can also influence smoking habits (Portugal and Gould, 2008; Bierut et al., 2008; Hoft et al., 2009). Interestingly, SNPs in the gene for nicotinic acetylcholine receptor $\beta 1$ subunit (CHRN1) are also associated with smoking (paradoxically, this subunit is expressed only in the neuromuscular junction (and not in the central nervous system)) (Lou et al., 2006; Jensen et al., 2005; Millar and Gotti, 2009; Mineur and Picciotto, 2008; Lessov-Schlaggar et al., 2008).

Studies using different nAChR subunit knock-out (KO) rodent strains have also provided valuable information about the role of various subunits in NIC dependence and NIC-evoked effects. $\beta 2$ subunit KO mice do not show the enhancing effects of NIC in hippocampus-dependent learning paradigms, nor do they self-administer NIC or show an NIC-induced increase in the firing rate of dopaminergic neurons or an NIC-evoked elevation in dopamine levels in the ventral striatum. Moreover, NIC-dependent $\beta 2$ subunit KO mice displayed typical somatic signs after NIC withdrawal, suggesting that $\beta 2$ subunits are not involved in the physical signs of NIC withdrawal. Intriguingly, studies with $\beta 2$ KO mice and others using $\beta 2$ subunit containing nAChR antagonists have suggested, however, that receptors containing $\beta 2$ subunits have an important role in the affective components of NIC withdrawal (Portugal and Gould, 2008; Mineur and Picciotto, 2008; Jackson et al., 2008). The lentiviral vector-mediated $\beta 2$ subunit gene delivery into the VTA in $\beta 2$ KO mice reestablished both NIC self-administration and NIC-evoked increase in dopamine levels in the NAcc. These results further suggest the essential role of the $\beta 2$ subunit in NIC addiction (Maskos et al., 2005; Portugal and Gould, 2008; Fowler et al., 2008). Given the frequent co-assembly of $\alpha 4$ and $\beta 2$ subunits (as $\alpha 4\beta 2^*$ nAChRs, see above), $\alpha 4$ KO mice not surprisingly show similarities to $\beta 2$ KO mice. For example, neither strain experienced an NIC-evoked elevation of striatal dopamine levels or an NIC-induced changes in body-temperature or locomotor activity, or NIC-induced analgesia in the hot-plate test (Portugal and Gould, 2008; Mineur and Picciotto, 2008; Marubio et al., 1999). NIC self-administration is also impaired in $\alpha 4$ KO mice, but the lentiviral vector-mediated re-expression of $\alpha 4$ subunit in the VTA restored NIC self-administration in $\alpha 4$ KO mice strain (Pons et al., 2008). Interestingly Tapper et al. (2004), using a knock-in mice strain with a single point mutation (Leu⁹ → Ala⁹) in the $\alpha 4$ subunit (this mutation renders $\alpha 4^*$ nAChRs hypersensitive to NIC), showed that these mutant mice exhibit a 50-fold increase in sensitivity to the rewarding effects of NIC compared to wild-type mice, as measured by the conditioned place-preference paradigm (Tapper et al., 2004; Portugal and Gould, 2008; Mineur and Picciotto, 2008; Fowler et al., 2008). $\alpha 6$ KO mice also showed loss of NIC self-administration behavior, and the lentiviral vector-mediated re-expression of this subunit in the VTA reestablished NIC self-administration in this KO strain. These results suggest that the $\alpha 6$ subunit containing nAChRs (i.e. $\alpha 6\beta 2^*$) in the reward pathway play a crucial role in NIC reward (Pons et al., 2008). The knock-out of the $\alpha 7$ subunit has no radical impact on NIC-evoked reward measured by conditioned place-preference or by self-administration paradigms. However, studies with the $\alpha 7$ KO mice strain

suggest the role of the $\alpha 7$ subunit in physical (i.e. withdrawal-induced hyperalgesia or decreased locomotion) but not in affective signs of NIC withdrawal (Portugal and Gould, 2008; Mineur and Picciotto, 2008; Jackson et al., 2008; Pons et al., 2008; Walters et al., 2006). $\beta 4$ subunit KO rodents display decreased somatic signs (i.e. changes in grooming, chewing, scratching, and tremors) of NIC withdrawal, which suggests this subunit may have a role in somatic symptoms after smoking cessation (Portugal and Gould, 2008; Mineur and Picciotto, 2008; Jackson et al., 2008; De Biasi and Salas, 2008).

2.4. Desensitization and upregulation of nAChRs

An aftermath of nAChRs agonist (i.e. NIC) administration is the desensitization (i.e. temporary inactivation) of both major types of brain nAChRs ($\alpha 4\beta 2$ and $\alpha 7$) with markedly different velocities of desensitization in regard to the two main subtypes (in a range of seconds for $\alpha 4\beta 2$ and milliseconds for $\alpha 7$) (Giniatullin et al., 2005; Léna and Changeux, 1998; Jacobsen et al., 2004; Prus et al., 2007; Robinson et al., 2006; Janhunen and Ahtee, 2007; Wooltorton et al., 2003; Picciotto et al., 2008). After agonist wash-out, the desensitized state of the $\alpha 4\beta 2$ receptor ceases within minutes (Jacobsen et al., 2004; Picciotto et al., 2008). Acute tolerance to NIC caused by the desensitization of nAChRs was demonstrated in various *in vivo* (i.e. NIC-evoked prolactin release or nicotine-stimulated synaptosomal $^{86}\text{Rb}^+$ efflux) models and also in behavioral (i.e. discriminative stimulus or conditioned taste aversion) paradigms, allowing for the conclusion that NIC could act as a functional antagonist *in vivo* (Prus et al., 2007; Kuryatov et al., 2005; Robinson et al., 2006; Hulihan-Giblin et al., 1990; Vann et al., 2006). This functional antagonist effect of NIC has great relevance from a clinical perspective. For example, it may explain how both agonists and antagonists of nAChRs can have antidepressant effects among patients with depression and in animal models of depression (George et al., 2008; Philip et al., 2009; Picciotto et al., 2008). Desensitization of nAChRs in different cell types of VTA is also very important in the regulation of activity of the mesolimbic reward pathway by NIC (see discussion below) (Picciotto et al., 2008; Wooltorton et al., 2003; Keath et al., 2007; Dani and Harris, 2005). One of the main supposed functions of nAChR desensitization is the protection of neurons from uncontrolled excitation. This theory is supported by a mutation leading to decreased desensitization of the $\alpha 7$ receptor, which is accompanied by the premature death of animals with this mutation (Wang and Sun, 2005; Mudo et al., 2007). Details about the molecular mechanisms underlying the desensitization of nicotinic receptors (i.e. receptor phosphorylation/dephosphorylation), characteristics of desensitization dependent on exposure time and/or ligand concentrations, and the diverse consequences of desensitization under physiological or pathological conditions can be found in Giniatullin et al. (2005), Wang and Sun (2005), Quick and Lester (2002).

The desensitization of nAChRs leads to a compensatory upregulation of nAChRs. Therefore, the chronic administration of both agonists and antagonists of nAChRs *in vivo* and *in vitro* lead to the upregulation of nAChRs (in contrast to the widely observed and accepted fact that cell membrane receptors are upregulated after antagonist administration and downregulated after agonist administration) (Gaimarri et al., 2007; Lloyd and Williams, 2000; Teaktong et al., 2004; Prus et al., 2007; Kuryatov et al., 2005; Wang and Sun, 2005; Gentry and Lukas, 2002; Hogg and Bertrand, 2007). The two most prevalent receptor subtypes in the CNS ($\alpha 4\beta 2$ and $\alpha 7$) differ in the nature of their upregulation, while the upregulation of $\alpha 4\beta 2$ nAChRs may require a shorter exposure and/or lower concentration of NIC to develop and is regionally more extended in the brain than the upregulation of $\alpha 7$ receptors

(in consonance with this, $\beta 2$ subunit knockout mice do not show upregulation of NIC binding sites) (Teaktong et al., 2004; Nuutinen et al., 2005, 2006; Picciotto et al., 2008; Ochoa and Lasalde-Dominicci, 2007; Corringer et al., 2006). In addition, the NIC concentration in the brain of smokers is probably not high enough to upregulate $\alpha 7$ receptors, since most studies have failed to demonstrate the upregulation of $\alpha 7$ receptors in the brains of smokers (only Teaktong et al. (2004) found an increase in $\alpha 7$ immunoreactive perikarya in the granular cell layer of the dentate gyrus – but not in other brain regions – of smokers) (Teaktong et al., 2004; Nuutinen et al., 2005, 2006; Picciotto et al., 2008; Ochoa and Lasalde-Dominicci, 2007; Corringer et al., 2006). However, the upregulation of the $\alpha 6\beta 2^*$ receptor *in vivo* has not yet been clearly confirmed (since previous studies found no change or up- or down-regulation of these receptors after chronic NIC treatment). A recent *in vitro* study has found that $\alpha 6\beta 2$ receptors need a higher concentration of NIC to its upregulation than $\alpha 4\beta 2$ receptors, and the velocity of $\alpha 6\beta 2$ upregulation is higher than for $\alpha 4\beta 2$ receptors (Walsh et al., 2008; Picciotto et al., 2008). Apparently, regulation of the two main subtypes of $\alpha 6^*$ subunits containing receptors ($\alpha 6\alpha 4\beta 2^*$ and $\alpha 6$ (non- $\alpha 4$) $\beta 2^*$) by NIC in the striatum differed because the $\alpha 6\alpha 4\beta 2^*$ receptor was downregulated, while the $\alpha 6$ (non- $\alpha 4$) $\beta 2^*$ receptor was upregulated after NIC treatment in rodents (Perez et al., 2008a,b). The upregulation characteristics of $\alpha 3\beta 2$ receptors and the $\alpha 4\beta 2$ receptors, measured *in vitro*, are also different from each other (Walsh et al., 2008). Upregulation of $\alpha 4\beta 2$ nAChRs develops within week(s) after the initiation of NIC administration and ceases within 7 days in mice, 20 days in rats, and 8 weeks in humans after the termination of NIC administration in post-mortem studies (Picciotto et al., 2008; Mamede et al., 2007; Koylu et al., 1997; Pietilä et al., 1998; Sacco et al., 2004; Gentry and Lukas, 2002; Breese et al., 1997). An *in vivo* (SPECT) study also found the upregulation of nAChRs as a consequence of long-term NIC administration in baboons. In addition, recent *in vivo* investigations in humans have also confirmed both the upregulation of $\alpha 4\beta 2$ receptors after chronic NIC administration (smoking) and the termination of upregulation after approximately 21 days of smoking cessation (Mamede et al., 2007; Staley et al., 2006; Wullner et al., 2008; Kassiou et al., 2001). While desensitized nAChRs have a greater affinity for agonists than their nondesensitized counterparts, it remains controversial whether the elevation of NIC binding sites after chronic NIC administration is the result of an increased rate of desensitized receptors or an increased number of functional, activatable nAChRs (Picciotto et al., 2008; Giniatullin et al., 2005). Recently, several studies have examined the mechanisms underlying nAChR upregulation, and the results of these studies implicate numerous different pathways in this process (Picciotto et al., 2008). NIC-induced receptor upregulation occurs by post-transcriptional mechanism(s), as several studies have found that chronic NIC administration was not associated with changes in mRNA levels of nAChRs subunits (Corringer et al., 2006; Millar and Harkness, 2008). The potential mechanisms of upregulation may be as follows: NIC (and other membrane-permeable ligands of nAChRs) acts as a pharmacological chaperone in the endoplasmic reticulum (ER) to facilitate the assembly of subunits (Kuryatov et al., 2005; Wells, 2008); chronic NIC treatment causes an increased half-life of nAChRs in the surface membrane (Kuryatov et al., 2005; Peng et al., 1994); NIC induces conformational changes in surface-membrane nAChRs, and receptors in this novel conformational state are more sensitive to activation, desensitize more slowly, and have a higher affinity for epibatidine (Vallejo et al., 2005; Kuryatov et al., 2005; Wells, 2008); NIC acts in the ER as a “maturation enhancer” and promotes the transition from an immature oligomer receptor state into a state with higher metabolic stability (Sallette et al., 2005; Corringer et al., 2006; Gaimarri et al., 2007); NIC may decrease – both by a direct and a nAChR-mediated

manner – the process of protein degradation via modulation of the activity of the ubiquitin-proteasome system (UPS), and this newly discovered action of NIC could lead to increased protein (for example, nAChR and glutamate receptor) levels (Rezvani et al., 2007). In addition, chaperone-type proteins (such as VILIP-1, protein 14-3-3 η , PICK-1, RIC-3, ubiquilin-1, BiP, and calnexin) could play a role in nAChR folding, assembly, and trafficking, and also in the modulation of receptor expression levels and the regulation of receptor sensitivity to agonists (Gaimarri et al., 2007; Wells, 2008; Millar, 2008).

2.5. Non-synaptic transmission through nAChRs

Neurons can communicate with each other via both synaptic and non-synaptic transmission. In non-synaptic communication (or so-called volume transmission), the nerve endings or nerve boutons release transmitters, but do not make synaptic contacts. The transmitter from these non-synaptic nerve endings or nerve boutons is therefore released into the extracellular space (ECS) and then may diffuse to relatively distant targets (i.e. to extrasynaptically located receptors or to receptors on non-neuronal cells) (Lendvai and Vizi, 2008; Vizi et al., 2004a; Vizi and Mike, 2006; Descarries et al., 1997). Not only non-synaptic nerve boutons may play a role in volume transmission, but transmitter transporters in reverse operation mode may also release transmitters into the ECS. Moreover, a leakage of transmitters from classic synapses into the ECS (a phenomenon called spillover) is known to occur (Vizi et al., 2004a). Non-synaptic transmission is considered the typical form of neurotransmission in monoaminergic (dopaminergic, serotonergic, and noradrenergic) and cholinergic systems, as evidenced by the following: nerve terminals and nerve boutons in these systems are mainly in a non-synaptic situation; the ACh degrading enzyme acetylcholinesterase (AChE) is frequently localized far from cholinergic nerve endings, which suggests that ACh may reach targets a great distance from its place of release; and nAChRs exist at non-synaptic sites (Lendvai and Vizi, 2008; Dani and Bertrand, 2007; Vizi et al., 2004a; Vizi and Mike, 2006). According to the assumption of Vizi et al. (2004a,b), the relatively low concentration of NIC in the brain during cigarette smoking may induce its neurobiological effects mainly via non-synaptic nAChRs, because these receptors are usually activated by lower ligand concentrations than their counterparts in synaptic localization (Vizi et al., 2004b; Lendvai and Vizi, 2008).

3. Mechanisms of nicotine's actions in the reward pathway(s) and the relevance of dopamine in nicotine addiction

3.1. Nicotine and the mesocorticolimbic dopamine system

The mesocorticolimbic dopamine system (MDS, sometimes referred to as the reward system) is regarded as the main morphological substrate of reward and reinforcement in the brain (Wonnacott et al., 2005; Nestler and Carlezon, 2006). Neuroanatomically the MDS is a neural circuitry that includes primarily the dopaminergic cells of the VTA and their projections to the nucleus accumbens (NAcc; also called ventral striatum), the prefrontal cortex (PFC), the amygdala, the ventral pallidum, and the hippocampus (Wonnacott et al., 2005; Nestler and Carlezon, 2006; Pierce and Kumaresan, 2006; Kalivas and Volkow, 2005). The dopaminergic neurons of the VTA are key players in the reward system, and dopamine release in NAcc is strongly associated with the administration of most drugs of abuse (i.e. ethanol, opiates, cannabinoids, phencyclidine, toluene (in inhalant abuse) and psychostimulants) (Pierce and Kumaresan, 2006; Riegel et al., 2007; Adinoff, 2004; Rose, 2007; Hutson et al., 2000; Britt and McGehee, 2008; Melis et al., 2005). Additionally, the MDS is also

activated by different kinds of natural rewards, such as humor, sexual activity, food, positive social interactions, play, aesthetic artworks, pictures of loved ones, etc. (Sabatinelli et al., 2007; Cannon and Bseikri, 2004; Mobbs et al., 2003).

nAChRs are widely distributed in the reward pathway. Mostly $\alpha 4\beta 2\alpha 5$ and $\alpha 4\beta 2\alpha 6\alpha 5$ receptors are found on dopaminergic cell bodies in the VTA; $\alpha 7$ receptors in a smaller proportion also occur on the surface of these cells; a lot of $\alpha 4\beta 2\alpha 5$ and a few $\alpha 7$ receptors are present on GABAergic cell bodies in the VTA; $\alpha 7$ receptors also appear on glutamatergic nerve endings in the VTA; $\alpha 4\beta 2^*$ receptors are found on GABAergic nerve endings in the VTA; $\alpha 4\beta 2$, $\alpha 4\beta 2\alpha 5$, $\alpha 6\beta 2\beta 3$, $\alpha 4\alpha 6\beta 2\beta 3$ receptors occur on dopaminergic terminals in the NAcc; and $\alpha 4\beta 2^*$ receptors appear on GABAergic nerve endings in the NAcc. Therefore, it is not surprising that like other substances of abuse, NIC can influence the activity of the reward pathway, resulting in an increased level of extracellular dopamine in the NAcc, striatum, and frontal cortex (Pierce and Kumaresan, 2006; Janhunen and Ahtee, 2007; Mameli-Engvall et al., 2006; Rose, 2007; Dani and Harris, 2005; Bednar et al., 2004; Picciotto, 2003; Picciotto et al., 2008; Fowler et al., 2008; Mansvelder et al., 2006; Pidoplichko et al., 2004; Exley et al., 2008). Studies of the usage of nAChRs antagonists have also underlined the direct effect of NIC on MDS. The administration of the nAChR antagonist mecamylamine (as a non-specific nAChR antagonist) into the VTA decreased the NIC-evoked dopamine release in the NAcc (although mecamylamine failed to reduce dopamine release when it was administered into the NAcc), while the administration of $\alpha 7$ antagonists (methyllycaconitine (MLA) or α -bungarotoxin) into the NAcc decreased the NIC-evoked dopamine release there (Pierce and Kumaresan, 2006; Janhunen and Ahtee, 2007; Walters et al., 2006; Papke et al., 2001; Fu et al., 2000; Rossi et al., 2005a,b). In animal studies, the systemic or intra-VTA administration of $\alpha 4\beta 2$ nAChR antagonist dihydro- β -erythroidine (DH β E) decreased NIC self-administration and the rewarding effect of NIC in the conditioned place-preference paradigm, but $\alpha 7$ antagonist MLA had no effect on NIC-induced conditioned place-preference. Moreover, effects of MLA in the NIC self-administration paradigm were contradictory, which suggests that $\alpha 4\beta 2$ receptors – compared with $\alpha 7$ receptors – have a bigger role in the mediation of rewarding effects of NIC (Laviolette and van der Kooy, 2003a,b, 2004; Picciotto et al., 2008; Fowler et al., 2008; Walters et al., 2006). Results of studies with genetically modified rodents (i.e. $\beta 2$ subunit gene knock-out strain; $\beta 2$ subunit gene knock-out strain with lentiviral mediated $\beta 2$ gene transfer to reexpress $\beta 2$ subunit; mouse strain with an $\alpha 4$ subunit variant with a point mutation which renders the $\alpha 4$ subunit containing nAChRs more sensitive to NIC; $\alpha 7$ subunit knock-out strain) offer further support for the supposition that $\alpha 4\beta 2$ nAChRs are primarily responsible for mediating the rewarding effects of NIC (Picciotto et al., 2008; Fowler et al., 2008; Walters et al., 2006; McCallum et al., 2006).

The role of the MDS in NIC addiction is also reinforced by the results of anatomical or pharmacological blockades of MDS, while the disruption of dopaminergic neurons in reward pathway by 6-hydroxydopamine or the administration of dopamine antagonists is associated with decreased NIC self-administration and NIC-evoked conditioned place-preference (Laviolette and van der Kooy, 2004; Sellings et al., 2008; Spina et al., 2006). Interestingly, according to recent results by Sellings et al. (2008), aversive and rewarding effects of NIC are segregated anatomically in the NAcc: the core part of NAcc provides the anatomical substrate for the aversive effects, while the shell part of the NAcc provides the anatomical substrate for the rewarding effects of NIC (Sellings et al., 2008).

Electrophysiologically, dopaminergic neurons of VTA have three kinds of patterns of activity, namely an inactive state, a tonic firing state, and a burst-firing mode (Grace et al., 2007;

Maskos, 2008; Mameli-Engvall et al., 2006). Dopamine release in terminal regions of the MDS is dependent on the firing state of dopaminergic neurons of VTA. Phasic burst firing leads to massive dopamine release in the NAcc, while slow single-spike tonic activity leads to stable low-level baseline dopamine concentration in the NAcc (Grace et al., 2007; Maskos, 2008; Mameli-Engvall et al., 2006). Tonic firing is driven by the intrinsic membrane potential oscillations of dopaminergic cells in contrast to burst-firing, which is dependent on intact afferent innervation of dopaminergic cells of VTA (Grace et al., 2007; Maskos, 2008; Mameli-Engvall et al., 2006). The afferent innervation of the MDS is very complex, originates in the cerebral cortex and in various subcortical structures, and involves many kinds of neurotransmitters (for details see Pierce and Kumaresan, 2006; Kalivas and Volkow, 2005; Janhunen and Ahtee, 2007; Grace et al., 2007; Laviolette and van der Kooy, 2004). An important source of afferent innervation are two adjacent nuclei in the brainstem: the laterodorsal tegmental nucleus (LDT) and the pedunculopontine tegmental nucleus (PPT), which comprise mainly cholinergic neurons interspersed with GABAergic and glutamatergic neurons. All of these cell types send connections to the VTA (Wonnacott et al., 2005; Janhunen and Ahtee, 2007; Grace et al., 2007; Dani and Harris, 2005; Wonnacott, 2008; Maskos, 2008). The switch from tonic to burst-firing of dopaminergic neurons in the VTA is driven by glutamate afferents derived mainly from the PFC and the PPT (Grace et al., 2007; Maskos, 2008; Wonnacott, 2008). The afferent innervation of the VTA from the LDT permits this glutamate-driven switch from tonic activity to burst-firing (Grace et al., 2007; Maskos, 2008; Wonnacott, 2008). The neurotransmitter mediating this effect is probably ACh (Grace et al., 2007). Cholinergic brainstem nuclei are an important aspect of NIC addiction, while a lesion of the posterior part of the PPT, which innervates the VTA, causes an alteration in intravenous NIC administration. Natural (such as food and sex) and drug (opiate) rewards are also known to be influenced by PPT lesions (Laviolette and van der Kooy, 2004; Maskos, 2008; Alderson et al., 2006).

NIC has a deep impact on the activity of MDS. First of all, NIC administration in the VTA activates $\alpha 4\beta 2$ receptors on dopaminergic and GABAergic cells and on GABAergic terminals, and $\alpha 7$ nAChRs on glutamatergic nerve terminals. Then, within minutes after the start of NIC exposure, $\alpha 4\beta 2$ receptors on GABAergic neurons and nerve terminals and on dopaminergic neurons undergo rapid desensitization (leading to a decrease in both GABA-mediated inhibition and direct activation of dopaminergic cells by NIC), but the concentration of NIC associated with smoking is not high enough to desensitize $\alpha 7$ -containing nAChRs on glutamatergic nerve endings. As a result, NIC is able to induce glutamate release in this stage too, which further activates dopaminergic cells of the VTA during prolonged NIC administration (i.e. smoking) (Janhunen and Ahtee, 2007; Dani and Harris, 2005; Picciotto et al., 2008; Fowler et al., 2008; Mansvelder et al., 2006; Pidoplichko et al., 2004; Keath et al., 2007). The net effect of NIC in the VTA thus results in an increased activity of dopaminergic cells and facilitates the switch from the tonic to the burst-firing mode of VTA dopaminergic neurons (Janhunen and Ahtee, 2007; Rose, 2007; Mameli-Engvall et al., 2006; Dani and Harris, 2005; Fowler et al., 2008; Zhang and Sulzer, 2004; Pidoplichko et al., 2004; Ikemoto, 2007). Dopamine release in the NAcc is influenced by NIC. Four types of nAChRs (see above) are present on dopaminergic nerve terminals in NAcc (where the endogenous ligand ACh is released from cholinergic interneurons of the NAcc). The administration of NIC desensitizes them, which then leads to both an increased release of dopamine during burst-firing, and a decreased release of dopamine during tonic low-frequency firing of dopaminergic cells (according to recent results, $\alpha 6\beta 2^*$ nAChRs are key players in the regulation of NIC-evoked dopamine release in

the NAcc) (Janhunen and Ahtee, 2007; Britt and McGehee, 2008; Picciotto, 2003; Rice and Cragg, 2004; Zhang and Sulzer, 2004; Exley and Cragg, 2008; Exley et al., 2008; Mansvelder et al., 2003; Dani and Bertrand, 2007). Because dopaminergic cells in the VTA are in burst-firing mode in response to reward-predicting stimuli or in unpredicted-reward situations, NIC administration selectively enhances reward-related dopamine release (Britt and McGehee, 2008; Rice and Cragg, 2004; Exley et al., 2008; Schultz, 1997; Schultz, 2007).

Interestingly, differences are found in NIC-evoked dopamine release in the two main parts of the striatum. NIC administration excites dopaminergic neurons that innervate either the dorsal striatum (caudate-putamen) or ventral striatum (NAcc). NIC-evoked dopamine release, however, is more pronounced in the NAcc than in the dorsal striatum (which is densely innervated by dopaminergic afferents originating mainly in the substantia nigra and to a lesser degree in the VTA; NAcc on the other hand is innervated by dopaminergic afferents originating mainly in the VTA and to a lesser degree in the substantia nigra) (Zhang et al., 2009). In addition, NIC-evoked activation, measured by the expression of immediate early genes c-Fos and Δ FosB, is more pronounced in the terminal region of the mesocorticolimbic pathway (NAcc) than in the terminal region of nigrostriatal pathway (caudate-putamen region) (Janhunen and Ahtee, 2007). The NIC-evoked phasic burst-firing of dopaminergic neurons was recently shown to be associated with a greater dopamine efflux in the NAcc than in the dorsal striatum (while an NIC-evoked decrease in dopamine efflux was experienced in both areas during the tonic firing of dopaminergic neurons). Moreover, the differences in the expression of various nicotinic receptor subunits on afferent nerve endings and dopaminergic cell bodies in the VTA vs. the substantia nigra may also explain the divergent responses of dopaminergic neurons to NIC in these two nuclei (Zhang et al., 2009; Keath et al., 2007).

3.2. Nicotine and the habenular complex

NIC may have effects on other brain systems linked to reward processing (Rose, 2007). The habenular complex (HbCpl) is an epithalamic structure consisting of cholinergic cells and substance P-containing neurons in its medial part (medial habenula) and GABAergic and glutamatergic neurons in its lateral part (lateral habenula). The two parts are in a unidirectional relationship, with axons of some neurons of the medial habenula having en passant boutons in the lateral habenula (Lecourtier and Kelly, 2007; Rose, 2007). The HbCpl receives its main afferents – via the stria medullaris – from various brain areas and sends its main outputs – via the fasciculus retroflexus – to several brain areas, too (for details see Lecourtier and Kelly, 2007; De Biasi and Salas, 2008). VTA and NAcc – as main components of the dopaminergic reward pathway – are in anatomical connection with the HbCpl (Rose, 2007; De Biasi and Salas, 2008). The lateral habenula sends glutamatergic axons to the GABAergic cell population of the VTA, which provides local inhibitory input to the dopaminergic cells of the VTA. According to this structural connection, the electrical stimulation of neurons in the lateral habenula suppresses the activity of dopaminergic neurons in the VTA (Wonnacott et al., 2005; Hikosaka et al., 2008; Ji and Shepard, 2007; Morra, 2007; Lecourtier et al., 2008; Ungless, 2004). Interestingly, neurons of the lateral habenula are activated by a cue that predicts the absence of reward or by the omission of a predicted reward, but they are inactivated by an unpredicted reward. Consequently, their responses in reward-related situations were opposite to those of dopaminergic neurons of the VTA (Hikosaka et al., 2008; Morra, 2007; Schultz, 2007). The close functional and anatomical relationship of HbCpl to the mesolimbic dopaminergic system

(discussed above), the presence of nAChRs (mainly as $\alpha 3\beta 4$ receptors) in large amounts in the medial habenula and interpeduncular nucleus (as one of the main output areas of the medial habenula), and the finding that the administration of 18-methoxycoronaridine (a selective $\alpha 3\beta 4$ receptor antagonist) may decrease the self-administration of various addictive agents (i.e. morphine, alcohol, cocaine and metamphetamine) in animal studies seriously raise the possibility that the habenular complex is one of the neural systems involved in NIC addiction (De Biasi and Salas, 2008; Glick et al., 2008). In accordance with this theory, the intraperitoneal administration of 18-methoxycoronaridine caused a decrease in i.v. self-administration of NIC in rodents in a dose-dependent manner (Glick et al., 2000). The link between NIC and HbCpl are further supported by the selective toxicity of chronic NIC administration to the habenula and fasciculus retroflexus (Rose, 2007; Ciani et al., 2005). That knock-out strains either for $\beta 4$ subunit, $\alpha 2$ subunit, or $\alpha 5$ subunit (which in addition to the $\alpha 3$ subunit are all highly expressed receptor subunits types in the medial habenula and/or in interpeduncular nucleus) show decreased somatic signs of nicotine withdrawal is in agreement with the idea that the habenular/interpeduncular system plays a major role in NIC dependence (Salas et al., 2009; De Biasi and Salas, 2008).

3.3. Nicotine and insula

The insular region has also emerged recently as an anatomical substrate of NIC addiction (Rose, 2007; Naqvi et al., 2007). Functional neuroimaging studies had previously described that the insula is activated by drug-related cue-elicited craving. Moreover, structural abnormalities of the insula have also been described in some forms of addiction (Rose, 2007; Naqvi et al., 2007; Contreras et al., 2007; Naqvi and Bechara, 2009). Contreras et al. (2007) found that the pharmacological inactivation of the insula in rodents was associated with impaired amphetamine-conditioned place-preference (Contreras et al., 2007; Naqvi and Bechara, 2009). Recently in their seminal paper, Naqvi et al. (2007) described how patients who had suffered a lesion in the insular region were more likely to abstain from smoking than patients who had suffered lesions in other brain regions (Naqvi et al., 2007).

3.4. Relevance of dopamine in nicotine addiction

Although a large body of results suggest that dopamine plays a crucial role in reward processing and/or the development of drug addiction, a number of caveats have been applied to this “evidence” from the start. First of all, dopaminergic neurons of the VTA (or at least a subpopulation of them) appear to increase their activity not only in response to unpredicted-reward or reward-predicting stimuli, but also in response to aversive stimuli. In addition, a great number of studies have found that aversive stimuli – like addictive stimuli – also elicit dopamine release in the ventral striatum (but results are ambiguous in this respect) (Brischoux et al., 2009; Roitman et al., 2008; Ungless, 2004; Horvitz, 2000). Moreover, in the tyrosine hydroxylase knock-out rodent (dopamine deficient mice) strain, dopamine did not prove necessary for hedonic responses evoked by opiate administration or for learned preferences for sweet tasting solutions over water (Berridge, 2007; Hyman et al., 2006; Hnasko et al., 2005). Hyperdopaminergic (dopamine transporter knockdown) mice also showed no difference compared with wild-type mice in hedonic reactions to sweet tasting solutions (Berridge, 2007; Britt and McGehee, 2008). The pharmacological (6-OHDA) lesion of the mesolimbic dopaminergic system is similarly not associated with the reduced hedonic impact of sweet taste. Furthermore the administration of dopamine receptor antagonists failed to

decrease the hedonic impact of addictive agents in some studies. For example flupenthixol administration leads to decreased aversive rather than decreased rewarding effects of NIC, but this effect is only observable in an acute state of NIC exposure, and not after long-term NIC exposure (Sellings et al., 2008; Berridge, 1996, 2007; Laviolette and van der Kooy, 2003a,b; Tan et al., 2009). Based on the above and other non-detailed results, several experts have suggested that dopamine may mediate the phenomenon of “wanting” (expectation of reward) more than the phenomenon of “liking” (the hedonic impact of reward) (Berridge, 2007; Adinoff, 2004).

NIC administration increases dopamine levels in several brain areas (i.e. hippocampus, striatum, cingulate and frontal cortex, amygdala and pontine nuclei) (Singer et al., 2004; Cao et al., 2005a,b; Janhunen and Ahtee, 2007). Interestingly, during NIC withdrawal the level of extracellular dopamine decreases in NAcc, but rises in the PFC. While stressful situations and aversive stimuli are associated with increased dopamine levels in the PFC, this alteration could mediate aversive aspects of NIC withdrawal (De Biasi and Salas, 2008).

Not only does NIC have a radical effect on the brain's dopaminergic systems, but it also influences the release of many kinds of neurotransmitters (i.e. serotonin, noradrenaline, GABA, acetylcholine, glutamate, and endocannabinoids) and neuropeptides (i.e. CRF, endogenous opioids, and orexins). For details on the relevance of these diverse actions of NIC in various brain functions and in the development and maintenance of NIC dependence, (see De Biasi and Salas, 2008; Di Matteo et al., 2007; Touiki et al., 2007, 2008; Seth et al., 2002; Galindo-Charles et al., 2008; Rossi et al., 2005a,b; Grilli et al., 2005; Markou, 2007, 2008; Liechti and Markou, 2008; Kenny et al., 2009; Hahn and Stoleran, 2005; Erhardt et al., 2000; George et al., 2007; Xue and Domino, 2008; Chen et al., 2008b; Merritt et al., 2008; Pasumarthi and Fadel, 2008).

4. Results of structural and functional brain-imaging studies on the influence of nicotine/smoking on neural systems

4.1. Structural and morphological alterations of a smokers' brain

In recent years numerous studies have investigated structural brain abnormalities associated with smoking, smoking-related changes in global and regional brain activities, and NIC-evoked changes at the molecular levels in the brain. Several studies have reported generalized brain atrophy by computed tomography (CT) in smokers (Kubota et al., 1987; Akiyama et al., 1997; Hayee et al., 2003; Durazzo et al., 2007). In magnetic resonance imaging (MRI) studies brain atrophy, white matter lesions and lacunar infarcts are also described as a consequence of smoking (but the results are ambiguous). Moreover, cigarette smoking was identified as a risk factor for the progression of white matter lesions (Yamashita et al., 1996; Shintani et al., 1998; Swan et al., 2000; Longstreth et al., 2001; Swan and Lessov-Schlaggar, 2007; van Dijk et al., 2008).

4.1.1. Gray matter alterations in smokers

In a structural brain-imaging study by Brody et al. (2004a), reduction in gray-matter volumes and densities are described in the dorso- and ventrolateral prefrontal cortex, the left dorsal anterior cingulate cortex, and the right cerebellum among smokers compared with non-smokers (Brody et al., 2004a). Almeida et al. (2008) found decreased gray-matter densities in the posterior cingulum, precuneus, precentral gyri and right thalamus in an elderly smoker population, and the authors note that these areas are also affected in incipient Alzheimer's disease (Almeida et al., 2008). Gallinat et al. (2006) found no difference in whole-brain volume between smokers and non-smokers, but did find decreased

regional gray-matter volumes in thalamic, cuneal, precuneal, frontal and occipital cortical regions among smokers (Gallinat et al., 2006). Interestingly, no volume deficit was found in the ventral striatum—a key structure in reward processing (Gallinat et al., 2006).

Some theories have been developed about the etiology of smoking-related regional gray-matter abnormalities. For instance, because gray matter is particularly vulnerable to ischemia and smoking is associated with the decreased oxygen-carrying capacity of blood (via elevated blood carbon monoxide levels) and/or impaired lung function, the consequential ischemia of brain tissues may lead to gray-matter damage (Durazzo et al., 2007). Cigarette smoke containing reactive oxygen species (with its known damaging effects on cellular membranes, DNA, carbohydrates, etc.) may also contribute to structural brain abnormalities in smokers (Brody et al., 2004a; Gallinat et al., 2006; Durazzo et al., 2007). Reduced gray-matter volume among smokers may be associated with cognitive decline related to long-term smoking, as suggested by prospective epidemiological studies (Gallinat et al., 2006; Almeida et al., 2008; Paul et al., 2008; Sabia et al., 2008). Interestingly, studies with special populations (patients with schizophrenia or alcohol dependency) also reported smoking-related gray matter changes. Durazzo et al. (2007) reported that smoking in heavy drinkers is associated with decreased total gray matter and temporal gray-matter volumes (Durazzo et al., 2007). According to a recent study by Tregellas et al. (2007), smokers with schizophrenia have less gray-matter shrinkage in the superior temporal gyri and lateral prefrontal cortex than do non-smokers with schizophrenia, suggesting that smoking has some kind of neuroprotective effects in schizophrenia (Tregellas et al., 2007).

4.1.2. White matter alterations in smokers

White matter abnormalities are also described in smokers. Gazdzinski et al. (2005) found that smoking is associated with increased white matter volume in the temporal region in a population with alcohol dependence (Gazdzinski et al., 2005). The same study suggested that alterations in the white matter might be a result of NIC-induced cytotoxic cell swelling secondary to NIC-induced osmotic imbalances. Vasogenic swelling (as a consequence of NIC-induced blood–brain barrier damage) characterized by plasma fluid leaking into the parenchymal interstitial space was considered another possible culprit (the findings of Paul et al. (2008), however, challenge the vasogenic swelling theory) (Gazdzinski et al., 2005; Paul et al., 2008). In their diffusion tensor imaging study, Paul et al. (2008) found that NIC dependence was associated with significantly higher fractional anisotropy (FA) in the body and whole corpus callosum, and also a trend of higher FA in the splenium. This suggests a superior integrity of the white matter, although the explanation of these findings is scarce (Paul et al., 2008). Interestingly, higher FA was also found in the anterior cortical white matter and the internal capsule of both adolescent smokers and adolescent non-smokers with prenatal exposure to cigarette smoke compared to adolescent non-smokers with no prenatal exposure to cigarette smoke (Jacobsen et al., 2007). Gallinat et al. (2007) measured concentrations of N-acetylaspartate (NAA), which is considered a marker for neuronal and axonal integrity, in their magnetic resonance spectroscopy study and found it was significantly reduced in smokers compared to non-smokers in the left hippocampus, but not in the anterior cingulate cortex (Gallinat et al., 2007; Gujar et al., 2005). This result suggests a local neurotoxic effect of smoking on the hippocampus, which may explain cognitive decline associated with chronic smoking (Gujar et al., 2005; Anstey et al., 2007; Gallinat et al., 2007; Swan and Lessov-Schlaggar, 2007; Peters et al., 2008).

4.2. The effects of nicotine on brain activity

Although the direction of NIC administration-evoked changes in global cerebral blood flow (gCBF) is ambiguous, some results suggest a decreased gCBF as a consequence of chronic NIC administration and an increase of gCBF after acute NIC administration (Almeida et al., 2008). Studies using the Xe¹³³ inhalation method or ^{99m}Tc-HMPAO-SPECT found a decrease in global cerebral or gray matter blood flow as an effect of chronic cigarette smoking with an increase after quitting in the long-term (Kubota et al., 1983; Rogers et al., 1983, 1985; Yamashita et al., 2000; Brody, 2006; Siennicki-Lantz et al., 2008). Using Doppler ultrasonography, Morioka et al. (1997) and Boyajian and Otis (2000) found an increase in the velocity of cerebral arterial blood flow as an acute consequence of smoking. Wennmalm (1982) using the N₂O-wash-in technique and Skinhoj et al. (1973) using the Xe¹³³ intracarotid injection method also found increased CBF after NIC administration (Skinhoj et al., 1973; Wennmalm, 1982; Silvestrini et al., 1996; Morioka et al., 1997; Boyajian and Otis, 2000; Terborg et al., 2002; Brody, 2006).

PET studies by Cruickshank et al. (1989) and Ghatan et al. (1998) found a decrease in gCBF or no change in gCBF after NIC administration, but authors of another study (Nagata et al., 1995) have shown an increase in global CBF in one set of measurements but not in another test performed immediately afterward (Cruickshank et al., 1989; Ghatan et al., 1998; Stapleton et al., 2003; Nagata et al., 1995). The SPECT studies by Yamamoto et al. (2003) and Rourke et al. (1997) and the PET study by Rose et al. (1998) described a decline in global CBF after smoking, too (Rourke et al., 1997; Stapleton et al., 2003; Yamamoto et al., 2003). Shinohara et al. (2006) found with PET no significant changes in global CBF after NIC administration (smoking) in smokers, however they found a statistically significant inverse correlation between arterial NIC concentrations and CBF (Shinohara et al., 2006). Global cerebral glucose metabolism was also found diminished after NIC administration (Stapleton et al., 2003; Rose et al., 2007).

Changes in regional brain activity as a consequence of NIC administration have also been under intensive investigation. Functional brain-imaging studies measuring regional CBF (rCBF) or glucose metabolism have commonly reported that administration of NIC or smoking activate different parts of the frontal cortex, thalamus, visual system, ventral striatum and cerebellum, while most studies have found decreased brain activities in the anterior cingulate cortex, amygdala and the hippocampus (however, different studies frequently provide contradictory results) (Ghatan et al., 1998; Domino et al., 2000, 2004; Rose et al., 2003; Lee et al., 2005; Zubieta et al., 2005; Brody, 2006; Ray et al., 2008; Siennicki-Lantz et al., 2008; Tanabe et al., 2008). NIC also modulates reticular arousal system activity in a dose-dependent manner: low doses activate while higher doses depress the activity of the reticular system. Thus finding is in accordance with the stimulatory effect of low-dose and the inhibitory effect of high-dose NIC on arousal (Rose et al., 2003). Some results suggest that NIC-evoked changes in regional brain activities are dependent on smoking history (smokers vs. non-smokers) and also on laterality (right vs. left hemisphere) (Ray et al., 2008).

A recent fMRI study has shown that subsequent administration of NIC, compared to acute NIC administration, is associated with the activation of different parts of the brain in rodents (i.e. NAcc, hippocampus, ventral pallidum, PFC and ventral tegmentum) (Li et al., 2008). Hong et al. (2009b) in their MRI study found that the increased severity of NIC addiction was associated with a decreased strength in functional connectivity between the dorsal anterior cingulate cortex and the striatum in a resting (task-independent) state. The authors have raised the possibility that

this phenomenon may serve as a novel biomarker for NIC addiction (Hong et al., 2009b). Moreover, they also report that short-term NIC supplementation does not significantly affect the association described above, suggesting that NIC replacement does not necessarily correct NIC addiction-related network abnormalities. This may partially explain why NIC supplementation is not a highly effective therapy for smoking cessation (Hong et al., 2009b).

4.3. Functional brain-imaging studies on smoking abstinence and craving

The effect of smoking abstinence (and associated craving) on rCBF were also investigated by several studies. A recent investigation found no change in gCBF after overnight smoking abstinence but significant increases in rCBF in the anterior cingulate cortex and medial part of the orbitofrontal cortex (OFC) did occur. The study also found that abstinence-induced craving correlated with gCBF and increased rCBF (compared with satiety situation) in the right dorsolateral PFC, OFC, and insula, as well as in the left inferior frontal cortex, occipital cortex, anterior cingulate cortex, ventral striatum, thalamus, amygdala, bilateral hippocampus, and left caudate (Wang et al., 2007b). The same group investigated the effects of some functional polymorphisms in the dopaminergic and opioidergic pathways (DRD2-141 Ins/DelC; DRD2 C957T, OPRM1 A118G, COMT Val158Met polymorphism) on overnight abstinence-associated changes in rCBF. They found that carriers of the DelC variant of the DRD2-141 polymorphism, the Val/Val variant of the COMT polymorphism, or the AA variant of OPRM1 polymorphism have significantly greater abstinence-induced rCBF increases in regions previously linked with cigarette cravings (Ray et al., 2008; Wang et al., 2008). In conclusion, these results suggest that genetic polymorphisms with reduced dopaminergic tone, and those associated with increased endogenous opioid binding, may be linked with patterns of regional brain activation that may increase the risk of relapse (Ray et al., 2008; Wang et al., 2008).

Recently, Tanabe et al. (2008) found that overnight abstinence is not associated with rCBF changes in the thalamus, medial frontal cortex, and ventral striatum, although they did find a significant inverse correlation between rCBF in the thalamus and the severity of withdrawal symptoms measured by the Minnesota Withdrawal Scale. Domino et al. (2004) and Zubieta et al. (2005), in their previous articles, however, described a decrease in rCBF in the ventral striatum including nucleus accumbens after smoking a cigarette subsequent to overnight abstinence. Wang et al. (2007b), on the other hand, found a positive association between increased thalamic rCBF and abstinence-induced craving (Domino et al., 2004; Zubieta et al., 2005; Wang et al., 2007b; Tanabe et al., 2008). The decrease in overnight abstinence-induced craving after smoking a cigarette correlated with a decrease in rCBF in the anterior cingulate cortex and right hippocampus according to the results of Zubieta et al. (2005).

Changes in the brain activity of smokers associated with exposure to smoking-related visual cues (pictures, videos, 3D environment simulation) is also an intriguing topic in neuroimaging (Brody et al., 2007; Ray et al., 2008). Most studies have found that the presentation of smoking-related cues activates the visuospatial cortical system (i.e. cuneus, precuneus, occipital cortex) and attention (i.e. anterior cingulate cortex, prefrontal and parietal cortex) and reward circuits (i.e. amygdala, ventral striatum) (Brody, 2006; Brody et al., 2007; Franklin et al., 2007, 2009; Wang et al., 2007b; McClernon et al., 2008a; Ray et al., 2008). Some studies have also found that the activation of different regions (i.e. in the anterior cingulate cortex, right orbitofrontal cortex, left inferior occipital gyrus, left globus pallidus, right caudate, left inferior parietal lobe, and medial occipital lobes) by

smoking-related cues are positively correlated with the level of NIC dependence and that the degree of cue-induced craving is associated with the extent to which the mesocorticolimbic region, midbrain and amygdala are activated (Ray et al., 2008). There are mixed results about the impact of abstinence (vs. smoking as usual situation) on the extent of brain activation induced by smoking-related cues (McClernon et al., 2009). Recently, Franklin et al. (2009) found that a well-known VNTR polymorphism in the 3'-untranslated region of the dopamine transporter gene (SLC6A3) has an effect on smoking cue-elicited activation in many brain areas (i.e. in the bilateral OFC and parahippocampal region, left ventral striatum, left dorsolateral PFC, right ventral medial PFC, fusiform gyrus, and superior temporal and frontal gyri). The results suggest that the carriers of the 9-repeat VNTR (the allele of which is associated with lower DAT expression) showed greater activation during exposure to smoking cues (vs. non-smoking cues) in the areas mentioned above compared with persons homozygous for the 10-repeat allele (Franklin et al., 2009). The brain regions most affected in different aspects of NIC dependence, as indicated by functional imaging studies, are rich in nAChRs (i.e. the ventral striatum, NAc, DLPFC, thalamus, inferior frontal cortex, visual cortex, and cerebellum) and these areas are also the key anatomical substrates of a wide range of cognitive processes (i.e. memory processes, attention, behavioral control, decision making, etc.) (Zubieta et al., 2005; Brody et al., 2007; Wang et al., 2007b; Tanabe et al., 2008).

While NIC has widely known procognitive effects, some neuroimaging studies have also focused on the impacts of NIC administration on brain activity during cognitive tasks (Brody, 2006). Results of these studies show that NIC administration during cognitive tasks has different effects on activity levels of the thalamus, visual cortex, ACC, prefrontal cortex, parietal cortex and the so-called "default system" (a network of brain regions that is active at rest and is deactivated during the performance of specific tasks. The default system consists of the medial frontal area, posterior cingulate cortex, and (pre)cuneal region) (for details see Brody, 2006; Hahn et al., 2007; Musso et al., 2007; Swan and Lessov-Schlaggar, 2007; Xu et al., 2007; Ray et al., 2008; Schilbach et al., 2008). Some of these studies have also found that the extent of activation is influenced by the smoking status of the probands and by the specific cognitive task used in the given study (Musso et al., 2007; Ray et al., 2008).

4.4. Results of brain-imaging studies on nAChRs

Imaging of nicotinic acetylcholine receptors (nAChRs) in the human brain is also an intensively investigated topic in neuroscience. Briefly, PET/SPECT studies have suggested the occurrence of an upregulation of $\alpha 4\beta 2^*$ nAChRs upon chronic nicotine exposure, normalization of $\alpha 4\beta 2^*$ receptor density after a few weeks abstinence in smokers, and nearly complete saturation of brain $\alpha 4\beta 2^*$ receptors during a typical daily pattern of smoking (Mamede et al., 2007; Brody et al., 2006b; Mukhin et al., 2008). Brody et al. (2009a,b) recently showed that smoking a denicotinized cigarette is not associated with pronounced receptor occupancy (Brody et al., 2009a). Therefore, NIC – and not other tobacco smoke ingredients – is responsible for the observed marked nAChR occupancy as a consequence of smoking regular cigarettes (Brody et al., 2009a). PET studies have also found an aging-associated decline in high-affinity nAChR densities in several brain regions (i.e. the thalamus, frontal/temporal/parietal/anterior cingulate/occipital cortex, and striatum), no significant difference in brain $\beta 2^*$ nAChR availability between men and women non-smokers, and no change in $\beta 2^*$ nAChR availability across the menstrual cycle (Brody et al., 2006b, 2009a; Staley et al., 2006; Cosgrove et al., 2007; Mamede et al., 2007; Mitsis et al.,

2008; Mukhin et al., 2008; Ray et al., 2008; Wullner et al., 2008). Preliminary results of a recent PET study by Le Foll et al. (2009) suggested that the baseline density of midbrain $\alpha 4\beta 2$ receptors in squirrel monkeys may affect their motivation to self-administer NIC (Le Foll et al., 2009).

4.5. Neuroimaging studies on smoking-related changes in the dopaminergic system

Several neuroimaging studies were targeted at smoking-associated changes in the dopamine system. Salokangas et al. (2000) found enhanced [^{18}F]fluorodopa uptake in the basal ganglia among smokers, which suggests smoking-related, enhanced dopamine activity in the striatum (Salokangas et al., 2000). Most PET studies using D2/D3 receptor radiotracers [^{11}C]raclopride or [^{18}F]fallypride primarily found decreased radiotracer binding in the ventral striatum (but not in the extrastriatal brain regions) following cigarette smoking or consumption of gum containing NIC, which suggests an NIC-evoked dopamine release in these regions. This contradicts a PET study using [^{11}C]raclopride by Scott et al. (2007) and two SPECT study using [^{123}I]IBZM by Yang et al. (2006, 2008), which showed no difference in D2/D3 density in the striatum between male smokers and non-smokers (Brody et al., 2004b; Brody, 2006; Yang et al., 2006; Scott et al., 2007; Fehr et al., 2008; Takahashi et al., 2008; Yang et al., 2008).

Decreased ventral striatal D2 receptor availability has also been observed in patients with a dependence on other substances of abuse (i.e. alcohol, heroin, cocaine, and methamphetamine), and this change may also be detected after long-term cessation (Fehr et al., 2008; Volkow et al., 2009). The decreased radiotracer binding in bilateral putamen is maintained after a period of overnight abstinence in smokers (Fehr et al., 2008). Negative results in regard to decreased [^{11}C]raclopride binding potential after NIC consumption from animal and human PET studies are also published. However, the low-level of NIC dependence of the probands could bias the results of these studies, since some investigations have suggested that NIC administration in non-smokers is not associated with a significant decrease in radiotracer binding, a phenomenon that could refer to enhanced dopamine release in heavy smokers compared to light (or non-) smokers (Montgomery et al., 2007; Fehr et al., 2008; Takahashi et al., 2008). However, the relationship between the level of NIC dependence and the extent of dopamine release associated with smoking was not replicated by Fehr et al. (2008) in their recent article (Fehr et al., 2008).

According to a current PET study by Brody et al. (2009a,b), NIC is essential in the release of dopamine associated with smoking, while smoking denicotinized cigarettes is associated with a decreased level of dopamine release compared to smoking NIC-containing “normal” cigarettes (Brody et al., 2009b).

Genetic studies suggest that interindividual differences in smoking-related dopamine release is influenced by genetic variants of some genes related to dopaminergic neurotransmission. Individuals with the Val/Val genotype of COMT and/or with the 9-repeat allele for a VNTR in the DAT gene and/or with the short (7-repeat) allele of the dopamine D4 receptor gene VNTR in exon 3 had greater smoking-induced decreases in [^{11}C]raclopride binding potential (as an indirect measure of dopamine release) in the striatum compared to individuals with the alternate genotypes (Brody et al., 2006a; Ray et al., 2008). Furthermore, a recent fMRI study reported that subjects with the Val/Val genotype of a COMT gene polymorphism exhibit better performances in N-back working memory tasks after cigarette smoking than after a 14 h abstinence period. Furthermore they showed a relative decrease in BOLD signal in bilateral DLPFC and dorsal cingulate/medial PFC during the working memory task after the abstinence period (compared to the activation of the affected regions after smoking).

The observed changes in Val/Val carriers were not characteristic of subjects with the Met/Val or Met/Met genotypes of COMT (Loughead et al., 2008).

Striatal DAT density is decreased in smokers compared to non-smokers according to two SPECT studies using [$^{99\text{m}}\text{Tc}$] TRODAT. Because synaptic dopamine concentrations interfere with DAT density, these results are probably the consequence of increased synaptic levels of dopamine (Newberg et al., 2007; Yang et al., 2008). In contrast, in a previous SPECT study, Staley et al. (2001) did not find altered DAT density in the striatum of smokers compared to non-smokers. Discrepant results of this study are possibly due to the decreased selectivity of [^{123}I]β-CIT to DAT compared with [$^{99\text{m}}\text{Tc}$] TRODAT (Staley et al., 2001; Brody, 2006). Dagher et al. (2001) using PET measured decreased striatal D1 receptor binding in smokers, and this result was later affirmed by Yasuno et al. (2007) (Dagher et al., 2001; Staley et al., 2001; Yasuno et al., 2007). The latter study also suggested that after a long-term abstinence period, decreased D1 receptor density could recover (Yasuno et al., 2007). The results of imaging studies on changes in monoamine oxidase (MAO, one of the main dopamine-degrading enzymes) activity in smokers is discussed in chapter 1.2. (Fowler et al., 1996a,b, 2005; McClernon and Gilbert, 2004).

5. Connections between smoking and mental disorders and/or suicidal behavior

5.1. Epidemiology of smoking and nicotine dependence among smokers

Tobacco smoking, a global epidemic, is one of the greatest challenges of our time. Currently about 1.1 billion people are cigarette smokers worldwide, and their consumption is 5.5 trillion cigarettes annually (Jha et al., 2006; Proctor, 2004). Approximately 5 million people are killed a year by tobacco in the world, and the number of annual deaths will increase to 10 million by the year 2030 (Jha et al., 2006; Proctor, 2004).

Based on the National Comorbidity Survey estimates, the risk of becoming tobacco-dependent among smokers (namely among those who have tried tobacco at least once) is 32% higher than corresponding rates for heroin (23%), alcohol (15%) and cocaine (17%) (Anthony et al., 2005; Piasecki, 2006). In prospective studies, rates of relapse (after a smoking cessation attempt) are similar to those found after ending heroin or alcohol consumption, but some retrospective studies may yield more positive results (Caggiula et al., 2001; Henningfield et al., 1991; Piasecki, 2006; Frenk and Dar, 2000; Hughes et al., 2004). In summary, despite the well-known low euphorogenic effects of NIC compared to other drugs, it remains a highly addictive agent (Hughes, 2006; Caggiula et al., 2001; Barr et al., 2008a,b).

Not surprisingly, smokers with NIC dependence have greater mortality than smokers without NIC dependence (Hughes et al., 2006). In their recent review, Hughes et al. (2006) concluded that NIC dependence (based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) criteria) is one of the most frequent (prevalence of lifetime dependence: 19–37%; prevalence of current dependence: 9–13%, in American and German samples) and most fatal psychiatric disorders (30–50% of current smokers will die of a tobacco related disorder) (Hughes et al., 2006; Tonstad and Andrew Johnston, 2006). Surprisingly, their review showed that only about 50% of current smokers fulfilled DSM/ICD criteria for NIC dependence in contrast to previous studies where the prevalence of NIC dependence was approximately 90% among smokers (Hughes et al., 2006). Other authors emphasized that NIC dependence based on DSM-IV criteria is not closely associated with heavy smoking and/or long smoking history (Donny and Dierker, 2007; Dierker

et al., 2007). This problem arises from the generic application of DSM-IV criteria to determine dependence not only for NIC, but for all addictive agents. Some criteria for dependence in DSM-IV, however, are hard to interpret with respect to NIC (Hughes, 2004; Hughes et al., 2006). For example, because NIC is a legal and easily available addictive agent without the propensity to cause acute intoxication, the criterion “a great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects” immediately appears problematic (Hughes, 2004; Hughes et al., 2006). Some other DSM-IV criteria (i.e. “important social, occupational, or recreational activities are given up or reduced because of substance use” and “a need for markedly increased amounts of the substance to achieve the desired effect”) also rarely apply to smokers (Hughes, 2004; Hughes et al., 2006). Because of the known weaknesses of a DSM-IV and ICD-10-based diagnosis of NIC dependence, researchers prefer to use other criteria systems for establishing NIC dependence (Hughes et al., 2006).

5.2. Epidemiology of smoking in psychiatric patients

The smoking rates of patient groups suffering from various psychiatric disorders (e.g. schizophrenia or schizoaffective disorder, major depressive disorder, bipolar or panic disorder, alcohol/opiate/cocaine/cannabis dependence, attention deficit hyperactivity disorder, or posttraumatic stress disorder) are significantly higher than the smoking rates of the general population. Only a few psychiatric disorders, such as obsessive-compulsive disorder, catatonic subtype of schizophrenia, and autism spectrum disorders are associated with lower rates of smoking than in the average population (Zvolensky and Bernstein, 2005; Bejerot and Nylander, 2003; de Leon and Diaz, 2005; Vanable et al., 2003; Hughes et al., 1986; Wu et al., 2006; Dome et al., 2005; Hapke et al., 2005; Fu et al., 2007b; Bejerot and Humble, 1999; Beratis et al., 2001; Shoptaw et al., 2002; Patkar et al., 2006; Littleton et al., 2007; Agrawal et al., 2008; Wilens et al., 2008a,b). Astonishingly, the 7% of the overall population who have both a psychiatric disorder and are nicotine dependent consume 34% of all cigarettes smoked in the USA. Furthermore, individuals with a current psychiatric disorder (with or without NIC dependence) make up 30% of the population and consume 46% of all cigarettes smoked in the USA. These data emphasize the relevance of the comorbidity of NIC dependence and other psychiatric disorders (Grant et al., 2004). Most large-scale population-based studies have found bidirectional predictive associations between the initiation of several forms of mental disorders (primarily affective, anxious, disruptive and substance use disorders were screened in these studies) and smoking, while many kinds of primary mental disorders predict the subsequent onset of smoking, conversely, primary smoking can also predict the subsequent onset of many kinds of mental disorders (Kessler et al., 2007; Breslau et al., 2004a,b; John et al., 2004; Cuijpers et al., 2007; Griesler et al., 2008; Ismail et al., 2000). However, the ability of a mental disorder to predict a substance- (for example NIC) use disorder, has been more strongly substantiated (Kessler et al., 2007; Griesler et al., 2008; Glantz et al., 2009). Moreover, some authors also suggest that the prevalence of anxiety and affective disorders among former smokers is lower than among current smokers. In addition, a subsequent increase in the amount of smoking is more closely associated with a current mental disorder than a remitted one (Breslau et al., 2004b; John et al., 2004; Mykletun et al., 2008).

5.3. Smoking and suicide

A striking connection exists between smoking and suicidal behavior. Epidemiological studies in general and also studies in

psychiatric patient populations suggest that smoking is associated with elevated risks of suicide attempts/ideation and/or completed suicide. Two prospective studies with large samples (50,000 US men and 300,000 US Army male personnel) showed that smoking is a risk factor for completed suicide after controlling for socio-demographic factors, but not for the presence of depression or a previous suicide attempt, two major risk factors for suicide (Miller et al., 2000a,b). Iwasaki et al. (2005), in their large-scale study with prospective design in a sample of Japanese men, also found a positive association between baseline smoking and completed suicide after controlling for some confounders (i.e. alcohol drinking habits, living with spouse, self-reported stress, and physical activity) but the study did not control for psychiatric diagnoses (Iwasaki et al., 2005). Bronisch et al. (2008), in their recent longitudinal study (with a 4-year follow-up period), investigated the smoking-suicide connection from a new perspective, namely the temporal relationship between smoking and suicidality. They found that both occasional smoking and non-dependent regular smoking and, in particular, NIC dependence at baseline were strongly associated with previous suicide ideation and suicide attempts (Bronisch et al., 2008). During the follow-up period, increased risks for new onset of suicide ideation and/or attempts – even after controlling for DSM-IV-based mood disorders – were positively associated with prior occasional and regular smoking (with or without NIC dependence). In contrast pre-existing suicidal ideations or attempts (assessed at baseline) were not associated with elevated risk for first onset of occasional/regular/dependent smoking during the follow-up period (Bronisch et al., 2008).

Tanskanen et al. (2000) in their prospective study also found a dose-dependent relationship between smoking and elevated risk for completed suicide even after adjusting for several confounding factors including “symptoms of depressed mood” and “symptoms of anxiety” (Tanskanen et al., 2000). In a recent longitudinal study by Breslau et al. (2005) the positive association between current daily cigarette smoking, but not past daily smoking, and increased risk for subsequent suicidal thoughts or attempts held even when potential confounding factors (i.e. prior suicidal behavior, current or past major depression, and current or past substance abuse) were taken into consideration (Breslau et al., 2005). Schneider et al. (2005) in their case-control study examined suicide attempters and found that among males, but not among females, current smoking was a risk factor for completed suicide after controlling for psychiatric disorders (Schneider et al., 2005). Riala et al. (2007a) found a similar gender related tendency in the connection between smoking and suicide in their large-scale prospective study. Regular smoking in early adolescence elevated the risk of completed suicide only among males, but it elevated the risk of hospital-treated suicide attempts in both genders (Riala et al., 2007a). Kessler et al. (2008), after a thorough statistical processing of data from the National Comorbidity Survey, reported that the highest level of smoking (early smoking initiation with lifetime NIC dependence, daily use, and dependence) was associated with suicide plans among suicide ideators (but not with other suicide-related outcomes such as suicide gestures or attempts). This result was independent of current smoking status, since among remitted smokers the above association was also detectable (Kessler et al., 2008). According to the authors this refutes a direct causal effect of NIC dependence itself on suicide plans, and instead refers to a causal association between the determinants of NIC dependence and suicide plans (Kessler et al., 2008). In their longitudinal study, Hemmingsson and Kriebel (2003) also found that smoking is a risk factor for suicide, but after the authors adjusted for some potential confounders (i.e. psychiatric diagnoses, “low emotional control”, alcohol consumption and medication for nervous problems, drug use, etc.) the relationship was dissipated and was no longer significant (Hemmingsson and Kriebel, 2003). Kessler et al. (2007)

in their cross-sectional study and Boden et al. (2008) and McGee et al. (2005) in their longitudinal studies also found that while smoking is associated with a higher risk of suicide, after introducing new confounding variables (i.e. mental disorders or low levels of parental attachment) into the statistical analysis or using more sophisticated statistical methods in the processing of data, the positive association between smoking and suicidal behavior vanished (McGee et al., 2005; Boden et al., 2008; Kessler et al., 2007, 2008). Some of the above studies found that current smoking is more strongly associated with suicidal behavior than past smoking (Breslau et al., 2005; Miller et al., 2000b; Iwasaki et al., 2005; Rihmer et al., 2007), but others failed to confirm this result (Kessler et al., 2008). The majority of the above studies found a dose-dependent association between cigarette smoking and suicidal behavior (suicidal behavior was more frequent among heavy smokers than among light smokers) (Miller et al., 2000a,b; Tanskanen et al., 2000; Riala et al., 2007a; Iwasaki et al., 2005; Bronisch et al., 2008; Boden et al., 2008; Schneider et al., 2009). In addition to the results of the surveys discussed above, which were taken in non-clinical populations, the investigations by Tanskanen et al. (1998) and Malone et al. (2003) showed that smoking is also a risk factor for suicidal behavior in adult psychiatric patient populations and a similar result was also found by Rihmer et al. (2007) in a Hungarian adult outpatient population (Tanskanen et al., 1998; Malone et al., 2003; Rihmer et al., 2007). This relationship was observed by Riala et al. (2007b) in an adolescent psychiatric patient population, too (Riala et al., 2007b). In a psychological autopsy study by Schneider et al. (2009), current smoking was associated with an elevated risk of suicide in patients with personality disorders and substance use disorders, but interestingly, current smoking was associated with a decreased risk of suicide among individuals with affective disorders (Schneider et al., 2009). Blood and urine levels of NIC and cotinine were higher among smokers who committed suicide compared with smokers who died of non-suicide-related causes according to an autopsy study. This result suggests that cigarette smokers who have committed suicide smoked more heavily than other cigarette smokers (Moriya et al., 2007).

Different theories exist concerning the background of the connection between smoking and suicide. The common cause hypothesis suggests that smoking is a non-causal marker of elevated risk of suicidal behavior (i.e. both smoking and suicidal behavior have common risk factors, for example mental disorders or more distal causes for which current mental disorders serve as proxies) (Kessler et al., 2007; Hughes, 2008b). The mediation hypothesis states that smoking is a physical/psychological toxin that first leads to mental disorders and after it to elevated risk of suicide (Kessler et al., 2007; Hughes, 2008b). One version of mediation theory raises the possibility that smoking causes physical illnesses and then physical illness(es) increases the risk of suicide. Interestingly, patients with some pulmonary diseases (i.e. asthma and COPD) have an increased risk of mood and anxiety disorders. While cigarette smoking increases the risk of development and/or negatively influences the course of these disorders, the positive association between smoking and mental disorders and suicide may also partially materialize via the lung damaging effects of smoking (Shanmugam et al., 2007; Katon et al., 2007; Hasler et al., 2005; Wagena et al., 2005; Mannino and Buist, 2007; Hughes, 2008b). A third possible explanation of the smoking-suicide connection views smoking as a form of self-medication in an already existing mental disorder (which is a risk factor for suicide) (Hughes, 2008b). Presently, however, the validity of these theories is still uncertain (Hughes, 2008b). According to our current knowledge, the risk of suicidal behavior does not increase during/after cessation. Recently, however, some findings have suggested that the administration of some smoking cessation

medications may elevate the risk of suicidal behavior (Hughes, 2008b; Christensen et al., 2007; McIntyre, 2008).

5.4. Different forms of nicotine administration and the risk of mental disorders

Recently Goodwin et al. (2008) have suggested that the route of NIC administration (smokeless tobacco or cigarette smoking) and NIC dependence (in contrast to non-dependence) have a profound impact on the relationship(s) between mood/anxiety disorders and NIC consumption. These results support the theory that smoking is not just a kind of NIC administration (Goodwin et al., 2008). The study processed data gained from NESARC (National Epidemiologic Survey for Alcohol and Related Conditions) with a representative sample of the adult US population (Goodwin et al., 2008). For subjects with NIC dependence, the use of smokeless tobacco was not associated with an increased likelihood of mood disorders, while smoking was. Interestingly, if subjects were not NIC-dependent, neither the use of smokeless tobacco nor cigarette smoking was associated with an increased likelihood of mood disorders. Among participants with NIC dependence the use of smokeless tobacco or smoking were associated with elevated likelihood of anxiety disorders, but among NIC non-dependent participants neither the use of smokeless tobacco nor smoking were associated with the increased likelihood of anxiety disorders (but NIC non-dependent smoking was associated with elevated risk of panic disorder) (Goodwin et al., 2008). These results suggest that smoking is not only a staggeringly addictive form of NIC consumption (discussed in detail in the chapter “Pharmacology and health consequences of smoking”), but is more closely associated with some forms of mental disorders than other modes of NIC administration (Goodwin et al., 2008).

6. Schizophrenia

6.1. Epidemiology and consequences of smoking in schizophrenia

de Leon and Diaz (2005) in their meta-analysis, which processed smoking epidemiological data of patient populations from different parts of the world, found that patients with schizophrenia have an approximately 5.3 times higher risk of being current smokers and a 3.1 times higher risk of ever smoking than people from the worldwide general population (de Leon and Diaz, 2005). The average current smoking rate was 62% among patients with schizophrenia according to this meta-analysis (de Leon and Diaz, 2005; Chapman et al., 2009). Although the elevated smoking rate in patients with schizophrenia is beyond dispute, a recent article calls attention to a strange publication trend: authors of many research articles or websites often report a more elevated rate of smoking in schizophrenia (“around,” “up to,” or “about” 90%) than was found in the above meta-analysis. These statements are dangerous, as clinicians reading these articles may conclude that almost all patients with schizophrenia smoke and that their smoking is intractable (Chapman et al., 2009).

The elevated smoking frequencies among patients with schizophrenia persists after correcting for such confounding factors as marital status, antipsychotic medication, institutionalization, socioeconomic status or alcohol and drug use (Lyons et al., 2002; Aguilar et al., 2005; Kumari and Postma, 2005). Heavy smoking, high NIC dependence, and lower smoking cessation rates are also more frequent among patients with schizophrenia compared to the general population (de Leon and Diaz, 2005). Furthermore, a recent study by Tidey et al. (2005) found that smokers with schizophrenia smoked cigarettes more “efficiently” compared to the control population (greater number of puffs per cigarette, shorter inter-puff intervals, and larger total cigarette puff

volumes in patients with schizophrenia vs. control) (Tidey et al., 2005). In accordance with this result, most, but not all, studies found that smokers with schizophrenia have higher blood or saliva levels of NIC and/or cotinine compared to controls matched for cigarette consumption (Bozikas et al., 2005; Strand and Nyback, 2005; Williams et al., 2005; Weinberger et al., 2007). An interaction between the metabolism of NIC and antipsychotics is improbable, since NIC is metabolized primarily by CYP2A6 and CYP2B6 enzymes, and these enzymes are not involved significantly in the metabolism of antipsychotics. Consequently, higher NIC levels among patients with schizophrenia are probably not a corollary of antipsychotic medication (Williams et al., 2005). Similar serum 3'-hydroxycotinine to cotinine ratios in patients with schizophrenia or schizoaffective disorder and in controls suggest that differences in the metabolism of NIC by the CYP2A6 enzyme among patients with schizophrenia are also unlikely; thus higher NIC levels in patients with schizophrenia compared to controls matched for cigarette consumption is not a metabolic effect, but the sequelae of the increased NIC intake per cigarette among patients (Williams et al., 2005).

Differences appear to exist between smokers with and without schizophrenia in their motivations to smoke (Gurpegui et al., 2007). Members of the patient group more frequently attributed their desire to smoke to the calming, mood-increasing, concentration- and agitation-heightening effects of smoking than did control persons (Gurpegui et al., 2007). Barr et al. (2008a) in their recent study showed that two motivation factors ("pleasure from the ritual of smoking" and "desire for stimulation") were indicated more frequently by patients than controls, and scores on both these factors were in positive correlation with the chlorpromazine equivalent of the antipsychotic dose given to patients. Consequently, authors have suggested that increased motivation may be a response to counter side-effects of antipsychotic medication (Barr et al., 2008a). Furthermore, some data indicate that patients with schizophrenia are more prone to NIC addiction, while the increased reinforcing effects of smoking were found to be associated with this disorder (Spring et al., 2003; Weinberger et al., 2007).

Smoking initiation in general (on average in 77% of cases) precedes the onset of schizophrenia and unaffected co-twins or siblings of patients with schizophrenia are more often smokers and have more difficulty quitting than controls (Lyons et al., 2002; de Leon and Diaz, 2005; Smith et al., 2008). Furthermore, those patients with schizophrenia who started smoking at least 5 years before beginning psychiatric medication had a higher risk of becoming regular (daily) smoker than normal controls of comparable age (Diaz et al., 2008). In addition, several studies have reported that the level of schizotypy (which is genetically and developmentally linked to schizophrenia and considered a phenotypical variant of schizophrenia) among healthy subjects correlated positively with smoking habits (Kumari and Postma, 2005; Esterberg et al., 2007, 2009). Although, as mentioned above, smoking precedes the onset of schizophrenia in most cases, patients with schizophrenia or who are vulnerable to schizophrenia are more likely to initiate daily smoking after age 20 (when subjects of the general population rarely initiate daily smoking) (de Leon et al., 2002; Gurpegui et al., 2005; Diaz et al., 2008). These data suggest that probably (genetic) vulnerability to schizophrenia rather than schizophrenia per se or the prodromal period of schizophrenia is positively associated with smoking habits (Lyons et al., 2002; de Leon and Diaz, 2005; Kumari and Postma, 2005; Esterberg et al., 2007; Diaz et al., 2008). On the other hand, data are ambiguous about whether smoking status at baseline affects the chances of the onset of schizophrenia in longitudinal studies (Zammit et al., 2003, 2007; Weiser et al., 2004; Wiles et al., 2006).

The mortality rate is higher among patients with schizophrenia. Moreover, in recent decades this mortality gap between the patient and general population has been increasing (Auquier et al., 2006; Saha et al., 2007). Approximately two-thirds of the excess mortality can be accounted for by deaths caused by natural (non-suicide) causes (Goff et al., 2005; Auquier et al., 2006; Saha et al., 2007). Cardiovascular diseases are twofold more frequent among patients with schizophrenia, and are responsible for a large portion of premature deaths among patients (more premature deaths are caused by cardiovascular disorders than suicide in this patient population) (Hennekens et al., 2005). Patients with schizophrenia also have a higher rate of COPD (one of the leading cause of mortality worldwide, and one of its main risk factors is smoking) compared with the general population (Mannino and Kiriz, 2006; Mannino and Buist, 2007; Shanmugam et al., 2007). Because the rate of smoking is so high in individuals with schizophrenia, it is easy to conclude that smoking alongside other highly prevalent cardiovascular risk factors in schizophrenia (i.e. obesity, diabetes mellitus, and hypertension) may be a major cause of premature death in this population (Hennekens et al., 2005; Hennekens, 2007). Furthermore, smoking seems to correlate positively with elevated suicide risk in schizophrenia patient population, as it does in the general population (Miller et al., 2000a,b; Altamura et al., 2003; Potkin et al., 2003; Iancu et al., 2006; Limosin et al., 2007).

6.2. Self-medication theory

Although some kind of "consensus" exists among laymen and psychiatrists that smoking is used as a way of self-medicating in schizophrenia, the following facts contradict this theory. First, there is no significant inverse relationship between smoking and classical symptoms of schizophrenia. Moreover, most studies have found a positive relationship between smoking and the intensity of positive and negative symptoms of schizophrenia (although nAChR agonists could have a beneficial effect on cognitive symptoms of schizophrenia, see below). Second, smoking reduction or cessation in most studies had no major effect on the symptoms of schizophrenia. Third, as mentioned above, smoking precedes the onset of schizophrenia in most cases (de Leon et al., 2006; Esterberg et al., 2007). Since NIC administration causes dopamine release in many parts of the brain, and smoking may decrease dopamine D2 receptor upregulation in the striatum caused by typical antipsychotic medication, another hypothesis suggests that smoking may alleviate extrapyramidal side-effects of antipsychotics (i.e. akathisia, parkinsonism and tardive dyskinesia). Results of epidemiological studies in this regard, however, are ambiguous (in fact, with tardive dyskinesia, smoking seems to be a risk factor rather than a protective factor) (Silvestri et al., 2004; de Leon et al., 2006; Diehl et al., 2009). Nowadays, the role played by the tobacco companies in research on the "self-medication hypothesis" is clear. First, the tobacco industry directly funded research supporting the "self-medication hypothesis". In addition, the tobacco industry also promoted research showing that patients with schizophrenia are less susceptible to the harmful health effects of smoking (Prochaska et al., 2008a).

6.3. The role of antipsychotics in smoking behavior

A complex relationship exists between antipsychotic medication and smoking. Since antipsychotics cause a dopamine receptor blockade which – at least theoretically – dampens NIC-evoked reward, antipsychotics could lead to higher NIC intake (smoking) among patients (Kelly and McCreadie, 2000). This assumption is strengthened by some studies which have found that haloperidol administration leads to increased smoking behavior, although

Brauer et al. (2001) reported the opposite (Brauer et al., 2001). Laviolette and van der Kooy (2003a) described how systemic or intra-NAcc administration of the antipsychotic agent flupenthixol decreased the aversive and increased the rewarding effects of NIC, which suggests that dopamine receptor blockades by antipsychotics can induce a unique phenotype extremely vulnerable to nicotine's rewarding properties (Laviolette and van der Kooy, 2003a).

Another aspect of the interaction between smoking and antipsychotic treatment is the accelerating effect of some ingredients of cigarette smoke (mainly polycyclic aromatic hydrocarbons) on the metabolism of several antipsychotics (i.e. clozapine, olanzapine, members of the phenothiazine group, and haloperidol), although smoking does not significantly change the metabolism of others (i.e. quetiapine, risperidone, ziprasidone, aripiprazole) (Desai et al., 2001; de Leon et al., 2006). Thus, not surprisingly, most investigations show that smoker patients with schizophrenia receive significantly higher neuroleptic doses compared with non-smoker patients with schizophrenia (Aguilar et al., 2005; de Leon et al., 2006).

6.4. Explanatory theories of elevated smoking rates among patients with schizophrenia

Several theories try to explain why smoking is more prevalent among patients with schizophrenia. According to the dopamine hypothesis of schizophrenia, patients with schizophrenia have a hypodopaminergic state in the prefrontal cortex (PFC), which could account for certain characteristic cognitive impairments in this disorder (Lewis and Gonzalez-Burgos, 2006; Guillin et al., 2007). In an animal model of schizophrenia, NIC or nAChR modulator galantamine administration elevated the level of dopamine in PFC, furthermore NIC alleviated impaired working memory in line with the normalization of the dopamine D1 receptor and dopamine levels in PFC. Therefore, molecules with nAChR agonist property may hypothetically restore dopaminergic disturbances in PFC in schizophrenia (Tsukada et al., 2005; Fallon et al., 2007; Schilström et al., 2007).

Excitation of VTA dopaminergic neurons is primarily dependent on glutamatergic innervation from the PFC, and in accordance with this, NMDA administration into the VTA activates the dopaminergic mesocorticolimbic fibers (Nisell et al., 1996; Ikemoto, 2004; Tseng et al., 2006; Wang et al., 2007a). Another theory of schizophrenia suggests a decreased activity of glutamatergic fibers projecting from the PFC onto mesencephalic dopaminergic nuclei (Knott et al., 2006; Lewis and Gonzalez-Burgos, 2006). nAChR agonists activate pre-synaptic $\alpha 7$ -containing nAChRs on glutamatergic terminals in the VTA, resulting in an increased, evoked release of glutamate, which in turn, excites NMDA receptors on dopaminergic neurons in the VTA (Knott et al., 2006; Mansvelder et al., 2006; Fallon et al., 2007; Wang et al., 2007a). In line with this, the non- $\alpha 7$ nAChRs on GABA neurons undergo rapid desensitization within minutes after the start of NIC exposure, and as a consequence, reduce the inhibitory input to the dopaminergic neurons (Mansvelder et al., 2006). These two effects of NIC in the VTA lead to increased burst-firing of dopaminergic neurons and a release of DA in the nucleus accumbens and PFC (Nisell et al., 1996; Knott et al., 2006; Mansvelder et al., 2006; Fallon et al., 2007; Wang et al., 2007a). Moreover, chronic NIC administration upregulates the expression of subunits of NMDA-type glutamate receptor in PFC (where there is reduced NMDA receptor-mediated signaling in schizophrenia), which suggests that chronic NIC administration causes a hyperglutamatergic neurotransmission within the mesocorticolimbic dopaminergic circuitry (Lewis and Gonzalez-Burgos, 2006; Wang et al., 2007a). Another interesting link also exists between glutamate hypothesis

of schizophrenia and NIC. The administration of molecules with NMDA receptor antagonist properties (i.e. ketamine, PCP) is widely known to cause either increased symptom severity among patients with schizophrenia or thought disorders and perceptual distortions among healthy individuals (Lewis and Gonzalez-Burgos, 2006; Pomarol-Clotet et al., 2006). Moreover, kynurenic acid – an endogenous tryptophan metabolite with NMDA receptor antagonist properties – could disrupt auditory gating and prepulse inhibition (see below in details). Furthermore, the brain tissue and cerebral spinal fluid of patients with schizophrenia contained elevated levels of kynurenic acid, which further suggests the relevancy of NMDA antagonists in the pathogenesis of schizophrenia (Shepard et al., 2003; Erhardt et al., 2004, 2007; Chess et al., 2007). Interestingly, kynurenic acid also exhibits antagonist properties on $\alpha 7$ nAChRs, and this activity of kynurenic acid is assumed to lead to working memory deficiency, a classical symptom of schizophrenia (Chess et al., 2007; Lewis and Gonzalez-Burgos, 2006).

6.5. Alterations of the cholinergic system in schizophrenia

The cholinergic system has been extensively researched in schizophrenia (Adams and Stevens, 2007). The number of cholinergic neurons is not altered significantly in the nucleus basalis Meynert, and laterodorsal tegmental nucleus of the brainstem, but is elevated in the pedunculopontine nucleus of the brainstem and decreased in the ventral striatum in patients with schizophrenia compared to controls (Garcia-Rill et al., 1995; Adams and Stevens, 2007; Berman et al., 2007). Cortical cholinesterase and choline acetyltransferase (ChAT) activity is unaltered, but ChAT activity is reduced in the pedunculopontine nucleus of patients with schizophrenia (Garcia-Rill et al., 1995; Berman et al., 2007). In addition, alterations in choline acetyltransferase and acetylcholinesterase activities were also described in the hippocampus, caudate, putamen, nucleus accumbens, thalamus and septal areas in patients with schizophrenia (Karson et al., 1993). nAChRs density changes are commonly reported in schizophrenia (see below). Furthermore, patients with schizophrenia have elevated levels of autoantibodies against many neurotransmitter receptors (i.e. nAChRs) (Margutti et al., 2006; Chandley et al., 2009). Post-mortem autoradiographic studies have revealed disturbances in the expression levels of $\alpha 7$ and $\alpha 4\beta 2$ nAChRs in various cerebral areas of patients with schizophrenia. Results are more certain regarding $\alpha 7$ nAChRs, since most investigations suggest the expression of $\alpha 7$ nAChRs is decreased in the hippocampus, the reticular nucleus of the thalamus, and the prefrontal cortex (Freedman et al., 1995; Court et al., 1999; Guan et al., 1999; Martin-Ruiz et al., 2003; Adams and Stevens, 2007; Olincy and Stevens, 2007). Moreover, Marutle et al. (2001) observed that in the brain of patients with schizophrenia, a reduction in α -bungarotoxin (a ligand with a high affinity for $\alpha 7$ nAChR) binding in the cingulate cortex occurs. In addition, non-significant changes in α -bungarotoxin binding in the orbitofrontal (Br 11, 12, and 47) and posterior temporal (Br 20, 21, and 36) cortex have been described in comparison with controls (Marutle et al., 2001; Martin-Ruiz et al., 2003; Ripoll et al., 2004; Adams and Stevens, 2007). Only two studies did not find significantly decreased $\alpha 7$ antagonist (^3H -methyllycaconitine or ^{125}I - α -BTX) binding in the frontal cortex (Br 8/9 and Br 46), and one of these did not detect any significant decrease in the ^3H -methyllycaconitine binding in the hippocampus (Breese et al., 2000; Adams and Stevens, 2007; Mathew et al., 2007). Although most studies investigating $\alpha 7$ nAChR densities in the brains of patients with schizophrenia had no matched control groups for smoking, this methodological shortcoming probably would not lead to the observed decline in

the density of $\alpha 7$ nAChR, since in patient groups – given the higher prevalence of smoking among patients with schizophrenia (see above) – the expected smoking rates are higher, and should be accompanied by a rise in $\alpha 7$ nAChR density because of smoking-induced receptor upregulation (Freedman et al., 1995; Court et al., 1999). Unfortunately, results of studies that investigated mRNA levels for $\alpha 7$ receptors in different brain regions in schizophrenia are not closely correlated with the results of autoradiographic and western blot studies (Hemby et al., 2002; Martin-Ruiz et al., 2003; De Luca et al., 2006a,b; Adams and Stevens, 2007; Mathew et al., 2007). Three studies did not find any reduction in mRNA levels for $\alpha 7$ receptors in PFC. Furthermore, one study found increased and one study found unaltered mRNA levels for $\alpha 7$ receptor in hippocampal formation or in the adjacent entorhinal cortex among patients with schizophrenia compared to controls (De Luca et al., 2006a,b; Adams and Stevens, 2007; Mathew et al., 2007; Martin-Ruiz et al., 2003; Breese et al., 2000). Decreased $\alpha 7$ nAChR density in the reticular nucleus of the thalamus is thought to possibly lead to hallucinations (Behrendt, 2006). In addition, two selective $\alpha 7$ nAChR agonists (SSR180711 and PNU-282987), like antipsychotics, appear to activate the shell region of NAcc and the PFC – measured by early response gene (c-fos) activation. Both regions are affected in the pathophysiology of schizophrenia, and the activation of NAcc and medial PFC by antipsychotics is considered the basis for their therapeutic effects on symptoms of schizophrenia. This has led to the conclusion that $\alpha 7$ nAChR agonists could be potential antipsychotics (Hansen et al., 2007). Recent investigations of SSR180711 and TC-5619 (a selective $\alpha 7$ agonist) in various animal models of schizophrenia further support this assumption, and there is some suggestion that SSR180711 and TC-5619 may ameliorate cognitive dysfunction (Hashimoto et al., 2008; Barak et al., 2009; Thomsen et al., 2009; Hauser et al., 2009). Recently, Mathew et al. (2007) found an association between the allele and haplotype frequencies of schizophrenia-associated polymorphisms in the neuregulin 1 gene and decreased $\alpha 7$ nAChR expression measured by 125 I- α -BTX binding (parallel with decreased mRNA level for $\alpha 7$ receptor) in the PFC. This result increases the likelihood that $\alpha 7$ nAChR has a role in the pathogenesis of schizophrenia (Mathew et al., 2007). The link between decreased $\alpha 7$ nAChR density and schizophrenia is further supported by the discovery that phencyclidine (PCP) administration (as an experimental model of psychotic states) leads to decreased $\alpha 7$ nAChR expression in the mouse brain (Hashimoto et al., 2008).

Conflicting data are available on the density of $\alpha 4\beta 2$ nAChR in schizophrenia (Adams and Stevens, 2007). Among patients with schizophrenia, the density of the $\alpha 4\beta 2$ receptor is decreased in the hippocampus, no change occurs in the density of high-affinity nAChR in the thalamus, and the direction of change in $\alpha 4\beta 2$ receptor's density in the striatum and the cortex is ambiguous (Freedman et al., 1995; Ripoll et al., 2004; Adams and Stevens, 2007). Breese et al. (2000) described an attenuated upregulation of $\alpha 4\beta 2$ in the hippocampus, thalamus and caudate of patients with schizophrenia who smoke compared to control smokers (Breese et al., 2000). Further results by the same authors suggested that concomitant NIC and antipsychotic (haloperidol) administration-induced nAChR upregulation did not differ significantly from the NIC administration-induced receptor upregulation measured by [3 H]epibatidine binding in the cortex of rats (Breese et al., 2000; Ochoa and Lasalde-Dominicci, 2007). In contrast, Lee et al. (2001) found that NIC and antipsychotic (haloperidol) co-treatment was associated with a decreased $\alpha 7$ nAChR upregulation in the hippocampus and $\alpha 4\beta 2$ nAChR upregulation in the thalamus compared to receptor upregulation induced by NIC treatment alone (Lee et al., 2001).

6.6. Genetic evidence for the role of nAChRs in schizophrenia

As mentioned, genetic investigations suggest that some polymorphisms in the region of the $\alpha 7$ subunit gene (CHRNA7) may be associated with sensory deficits in schizophrenia, while additional linkage of schizophrenia itself to the region 15q13-14 (the chromosomal localization of the $\alpha 7$ subunit gene) has been revealed in most – but not all – of investigated pedigrees (Ripoll et al., 2004; Adams and Stevens, 2007; Ochoa and Lasalde-Dominicci, 2007). In addition, a recent investigation found that a polymorphism (rs3087454) located in a putative repressor region upstream of CHRNA7 was significantly associated with schizophrenia (Stephens et al., 2009). Moreover, De Luca et al. (2006a,b) observed that genetic interaction between the $\alpha 4$ (CHRNA4) and $\beta 2$ (CHRN2) genes was significant in patients with schizophrenia, whereas when the two genes were investigated separately, neither was sufficient to confer susceptibility to schizophrenia (De Luca et al., 2006a,b; Adams and Stevens, 2007). The same investigators also found an association between heavy smoking and a genetic variant of CHRNA4 among patients with schizophrenia, although further studies are needed to confirm these findings (Adams and Stevens, 2007; Voineskos et al., 2007).

6.7. Antipsychotic treatment and the cholinergic system

Antipsychotic treatment has a wide range of effects on the cholinergic system (Terry et al., 2003; Levin et al., 2006; Terry and Gearhart, 2007; Terry and Mahadik, 2007). Although the opinion that second-generation antipsychotics (SGAs) are better than first-generation antipsychotics (FGAs) in point of their beneficial effects on cognition was widely accepted in the past, recent animal studies with long-term antipsychotics administration and some human studies also suggest that both FGAs and SGAs could have deleterious effects on memory functions (Levin and Rezvani, 2007; Terry and Mahadik, 2007). Considering that nicotinic cholinergic systems have an essential role in memory functions, the deteriorating effects of some antipsychotics on memory functions can presumably be linked to their possible actions on nicotinic cholinergic systems (Dani and Bertrand, 2007). Investigations seem to support this assumption. Risperidone significantly decreased the density of $\alpha 7$ nAChR in many brain areas (including in different parts of hippocampal formation) after 180 days of treatment in rats (Terry et al., 2005b). Olanzapine also significantly decreased the density of $\alpha 7$ nAChR in dentate gyrus after 90 (but not after 180) days of treatment (Terry et al., 2005b), while both haloperidol and risperidone decreased $\alpha 7$ nAChR density in other memory-related brain areas (frontal cortex and basal forebrain) after 90 days of treatment (Terry and Gearhart, 2007). Choline acetyltransferase (ChAT) levels are significantly decreased after 90 days of haloperidol treatment in the hippocampus, cortex and striatum in rats (Terry et al., 2003). Risperidone administration after 90 days also decreased ChAT levels in the hippocampus and striatum (but not in the cortex) in rats (Terry et al., 2003), while olanzapine or clozapine treatment for 90 days did not cause diminution in ChAT levels in the hippocampus, cortex and striatum (Terry et al., 2002, 2003). Investigations also showed that representative FGAs (haloperidol and chlorpromazine) and SGAs (olanzapine and risperidone) do not affect high-affinity $\alpha 4\beta 2$ nAChR density in the hippocampal formation, cortex and thalamic nuclei after their long-term (90 or 180 days) administration in rats (Terry et al., 2006; Galletly, 2009).

Another possible link between nicotinic cholinergic systems and antipsychotic treatment is that some antipsychotics, such as clozapine, chlorpromazine, haloperidol and quetiapine were shown to inhibit the function of nAChRs (Grinevich et al., 2009; Xu et al., 2006; Singhal et al., 2007).

6.8. The role of the nicotinic system in sensory processing

Sensory processing deficits have been frequently described in schizophrenia and they are correlated with some impairments commonly reported in schizophrenia patients (i.e. disturbances of thought and attention) (Adams and Stevens, 2007; Martin and Freedman, 2007; Thaker, 2007; Turetsky et al., 2007). Three experimental paradigms (P50 auditory gating test and prepulse inhibition in the acoustic startle test, and eye tracking tests, such as the smooth pursuit eye movement task and antisaccade task) are widely used to assess sensory processing deficits in schizophrenia (for a review, see Zanelli et al., 2005; Turetsky et al., 2007).

The aim of the P50 test is to measure with EEG the blocking of response to an auditory stimulus received immediately after a preceding (conditioning) auditory stimulus. Patients with schizophrenia showed an increased P50 ratio (the amplitude of the P50 to the second (test) stimulus divided by the amplitude of the P50 to the first (conditioning) stimulus) compared to control individuals without schizophrenia (Adler et al., 2004; Martin and Freedman, 2007; Turetsky et al., 2007). This aberration is already present at the first episode of psychosis. Furthermore, family members of patients with schizophrenia also have this aberration (de Wilde et al., 2007; Martin and Freedman, 2007). Impairment in the P50 test suggests that patients with schizophrenia have a decreased ability to filter information, and consequently are flooded by external and internal information, which could lead to personality decompensation (Adams and Stevens, 2007; Turetsky et al., 2007). The primary anatomical correlates of the P50 test are the hippocampus, the PFC and temporoparietal junction (Turetsky et al., 2007). Findings of decreased $\alpha 7$ nAChR density in the hippocampus in schizophrenia suggest that this nicotinic receptor plays an important role in the impairment of auditory gating (Leonard et al., 1998). Results of biochemical and genetic investigations also point to $\alpha 7$ nAChRs as the culprits responsible for impairment in the P50 paradigm of auditory gating among patients (inconsistencies in the results, however, leave open the question of whether variations in the gene encoding this subunit (CHRNA7) alter the risk of schizophrenia) (Leonard et al., 1998; Olincy et al., 2007; Zammit et al., 2007). The role of $\alpha 7$ subunits in schizophrenia is further supported by the results with the DBA/2 mouse strain, which exhibit decreased $\alpha 7$ nAChR expression in the hippocampus and also an impaired auditory gating (Martin and Freedman, 2007). In addition to some antipsychotics (i.e. clozapine and perhaps olanzapine), smoking, NIC-containing patches or gum, and the partial $\alpha 7$ agonist DMXB-A repair P50 deficiencies in schizophrenia (Ripoll et al., 2004; Martin and Freedman, 2007; Turetsky et al., 2007). NIC administration (like clozapine administration) has a positive effect on impaired sensory gating in the DBA/2 mouse strain, too (Levin et al., 2006; Olincy et al., 2007). Some data also point to the involvement of $\alpha 4\beta 2$ nAChRs in the beneficial effect of NIC in the rodent model of auditory gating (Radek et al., 2006). In conclusion, these results suggest that NIC may have beneficial effects on extraneous information filtering in patients with schizophrenia (Olincy et al., 2007).

Patient with schizophrenia also have impairments in prepulse inhibition (PPI), which is a sensory motor gating probe (Thaker, 2007; Turetsky et al., 2007). In PPI, a weak “prepulse” stimulus, which precedes the “pulse” or “startling” stimulus by 30–500 ms, inhibits the motor response of the orbicularis oculi muscle (measured by EMG) to the “pulse” or “startling” stimulus (Kumari and Postma, 2005; Campbell et al., 2007; Thaker, 2007; Turetsky et al., 2007). Deficient (reduced) inhibition associated with the “prepulse” stimulus is reported among patients with schizophrenia and also among their unaffected family members (Kumari and Postma, 2005; Thaker, 2007; Turetsky et al., 2007). This deficiency correlates more strongly with cognitive abnormalities and thought

disorder than with other schizophrenic symptoms (Kumari and Postma, 2005; Thaker, 2007; Turetsky et al., 2007). PPI impairment (like deficiency in the P50 test) also suggests problems of extraneous information filtering (Van den Buuse et al., 2003). NIC corrects PPI deficiency elicited by the NMDA-R antagonist phencyclidine (an agent which is capable of inducing psychotic symptoms) in animal studies and also repairs reduced PPI among patients with schizophrenia (Carls and Ruehter, 2006; Hong et al., 2008).

Abnormal smooth pursuit eye movement (SPEM) is a consistently observed neurophysiologic deficit in patients with schizophrenia and their relatives. Moreover, this impairment is not affected by dopamine D2 receptor antagonist antipsychotics (Tanabe et al., 2006; Thaker, 2007; Lencer et al., 2008), but is also attenuated by NIC administration (by cigarette smoking, NIC patch, or nasal spray) among patients with schizophrenia (Martin and Freedman, 2007). A recent fMRI study by Tanabe et al. (2006) showed that NIC improves abnormal SPEM in schizophrenia through modulation of hippocampal and anterior cingulate activity (Tanabe et al., 2006).

6.9. Nicotinic agents and AChE inhibitors as possible therapeutics for cognitive dysfunctions in schizophrenia

Results of some studies suggest that nAChR agonists may have a therapeutic role in the treatment of cognitive impairments (i.e. disturbances in attention and in verbal, visual and working memories) in schizophrenia, and in turn, smoking abstinence could lead to a deterioration of cognitive functions and psychomotor performance in this patient population (Sacco et al., 2005; Smith et al., 2006; Buchanan et al., 2007; Levin et al., 2006; Barr et al., 2008b). On the other hand, NIC also has beneficial effects on cognitive dysfunctions caused by antipsychotic therapy (Levin and Rezvani, 2006, 2007; Buchanan et al., 2007). Some studies investigating the effect of NIC on cognition have been conducted among smoker patients with schizophrenia; thus the results of these studies could be biased because of withdrawal symptoms and tachyphylaxis (rapidly decreasing response to a drug due to receptor desensitization). Studies investigating non-smoker patients with schizophrenia, however, have found that NIC has beneficial effects on cognitive functions (Harris et al., 2004; Barr et al., 2008b). While the procognitive effects of NIC are limited by tachyphylaxis and the possible toxicity of NIC (and other ingredients of cigarettes when the form of NIC intake is smoking), less toxic and more chronically effective cholinergic treatments are required (Buchanan et al., 2007). For example, the $\alpha 7$ nAChR partial agonist 3-2,4-dimethoxybenzylidene anabaseine (DMXB-A, also known as GTS-21) amended cognitive functions in healthy persons and in various animal models (Martin et al., 2004; Olincy et al., 2007). In a small proof-of-concept trial, the administration DMXB-A had a positive effect on neurocognition in patients with schizophrenia. However, in a later phase-2 trial, investigators did not find any significant improvement in the cognitive functions of patients (but they found that DMXB-A has a therapeutic effect on the negative symptoms of schizophrenia) (Olincy et al., 2006, 2007; Freedman et al., 2008; Galletty, 2009). The procognitive effects of SSR180711 (a partial $\alpha 7$ nAChR agonist) and TC-5619 (a selective $\alpha 7$ agonist) in experimental models of schizophrenia have already been discussed above (Barak et al., 2009; Hauser et al., 2009).

Both nAChR and muscarinic AChRs (mAChRs) are involved in the pathophysiology of schizophrenia, while their agonists – at least in some studies – have procognitive effects in this population. Thus it would be reasonable to conclude that the administration of acetylcholinesterase inhibitors (AChEIs) also has favorable effects on neurocognitive functions in schizophrenia. Unfortunately,

according to the results of clinical studies, this supposed beneficial effect of AChEIs is far from proved (Buchanan et al., 2007, 2008; Chouinard et al., 2007; Green, 2007; Stip et al., 2007; Dyer et al., 2008; Freedman et al., 2008; Sellin et al., 2008; Galletly, 2009). Furthermore, favorable effects of AChEIs on core (positive and negative) symptoms of schizophrenia are also questionable. Only a few studies have suggested that some AChEIs have some beneficial effects on negative symptoms (Akhondzadeh et al., 2008; Buchanan et al., 2008; Conley et al., 2009; Sacco et al., 2008). Galantamine, in addition to its AChEI activity, is also a positive allosteric modulator of the $\alpha 4\beta 2$ and $\alpha 7$ nAChRs. Among AChEIs, galantamine appears superior to donepezil and rivastigmine in its procognitive effect in schizophrenia. Considering these two facts together, it seems likely that the mere inhibition of AChE does not impact on cognitive dysfunctions in schizophrenia, but different kinds of nAChRs may be promising targets for further drug development (Buchanan et al., 2007; Villarroja et al., 2007; Galletly, 2009).

7. Affective disorders

7.1. Bipolar disorder

7.1.1. Epidemiology

Bipolar disorder is a chronic condition with recurring episodes of hypomania/mania and depression (Belmaker, 2004). The lifetime prevalence of bipolar I disorder (major depression with mania) is as high as 2.4%. However, if the bipolar II (major depression with hypomania, but not with mania) and the subthreshold cases were also considered, much higher lifetime prevalence rates of the broadly defined bipolar disorders, up to at least 7.2%, were reported (Rihmer and Angst, 2005). Several epidemiological data have unequivocally shown that the smoking rate among bipolar patients exceeds the smoking rate of the general population. In their classic article, Hughes et al. (1986) found that the prevalence of current smoking in bipolar patients in their psychiatric patient population was approximately 2.5 times higher than the smoking rate of the control population (70% vs. 30%, respectively) (Hughes et al., 1986). Lasser et al. (2000) – using data from the National Comorbidity Survey (a nationally representative sample of U.S. adults) – reported that the prevalence of current and life-time smoking among patients with bipolar disorder was 68.8% and 82.5% respectively (the prevalence of current and life-time smoking was 22.5% and 39.1% in the control population without mental illness) (Lasser et al., 2000). In a sample of psychiatric outpatients, Vanable et al. (2003) found that bipolar patients had higher smoking rates than patients with schizophrenia or major depression (66% vs. 63% vs. 60%, respectively) (Vanable et al., 2003). A recent article by Diaz et al. (2009) has also suggested that patients with a bipolar disorder have higher odds of ever and current smoking than individuals from the general population (Diaz et al., 2009). The association between bipolar disorder and elevated smoking rates is obviously true from the opposing perspective, too. For example, according to data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), an individual with NIC dependence has an approximately four times higher chance of suffering from bipolar-I disorder (Grant et al., 2004). Findings on the smoking rate of bipolar patients in other parts of the world are similar to the US samples. For example, in a Spanish sample, Gonzalez-Pinto et al. (1998) also found a higher life-time and point prevalence of smoking among patients with bipolar disorder compared to the control population, while Itkin et al. (2001) reported that the current smoking rate was 43% in a patient population with bipolar disorder from southern Israel, which was higher than the current smoking rate of control population (27.5%) and it was comparable

to the smoking rate of patients with schizophrenia (45%). A study from Turkey also found higher smoking rates in bipolar patients (55.1%) than in the control population (47.3%) (although the difference was not statistically significant, perhaps because of the relatively small sample size and/or the high smoking rate in the general population). A Hungarian study also reported significantly higher rates of current and ever smoking among bipolar patients compared to the general population (Gonzalez-Pinto et al., 1998; Itkin et al., 2001; Uçok et al., 2004; Dome et al., 2005).

Data on successful cessation rates among patients with bipolar disorder are scarce and ambiguous. Some epidemiological studies have described decreased rates of successful cessation among patients with bipolar disorder, but a naturalistic treatment study did not find a lower quit rate in bipolar patient groups (Diaz et al., 2009; Lasser et al., 2000; Gershon Grand et al., 2007).

7.1.2. Smoking-related changes in clinical characteristics of bipolar disorder

A great number of studies also suggest that smoking habits may significantly influence the clinical characteristics of bipolar disorder. Berk et al. (2008) found that smoker patients with a current episode of mania showed poorer treatment response compared to their non-smoker counterparts. Moreover, they found that non-smokers had a significantly longer time to discontinuation from the trial for any reason (Berk et al., 2008). Waxmonsky et al. (2005) found in their cross-sectional study that bipolar patients who smoke have more (and more serious) previous episodes of both mania and depression compared to non-smokers with bipolar disorder (Waxmonsky et al., 2005). In addition they reported that smoking was positively associated with rapid-cycling, suicidal behavior, psychiatric comorbidity, and the use of alcohol, caffeine, and illicit drugs (Waxmonsky et al., 2005). In a retrospective study authors also found that a life-time history of smoking was significantly related to a more severe course of illness and elevated rates of comorbid psychiatric problems (Ostacher et al., 2006). Goldstein et al. (2008) also found positive relationships between smoking status and the severity of depressive episodes and higher rates of comorbid substance use disorder in a sample of adolescents with bipolar disorder (Goldstein et al., 2008). Some studies suggest that smokers with bipolar disorder are more vulnerable to psychotic episodes than non-smokers, but other studies failed to confirm this association (Waxmonsky et al., 2005; Corvin et al., 2001; Cassidy et al., 2002; Heffner et al., 2008). Not all investigations found similar results to the above; for example Heffner et al. (2008) found no association between smoking status and the severity and characteristics of bipolar disorder (i.e. rapid cycling, symptom severity) in a sample with an early course of bipolar disorder (data collection was conducted at the admission of patients with a first episode of mania) (Heffner et al., 2008). According to scarce data available in the literature, smoking status and cognitive functions are not closely related among bipolar patients (Law et al., 2009). Data are unclear regarding temporal relationships between the initiation of smoking and bipolar disorder. Some studies have found that the onset of smoking precedes the onset of bipolar disorder in most cases, but the results of other investigations do not support this result (Gonzalez-Pinto et al., 1998; Goldstein et al., 2008). Also uncertain is whether smoking is associated with an earlier onset of bipolar disorder (Waxmonsky et al., 2005; Goldstein et al., 2008; Ostacher et al., 2006; Heffner et al., 2008). The role of smoking in an elevated risk of suicide in bipolar disorder is also ambiguous. Some studies found that smoking is associated with a higher risk of suicidal behavior, but other studies have not confirmed this association (Waxmonsky et al., 2005; Goldstein et al., 2008; Ostacher et al., 2006; Neves et al., 2009; Oquendo et al., 2004; Valtonen et al., 2006; Marangell et al., 2006; Galfalvy et al., 2006).

Individuals suffering from bipolar disorder are well known to have an elevated risk of suicide mortality compared to the general population (Pompili et al., 2009). In addition, a recent literature review concluded that sufferers of bipolar disorder have an increased rate of premature death from natural causes (mainly by cardiovascular, respiratory, cerebrovascular, and endocrine disorders), too. Only a few studies have investigated cancer risk in this patient population, and results of these studies are unclear (Roshanaei-Moghaddam and Katon, 2009; BarChana et al., 2008; Carney and Jones, 2006). Results of investigations from different parts of the world suggest that the higher mortality rate in this patient population is a consequence not only of frequent obesity, metabolic syndrome, alcohol and other substance use, and poor diet, but also of smoking (Roshanaei-Moghaddam and Katon, 2009; Garcia-Portilla et al., 2009; Birkenaes et al., 2007; Salvi et al., 2008).

7.1.3. Relationships between the nicotinic system and bipolar disorder

Current knowledge about neurobiological relationships between the nicotinic system and bipolar disorder is scarce. Some findings suggest that patients with bipolar disorder with psychotic episode(s) in their medical history and also their unaffected relatives have deficits in P50 auditory gating (the P50 paradigm is discussed in details in the chapter on schizophrenia) (Schulze et al., 2007; Olincy and Martin, 2005; Hall et al., 2008; Sánchez-Morla et al., 2008). While deficiencies in the P50 response are associated with a potential susceptibility locus on chromosome 15q, which contains the $\alpha 7$ nicotinic receptor subunit gene cluster, the nicotinic system may be involved in the pathophysiology of bipolar disorder (Schulze et al., 2007; Olincy and Martin, 2005; Hall et al., 2008; Sánchez-Morla et al., 2008). The possible role of $\alpha 7$ nAChRs in bipolar disorder is further supported by the altered ratio of $\alpha 7$ and $\alpha 7$ -like mRNA expression levels in the post-mortem prefrontal cortex of bipolar patients compared to controls (De Luca et al., 2006a,b). Genetic studies, however, have not fully supported the association between $\alpha 7$ nAChRs and bipolar disorder, since they have provided equivocal results on the association between genetic variants of the $\alpha 7$ nAChR gene (CHRNA7) and bipolar disorder (De Luca et al., 2006a,b; Serretti and Mandelli, 2008; Flomen et al., 2008; Flomen et al., 2006; Hong et al., 2004; Shi et al., 2007). The association of other nicotinic receptor genes with bipolar disorder has been poorly investigated, and existing results do not support a consistent association (Shi et al., 2007; Serretti and Mandelli, 2008; Lohoff et al., 2005; Kato, 2007).

7.2. Major depression

7.2.1. Epidemiology

Major depression, a serious public health problem associated with an increased risk of disability and mortality (according to estimates by the WHO, depression will be the second leading cause of disability worldwide in 2020), is a common diagnosis worldwide with a life-time prevalence 5–17% (Rihmer and Angst, 2005; Chachamovich et al., 2008; Ebmeier et al., 2006).

Results of epidemiological studies in general and clinical populations suggest a bidirectional positive relationship between smoking and major depression. For example, in the National Comorbidity Survey nearly 60% of individuals with a life-time history of depression were current or past smokers, while only 39% of the general population were current or past smokers (Lasser et al., 2000; Ziedonis et al., 2008). Additionally 16.5% of NIC-dependent individuals suffered from a current episode of major depression in the NESARC investigation, a rate several times higher than the rate of current major depression in the general population (2–7% in studies from different parts of the world) (Rihmer and Angst, 2005; Grant et al., 2004). In clinical smoking treatment studies, the life-time prevalence of major depression was much

higher than in the general population (Covey et al., 1998). In most longitudinal and retrospective studies, smoking at baseline was associated with an elevated rate of onset of depression during the follow-up period, which may suggest that smoking could be a risk factor for depression. Most of these results also suggest that this relationship is more pronounced among females, although a study from Finland found the above association to be true only among males (Ziedonis et al., 2008; Steuber and Danner, 2006; Klungsøyr et al., 2006; Pasco et al., 2008; Pedersen and von Soest, 2009; Munafò et al., 2008; Korhonen et al., 2007; Husky et al., 2008). Conversely, depression may be a risk factor for the progression of smoking (Ziedonis et al., 2008; Pasco et al., 2008; Pedersen and von Soest, 2009). According to the current results of Leventhal et al. (2008, 2009), some depressive symptoms are more strongly linked with nicotine dependence than others (Leventhal et al., 2008, 2009). Namely, symptoms of the melancholic subtype of major depression are associated more strongly with NIC dependence than symptoms of atypical depression (melancholic and atypical depression are DSM-IV-based subtypes of major depression and differ from each other in some of their symptoms) (Leventhal et al., 2008, 2009).

However, data on the effect of depression on the success rate of quitting are mixed. Ziedonis et al. (2008) in a recent review concluded, based on data from smoking cessation trials published from 1988 to 2006, that smokers with a past history of depression have a similar chance of achieving short-term (less than 3 months) abstinence, but a decreased chance of achieving long-term abstinence (more than 6 months). This result pertained only to nonmedicated patients, while “the analysis was restricted to the participants randomized to the placebo or the alternative lowest intensity treatment arm of each study to remove the potential influence of any experimental interventions hypothesized to benefit depressive smokers specifically” (Ziedonis et al., 2008). A previous meta-analysis by Hitsman et al. (2003), which processed data from smoking cessation trials published from 1988 to 2000 and included patients on active arms of studies, concluded that depression history was not a risk factor for relapse. Later, the same authors reanalyzed the data restricting the meta-analysis to participants randomized to the least intensive treatment conditions and again failed to detect a relationship between depression history and relapse (Hitsman et al., 2003, 2004; Ziedonis et al., 2008; Japuntich et al., 2007). However, data on the effect of current depressive episodes on the success of cessation attempts are scarce. Based on the results of three published smoking treatment studies, Ziedonis et al. (2008) concluded that cessation intervention among patients with a current episode of depression resulted in a similar rate of abstinence to that among non-depressed smokers (Ziedonis et al., 2008). Conversely, in a recent study by Japuntich et al. (2007), current depression was a more strong predictor of short-term (1 week), but not long-term (3 months, 6 months) cessation failure than previous episode(s) of depression. Moreover, in a treatment study (NIC replacement therapy (NRT) vs. placebo), individuals on the placebo arm with a current episode of depression at baseline were significantly more likely to smoke at 12 months post-quit compared to non-depressed individuals on NRT or placebo arms or depressed individuals on NRT arm (Japuntich et al., 2007; Kinnunen et al., 2008). In contrast, those patients with a current episode of major depression who successfully stop smoking appear to have a greater chance of mood improvement compared to depressed patients who are unable to achieve abstinence (Blalock et al., 2008; Prochaska et al., 2008b). Additionally, in a recent population-based study authors found that smokers who had unsuccessfully attempted to quit in the past year experienced current depression at a higher rate than either smokers who had not attempted to quit in the past year or former smokers (successful quitters). Moreover, successful

quitters were less likely to be currently depressed than either unsuccessful quitters or non-quitters (McClave et al., 2009). Recurrent depression in medical history appears more closely related to cessation failure than a single episode of major depression (Ziedonis et al., 2008). Post-cessation depressive episodes are more frequent among individuals with previous episode(s) of depression than among individuals without depressive episode(s) in their medical history. Some results also suggest that an elevation in depressive symptoms during cessation is more closely associated with relapse than a baseline level of depression. Ziedonis et al. (2008) in their recent review, however, concluded that “it remains unclear whether depressive episodes during treatment contribute to relapse among depression vulnerable smokers” (Ziedonis et al., 2008; Hughes, 2007; Kinnunen et al., 2008; Catley et al., 2005; Killen et al., 2003). Results also suggest that a past or new episode of depression during cessation are linked to elevated levels of withdrawal symptoms and/or with a prolonged period of withdrawal (Strong et al., 2004; Covey et al., 1990, 1997, 1998; John et al., 2004; Breslau et al., 1992; Thorndike et al., 2008; Weinberger et al., 2009). Also in special populations (for example in patients admitted to hospital with acute cardiovascular events) depression at baseline was a predictor of smoking cessation failure (Thorndike et al., 2008; Perez et al., 2008a,b).

The elevated total (suicide and non-suicide (including cardiovascular)) mortality in patients with major depression is well documented (Surtees et al., 2008; Cuijpers and Schoevers, 2004; Rihmer, 2007; Pozuelo et al., 2009). Although some investigations also suggest that depression could be an “independent” risk factor for cardiovascular disorders and cancer, it is easy to imagine that an elevated rate of smoking in depression may further strengthen the association between depression and the increased risk of mortality (Surtees et al., 2008; Cuijpers and Schoevers, 2004; Pozuelo et al., 2009; Oerlemans et al., 2007).

7.2.2. Explaining theories of elevated smoking rates among patients with major depression

As discussed, results of epidemiological studies clearly suggest an elevated risk of smoking in people with mood disorders. Three explanations have been proposed for this association. The “self-medication theory” supposes that depression leads to smoking because NIC and/or other tobacco smoke ingredients have antidepressant effects, while the second theory holds that smoking and depression have common environmental or genetic risk factors, and the third that depression is the sequelae of smoking (while smoking leads to brain dysfunction) (Duncan and Rees, 2005).

The pathophysiological background of depression seems to be extremely complex. One of the several theories is the cholinergic hypothesis of depression (Picciotto et al., 2008). This is based on the results of the last decades, namely that physostigmine (an acetylcholinesterase inhibitor (AChE-I)) could exacerbate a depressed mood (although some later investigations with other AChE-I-s found the opposite trend) and that elevated choline (the rate-limiting precursor to acetylcholine) levels were found in the brains of patients with depression (Picciotto et al., 2008; Elgamal and MacQueen, 2008; Shytle et al., 2002). The neurobiological link between depression and the cholinergic system is also supported by the potent antidepressant activity of muscarinic antagonist scopolamine (furthermore some tricyclic antidepressant agents also have antimuscarinic actions). Moreover, investigations have found exaggerated neuroendocrine and pupillary responses among patients with mood disorders after administration of cholinomimetic agents. In addition, ACh facilitates the release of several stress-sensitive transmitter molecules (i.e. corticosterone, ACTH, and CRF) (Furey and Drevets, 2006; Shytle et al., 2002). The role of

nAChRs in the pathophysiology of depression at first seems contradictory, since both nAChRs agonists/partial agonists (i.e. NIC, varenicline, cytisine, ispronicline) and nAChRs antagonists (i.e. mecamylamine, dihydro- β -erythroidine, methyllycaconitine) have antidepressant activities in both animal and human investigations (a recent article, however, reports that RJR-2403 ($\alpha 4\beta 2$ -selective agonist) and PNU-282987 ($\alpha 7$ -selective agonist) lack efficacy in the forced swim test and the tail-suspension test in mice) (Picciotto et al., 2008; Philip et al., 2009; Lodge and Li, 2008; Patterson et al., 2009; George et al., 2008; Popik et al., 2003; Vázquez-Palacios et al., 2004; Rabenstein et al., 2006; McClernon et al., 2006; Malpass and Higgs, 2007; Rollema et al., 2009; Andreasen et al., 2008). Also importantly, several members of different families of antidepressants (i.e. amitriptyline, imipramine, fluoxetine, bupropion, nefazodone) have shown remarkable antagonist activity at nAChRs (Shytle et al., 2002; Pacher and Kecskemeti, 2004). The most probable and acknowledged explanation of the above contradiction is a hypothesis stating that the inhibition of nAChRs leads to the antidepressant effects of a given drug. The inhibition of nAChRs may be realized either directly (as in the case of nAChR antagonist administration) or indirectly (as in the case of desensitization of nAChRs as a consequence of nAChR agonists administration (this phenomenon is called functional antagonism)) (Picciotto et al., 2008; Andreasen and Redrobe, 2009; Lodge and Li, 2008; George et al., 2008). The significance of nAChRs in the pathophysiology of depression is further supported by the results of investigations with knock-out (KO) animals. For example $\alpha 7$ or $\beta 2$ KO mice were insensitive to the antidepressant effects of mecamylamine (Rabenstein et al., 2006). In addition, Caltarone et al. (2004) demonstrated that $\beta 2$ KO mice are resistant to the antidepressant effects of the tricyclic antidepressant amitriptyline in three types of behavioral depression models (tail-suspension, forced swim and learned helplessness tests). Moreover $\beta 2$ KO mice were also resistant to amitriptyline-evoked hippocampal cell proliferation (which is also a common marker of antidepressant action); thus these results strongly suggest that the $\beta 2$ subunit is involved in an antidepressant response to amitriptyline (Caltarone et al., 2004; Picciotto et al., 2008; Lodge and Li, 2008). The role of nAChRs in depression is further bolstered by findings that in different kinds of rodent strains (i.e. Flinders Sensitive rats or Fawn-Hooded rats) with depressive features or in rodents after olfactory bulbectomy (as a model of depression), altered neuronal nAChR densities were described (Tizabi et al., 2000; Tizabi et al., 2009; Slotkin and Seidler, 2006). Also remarkably, some antidepressants are effective smoking cessation agents, which suggests that depression and nicotine dependence may share some common neuronal substrates (Picciotto et al., 2008).

Several neurobiological theories have tried to explain the antidepressant impact of NIC (and other nAChRs agonists). For instance, the activation of hippocampal nAChRs (probably the $\alpha 4\beta 2$ isoform) leads to increased neurogenesis in the hippocampus, which is considered a common action of antidepressants, as well. In consonance with this, chronic stress and depression is associated with decreased hippocampal volume (Millan, 2006; Gershon et al., 2007; Banasr and Duman, 2007). The antidepressant effect of NIC may also be linked to the monoaminergic theory of depression, since the activity of monoaminergic systems in the brain are deeply influenced by nAChRs (Andreasen and Redrobe, 2009; Millan, 2006). In this respect, the role of the dopaminergic reward system seems to be of paramount importance, since impaired function of it is associated with depression, and in line with this, smokers with depression may perceive NIC consumption more rewarding than smokers without depression (Spring et al., 2003; Cardenas et al., 2002; Martin-Soelch, 2009). Although results are not fully consistent, the exposure of a stressful environment on animals appears associated with increased, while chronic

administration of antidepressants is associated with decreased activation of the amygdala (measured by c-fos immunoreactivity). Both cytosine (as a partial nAChR agonist) and mecamylamine (a non-selective nAChR antagonist) have antidepressant activities and their administration leads to decreased c-fos expressions in amygdala, which is in consonance with the above findings (Picciotto et al., 2008; Mineur et al., 2007; Cunningham et al., 2008; Roche et al., 2007; Andreasen et al., 2008). Popik et al. (2005) found that the chronic administration of NIC to Wistar rats leads to beta-adrenoceptor down-regulation in the cortex, which is also a common finding after chronic antidepressant treatment, electroconvulsive, and sleep deprivation treatments for depression (Popik et al., 2005; Millan, 2006). As noted previously, smoking is not equivalent to pure NIC administration, since tobacco smoke contains several other bioactive ingredients, some of which (i.e. harman or norharman with MAO inhibitory properties) also may have antidepressant effects (Lewis et al., 2007).

As discussed above, one theory suggests the “depressogenic” effect of some tobacco ingredients is responsible for the frequent co-occurrence of depression and smoking, and there are several results that support this. For example, Malone et al. (2003) reported that cigarette smoking is associated with impaired serotonin function (measured by CSF 5-HIAA levels and the fenfluramine challenge test) in depressed patients (Malone et al., 2003). Acute tryptophan depletion (ATD) has a mood-lowering effect in euthymic individuals with mood disorder in their personal medical history or family history (Spring et al., 2007). Recently, the depression-triggering effect of ATD was shown to be more pronounced in smokers with a history of major depression compared to their non-smoking counterparts (Spring et al., 2007). Chronic stress and depression are associated with the dysregulation of the hypothalamo–pituitary–adrenal (HPA) axis (Carroll et al., 2007). While smoking has a strong influence on the activity of the HPA axis, this effect could be another link between smoking and depression (Badrick et al., 2007; Mendelson et al., 2008; Chen et al., 2008a). Smoking-induced oxidative stress may also be responsible for the frequent co-occurrence of depression and smoking, while it seems obvious that increased oxidative stress occurs in major depression (and antidepressant treatment could reverse this oxidative imbalance) (Zafir et al., 2009; Pasco et al., 2008). Another possible mechanism of smoking-induced depression is related to chronic obstructive pulmonary disease (COPD). Smoking is a clear-cut risk factor for COPD, and the prevalence of depression among individuals with COPD is elevated compared to the general population (Decramer et al., 2008; Agusti and Soriano, 2008). The permanent state of systemic inflammation and/or the chronic hypoxia that are hallmarks of COPD may explain the elevated rate of mood disorders in the COPD population (see details in Decramer et al., 2008). Another theory states that smoking may provoke mood disturbances in smokers because of the appearances of acute NIC deprivation periods several times a day, and – in consonance with this – several studies found that smoking cessation is associated with decreased levels of stress and anxiety in the long run (Parrott, 2006; Aronson et al., 2008). A recent investigation by Aronson et al. (2008) has strengthened this theory, as the authors found – in contrast to the experiences of smokers – that heavy smoking is associated with greater negative affects, and this association is more pronounced on stressful days (Aronson et al., 2008).

As mentioned above, a third theory suggests that a common genetic or environmental vulnerability is responsible for the high co-occurrence of smoking and depression (Ziedonis et al., 2008). This theory is confirmed by twin-studies (Ziedonis et al., 2008; McCaffery et al., 2008; Fu et al., 2007a; Lyons et al., 2008; Korhonen et al., 2007). In conjunction with this, a few studies found that some genetic variations in genes of the dopaminergic pathway or

in the gene of the μ -opioid receptor are associated with smoking-evoked mood effects. Data on the associations between susceptibility to major depression and polymorphisms of genes of nicotinic receptor subunits is scarce (Ziedonis et al., 2008; Perkins et al., 2008; López-León et al., 2008).

Another startling connection between smoking and depression is the association of NIC administration (smoking) during pregnancy and elevated vulnerability to mood disorders in offspring, according to results of both epidemiological studies and animal models. This association could be the consequence of NIC-evoked dramatic changes in the developing nervous system (Fergusson et al., 1998; Paz et al., 2007; Heath and Picciotto, 2009).

8. Alzheimer disease (AD)

8.1. Epidemiology

AD is the most frequent cause of dementia, accounting for 50–60% of all cases (Blennow et al., 2006). Most studies with case-control (retrospective) design have found that smoking is protective against AD, but prospective studies have shown that current, and not former, smoking is a risk factor for AD (Almeida et al., 2002; Reitz et al., 2007; Anstey et al., 2007; Purnell et al., 2009; Peters et al., 2008). The difference between the results of case-control and cohort studies may be due to survival bias, but a theoretical study contradicts this assumption (Almeida et al., 2002; Reitz et al., 2007; Debanne et al., 2007). In addition, in a recent article, authors found that smoking is associated with an elevated risk of AD or dementia only in those prospective studies where participants were younger (55–74 years old) at baseline (but not in those studies where participants were older (more than 75 years) at baseline). Selection bias in prospective studies may account for the above relationship between the age of study participants and the smoking-related risk of AD. Another possible explanation of the result, namely that smoking is harmful at younger ages but beneficial at older ages, was also offered (Hernán et al., 2008).

8.2. Neuropathological findings and alterations of the cholinergic (nicotinic) system in AD

Extracellular β -amyloid senile plaques, intracellular neurofibrillary tangles (NFT, mainly composed of abnormally hyperphosphorylated tau protein), and neuronal loss are hallmark lesions of Alzheimer disease (Silvestrelli et al., 2006; Oddo and LaFerla, 2006).

Several neurotransmitter systems (i.e. noradrenergic, histaminergic, serotonergic, dopaminergic) are affected in AD, but the most consistently described change is the degeneration of the cholinergic system originating in the basal forebrain, i.e. cell loss in the nucleus basalis Meynerti and loss of cholinergic fibers in the cerebral cortex (mainly in temporal and frontal regions) in the hippocampus and amygdala. Moreover, the density of NFT in the nucleus basalis Meynerti is elevated and the ratio of different isoforms of tau protein are altered in AD patients compared to normal subjects (Lyness et al., 2003; Silvestrelli et al., 2006; Hogg and Bertrand, 2004; Carreiras and Marco, 2004; Frölich, 2002; Ladner and Lee, 1998; Mufson et al., 2008; Nelson et al., 2009; Mesulam et al., 2004). Relatively preserved cholinergic innervations of the thalamus (from the brainstem) and the striatum (from striatal interneurons) and some regions of cortex (anterior cingulum, primary visual, somatosensory and motor cortex) were reported in AD (Geula and Mesulam, 1996; Lane et al., 2006). Decreases in the levels of ACh in the cortex and hippocampus, and decreases in the levels of some enzymes of the cholinergic system (i.e. acetylcholine synthesizing enzyme, choline acetyltransferase (ChAT) in the cortex and in the hippocampus; and ACh hydrolyzing

enzyme acetylcholinesterase (AChE) in the cortex) are also described in AD (Silvestrelli et al., 2006; Hogg and Bertrand, 2004; Lanari et al., 2006; Shinotoh et al., 2000; Geula and Mesulam, 1996; Kar and Quirion, 2004; Lane et al., 2004, 2006; Lyness et al., 2003; Carreiras and Marco, 2004; Sivaprakasam, 2006; Nordberg, 2006a,b; Frölich, 2002; Giménez-Llort et al., 2007). The direction of change in the level of high-affinity choline transporters in AD is contradictory, while the expression level of vesicular ACh transporter (VACHT) is not altered in AD (Okuda et al., 2000; Mufson et al., 2008). Decreased ChAT and AChE activities are in significant correlation with cognitive deficit and senile plaque numbers in AD (Hogg and Bertrand, 2004; Kar and Quirion, 2004; Nordberg, 2006a,b; Giacobini, 2003; Giménez-Llort et al., 2007; Perry et al., 1978). Butyrylcholinesterase (BuChE), also called serum cholinesterase or pseudo-cholinesterase, is another important enzyme of the cholinergic system which – like AChE – degrades ACh in the synaptic cleft (Musiał et al., 2007; Lane et al., 2006). In contrast to the level of AChE, the level of BuChE is elevated in the brain during the progression of AD, rendering meaningless the inhibition of AChE in severe AD—whilst activity of AChE is minimal in this stage. The selective inhibition of BuChE, however, could be a good therapeutic target in severe AD (Kamal et al., 2008; Musiał et al., 2007; Giacobini, 2003; Lane et al., 2006; Perry et al., 1978). Interestingly, degeneration of the brain's cholinergic system has also been observed in a number of other disorders with dementia, such as Down-syndrome, olivoponto cerebellar atrophy, Parkinson's disease, Jakob–Creutzfeldt disease, progressive supranuclear palsy, Korsakoff's syndrome, chronic ethanol intake, and dementia pugilistica (Schliebs and Arendt, 2006). Surprisingly, patients with mild cognitive impairment (MCI) – the transition state between cognitive decline due to normal aging and dementia – have elevated levels of frontal cortical and hippocampal ChAT in post-mortem studies, and have unaltered cholinergic innervation (measured by ChAT-immunoreactive fiber and axon varicosity densities) in the superior frontal cortex in contrast to significantly reduced cholinergic innervation of the frontal cortex in AD (Nordberg, 2006a,b; Ikonomic et al., 2007). The above results could suggest that a compensatory upregulation of the cholinergic system may delay the transition of MCI to AD (Nordberg, 2006a,b; Ikonomic et al., 2007).

According to the results of different post-mortem studies, levels of the $\alpha 7$ nAChR protein are reduced or unaltered in the temporal cortex and decreased in the hippocampus of patients with AD, but the mRNA level of the $\alpha 7$ subunit is increased in the hippocampus (Nordberg, 2001; Yu et al., 2005; Guan et al., 2000; Martin-Ruiz et al., 1999). Results regarding the $\alpha 7$ nAChR protein levels in the frontal cortex are also ambiguous (Conejero-Goldberg et al., 2008; Ikonomic et al., 2009). mRNA of the $\alpha 7$ subunit is upregulated in neurons of nucleus basalis in AD (but not in MCI), perhaps as a compensation of decreased cholinergic function. Moreover, the extent of increase in the $\alpha 7$ subunit mRNA level was inversely correlated to cognitive decline, although the upregulation of $\alpha 7$ nAChR could also be dangerous since $\alpha 7$ nAChR interacts with APP and amyloid- β . On the other hand, some results suggest that the administration of $\alpha 7$ agonists/antagonists may be protective against amyloid- β toxicity (Counts et al., 2007; Mufson et al., 2008; Söderman et al., 2008). $\alpha 7$ nAChRs also have a role in cerebrovascular amyloid angiopathy (the deposition of amyloid- β in the cerebral vessel's wall, which is significantly more frequent in AD compared to normal aging), while the expression of $\alpha 7$ nAChRs by smooth muscle cells in the walls of blood vessels may facilitate the selective accumulation of amyloid- β peptides in these cells (Clifford et al., 2008). In mouse models of AD, the expression levels of the $\alpha 7$ nAChR protein/mRNA in the brain are also unclear (levels are elevated in the hAChE-Tg, APP_{SWE}Tg, and APP_{SWE}/hAChE-Tg mouse strains, but decreased in the 3xTG-AD mouse strain)

(Mousavi and Nordberg, 2006; Oddo et al., 2005). $\alpha 7$ nAChR expression of astrocytes appears elevated in both sporadic AD and AD caused by mutation of the APP (Yu et al., 2005). Although the direction of change in the density of $\alpha 7$ nAChRs in AD is uncertain, the $\alpha 7$ KO mouse strain shows impairment in some cognitive domains (i.e. attention, spatial memory, specific types of learning), which suggests the eminent role of this subunit in cognitive functions (Cincotta et al., 2008).

Results regarding $\alpha 4\beta 2$ nAChR are more definite, while most studies found decreased levels of this receptor type in the cortex and hippocampus (Yu et al., 2005; Gotti et al., 2006; Gotti and Clementi, 2004). The mRNA level of the $\alpha 4$ subunit is unaltered in the nucleus basalis in AD (Counts et al., 2007). In a recent study, epibatidine (a potent but non-selective nAChR agonist) binding was decreased in various parts of the cortex (Brodmann areas 38, 39 and 46) in AD but not in MCI compared with control subjects without dementia (Sabbagh et al., 2006; White et al., 2006; Yogeeswari et al., 2006). The loss of nAChRs in post-mortem studies probably does not result from post-mortem artifacts, since PET and SPECT investigations also found decreased levels of (mainly $\alpha 4\beta 2$) nAChRs in frontal, striatal, and medial temporal regions of the brain of AD patients (these changes seem rather characteristic of moderately severe AD and not mild AD) (Sabbagh et al., 2006; Oddo and LaFerla, 2006; Sabri et al., 2008; O'Brien et al., 2007; Ellis et al., 2008). Interestingly, two neuroimaging studies found a decreased level of $\alpha 4\beta 2$ nAChR in patients with MCI (it is mentionable that the levels of high-affinity nAChRs are decreased during normal aging, too, in various cortical and subcortical areas according to previous post-mortem studies and a recent SPECT study) (Sabri et al., 2008; Mitsis et al., 2008; Terrière et al., 2008). C^{11} -nicotine binding in the brain, measured by PET, has a significant negative correlation with cognitive performance in AD (Kadir et al., 2006; Nordberg et al., 1995). In accordance with the decreased number of high-affinity nAChRs in AD, $\beta 2$ knock-out mice show increased deficit in memory functions and increased cell loss in the hippocampus after intrahippocampal excitotoxic lesion. Moreover, the hippocampal remodeling after exposure to an enriched environment was decreased in the $\beta 2$ -/- strain (Zanardi et al., 2007).

Many other interesting aspects of the link between cholinergic system and AD exist. For example, β -amyloid can bind to $\alpha 7$ and $\alpha 4\beta 2$ nAChRs. Furthermore, β -amyloid peptide can upregulate the expression of AChE. This can lead to decreased levels of acetylcholine, and consequently to impaired cholinergic neurotransmission. In addition, AChE can bind to β -amyloid ($A\beta$ -AChE complexes are more toxic than $A\beta$ fibrils alone). Moreover, AChE in this complex has elevated V_{max} and K_m values and has a decreased affinity to AChEIs, and is more resistant to the inhibitory effect of a high substrate concentration. Furthermore, according to results of PET and cell-culture studies, AChEI treatment has effects on nAChR density, while some forms of AD treatment (i.e. ginkgo biloba extract) may have a favorable effect on the non-amyloidogenic way of amyloid precursor protein (APP) processing. Also, activation of muscarinic M1 receptors promotes non-amyloidogenic processing of APP and decreases the hyperphosphorylation of tau protein, while chronic exposure to $A\beta$ in vitro leads to upregulation of $\alpha 7$ nAChRs. Finally, peptide fragments from the C-terminus of the tailed (synaptic) isoforms of AChE have a striking homology and structural similarity to β -amyloid. These peptides bind to $\alpha 7$ nAChRs and alter the affinity of $\alpha 7$ nAChRs to their natural ligands and also upregulate $\alpha 7$ nAChRs. All the interactions mentioned above, however, are too complex to be discussed in detail here (Lane et al., 2006; Oddo and LaFerla, 2006; Liu and Wu, 2006; Dineley, 2007; Small et al., 2007; Kadir et al., 2008; Kadir et al., 2007; Nordberg, 2006a,b; Colciaghi et al., 2004; Inestrosa et al., 2008; Fisher, 2007; Bond et al., 2009; Greenfield et al., 2004; Perry et al., 2004).

8.3. Smoking effects on nAChR expression in AD

Smoking has various effects on nAChR expression in AD. Mousavi et al. (2003) found that the $\alpha 4$ nAChR subunit protein is significantly upregulated in the temporal cortex, while the $\alpha 7$ nAChR subunit protein showed a quasi significant upregulation in same region in AD patients who smoke compared to non-smoker AD patients. Protein levels of $\alpha 3/\alpha 4/\alpha 7$ nAChR subunits in the hippocampus, however, were independent of smoking status in AD patients (Mousavi et al., 2003; Picciotto and Zoli, 2008). In this study, the levels of $\alpha 3/\alpha 4$ but not $\alpha 7$ nAChR subunit proteins in the temporal cortex and all investigated receptor subunit ($\alpha 3/\alpha 4/\alpha 7$) proteins in the hippocampus in AD patients who smoke are still lower than levels in non-smoker and non-demented controls (Mousavi et al., 2003; Picciotto and Zoli, 2008). In accordance with the above results, cytosine (a $\alpha 4$ ligand) binding was higher in smokers with AD compared to non-smokers with AD in the temporal cortex, but not in the hippocampus or frontal cortex (Hellstrom-Lindahl et al., 2004). α -bungarotoxin (an $\alpha 7$ ligand) bindings were not significantly different in the frontal and temporal cortex or in the hippocampus of smokers with AD compared to non-smokers with AD (Hellstrom-Lindahl et al., 2004).

8.4. Effects of smoking or pure nicotine administration on AD pathology

Several studies have investigated the influence of smoking on AD pathology, but found inconsistent results. Court et al. (2005) demonstrated less β -amyloid pathology in the entorhinal cortex of smokers compared with non-smokers in a sample of elderly subjects free from neurological or psychiatric disorders. In this study, tau-type pathology was independent of smoking status (Court et al., 2005). Ulrich et al. (1997) found decreased senile plaque numbers in smokers compared with non-smokers in females, but also found a more severe NFT pathology in both sexes among smokers in an unselected sample of elderly subjects (Ulrich et al., 1997; Court et al., 2005; Oddo and LaFerla, 2006). Sabbagh et al. (2005) did not find an effect of smoking on neuropathologic markers (neuritic plaque and NFT numbers) in the mid-frontal cortex in an AD sample (Sabbagh et al., 2005). Perry et al. (2000) found that smokers have a diminished senile plaque formation in the entorhinal cortex and hippocampus, but NFT formation did not differ between smokers and non-smokers in an elderly population without dementia (Perry et al., 2000). Tyas et al. (2003) did not find a strong relationship between smoking and tau pathology, but did find that the numbers of neuritic plaque increased in the neocortex and hippocampus in current and former smokers. Interestingly, in very heavy smokers the plaque number was diminished in both the hippocampus and neocortex compared with heavy and medium smokers (Tyas et al., 2003; Oddo and LaFerla, 2006). Hellstrom-Lindahl et al. (2004) found that the levels of both soluble and insoluble A β 40 and A β 42 were significantly lower in the frontal and temporal cortex (but not in the hippocampus) of smokers without dementia compared with non-smokers without dementia. Among AD patients, levels of both insoluble and soluble A β 40 and A β 42 were significantly reduced in the frontal cortex of smokers compared with non-smokers, but in the temporal cortex and hippocampus only levels of insoluble and soluble A β 40 (but not soluble or insoluble A β 42) were significantly reduced in smokers with AD compared with non-smokers with AD (Hellstrom-Lindahl et al., 2004; Court et al., 2005). Hellström-Lindahl et al. (2008) have demonstrated that smoking status does not affect neprilysin (one of the main enzymes involved in β -amyloid degradation) levels in the brain of either patients with AD or control individuals; thus the lower levels of β -amyloid do not appear linked to an elevated level of amyloid degradation in smokers (Hellström-Lindahl et al., 2008).

In different mouse models of AD (i.e. using APP_{swe} or hAChE-Tg/APP_{swe} or J20 triple-APP mutation strains) the effect of chronic NIC administration on beta-amyloid pathology is ambiguous (Hedberg et al., 2008; Unger et al., 2006; Sabbagh et al., 2008).

Amyloid plaques arise from amyloid monomers through dimers, oligomers, protofibrils and fibrils in a multistep process called aggregation (Finder and Glockshuber, 2007). In vitro studies suggest that NIC binds directly to β -amyloid in its α -helical conformation and retards the amyloid aggregation process by inhibiting an α -helix $\rightarrow$ β -sheet conformational transformation of β -amyloid. Moreover NIC could disassemble the preformed amyloid fibrils and also facilitate – via both $\alpha 7$ and $\alpha 4\beta 2$ nAChRs – the non-amyloidogenic alpha-secretase cleavage of the amyloid precursor protein (APP), which would release soluble sAPP α (considered neuroprotective) (Oddo and LaFerla, 2006; Unger et al., 2006; Estrada and Soto, 2007; Pogocki et al., 2007; Nordberg, 2006a,b; Mousavi and Hellström-Lindahl, 2009). Nicotine – a major NIC metabolite – also binds to the β -amyloid peptide, which leads to the inhibition of amyloid aggregation (Dickerson and Janda, 2003; Oddo and LaFerla, 2006). NIC could also indirectly inhibit the formation of toxic β -amyloid fibrils via elevation of the transthyretin (TTR) levels in CSF (Raghu and Sivakumar, 2004). TTR could bind soluble β -amyloid and thereby prevent β -amyloids from aggregating to form toxic fibrils (Estrada and Soto, 2007; Raghu and Sivakumar, 2004; Sousa et al., 2007; Liu and Murphy, 2006). NIC may attenuate neurotoxic effects of extracellular β -amyloid via the facilitation of extracellular A β internalization and degradation in autophagic processes (Hung et al., 2009).

Unfortunately NIC has unfavorable effects on tau pathology as demonstrated by in vivo and in vitro animal studies (Oddo and LaFerla, 2006). For example, chronic administration of NIC (5 months via the drinking water) to 3xTG-AD mice resulted in elevated levels of tau phosphorylation, probably via the activation of p38-mitogen-activated protein kinase (Oddo et al., 2005). Furthermore, two in vitro studies have found similar results. In one of these two studies, Hellström-Lindahl et al. (2000) demonstrated that NIC or epibatidine (a non-selective nAChR agonist) treatment of the human neuroblastoma cell line SH-SY5Y led to an increased level of tau protein and also enhanced levels of tau phosphorylation (Hellström-Lindahl et al., 2000; Oddo and LaFerla, 2006). The other study found that NIC or A β 42 (as a ligand for nAChRs, see above) or epibatidine administration-induced tau phosphorylation in SK-N-MC neuroblastoma cell line and in hippocampal synaptosomes. The effect of A β 42 on tau phosphorylation was blocked by $\alpha 7$ antagonist pretreatment, suggesting a critical role for $\alpha 7$ nAChRs in A β 42-induced tau phosphorylation. Results also suggested that proteins of the mitogen-activated protein kinase cascade (i.e. extracellular receptor kinases and c-Jun N-terminal kinase) play a role in the $\alpha 7$ nAChR-mediated A β 42-induced tau phosphorylation (Wang et al., 2003; Oddo and LaFerla, 2006). In partial contrast to previous reports, Bitner et al. (2009) found that $\alpha 7$ agonist administration may also be protective against tau hyperphosphorylation. They found that the administration of a selective $\alpha 7$ agonist (A-582941) leads to the inhibition of glycogen synthase kinase3 β (GSK3 β)-mediated tau phosphorylation (Bitner et al., 2009). Recently, results of a human study by Chalmers et al. (2009) have further supported the possibility that the facilitation of the cholinergic transmission in the brain may lead to increased tau pathology (in this investigation the amount of hyperphosphorylated tau in the cerebral cortex of AD patients treated with AChEI was higher than had untreated AD patients) (Chalmers et al., 2009).

8.5. Smoking and cognitive decline

Many investigations found that chronic smoking accelerates cognitive decline (measured by a variety of markers of cognitive

function, i.e. working, arithmetic and prospective memory, auditory-verbal learning, psychomotor speed or cognitive flexibility) (Swan and Lessov-Schlaggar, 2007; Durazzo and Meyerhoff, 2007). Several factors could explain the link between tobacco smoking and the higher risk of cognitive decline. For instance, tobacco smoke contains lead, and chronic lead exposure is a well-known risk factor for cognitive deterioration. Another ingredient of tobacco smoke, cadmium, also has neurotoxic properties. Furthermore smokers have decreased levels of circulating antioxidants (vitamin C, carotene α and β , cryptoxanthin), and oxidative stress is closely linked to AD. Impaired lung function (a consequence of tobacco smoking) presents yet another risk state for cognitive decline. Smoking also seems to be a risk factor for silent and symptomatic vascular intracerebral lesions and decreased brain volume (Swan and Lessov-Schlaggar, 2007; Min et al., 2007). Although the accelerating effects of smoking on the development of AD and – principally – of cognitive decline generally appear unambiguous, NIC and some other agonists of nicotinic receptors have neuroprotective effects in many in vitro and in vivo models of neurotoxicity. NIC, however, could be toxic under some circumstances, mainly in during the administration of high doses or continuous administration, and especially during administration for developing neurons (Picciotto and Zoli, 2008; Egea et al., 2007; Shin et al., 2007; Shimohama et al., 1998). A wide range of mechanisms may underlie the neuroprotective effects of NIC (i.e. upregulation of growth factor (NGF and FGF-2) pathways, inhibition of apoptosis, oxidative stress reduction via different mechanisms, and influencing intracellular calcium dependent events). Moreover, NIC has a direct influence on AD pathology (see above) (Picciotto and Zoli, 2008; Pogocki et al., 2007; Dajas-Bailador and Wonnacott, 2004).

8.6. Nicotinic agents as possible therapeutics for cognitive decline in AD

The relevance of nAChRs in cognitive functions is bolstered by the results of studies with $\alpha 7$ or $\beta 2$ subunit knock-out rodent strains and by the detrimental effects of nAChR antagonists on cognitive functions in animal and human studies (Cincotta et al., 2008; Newhouse et al., 2001). Although the impact of NIC on cognition in healthy individuals is doubtful, among patients with neurodegenerative diseases NIC clearly may have beneficial effects on cognitive functions (Sacco et al., 2004). A variety of investigations have studied the effects of administering NIC and $\alpha 7$ or $\alpha 4\beta 2$ nAChR agonists (i.e. ABT-418, GTS-21, ispronicline (TC-1734)) on cognition in AD, MCI, and age-related cognitive decline. The results of these studies suggest that NIC has a more pronounced ameliorating effect on attention than memory performances in AD (Oddo and LaFerla, 2006; Levin et al., 2006). ABT-418 (an $\alpha 4\beta 2$ agonist) has ameliorating effects on cognitive functions (i.e. on verbal and spatial learning) in AD (Pogocki et al., 2007; Sacco et al., 2004). Ispronicline (a partial $\alpha 4\beta 2$ agonist) and NIC have favorable effects on cognitive functions in age-associated cognitive decline (Newhouse et al., 2004b; Dunbar et al., 2007). nAChR agonist treatment is probably more efficacious in MCI than in AD because nAChRs are preserved in MCI to a greater extent than in AD (Newhouse et al., 2004b).

8.7. Genetic findings

Several studies have explored the genetic background of the relationship between the cholinergic system and AD (Vasto et al., 2007; Cook et al., 2004). Investigations into the association between $\alpha 4$ subunit gene polymorphisms and AD have obtained dubious results. Studies of the associations between AD and polymorphisms in either gene encoding choline acetyltransferase

(ChAT) or gene encoding butyrylcholinesterase (BuChE) have had similarly unclear outcomes (Vasto et al., 2007; Serretti et al., 2007; Piccardi et al., 2007). A recent study has shown that a genetic variation in the $\alpha 7$ subunit (CHRNA7) gene is associated with the risk of AD. An association between the presence of the T allele in the polymorphic site rs6494223 of the CHRNA7 gene and the risk of delusional symptoms in AD was also discovered by the same authors (Carson et al., 2008a,b). A noncoding polymorphism in the gene encoding $\beta 2$ subunit was also observed to be significantly associated with susceptibility to AD (Cook et al., 2004).

9. Attention-deficit/hyperactivity disorder

9.1. Epidemiology

Attention-deficit/hyperactivity disorder (ADHD) is known to affect approximately 5–10% of children and continues into adulthood at a considerably high rate (range: 5–70%) among those who were diagnosed in childhood. Prevalence of ADHD is estimated at 3–5% of the adult population (Kalbag and Levin, 2005; Biederman, 2005). ADHD is highly comorbid with other psychiatric disorders such as anxiety, mood, and antisocial disorders in the adult population and anxiety, mood, conduct, and oppositional defiant disorders in the child/adolescent population (McGough et al., 2005; Biederman, 2005; Wilson and Levin, 2005).

Never-treated adults with ADHD are twice as likely to develop a substance use disorder (SUD), and if they have a comorbid bipolar disorder or juvenile conduct disorder, then the likelihood increases further. Moreover, children with ADHD have a four times greater risk of developing an SUD by adulthood (16% vs. 4% of control subjects) (Wilson and Levin, 2005; Wilens, 2006). Conversely, alcohol and drug dependent adolescents and adults suffer more often from ADHD than members of the general population (Gordon et al., 2004; Wilson and Levin, 2005; Wilens, 2004). ADHD itself appears to be a risk factor for later SUD, with a worse outcome, greater severity, longer duration, and more rapid transition from substance use to abuse and dependence (Wilens, 2006; Faraone et al., 2007; Wilson, 2007). High rates of ADHD have been reported in first-degree relatives of individuals with SUD and vice versa: parents of children with ADHD have an elevated risk for SUD (Wilson and Levin, 2005; Wilens, 2004, 2006).

Not only SUD in general, but smoking in particular is more common in both adolescent (19.0–46% vs. 10–24% for ADHD and non-ADHD) and adult (41–42% vs. 26% for ADHD and non-ADHD) ADHD populations. In addition, patients with ADHD are more likely to initiate smoking earlier than control persons (Humfleet et al., 2005; Monuteaux et al., 2007; Fuemmeler et al., 2007; McClernon and Kollins, 2008; Wilens et al., 2008b). Although ADHD is a risk factor for smoking even after controlling for confounding variables (i.e. psychiatric comorbidity), the increased risk of smoking is further elevated in the presence of comorbid conduct disorder, major depression, bipolar and anxiety disorders (Humfleet et al., 2005; Wilens et al., 2000; Molina and Pelham, 2003; Milberger et al., 1997). Moreover, smokers with ADHD compared with non-smokers with ADHD are at greater risk for subsequent use of other addictive agents besides NIC. In other words, NIC seems to be a gateway drug among patients with ADHD (Biederman et al., 2006b). Additionally, some results suggest that smokers with ADHD have elevated levels of NIC dependence compared to control smokers and the severity of ADHD is positively associated with the extent of smoking (but results are not completely clear in this regard) (McClernon and Kollins, 2008; Wilens et al., 2008b).

Quitting rates are lower among both adult and adolescent patients with ADHD than among patients without ADHD. Hyperactivity/impulsivity symptoms seem to be associated more strongly with cessation failure than inattention. Moreover, some

results suggest that quitting is associated with more severe withdrawal symptoms and disturbances in cognitive functions in ADHD populations (but results regarding the severity of withdrawal symptoms are not totally conclusive) (Humfleet et al., 2005; Upadhyaya, 2006; Pomerleau et al., 1995; McClernon et al., 2008b; McClernon and Kollins, 2008; Covey et al., 2008). Importantly, increases in attention deficit and hyperactivity–impulsivity symptoms measured by a self-report checklist during smoking cessation (with nicotine replacement therapy) predict the increased likelihood of relapse (Rukstalis et al., 2005).

Not only clinical diagnosis of ADHD, but symptoms of ADHD correlate positively with smoking in nonclinical (community) samples (Kollins et al., 2005; Fuemmeler et al., 2007; Barman et al., 2004; Lerman et al., 2001; Tercyak et al., 2002; McClernon and Kollins, 2008). There is some debate in the literature over whether hyperactivity/impulsivity or inattention is primarily accountable for elevated smoking rates in ADHD (and whether they increase the chance of NIC-dependence to a different extent in adolescence and young adulthood) (Burke et al., 2007; Diamond, 2005; Elkins et al., 2007; Rodriguez et al., 2008).

9.2. Neurobiological explanations of frequent co-occurrence of ADHD and smoking

There are numerous explanations for the elevated rate of smoking among patients with ADHD. First of all, the mechanism underlying NIC's ability to reduce symptoms of ADHD may be similar to that of medications (psychostimulants, atomoxetine and bupropion) used to treat this disorder, since they all have enhancing effects on dopaminergic and/or noradrenergic systems, which may suggest that smoking is a way of self-medicating in this patient population (Solhkhah et al., 2005; Wilens et al., 2005a,b; Sacco et al., 2004; Hahn and Stoleran, 2005; Cao et al., 2005a,b).

Elevated slow-wave (delta–theta) activity (the EEG sign of reduced arousal) is commonly described in children, adolescent, and adult populations with ADHD. This electrophysiological aberration could refer to decreased cholinergic activity, which may partially explain both the effectiveness of nicotinic agonists in the therapy of ADHD and the increased risk of smoking in ADHD (Rowe and Hermens, 2006). Furthermore, a reduction in the amplitude of the P300 wave is a frequently reported electrophysiological alteration in ADHD and nicotinic agonists are also known to increase P300 amplitude (Rowe and Hermens, 2006).

Furthermore, the possibility of a common genetic background accountable for the high comorbidity of smoking and ADHD may also emerge (Laucht et al., 2007; McClernon and Kollins, 2008). Most genetic investigations have found that some polymorphisms of the $\alpha 4$ nAChR subunit gene (CHRNA4) are associated with ADHD, while investigated polymorphisms of the CHRNA7 gene are not (Waldman and Gizer, 2006; McClernon and Kollins, 2008; Wallis et al., 2008). In addition, the smoking rate was found to be significantly higher among subjects who carried the A2 allele in *Taq1A* DRD2 polymorphism and exhibited at least six symptoms of hyperactivity–impulsivity than among carriers of the A1 allele; this result offers further support for a genetic explanation of the association between smoking and ADHD (McClernon and Kollins, 2008). The hypothesis that nicotinic receptors may play role in the pathophysiology of ADHD is strengthened by the presence of some symptoms of ADHD (such as inattention, lack of inhibitory control and hyperactivity) among $\beta 2$ nAChR subunit KO mice. This mouse strain could thus serve as an animal model of ADHD (Granon and Changeux, 2006).

Previous studies showed that NIC exposure during pregnancy and/or postnatal parental smoking appear to be risk factors for ADHD in offspring, but some contradictions exist between survey results (Linnet et al., 2005; Langley et al., 2005; Kollins et al., 2009;

Button et al., 2005; Thapar et al., 2003; Banerjee et al., 2007; Obel et al., 2009). This relationship is also influenced by genetic susceptibility (i.e. carriers of some genetic variations of DAT1 or DRD4 or CHRNA4 genes are more susceptible than non-carriers of these polymorphisms) (McClernon and Kollins, 2008). However, a very recent result seems to refute the causal relationship between prenatal exposure to tobacco smoke and elevated risk of ADHD. Thapar et al. (2009), with a clever experimental design, found that maternal smoking during pregnancy was a much stronger predictor of ADHD in offspring in genetically related mother–offspring pairs compared to genetically unrelated mother–offspring pairs (in the latter case, mothers conceived through assisted reproduction technologies (i.e. oocyte donation or embryo donation)). This result suggests that the previously described association between in utero exposure to tobacco smoke ingredients and elevated risk of ADHD is mainly attributed to inherited factors and not to the harmful effects of tobacco smoke per se (Thapar et al., 2009).

Neuroimaging (PET, MRI, SPECT) studies have shown that striatal structures could be involved in the pathophysiology of ADHD (Krause et al., 2006). Although results are far from unequivocal, most studies have found an elevated expression of dopamine transporter (DAT) – expressed mainly in the striatum – among patients with ADHD compared to controls. This is especially true for those patients with ADHD who respond well to stimulant therapy (Krause et al., 2003, 2006; Madras et al., 2005; Hesse et al., 2009; Krause, 2008). It is important to note that smoking decreases DAT density among patients with ADHD, as do psychostimulants used to treat this disorder (Krause et al., 2003, 2006; Krause, 2008). DAT knockout mice have been found to exhibit striking, spontaneous behavioral hyperactivity, while psychostimulants have had an ameliorating effect on this KO strain (Mehler-Wex et al., 2006). Both these findings are at odds with the theory of increased DAT density in ADHD.

Although in non-ADHD samples, investigations have found that psychostimulant (methylphenidate or d-amphetamine) treatment increased ad libitum smoking, many studies of patients with ADHD have shown that stimulant (but not bupropion) treatment decreased the risk of SUD in general and smoking in particular (but some studies achieved the opposite results) (Rush et al., 2005; Wilens et al., 2008a, 2003; Whalen et al., 2003; Upadhyaya et al., 2005; Wilson and Levin, 2005; Wilens, 2006; Monuteaux et al., 2007; Cousins et al., 2001; Huizink et al., 2009; Huss et al., 2008; Katusic et al., 2005). In accordance with these results, there is some evidence from animal studies too that the treatment of adolescent rats with psychostimulant may reduce the risk of later SUD (Carlezon et al., 2003).

9.3. Nicotinic agents and AChE inhibitors as possible therapeutics for ADHD

Based on the above facts and the essential role played by the (nicotinic) cholinergic system in attention, motivation and cognitive functions, NIC can be assumed to have a possible therapeutic effect in ADHD (Sacco et al., 2004; Sarter et al., 2006; You et al., 2008; Inglis and Winn, 1995). According to this assumption, NIC and in some studies selective $\alpha 4\beta 2$ nAChR agonists (ABT-418 and ABT-089) have beneficial impacts on behavioral symptoms of ADHD and/or ADHD-related cognitive disturbances (measured by behavioral inhibition, delay aversion and sustained attention tasks) (Gehricke et al., 2006; Potter and Newhouse, 2004, 2008; Poltavski and Petros, 2006; Wilens et al., 2005a,b; Wilens and Decker, 2007; Levin et al., 2006; Potter et al., 2006). Studies investigating the effect of AChE inhibitors (donepezil or galantamine) on symptoms of ADHD have yielded inconsistent results (Wilens et al., 2005a; Doyle et al., 2006; Yoo

et al., 2007; Biederman et al., 2006a). The importance of cholinergic system in ADHD is further supported by recent data demonstrating that atomoxetine (an approved therapy for ADHD) increases cholinergic neurotransmission in cortical regions, and accordingly enhances memory functions measured by radial arm-maze and object recognition tests in rats (Tzavara et al., 2006).

10. Parkinson's disease (PD)

10.1. Epidemiology of smoking in PD

Most epidemiological studies (both with case–control and prospective design) and meta-analyses show that smokers present a lower risk of developing Parkinson's disease (PD), although some studies could not confirm this inverse relationship (Allam et al., 2002, 2004; Grandinetti et al., 1994; De Michele et al., 1996; Liou et al., 1997; Hellenbrand et al., 1997; McCann et al., 1998; Ritz et al., 2007). A recent preliminary study has shown that passive smoking could also protect against PD (Mellick et al., 2006). Two twin studies and one family-based study also support the inverse relationship between smoking and PD (Wirdefeldt et al., 2005; Tanner et al., 2002; Scott et al., 2005). The onset of PD symptoms, the time of diagnosis of PD, and the time at which levodopa treatment is introduced occurred at an older age in ever-smoking group compared with never-smoking group according to a recent investigation (although two other studies failed to find a relationship between smoking and later onset of PD) (De Reuck et al., 2005; Alves et al., 2004; Papapetropoulos et al., 2005). Another recent case–control study suggests that the protective effects of smoking, coffee drinking, and nonsteroidal anti-inflammatory drug (NSAID) consumption on the risk of PD are cumulative (Powers et al., 2008).

10.2. Regulation of the nigrostriatal pathway by nAChRs

NIC is important in promoting the release of DA in the nigrostriatal pathway, either by stimulation of dopaminergic neurons of the substantia nigra through its receptors (with $\alpha 6\alpha 4\beta 2\beta 3$ or $\alpha 6\beta 2\beta 3$ or $\alpha 7$ or $\alpha 4\beta 2$ subunit compositions) on cell bodies, or through its receptors (with $\alpha 6\beta 2^*$ ($\alpha 6\alpha 4\beta 2^*$ or $\alpha 6(\text{non}\alpha 4)\beta 2^*$) and $\alpha 4\beta 2^*$ ($\alpha 4\beta 2$, $\alpha 4\alpha 5\beta 2$, $\alpha 4\alpha 2\beta 2$) subunit compositions) on dopaminergic nerve terminals in the striatum ($\alpha 7$ receptors are not present on striatal dopaminergic terminals) (Gotti and Clementi, 2004; Matsubayashi et al., 2004; Quik and McIntosh, 2006; Quik, 2004; Quik et al., 2007; Huang et al., 2009). Not only NIC but its main metabolite, cotinine, also has a dopamine-releasing effect in the nigrostriatal system (O'Leary et al., 2008).

The proportion of $\alpha 6\beta 2^*$ and $\alpha 4\beta 2^*$ receptors on striatal dopaminergic terminals is species dependent; in primates the larger proportion of these receptors are $\alpha 6\beta 2^*$ while in rodents it is $\alpha 4\beta 2^*$. Accordingly, during low-frequency firing of dopaminergic cells, dopamine release was mainly regulated by $\alpha 3/\alpha 6\beta 2^*$ receptors in the primate dorsal and ventral putamen. During burst firing, both $\alpha 3/\alpha 6\beta 2^*$ and $\alpha 4\beta 2^*$ regulate dopamine release in the ventral putamen, but neither of them regulate dopamine release in the dorsal putamen (Gotti and Clementi, 2004; McCallum et al., 2005; Quik et al., 2008; Perez et al., 2009). Elements of other transmitter systems that influence the activity of the nigrostriatal system contain nAChRs, too. For example, $\alpha 7$ receptors are found on glutamatergic nerve endings in striatum, $\alpha 4\beta 2$ and $\alpha 7$ receptors on cholinergic interneurons of the striatum, and $\alpha 6\alpha 4\beta 2$ and $\alpha 7$ and $\alpha 4\beta 2$ receptors on GABAergic neurons of the striatum (Gotti and Clementi, 2004; Quik and McIntosh, 2006; Quik, 2004). Results of experiments with different nAChR subunit knockout mice strains also support the role of

nAChRs in the regulation of nigrostriatal dopaminergic activity, and show that receptors containing $\alpha 6$, $\alpha 4$, $\beta 2$ subunits are essential to NIC-evoked dopamine release in rodent striatum (Quik and McIntosh, 2006).

10.3. Neuropathological findings and alterations of the nicotinic system in PD

PD is a neurodegenerative disorder mainly characterized by degeneration of dopaminergic neurons in the substantia nigra and VTA with consequential dysfunction of the nigrostriatal and mesocorticolimbic pathways (Bosboom et al., 2004). Non-dopaminergic nuclei (i.e. serotonergic dorsal raphe nuclei or noradrenergic locus coeruleus) are also involved in the pathological process (Bosboom et al., 2004; Fornai et al., 2007; Zarow et al., 2003). Furthermore, the appearance of Lewy bodies (one of the pathological hallmarks of PD) and/or cell loss have been described in cholinergic nuclei (i.e. nucleus basalis (n. Meynert) and pedunculopontine nucleus) in PD (Bosboom et al., 2004; Zarow et al., 2003; Pahapill and Lozano, 2000; Jellinger, 1988). In addition, the pedunculopontine nucleus may play a role in the pathogenesis of some symptoms of PD (e.g. the degree of akinesia is associated with the extent of cholinergic cell loss in the pedunculopontine nucleus) and deep brain stimulation of this area seems to be effective in alleviating some symptoms of PD (Pahapill and Lozano, 2000; Nandi et al., 2002; Plaha and Gill, 2005; Winn, 2008).

Neuronal nAChR densities appear to be decreased among patients with PD in various areas of their brain. NIC binding was decreased in an autoradiography study by Court et al. (2000) in the postmortem caudatum and putamen of patients with PD (Court et al., 2000). Recently, three studies using PET or SPECT and iodinated or fluorinated derivatives of A-85380 as radioligands for $\beta 2$ subunit containing nAChRs (i.e. $\alpha 4\beta 2$, $\alpha 3\beta 2$ and $\alpha 6\beta 2$ receptors) investigated the densities of nAChRs in patients with PD. All of the studies have found that the densities of the $\beta 2$ subunit containing nAChRs were reduced in cortical and/or subcortical regions (i.e. striatum and substantia nigra) in non-demented PD patients compared to age-matched control individuals (Kas et al., 2009; Fujita et al., 2006; Oishi et al., 2007; Ward et al., 2008). Two studies using postmortem PD brains found that the A-85380 uptake was diminished in the striatum and thalamus, indicating $\alpha 4\beta 2$ receptor loss in these structures (Schmaljohann et al., 2006; Pimlott et al., 2004). α -conotoxinMII (which interacts with receptors containing $\alpha 3$ and $\alpha 6$ subunits) binding is decreased in the caudate and putamen of patients with Parkinson's disease (Quik et al., 2004). In contrast to previous studies, Martin-Ruiz et al. (2000) did not find changes in the expression level of $\alpha 3$, $\alpha 4$, $\alpha 7$, and $\beta 2$ subunits in the putamen of patients with PD (Martin-Ruiz et al., 2000). In the cerebral cortex of patients with PD, $\alpha 4$ and $\alpha 7$ subunit protein levels are decreased (Burghaus et al., 2003). The protein level of the $\alpha 7$ subunit did not show a decrease in the caudatum or hippocampus in patients with PD. Furthermore, the level of the $\alpha 7$ subunit was increased in the temporal cortex of patients with PD compared to control subjects (Guan et al., 2002; Ward et al., 2008). Densities of $\alpha 2$ – $\alpha 6^*$ (but not $\alpha 7$) nAChRs in the striatum are decreased in experimental animal models of PD too (i.e. in MPTP-lesioned primates and rodents), which further supports the role of nAChRs in the pathophysiology of PD (Quik, 2004). Different kinds of nAChRs in the striatum are also different in their vulnerability to nigrostriatal damage. $\alpha 6\beta 2^*$ receptors appear particularly vulnerable (within this group $\alpha 6\alpha 4\beta 2^*$ receptors are more vulnerable than the $\alpha 6(\text{non}\alpha 4)\beta 2^*$ subtype), while $\alpha 4\beta 2^*$ receptors are less vulnerable (i.e. their number is decreased only after severe nigrostriatal damage) (Huang et al., 2009; Bordia et al., 2007). In addition, $\alpha 6\alpha 4\beta 2^*$ and $\alpha 6(\text{non}\alpha 4)\beta 2^*$ receptors also differed from each other in their expression level

after chronic NIC treatment: $\alpha 6(\text{non}\alpha 4)\beta 2^*$ receptors were upregulated, while $\alpha 6\alpha 4\beta 2^*$ were downregulated after long-term NIC administration in striatum (Perez et al., 2008a,b).

10.4. Neuroprotective effects of nicotine and other tobacco smoke ingredients in PD

The results of recent examinations suggest that striatal $\alpha 4\beta 2^*$ and $\alpha 3/\alpha 6\beta 2^*$ nAChR loss following experimental nigrostriatal damage could be prevented by long-term NIC administration before experimental lesion. Furthermore, NIC pretreatment is associated with a lesser dopaminergic dysfunction (measured by striatal tyrosine hydroxylase, dopamine transporter, vesicular monoamine transporter and dopamine levels) in the striatum after MPTP lesions in squirrel monkeys (Bordia et al., 2006; Quik et al., 2006; Huang et al., 2009). During high-dose (up to 105 mg/day) and long-term NIC therapy in patients with PD the dopamine transporter binding (measured by SPECT) in the basal ganglia decreased less than expected given the results of previous studies in PD patients without NIC treatment. This suggests that NIC-administration may lead to diminished striatal neuronal loss during the progression of PD (Itti et al., 2009). NIC also attenuates 6-hydroxydopamine (6-OHDA)-induced nigrostriatal neurodegeneration (6-OHDA administration is another experimental model of PD in addition to MPTP administration) (Grunblatt et al., 2000; Costa et al., 2001; Ryan et al., 2001). NIC is also protective against nigral dopaminergic nerve cell degeneration in a mechanically induced degeneration of the dopaminergic system (Janson and Moller, 1993; Janson et al., 1994). In addition, NIC may attenuate the salsolinol-induced apoptosis in a neuroblastoma cell population served as a model of the nigral dopaminergic cell population (salsolinol, a dopamine derivative with a selective toxic effect on the nigrostriatal dopaminergic system, has elevated concentrations in the liquor, brain tissue, and urine among patients with PD, and consequently, may be a possible marker of PD) (Copeland et al., 2007; Mravec, 2006). Furthermore, chronic NIC administration in rats slowed age-associated dopaminergic receptor loss in the nigrostriatal system (Prasad et al., 1994). A recent investigation concluded that NIC has more neuroprotective than neuroregenerative effects in experimental lesion models of PD in rodents and primates, while NIC administration protects against nigrostriatal damage (measured by changes in densities of nAChRs and dopamine transporter and behavioral deficits after lesion) only when given prior to lesioning, but not after nigrostriatal damage (Huang et al., 2009). NIC may be protective against PD via mechanisms other than direct control of the nigrostriatal dopamine pathway, since NIC has several kinds of neuroprotective properties. For example, NIC has direct antioxidant activity, moreover the activation of nAChRs may increase the expression of neurotrophic factors. In addition, NIC modulates the activity of the mitochondrial complex I of the electron transport chain which results in a reduction in reactive oxygen species production. Finally, NIC has anti-inflammatory effects (Quik, 2004; Mudo et al., 2007; Imamura et al., 2006; Xie et al., 2005; Park et al., 2007). Recently, NIC and another cigarette smoke component (hydroquinone) were also shown capable of inhibiting the process of α -synuclein fibrillation (Lewy bodies contain ubiquitin and fibrils of α -synuclein) (Hong et al., 2009a; Bisaglia et al., 2009). Inhibitors of α -synuclein fibrillation may be potential therapeutic agents for the prevention or control of PD (Hong et al., 2009a).

Other compounds in cigarette smoke besides NIC could be protective against PD. For example, some MAO enzyme inhibitors (harman, norharman, 2,3,6-trimethyl-1,4-naphthoquinone, 2-naphthylamine, and farnesylacetone) are found in cigarette smoke, and MAO inhibition is one known way to achieve symptomatic relief in PD (Herraziz and Chaparro, 2005; Khalil et al., 2006).

Hydralazine, another component of cigarette smoke, has a significant effect in protecting dopaminergic nigrostriatal neurons from damage by MPTP (De Reuck et al., 2005). The elevated expression of some CYP enzymes (CYP2D6, CYP2E1, CYP2B6) in the brain as a consequence of exposure to components of cigarette smoke (including NIC) could be another mechanism of the peculiar neuroprotection offered by smoking, since these enzymes metabolise many xenobiotics (i.e. MPTP and related structures) that can cause PD-like syndromes (Miksys and Tyndale, 2006).

10.5. Nicotinic agents and AChE inhibitors as possible therapeutics for PD: results of clinical and animal studies

Although data from epidemiological investigations have identified mainly inverse relationships between smoking and PD, results of studies looking at the efficacy of NIC treatment on symptoms of PD are disappointing. Vieregge et al. (2001) investigated the effectiveness of transdermal NIC patches as an add-on treatment for symptoms of PD in their double-blind placebo-controlled trial and found no significant beneficial drug effects on motor and affective symptoms (Vieregge et al., 2001). Similarly, two other studies concluded that NIC administration is ineffective in treating either motor or cognitive deficits of PD (Clemens et al., 1995; Lemay et al., 2004; Allam et al., 2002). NIC treatment worsened motor symptoms of PD in one study (Ebersbach et al., 1999). Furthermore, SIB-1508Y, an $\alpha 4\beta 2$ nAChR agonist agent (previously found effective in improving motor performance, attention, and alertness in animal models of PD), did not show beneficial effects on motor and cognitive disturbances of patients with PD (Parkinson Study Group, 2006). These findings are in accordance both with observations of no beneficial disease-modifying effects of smoking among patients with already diagnosed PD (i.e. among those who continued smoking after their diagnosis) and with the above discussed results from experimental animal models of PD by Huang et al. (2009) (Alves et al., 2004; Kandinov et al., 2007). Moreover, a recent prospective study found that current smoking (compared with non-smoking) at PD onset is associated with a more rapid cognitive deterioration in accordance with results of two previous cohort studies (Weisskopf et al., 2007; Ebmeier et al., 1990; Levy et al., 2002). The symptom-alleviating effect of NIC is also contradictory in animal models of PD, although some results from both primate and rodent models of PD show that NIC may reduce L-DOPA-induced dyskinesias or L-DOPA-induced cognitive deficits (L-DOPA is the gold standard for treating PD) (Quik et al., 2007; Bordia et al., 2008; Janhunen and Ahtee, 2007; Abdel-Salam, 2008; Decamp and Schneider, 2009). In partial contrast to the results discussed above, some case-reports and studies found that NIC has symptom-alleviating and cognition-improving effects in PD. Furthermore, a recent investigation found evidence that long-term and high-dose NIC administration is required to attain beneficial effects on symptoms of PD (Hanagasi et al., 2007; Kelton et al., 2000; Fagerstrom et al., 1994; Ishikawa and Miyatake, 1993; Villafane et al., 2007).

Evidence of serious cholinergic deficits in PD have raised the possibility that AChE-inhibitor therapy may be effective in the treatment of cognitive deterioration, which is very frequently associated with PD (Oertel et al., 2008). Placebo-controlled studies with donepezil and rivastigmine found that these two agents improve cognitive deficits without significant long-term worsening of motor symptoms in PD (Grace et al., 2009; Dodel et al., 2008; Oertel et al., 2008). In contrast, a recent study found that non-demented PD patients treated with galantamine (an agent with both AChE inhibitor and nAChRs allosteric modulator properties) did not show improvement in various aspects of cognition (i.e. attention, memory, visuospatial performance). Moreover, the rate of self-reported worsening of PD symptoms was higher in the

treatment arm compared to the placebo arm (Grace et al., 2009; Razay and Wilcock, 2008).

11. Discussion

Smoking is the most frequent and also the most harmful form of NIC consumption. In addition, NIC from tobacco smoke – based on the pharmacological properties of smoking – is extremely addictive compared to NIC from other possible sources (i.e. NIC replacement products). Considering the ubiquitous presence of nAChRs in various parts of the central nervous system, NIC not surprisingly has diverse effects on various brain functions, and influences the activity of several neurotransmitter systems. Moreover neuroimaging studies have found smoking-associated functional and structural changes in the brain. Strong epidemiological data suggest that smoking rates are higher among individuals with different kinds of psychiatric disorders compared to the general population. Furthermore, subjects with a current psychiatric disorder consume a disproportionately large part of tobacco products. Replicated findings suggest that smoking may be an independent risk factor for suicide. A growing body of results indicates that smoking may alter the clinical features of neuropsychiatric disorders and may also be partially responsible for elevated non-suicide mortality in patients with some of these diseases. Several possible mechanisms may explain the disease-modifying effects of smoking. First of all, pharmacological evidence points to the involvement of nAChRs in the regulation of different neural circuits. Second, changes in different levels of the cholinergic system (enzymes, transporters, and receptors) are described in neuropsychiatric disorders. Third, genetic findings indicate that some polymorphisms of nAChR genes are associated with an altered risk of both neuropsychiatric disorders and smoking behavior. In addition, not only NIC but some other ingredients of tobacco smoke are also known to have various direct neuroactive effects too. Because of the close relationship between the (nicotinic) cholinergic system and neuropsychiatric disorders, and also the possible role of self-medication in the elevated smoking rates in these disorders, several nicotinic agents were tested for therapeutic efficacy, and some were found to be useful in the treatment of these states. Finally, it should be mentioned that tobacco smoke contains many compounds (i.e. polycyclic aromatic hydrocarbons, carbon monoxide, and heavy metals) that either stimulate or inhibit CYP450 enzymes, so pharmacokinetic interactions between smoking and psychopharmacological agents are frequent and are worth considering (Zevin and Benowitz, 1999; Desai et al., 2001).

Acknowledgement

Author Peter Dome was supported by the Norwegian Financial Mechanism (HU0125) during the time of writing this paper.

References

- Abdel-Salam, O.M., 2008. Drugs used to treat Parkinson's disease, present status and future directions. *CNS Neurol. Disord. Drug Targets* 7, 321–342.
- Adams, C.E., Stevens, K.E., 2007. Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. *Front. Biosci.* 12, 4755–4772.
- Adinolfi, B., 2004. Neurobiological processes in drug reward and addiction. *Harv. Rev. Psychiatry* 12, 305–320.
- Adler, L.E., Olincy, A., Cawthra, E.M., McRae, K.A., Harris, J.G., Nagamoto, H.T., Waldo, M.C., Hall, M.H., Bowles, A., Woodward, L., Ross, R.G., Freedman, R., 2004. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. *Am. J. Psychiatry* 161, 1822–1828.
- Agrawal, A., Lynskey, M.T., Pergadia, M.L., Bucholz, K.K., Heath, A.C., Martin, N.G., Madden, P.A., 2008. Early cannabis use and DSM-IV nicotine dependence: a twin study. *Addiction* 103, 1896–1904.
- Aguilar, M.C., Gurpegui, M., Diaz, F.J., de Leon, J., 2005. Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions. *Br. J. Psychiatry* 186, 215–221.
- Agusti, A., Soriano, J.B., 2008. COPD as a systemic disease. *COPD* 5, 133–138.
- Akhondzadeh, S., Gerami, M., Noroozian, M., Karamghadiri, N., Ghoreishi, A., Abbasi, S.H., Rezazadeh, S.A., 2008. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 32, 1810–1815.
- Akiyama, H., Meyer, J.S., Mortel, K.F., Terayama, Y., Thornby, J.L., Konno, S., 1997. Normal human aging: factors contributing to cerebral atrophy. *J. Neurol. Sci.* 152, 39–49.
- Alderson, H.L., Latimer, M.P., Winn, P., 2006. Intravenous self-administration of nicotine is altered by lesions of the posterior, but not anterior, pedunculopontine tegmental nucleus. *Eur. J. Neurosci.* 23, 2169–2175.
- Alkondon, M., Albuquerque, E.X., 2006. Subtype-specific inhibition of nicotinic acetylcholine receptors by choline: a regulatory pathway. *J. Pharmacol. Exp. Ther.* 318, 268–275.
- Allam, M.F., Del Castillo, A.S., Navajas, R.F., 2002. Smoking and Parkinson's disease. *Eur. J. Neurol.* 9, 315–316.
- Allam, M.F., Campbell, M.J., Hofman, A., Del Castillo, A.S., Fernandez-Crehuet Navajas, R., 2004. Smoking and Parkinson's disease: systematic review of prospective studies. *Mov. Disord.* 19, 614–621.
- Almeida, O.P., Hulse, G.K., Lawrence, D., Flicker, L., 2002. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. *Addiction* 97, 15–28.
- Almeida, O.P., Garrido, G.J., Lautenschlager, N.T., Hulse, G.K., Jamrozik, K., Flicker, L., 2008. Smoking is associated with reduced cortical regional gray matter density in brain regions associated with incipient Alzheimer disease. *Am. J. Geriatr. Psychiatry* 16, 92–98.
- Altamura, A.C., Bassetti, R., Bignotti, S., Pioli, R., Mundo, E., 2003. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. *Schizophr. Res.* 60, 47–55.
- Alves, G., Kurz, M., Lie, S.A., Larsen, J.P., 2004. Cigarette smoking in Parkinson's disease: influence on disease progression. *Mov. Disord.* 19, 1087–1092.
- Ambrose, J.A., Barua, R.S., 2004. The pathophysiology of cigarette smoking and cardiovascular disease: an update. *J. Am. Coll. Cardiol.* 43, 1731–1737.
- Amos, C.I., Wu, X., Broderick, P., Gorlov, I.P., Gu, J., Eisen, T., Dong, Q., Zhang, Q., Gu, X., Vijayakrishnan, J., Sullivan, K., Matakidou, A., Wang, Y., Mills, G., Doheny, K., Tsai, Y.Y., Chen, W.V., Shete, S., Spitz, M.R., Houlston, R.S., 2008. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nat. Genet.* 40, 616–622.
- Amtage, F., Neugebauer, B., McIntosh, J.M., Freiman, T., Zentner, J., Feuerstein, T.J., Jackisch, R., 2004. Characterization of nicotinic receptors inducing noradrenaline release and absence of nicotinic autoreceptors in human neocortex. *Brain Res. Bull.* 62, 413–423.
- Andreasen, J.T., Redrobe, J.P., 2009. Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. *Behav. Brain Res.* 197, 150–156.
- Andreasen, J.T., Olsen, G.M., Wiborg, O., Redrobe, J.P., 2008. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. *J. Psychopharmacol.* [Epub ahead of print].
- Anstey, K.J., von Sanden, C., Salim, A., O'Kearney, R., 2007. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. *Am. J. Epidemiol.* 166, 367–378.
- Anthony, J.C., Chen, C.Y., Storr, C.L., 2005. Drug dependence epidemiology. *Clin. Neurosci. Res.* 5, 55–68.
- Arias, H.R., Bhumireddy, P., 2005. Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. *Curr. Protein. Pept. Sci.* 6, 451–472.
- Aronson, K.R., Almeida, D.M., Stawski, R.S., Klein, L.C., Kozlowski, L.T., 2008. Smoking is associated with worse mood on stressful days: results from a national diary study. *Ann. Behav. Med.* 36, 259–269.
- Attwood, A.S., Penton-Voak, I.S., Munafò, M.R., 2009. Effects of acute nicotine administration on ratings of attractiveness of facial cues. *Nicotine Tob. Res.* 11, 44–48.
- Auquier, P., Lancon, C., Rouillon, F., Lader, M., Holmes, C., 2006. Mortality in schizophrenia. *Pharmacoepidemiol. Drug Saf.* 15, 873–879.
- Ayers, J.T., Xu, R., Dwoskin, L.P., Crooks, P.A., 2005. A general procedure for the enantioselective synthesis of the minor tobacco alkaloids nornicotine, anabasin, and anabatin. *AAPS J.* 7, E752–E758.
- Badrick, E., Kirschbaum, C., Kumari, M., 2007. The relationship between smoking status and cortisol secretion. *J. Clin. Endocrinol. Metab.* 92, 819–824.
- Baird, W.M., Hooven, L.A., Mahadevan, B., 2005. Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. *Environ. Mol. Mutagen* 45, 106–114.
- Baker, R.R., 1987. A review of pyrolysis studies to unravel reaction steps in burning tobacco. *J. Anal. Appl. Pyroly.* 11, 555–573.
- Baker, E.R., Zwart, R., Sher, E., Millar, N.S., 2004a. Pharmacological properties of alpha 9 alpha 10 nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras. *Mol. Pharmacol.* 65, 453–460.
- Baker, T.B., Brandon, T.H., Chassin, L., 2004b. Motivational influences on cigarette smoking. *Annu. Rev. Psychol.* 55, 463–491.
- Balbani, A.P., Montovani, J.C., 2005. Methods for smoking cessation and treatment of nicotine dependence. *Rev. Bras. Otorrinolaringol.* 71, 820–827.
- Banasr, M., Duman, R.S., 2007. Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. *CNS Neurol. Disord. Drug Targets* 6, 311–320.
- Banerjee, T.D., Middleton, F., Faraone, S.V., 2007. Environmental risk factors for attention-deficit hyperactivity disorder. *Acta Paediatr.* 96, 1269–1274.

- Barak, S., Arad, M., De Levie, A., Black, M.D., Griebel, G., Weiner, I., 2009. Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. *Neuropsychopharmacology* 34, 1753–1763.
- BarChana, M., Levav, I., Lipshitz, I., Pugachova, I., Kohn, R., Weizman, A., Grinshpoon, A., 2008. Enhanced cancer risk among patients with bipolar disorder. *J. Affect. Disord.* 108, 43–48.
- Barman, S.K., Pulkkinen, L., Kaprio, J., Rose, R.J., 2004. Inattentiveness, parental smoking and adolescent smoking initiation. *Addiction* 99, 1049–1061.
- Barnoya, J., Glantz, S.A., 2005. Cardiovascular effects of secondhand smoke: nearly as large as smoking. *Circulation* 111, 2684–2698.
- Barr, A.M., Procyshyn, R.M., Hui, P., Johnson, J.L., Honer, W.G., 2008a. Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. *Schizophr. Res.* 100, 252–260.
- Barr, R.S., Culhane, M.A., Jubelt, L.E., Mufti, R.S., Dyer, M.A., Weiss, A.P., Deckersbach, T., Kelly, J.F., Freudenreich, O., Goff, D.C., Evins, A.E., 2008b. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. *Neuropsychopharmacology* 33, 480–490.
- Barr, R.S., Pizzagalli, D.A., Culhane, M.A., Goff, D.C., Evins, A.E., 2008c. A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence. *Biol. Psychiatry* 63, 1061–1065.
- Bednar, I., Friberg, L., Nordberg, A., 2004. Modulation of dopamine release by the nicotinic agonist epibatidine in the frontal cortex and the nucleus accumbens of naive and chronic nicotine treated rats. *Neurochem. Int.* 45, 1049–1055.
- Behrendt, R.P., 2006. Dysregulation of thalamic sensory “transmission” in schizophrenia: neurochemical vulnerability to hallucinations. *J. Psychopharmacol.* 20, 356–372.
- Bejerot, S., Humble, M., 1999. Low prevalence of smoking among patients with obsessive-compulsive disorder. *Compr. Psychiatry* 40, 268–272.
- Bejerot, S., Nylander, L., 2003. Low prevalence of smoking in patients with autism spectrum disorders. *Psychiatry Res.* 119, 177–182.
- Belmaker, R.H., 2004. Bipolar disorder. *N. Engl. J. Med.* 351, 476–486.
- Benowitz, N.L., 2008. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. *Clin. Pharmacol. Ther.* 83, 531–541.
- Benowitz, N.L., Jacob 3rd, P., 2000. Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. *Clin. Pharmacol. Ther.* 67, 653–659.
- Beratis, S., Katriavanou, A., Gourzis, P., 2001. Factors affecting smoking in schizophrenia. *Compr. Psychiatry* 42, 393–402.
- Berk, M., Ng, F., Wang, W.V., Tohen, M., Lubman, D.I., Vieta, E., Dodd, S., 2008. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. *J. Affect. Disord.* 110, 126–134.
- Berman, J.A., Talmage, D.A., Role, L.W., 2007. Cholinergic circuits and signaling in the pathophysiology of schizophrenia. *Int. Rev. Neurobiol.* 78, 193–223.
- Berridge, K.C., 1996. Food reward: brain substrates of wanting and liking. *Neurosci. Biobehav. Rev.* 20, 1–25.
- Berridge, K.C., 2007. The debate over dopamine's role in reward: the case for incentive salience. *Psychopharmacology (Berl.)* 191, 391–431.
- Bersch, V.P., Osvaldt, A.B., Edelweiss, M.I., Schumacher Rde, C., Wendt, L.R., Abreu, L.P., Blom, C.B., Abreu, G.P., Costa, L., Piccinini, P., Rohde, L., 2009. Effect of nicotine and cigarette smoke on an experimental model of intraepithelial lesions and pancreatic adenocarcinoma induced by 7,12-dimethylbenzanthracene in mice. *Pancreas* 38, 65–70.
- Bertrand, D., Gopalakrishnan, M., 2007. Allosteric modulation of nicotinic acetylcholine receptors. *Biochem. Pharmacol.* 74, 1155–1163.
- Biederman, J., 2005. Attention-deficit/hyperactivity disorder: a selective overview. *Biol. Psychiatry* 57, 1215–1220.
- Biederman, J., Mick, E., Faraone, S., Hammerness, P., Surman, C., Harpold, T., Dougherty, M., Aleardi, M., Spencer, T., 2006a. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. *J. Clin. Psychopharmacol.* 26, 163–166.
- Biederman, J., Monuteaux, M.C., Mick, E., Wilens, T.E., Fontanella, J.A., Poetzel, K.M., Kirk, T., Masse, J., Faraone, S.V., 2006b. Is cigarette smoking a gateway to alcohol and illicit drug use disorders? A study of youths with and without attention deficit hyperactivity disorder. *Biol. Psychiatry* 59, 258–264.
- Bierut, L.J., Stitzel, J.A., Wang, J.C., Hinrichs, A.L., Grucza, R.A., Xuei, X., Saccone, N.L., Saccone, S.F., Bertelsen, S., Fox, L., Horton, W.J., Breslau, N., Budde, J., Cloninger, C.R., Dick, D.M., Foroud, T., Hatsukami, D., Hesselbrock, V., Johnson, E.O., Kramer, J., Kuperman, S., Madden, P.A., Mayo, K., Nurnberger Jr., J., Pomerleau, O., Porjesz, B., Reyes, O., Schuckit, M., Swan, G., Tischfield, J.A., Edenberg, H.J., Rice, J.P., Goate, A.M., 2008. Variants in nicotinic receptors and risk for nicotine dependence. *Am. J. Psychiatry* 165, 1163–1171.
- Birkenaes, A.B., Opjordsmoen, S., Brunborg, C., Engh, J.A., Jonsdottir, H., Ringen, P.A., Simonsen, C., Vaskinn, A., Birkeland, K.L., Friis, S., Sundet, K., Andreassen, O.A., 2007. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. *J. Clin. Psychiatry* 68, 917–923.
- Bisaglia, M., Mammì, S., Bubacco, L., 2009. Structural insights on physiological functions and pathological effects of alpha-synuclein. *FASEB J.* 23, 329–340.
- Bitner, R.S., Nikkel, A.L., Markosyan, S., Otte, S., Puttfarcken, P., Gopalakrishnan, M., 2009. Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. *Brain Res.* 1265, 65–74.
- Blalock, J.A., Robinson, J.D., Wetter, D.W., Schreindorfer, L.S., Cinciripini, P.M., 2008. Nicotine withdrawal in smokers with current depressive disorders undergoing intensive smoking cessation treatment. *Psychol. Addict. Behav.* 22, 122–128.
- Blaxter, M., 1998. *Caenorhabditis elegans* is a nematode. *Science* 282, 2041–2046.
- Blennow, K., de Leon, M.J., Zetterberg, H., 2006. Alzheimer's disease. *Lancet* 368, 387–403.
- Bocquet, N., Prado de Carvalho, L., Cartaud, J., Neyton, J., Le Poupon, C., Taly, A., Grutter, T., Changeux, J.P., Corringer, P.J., 2007. A prokaryotic proton-gated ion channel from the nicotinic acetylcholine receptor family. *Nature* 445, 116–119.
- Boden, J.M., Fergusson, D.M., Horwood, L.J., 2008. Cigarette smoking and suicidal behaviour: results from a 25-year longitudinal study. *Psychol. Med.* 38, 433–439.
- Bond, C.E., Zimmermann, M., Greenfield, S.A., 2009. Upregulation of alpha7 nicotinic receptors by acetylcholinesterase C-Terminal peptides. *PLoS ONE* 4 (3), e4846.
- Bordia, T., Parameswaran, N., Fan, H., Langston, J.W., McIntosh, J.M., Quirk, M., 2006. Partial recovery of striatal nicotinic receptors in MPTP-lesioned monkeys with chronic oral nicotine. *J. Pharmacol. Exp. Ther.* 319, 285–292.
- Bordia, T., Grady, S.R., McIntosh, J.M., Quirk, M., 2007. Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum. *Mol. Pharmacol.* 72, 52–61.
- Bordia, T., Campos, C., Huang, L., Quirk, M., 2008. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. *J. Pharmacol. Exp. Ther.* 327, 239–247.
- Bosboom, J.L., Stoffers, D., Wolters, E.Ch., 2004. Cognitive dysfunction and dementia in Parkinson's disease. *J. Neural. Transm.* 111, 1303–1315.
- Bowman, T.S., Gaziano, J.M., Buring, J.E., Sesso, H.D., 2007. A prospective study of cigarette smoking and risk of incident hypertension in women. *J. Am. Coll. Cardiol.* 50, 2085–2092.
- Boyajian, R.A., Otis, S.M., 2000. Acute effects of smoking on human cerebral blood flow: a transcranial Doppler ultrasonography study. *J. Neuroimaging* 10, 204–208.
- Bozika, V.P., Niopas, I., Kafantari, A., Kanaze, F.I., Gabrieli, C., Melissidis, P., Gamvula, K., Fokas, K., Karavatos, A., 2005. No increased levels of the nicotine metabolite cotinine in smokers with schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 29, 1–6.
- Brauer, L.H., Cramblett, M.J., Paxton, D.A., Rose, J.E., 2001. Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. *Psychopharmacology (Berl.)* 159, 31–37.
- Breese, C.R., Marks, M.J., Logel, J., Adams, C.E., Sullivan, B., Collins, A.C., Leonard, S., 1997. Effect of smoking history on [3H]nicotine binding in human postmortem brain. *J. Pharmacol. Exp. Ther.* 282, 7–13.
- Breese, C.R., Lee, M.J., Adams, C.E., Sullivan, B., Logel, J., Gillen, K.M., Marks, M.J., Collins, A.C., Leonard, S., 2000. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. *Neuropsychopharmacology* 23, 351–364.
- Breslau, N., Kilbey, M.M., Andreski, P., 1992. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. *Am. J. Psychiatry* 149, 464–469.
- Breslau, N., Novak, S.P., Kessler, R.C., 2004a. Daily smoking and the subsequent onset of psychiatric disorders. *Psychol. Med.* 34, 323–333.
- Breslau, N., Novak, S.P., Kessler, R.C., 2004b. Psychiatric disorders and stages of smoking. *Biol. Psychiatry* 55, 69–76.
- Breslau, N., Schultz, L.R., Johnson, E.O., Peterson, E.L., Davis, G.C., 2005. Smoking and the risk of suicidal behavior: a prospective study of a community sample. *Arch. Gen. Psychiatry* 62, 328–334.
- Brewer, B.G., Roberts, A.M., Rowell, P.P., 2004. Short-term distribution of nicotine in the rat lung. *Drug Alcohol Depend.* 75, 193–198.
- Brischoux, F., Chakraborty, S., Brierley, D.I., Ungless, M.A., 2009. Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli. *Proc. Natl. Acad. Sci. U.S.A.* 106, 4894–4899.
- Britt, J.P., McGehee, D.S., 2008. Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens. *J. Neurosci.* 28, 1672–1681.
- Brody, A.L., 2006. Functional brain imaging of tobacco use and dependence. *J. Psychiatr. Res.* 40, 404–418.
- Brody, A.L., Mandelkern, M.A., Jarvik, M.E., Lee, G.S., Smith, E.C., Huang, J.C., Bota, R.G., Bartzikis, G., London, E.D., 2004a. Differences between smokers and nonsmokers in regional gray matter volumes and densities. *Biol. Psychiatry* 55, 77–84.
- Brody, A.L., Olmstead, R.E., London, E.D., Farahi, J., Meyer, J.H., Grossman, P., Lee, G.S., Huang, J., Hahn, E.L., Mandelkern, M.A., 2004b. Smoking-induced ventral striatum dopamine release. *Am. J. Psychiatry* 161, 1211–1218.
- Brody, A.L., Mandelkern, M.A., Olmstead, R.E., Scheibal, D., Hahn, E., Shiraga, S., Zamora-Paja, E., Farahi, J., Saxena, S., London, E.D., McCracken, J.T., 2006a. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. *Arch. Gen. Psychiatry* 63, 808–816.
- Brody, A.L., Mandelkern, M.A., London, E.D., Olmstead, R.E., Farahi, J., Scheibal, D., Jou, J., Allen, V., Tionson, E., Chefer, S.I., Koren, A.O., Mukhin, A.G., 2006b. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. *Arch. Gen. Psychiatry* 63, 907–915.
- Brody, A.L., Mandelkern, M.A., Olmstead, R.E., Jou, J., Tionson, E., Allen, V., Scheibal, D., London, E.D., Monterosso, J.R., Tiffany, S.T., Korb, A., Gan, J.J., Cohen, M.S., 2007. Neural substrates of resisting craving during cigarette cue exposure. *Biol. Psychiatry* 62, 642–651.
- Brody, A.L., Mandelkern, M.A., Costello, M.R., Abrams, A.L., Scheibal, D., Farahi, J., London, E.D., Olmstead, R.E., Rose, J.E., Mukhin, A.G., 2009a. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. *Int. J. Neuropsychopharmacol.* 12, 305–316.

- Brody, A.L., Mandelkern, M.A., Olmstead, R.E., Allen-Martinez, Z., Scheibal, D., Abrams, A.L., Costello, M.R., Farahi, J., Saxena, S., Monterosso, J., London, E.D., 2009b. Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. *Neuropsychopharmacology* 34, 282–289.
- Bronisch, T., Höfler, M., Lieb, R., 2008. Smoking predicts suicidality: findings from a prospective community study. *J. Affect. Disord.* 108, 135–145.
- Brownson, R.C., Eriksen, M.P., Dawis, R.M., Warner, K.E., 1997. Environmental tobacco smoke. Health effects and policies to reduce exposure. *Annu. Rev. Public Health* 18, 163–185.
- Buccafusco, J.J., 2004. Neuronal nicotinic receptor subtypes: defining therapeutic targets. *Mol. Interv.* 4, 285–295.
- Buchanan, R.W., Freedman, R., Javitt, D.C., Abi-Dargham, A., Lieberman, J.A., 2007. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. *Schizophr. Bull.* 33, 1120–1130.
- Buchanan, R.W., Conley, R.R., Dickinson, D., Ball, M.P., Feldman, S., Gold, J.M., McMahon, R.P., 2008. Galantamine for the treatment of cognitive impairments in people with schizophrenia. *Am. J. Psychiatry* 165, 82–89.
- Burghaus, L., Schütz, U., Krempel, U., Lindstrom, J., Schröder, H., 2003. Loss of nicotinic acetylcholine receptor subunits alpha4 and alpha7 in the cerebral cortex of Parkinson patients. *Parkinsonism Relat. Disord.* 9, 243–246.
- Burke, J.D., Loeber, R., White, H.R., Stouthamer-Loeber, M., Pardini, D.A., 2007. Inattention as a key predictor of tobacco use in adolescence. *J. Abnorm. Psychol.* 116, 249–259.
- Burns, D.M., 2001. Nicotine addiction. In: Braunwald, E., Fauci, S.A., Isselbacher, J.K., Kasper, D.L., Hauser, S.L., Longo, D.L., Jameson, J.L. (Eds.), *Harrison's Principles of Internal Medicine*. 15th ed. The McGraw-Hill Companies, New York, pp. 2574–2577.
- Button, T.M., Thapar, A., McGuffin, P., 2005. Relationship between antisocial behaviour, attention-deficit hyperactivity disorder and maternal prenatal smoking. *Br. J. Psychiatry* 187, 155–160.
- Caggiula, A.R., Donny, E.C., White, A.R., Chaudhri, N., Booth, S., Gharib, M.A., Hoffman, A., Perkins, K.A., Sved, A.F., 2001. Cue dependency of nicotine self-administration and smoking. *Pharmacol. Biochem. Behav.* 70, 515–530.
- Cai, J., Liu, B., Lin, P., Su, Q., 2003. Fast analysis of nicotine related alkaloids in tobacco and cigarette smoke by megabore capillary gas chromatography. *J. Chromatogr. A* 1017, 187–193.
- Caldarone, B.J., Harriat, A., Cleary, M.A., Beech, R.D., King, S.L., Picciotto, M.R., 2004. High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. *Biol. Psychiatry* 56, 657–664.
- Campbell, L.E., Hughes, M., Budd, T.W., Cooper, G., Fulham, W.R., Karayanidis, F., Hanlon, M.C., Stojanov, W., Johnston, P., Case, V., Schall, U., 2007. Primary and secondary neural networks of auditory prepulse inhibition: a functional magnetic resonance imaging study of sensorimotor gating of the human acoustic startle response. *Eur. J. Neurosci.* 26, 2327–2333.
- Cannon, C.M., Bseikri, M.R., 2004. Is dopamine required for natural reward? *Physiol. Behav.* 81, 741–748.
- Cao, Y.J., Surowy, C.S., Puttfarcken, P.S., 2005a. Nicotinic acetylcholine receptor-mediated [3H]dopamine release from hippocampus. *J. Pharmacol. Exp. Ther.* 312, 1298–1304.
- Cao, Y.J., Surowy, C.S., Puttfarcken, P.S., 2005b. Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H] dopamine release. *Neuropharmacology* 48, 72–79.
- Cardenas, L., Tremblay, L.K., Naranjo, C.A., Herrmann, N., Zack, M., Busto, U.E., 2002. Brain reward system activity in major depression and comorbid nicotine dependence. *J. Pharmacol. Exp. Ther.* 302, 1265–1271.
- Carlezon W.A.Jr., Mague, S.D., Andersen, S.L., 2003. Enduring behavioral effects of early exposure to methylphenidate in rats. *Biol. Psychiatry* 54, 1330–1337.
- Carls, K.A., Ruehler, V.L., 2006. An evaluation of phencyclidine (PCP) psychosis: a retrospective analysis at a state facility. *Am. J. Drug Alcohol Abuse* 32, 673–678.
- Carney, C.P., Jones, L.E., 2006. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. *Psychosom. Med.* 68, 684–691.
- Carreiras, M.C., Marco, J.L., 2004. Recent approaches to novel anti-Alzheimer therapy. *Curr. Pharm. Des.* 10, 3167–3175.
- Carroll, B.J., Cassidy, F., Naftolowitz, D., Tatham, N.E., Wilson, W.H., Iranmanesh, A., Liu, P.Y., Veldhuis, J.D., 2007. Pathophysiology of hypercortisolism in depression. *Acta Psychiatr. Scand. Suppl.* 433, 90–103.
- Carson, R., Craig, D., McGuinness, B., Johnston, J., O'Neill, T., Passmore, P., Ritchie, C., 2008a. Alpha 7 Nicotinic acetylcholine receptor gene and reduced risk of Alzheimer's disease. *J. Med. Genet.* 45, 244–248.
- Carson, R., Craig, D., Hart, D., Todd, S., McGuinness, B., Johnston, J.A., O'Neill, F.A., Ritchie, C.W., Passmore, A.P., 2008b. Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. *Neuromolecular Med.* 10, 377–384.
- Cassels, B.K., Bermudez, I., Dajas, F., Abin-Carriquiry, J.A., Wonnacott, S., 2005. From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. *Drug Discov. Today* 10, 1657–1665.
- Cassidy, F., McEvoy, J.P., Yang, Y.K., Wilson, W.H., 2002. Smoking and psychosis in patients with bipolar I disorder. *Compr. Psychiatry* 43, 63–64.
- Castagnoli, K., Steyn, S.J., Magnin, G., Van Der Schyf, C.J., Fourie, I., Khalil, A., Castagnoli Jr., N., 2002. Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase. *Neurotox. Res.* 4, 151–160.
- Catanzaro, D.F., Zhou, Y., Chen, R., Yu, F., Catanzaro, S.E., De Lorenzo, M.S., Subbaramaiah, K., Zhou, X.K., Pratico, D., Dannenberg, A.J., Weksler, B.B., 2007. Potentially reduced exposure cigarettes accelerate atherosclerosis: evidence for the role of nicotine. *Cardiovasc. Toxicol.* 7, 192–201.
- Catley, D., Harris, K.J., Okuyemi, K.S., Mayo, M.S., Pankey, E., Ahluwalia, J.S., 2005. The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. *Nicotine Tob. Res.* 7, 859–870.
- Chachamovich, E., Fleck, M., Laidlaw, K., Power, M., 2008. Impact of major depression and subsyndromal symptoms on quality of life and attitudes toward aging in an international sample of older adults. *Gerontologist* 48, 593–602.
- Chalmers, K.A., Wilcock, G.K., Vinters, H.V., Perry, E.K., Perry, R., Ballard, C.G., Love, S., 2009. Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. *J. Neurol.* 256, 717–720.
- Chandley, M.J., Miller, M.N., Kwasigroch, C.N., Wilson, T.D., Miller, B.E., 2009. Increased antibodies for the alpha7 subunit of the nicotinic receptor in schizophrenia. *Schizophr. Res.* 109, 98–101.
- Changeux, J.P., Taly, A., 2008. Nicotinic receptors, allosteric proteins and medicine. *Trends Mol. Med.* 14, 93–102.
- Chapman, S., Ragg, M., McGeechan, K., 2009. Citation bias in reported smoking prevalence in people with schizophrenia. *Aust. N. Z. J. Psychiatry* 43, 277–282.
- Chen, H., Fu, Y., Sharp, B.M., 2008a. Chronic nicotine self-administration augments hypothalamic-pituitary-adrenal responses to mild acute stress. *Neuropsychopharmacology* 33, 721–730.
- Chen, X., Williamson, V.S., An, S.S., Hettema, J.M., Aggen, S.H., Neale, M.C., Kendler, K.S., 2008b. Cannabinoid receptor 1 gene association with nicotine dependence. *Arch. Gen. Psychiatry* 65, 816–824.
- Chess, A.C., Simoni, M.K., Alling, T.E., Buccini, D.J., 2007. Elevations of endogenous kynurenic acid produce spatial working memory deficits. *Schizophr. Bull.* 33, 797–804.
- Chouinard, S., Sepehry, A.A., Stip, E., 2007. Oral cholinesterase inhibitor add-on therapy for cognitive enhancement in schizophrenia: a quantitative systematic review. Part I. *Clin. Neuropharmacol.* 30, 169–182.
- Christensen, R., Kristensen, P.K., Bartels, E.M., Bliddal, H., Astrup, A., 2007. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. *Lancet* 370, 1706–1713.
- Ciani, E., Severi, S., Bartesaghi, R., Contestabile, A., 2005. Neurochemical correlates of nicotine neurotoxicity on rat habenulo-interpeduncular cholinergic neurons. *Neurotoxicology* 26, 467–474.
- Cincotta, S.L., Yorek, M.S., Moschak, T.M., Lewis, S.R., Rodefer, J.S., 2008. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. *Curr. Opin. Investig. Drugs* 9, 47–56.
- Clemens, P., Baron, J.A., Coffey, D., Reeves, A., 1995. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. *Psychopharmacology (Berl.)* 117, 253–256.
- Clifford, P.M., Siu, G., Kosciuk, M., Levin, E.C., Venkataraman, V., D'Andrea, M.R., Nagele, R.G., 2008. Alpha7 nicotinic acetylcholine receptor expression by vascular smooth muscle cells facilitates the deposition of Abeta peptides and promotes cerebrovascular amyloid angiopathy. *Brain Res.* 1234, 158–171.
- Colciaghi, F., Borroni, B., Zimmermann, M., Bellone, C., Longhi, A., Padovani, A., Cattabeni, F., Christen, Y., Di Luca, M., 2004. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. *Neurobiol. Dis.* 16, 454–460.
- Conejero-Goldberg, C., Davies, P., Ulloa, L., 2008. Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration. *Neurosci. Biobehav. Rev.* 32, 693–706.
- Conley, R.R., Boggs, D.L., Kelly, D.L., McMahon, R.P., Dickinson, D., Feldman, S., Ball, M.P., Buchanan, R.W., 2009. The effects of galantamine on psychopathology in chronic stable schizophrenia. *Clin. Neuropharmacol.* 32, 69–74.
- Connolly, G.N., Wayne, G.D., Lymperis, D., Doherty, M.C., 2000. How cigarette additives are used to mask environmental tobacco smoke. *Tob. Control.* 9, 283–291.
- Contreras, M., Ceric, F., Torrealba, F., 2007. Inactivation of the interoceptive insula disrupts drug craving and malaise induced by lithium. *Science* 318, 655–658.
- Cook, L.J., Ho, L.W., Taylor, A.E., Brayne, C., Evans, J.G., Xuereb, J., Cairns, N.J., Pritchard, A., Lemmon, H., Mann, D., St Clair, D., Turic, D., Hollingworth, P., Moore, P.J., Jehu, L., Archer, N., Walter, S., Foy, C., Edmondson, A., Powell, J., Lovestone, S., Owen, M.J., Williams, J., Lendon, C., Rubinsztein, D.C., 2004. Candidate gene association studies of the alpha 4 (CHRNA4) and beta 2 (CHRNA2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. *Neurosci. Lett.* 358, 142–146.
- Copeland R.L.Jr., Das, J.R., Kanaan, Y.M., Taylor, R.E., Tizabi, Y., 2007. Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity. *Neurotox. Res.* 12, 61–69.
- Corringer, P.J., Sallette, J., Changeux, J.P., 2006. Nicotine enhances intracellular nicotinic receptor maturation: a novel mechanism of neural plasticity? *J. Physiol. Paris* 99, 162–171.
- Corvin, A., O'Mahony, E., O'Regan, M., Comerford, C., O'Connell, R., Craddock, N., Gill, M., 2001. Cigarette smoking and psychotic symptoms in bipolar affective disorder. *Br. J. Psychiatry* 179, 35–38.
- Cosgrove, K.P., Mitsis, E.M., Bois, F., Frohlich, E., Tamagnan, G.D., Krantzler, E., Perry, E., Maciejewski, P.K., Epperson, C.N., Allen, S., O'Malley, S., Mazure, C.M., Seibyl, J.P., van Dyck, C.H., Staley, J.K., 2007. 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase. *J. Nucl. Med.* 48, 1633–1640.
- Costa, G., Abin-Carriquiry, J.A., Dajas, F., 2001. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. *Brain Res.* 888, 336–342.

- Counts, S.E., He, B., Che, S., Ikonomic, M.D., DeKosky, S.T., Ginsberg, S.D., Mufson, E.J., 2007. Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. *Arch. Neurol.* 64, 1771–1776.
- Court, J., Spurdin, D., Lloyd, S., McKeith, I., Ballard, C., Cairns, N., Kerwin, R., Perry, R., Perry, E., 1999. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. *J. Neurochem.* 73, 1590–1597.
- Court, J.A., Piggott, M.A., Lloyd, S., Cookson, N., Ballard, C.G., McKeith, I.G., Perry, R.H., Perry, E.K., 2000. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. *Neuroscience* 98, 79–87.
- Court, J.A., Johnson, M., Religa, D., Keverne, J., Kalaria, R., Jaros, E., McKeith, I.G., Perry, R., Naslund, J., Perry, E.K., 2005. Attenuation of Abeta deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking. *Neuropathol. Appl. Neurobiol.* 31, 522–535.
- Cousins, M.S., Stamat, H.M., de Wit, H., 2001. Acute doses of d-amphetamine and bupropion increase cigarette smoking. *Psychopharmacology (Berl.)* 157, 243–253.
- Covey, L.S., Glassman, A.H., Stetner, F., 1990. Depression and depressive symptoms in smoking cessation. *Compr. Psychiatry* 31, 350–354.
- Covey, L., Glassman, A., Stetner, F., 1997. Major depression following smoking cessation. *Am. J. Psychiatry* 154, 263–265.
- Covey, L.S., Glassman, A.H., Stetner, F., 1998. Cigarette smoking and major depression. *J. Addict. Dis.* 17, 35–46.
- Covey, L.S., Manubay, J., Jiang, H., Nortick, M., Palumbo, D., 2008. Smoking cessation and inattention or hyperactivity/impulsivity: a post hoc analysis. *Nicotine Tob. Res.* 10, 1717–1725.
- Cruikshank, J.M., Neil-Dwyer, G., Dorrance, D.E., Hayes, Y., Patel, S., 1989. Acute effects of smoking on blood pressure and cerebral blood flow. *J. Hum. Hypertens.* 3, 443–449.
- Cucina, A., Fuso, A., Coluccia, P., Cavallaro, A., 2008. Nicotine inhibits apoptosis and stimulates proliferation in aortic smooth muscle cells through a functional nicotinic acetylcholine receptor. *J. Surg. Res.* 150, 227–235.
- Cuijpers, P., Schoevers, R.A., 2004. Increased mortality in depressive disorders: a review. *Curr. Psychiatry Rep.* 6, 430–437.
- Cuijpers, P., Smit, F., ten Have, M., de Graaf, R., 2007. Smoking is associated with first-ever incidence of mental disorders: a prospective population-based study. *Addiction* 102, 1303–1309.
- Cunningham, J.T., Mifflin, S.W., Gould, G.G., Frazer, A., 2008. Induction of c-Fos and DeltaFosB immunoreactivity in rat brain by Vagal nerve stimulation. *Neuropsychopharmacology* 33, 1884–1895.
- Dagher, A., Bleicher, C., Aston, J.A., Gunn, R.N., Clarke, P.B., Cumming, P., 2001. Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. *Synapse* 42, 48–53.
- Dajas-Bailador, F., Wonnacott, S., 2004. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. *Trends Pharmacol. Sci.* 25, 317–324.
- Daly, J.W., 2005. Nicotinic agonists, antagonists, and modulators from natural sources. *Cell. Mol. Neurobiol.* 25, 513–552.
- Dani, J.A., Bertrand, D., 2007. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. *Annu. Rev. Pharmacol. Toxicol.* 47, 699–729.
- Dani, J.A., Harris, R.A., 2005. Nicotine addiction and comorbidity with alcohol abuse and mental illness. *Nat. Neurosci.* 8, 1465–1470.
- Dar, R., Frenk, H., 2004. Do smokers self-administer pure nicotine? A review of the evidence. *Psychopharmacology (Berl.)* 173, 18–26.
- De Biasi, M., Salas, R., 2008. Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. *Exp. Biol. Med. (Maywood)* 233, 917–929.
- de Leon, J., Diaz, F.J., 2005. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. *Schizophr. Res.* 76, 135–157.
- de Leon, J., Diaz, F.J., Rogers, T., Browne, D., Dinsmore, L., 2002. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. *Schizophr. Res.* 56, 47–54.
- de Leon, J., Diaz, F.J., Aguilar, M.C., Jurado, D., Gurpegui, M., 2006. Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis. *Schizophr. Res.* 86, 256–268.
- De Luca, V., Voineskos, S., Wong, G., Kennedy, J.L., 2006a. Genetic interaction between alpha4 and beta2 subunits of high affinity nicotinic receptor: analysis in schizophrenia. *Exp. Brain Res.* 174, 292–296.
- De Luca, V., Likhodi, O., Van Tol, H.H., Kennedy, J.L., Wong, A.H., 2006b. Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. *Acta Psychiatr. Scand.* 114, 211–215.
- De Michele, G., Filla, A., Volpe, G., De Marco, V., Gogliettino, A., Ambrosio, G., Marconi, R., Castellano, A.E., Campanella, G., 1996. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. *Mov. Disord.* 11, 17–23.
- De Reuck, J., De Weire, M., Van Maele, G., Santens, P., 2005. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease. *J. Neurol. Sci.* 231, 35–39.
- de Wilde, O.M., Bour, L.J., Dingemans, P.M., Koelman, J.H., Linszen, D.H., 2007. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. *Schizophr. Res.* 97, 137–151.
- Debanne, S.M., Bielefeld, R.A., Cheruvu, V.K., Fritsch, T., Rowland, D.Y., 2007. Alzheimer's disease and smoking: bias in cohort studies. *J. Alzheimers Dis.* 11, 313–321.
- Decamp, E., Schneider, J.S., 2009. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. *Brain. Res.* 1262, 109–114.
- Decramer, M., Rennard, S., Troosters, T., Mapel, D.W., Giardino, N., Mannino, D., Wouters, E., Sethi, S., Cooper, C.B., 2008. COPD as a lung disease with systemic consequences—clinical impact, mechanisms, and potential for early intervention. *COPD* 5, 235–256.
- Desai, H.D., Seabolt, J., Jann, M.W., 2001. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. *CNS Drugs* 15, 469–494.
- Descarries, L., Gisiger, V., Steriade, M., 1997. Diffuse transmission by acetylcholine in the CNS. *Prog. Neurobiol.* 53, 603–625.
- Di Matteo, V., Pierucci, M., Di Giovanni, G., Benigno, A., Esposito, E., 2007. The neurobiological bases for the pharmacotherapy of nicotine addiction. *Curr. Pharm. Des.* 13, 1269–1284.
- Diamond, A., 2005. Attention-deficit disorder (attention-deficit/hyperactivity disorder without hyperactivity): a neurobiologically and behaviorally distinct disorder from attention-deficit/hyperactivity disorder (with hyperactivity). *Dev. Psychopathol.* 17, 807–825.
- Diaz, F.J., Velasquez, D.M., Susce, M.T., de Leon, J., 2008. The association between schizophrenia and smoking: unexplained by either the illness or the prodromal period. *Schizophr. Res.* 104, 214–219.
- Diaz, F.J., James, D., Botts, S., Maw, L., Susce, M.T., de Leon, J., 2009. Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression. *Bipolar Disord.* 11, 154–165.
- Dickerson, T.J., Janda, K.D., 2003. Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease. *Proc. Natl. Acad. Sci. U.S.A.* 100, 8182–8187.
- Diehl, A., Reinhard, I., Schmitt, A., Mann, K., Gattaz, W.F., 2009. Does the degree of smoking affect the severity of tardive dyskinesia? A longitudinal clinical trial. *Eur. Psychiatry* 24, 33–40.
- Dierker, L.C., Donny, E., Tiffany, S., Colby, S.M., Perrine, N., Clayton, R.R., Tobacco Etiology Research Network, 2007. The association between cigarette smoking and DSM-IV nicotine dependence among first year college students. *Drug Alcohol Depend.* 86, 106–114.
- Dineley, K.T., 2007. Beta-amyloid peptide–nicotinic acetylcholine receptor interaction: the two faces of health and disease. *Front. Biosci.* 12, 5030–5038.
- Dodel, R., Csoti, I., Ebersbach, G., Fuchs, G., Hahne, M., Kuhn, W., Oechsner, M., Jost, W., Reichmann, H., Schulz, J.B., 2008. Lewy body dementia and Parkinson's disease with dementia. *J. Neurol.* 255 (Suppl 5), 39–47.
- Dome, P., Rihmer, Z., Gonda, X., Pestalipy, P., Kovacs, G., Teleki, Z., Mandl, P., 2005. Cigarette smoking and psychiatric disorders in Hungary. *Int. J. Psychiatry Clin. Pract.* 9, 145–148.
- Domino, E.F., Minoshima, S., Guthrie, S.K., Ohl, L., Ni, L., Koeppe, R.A., Cross, D.J., Zubietta, J., 2000. Effects of nicotine on regional cerebral glucose metabolism in awake resting tobacco smokers. *Neuroscience* 101, 277–282.
- Domino, E.F., Ni, L., Xu, Y., Koeppe, R.A., Guthrie, S., Zubietta, J.K., 2004. Regional cerebral blood flow and plasma nicotine after smoking tobacco cigarettes. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 28, 319–327.
- Donny, E.C., Dierker, L.C., 2007. The absence of DSM-IV nicotine dependence in moderate-to-heavy daily smokers. *Drug Alcohol Depend.* 89, 93–96.
- Doolittle, D.J., Winegar, R., Lee, C.K., Caldwell, W.S., Hayes, A.W., de Bethizy, J.D., 1995. The genotoxic potential of nicotine and its major metabolites. *Mutat. Res.* 344, 95–102.
- Doyle, R.L., Frazier, J., Spencer, T.J., Geller, D., Biederman, J., Wilens, T., 2006. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. *J. Atten. Disord.* 9, 543–549.
- Dunbar, G.C., Inglis, F., Kuchibhatla, R., Sharma, T., Tomlinson, M., Wamsley, J., 2007. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). *J. Psychopharmacol.* 21, 171–178.
- Duncan, B., Rees, D.L., 2005. Effect of smoking on depressive symptomatology: a reexamination of data from the National Longitudinal Study of Adolescent Health. *Am. J. Epidemiol.* 162, 461–470.
- Durazzo, T.C., Meyerhoff, D.J., 2007. Neurobiological and neurocognitive effects of chronic cigarette smoking and alcoholism. *Front. Biosci.* 12, 4079–4100.
- Durazzo, T.C., Cardenas, V.A., Studholme, C., Weiner, M.W., Meyerhoff, D.J., 2007. Non-treatment-seeking heavy drinkers: effects of chronic cigarette smoking on brain structure. *Drug Alcohol Depend.* 87, 76–82.
- Dyer, M.A., Freudenreich, O., Culhane, M.A., Pachas, G.N., Deckersbach, T., Murphy, E., Goff, D.C., Evins, A.E., 2008. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. *Schizophr. Res.* 102, 88–95.
- Ebersbach, G., Stock, M., Muller, J., Wenning, G., Wissel, J., Poewe, W., 1999. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. *Mov. Disord.* 14, 1011–1013.
- Ebmeier, K.P., Calder, S.A., Crawford, J.R., Stewart, L., Besson, J.A., Mutch, W.J., 1990. Clinical features predicting dementia in idiopathic Parkinson's disease: a follow-up study. *Neurology* 40, 1222–1224.
- Ebmeier, K.P., Donaghey, C., Steele, J.D., 2006. Recent developments and current controversies in depression. *Lancet* 367, 153–167.
- Egea, J., Rosa, A.O., Sobrado, M., Gandia, L., Lopez, M.G., Garcia, A.G., 2007. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in alpha7 nicotinic receptor knockout mice. *Neuroscience* 145, 866–872.

- Egleton, R.D., Brown, K.C., Dasgupta, P., 2008. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. *Trends Pharmacol. Sci.* 29, 151–158.
- Elgamal, S., MacQueen, G., 2008. Galantamine as an adjunctive treatment in major depression. *J. Clin. Psychopharmacol.* 28, 357–359.
- Eliasson, B., 2003. Cigarette smoking and diabetes. *Prog. Cardiovasc. Dis.* 45, 405–413.
- Elkins, I.J., McGue, M., Iacono, W.G., 2007. Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. *Arch. Gen. Psychiatry* 64, 1145–1152.
- Ellis, J.R., Villemagne, V.L., Nathan, P.J., Mulligan, R.S., Gong, S.J., Chan, J.G., Sachinid, J., O'Keefe, G.J., Pathmaraj, K., Wesnes, K.A., Savage, G., Rowe, C.C., 2008. Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. *Neurobiol. Learn. Mem.* 90, 404–412.
- Erhardt, S., Hajos, M., Lindberg, A., Engberg, G., 2000. Nicotine-induced excitation of locus coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid. *Synapse* 37, 104–108.
- Erhardt, S., Schwieler, L., Emanuelsson, C., Geyer, M., 2004. Endogenous kynurenic acid disrupts prepulse inhibition. *Biol. Psychiatry* 56, 255–260.
- Erhardt, S., Schwieler, L., Nilsson, L., Linderholm, K., Engberg, G., 2007. The kynurenic acid hypothesis of schizophrenia. *Physiol. Behav.* 92, 203–209.
- Esterberg, M.L., Jones, E.M., Compton, M.T., Walker, E.F., 2007. Nicotine consumption and schizotypy in first-degree relatives of individuals with schizophrenia and non-psychiatric controls. *Schizophr. Res.* 97, 6–13.
- Esterberg, M.L., Goulding, S.M., McClure-Tone, E.B., Compton, M.T., 2009. Schizotypy and nicotine, alcohol, and cannabis use in a non-psychiatric sample. *Addict. Behav.* 34, 374–379.
- Estrada, L.D., Soto, C., 2007. Disrupting beta-amyloid aggregation for Alzheimer disease treatment. *Curr. Top. Med. Chem.* 7, 115–126.
- Etter, J.F., 2009. Dependence on the nicotine gum in former smokers. *Addict. Behav.* 34, 246–251.
- Exley, R., Cragg, S.J., 2008. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. *Br. J. Pharmacol.* 153, S283–S297.
- Exley, R., Clements, M.A., Hartung, H., McIntosh, J.M., Cragg, S.J., 2008. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. *Neuropsychopharmacology* 33, 2158–2166.
- Fagerstrom, K.O., Pomerleau, O., Giordani, B., Stelson, F., 1994. Nicotine may relieve symptoms of Parkinson's disease. *Psychopharmacology* 116, 117–119.
- Fallon, S., Shearman, E., Sershen, H., Lajtha, A., 2007. The effects of glutamate and GABA receptor antagonists on nicotine-induced neurotransmitter changes in cognitive areas. *Neurochem. Res.* 32, 535–553.
- Faraone, S.V., Wilens, T.E., Petty, C., Antshel, K., Spencer, T., Biederman, J., 2007. Substance use among ADHD adults: implications of late onset and subthreshold diagnoses. *Am. J. Addict.* 16 (Suppl. 1), 24–32.
- Farber, L., Haus, U., Spath, M., Drechsler, S., 2004. Physiology and pathophysiology of the 5-HT₃ receptor. *Scand. J. Rheumatol.* 33, 2–8.
- Fehr, C., Yakushev, I., Hohmann, N., Buchholz, H.G., Landvogt, C., Deckers, H., Eberhardt, A., Klager, M., Smolka, M.N., Scheurich, A., Dielenheis, T., Schmidt, L.G., Rosch, F., Bartenstein, P., Grunder, G., Schreckenberger, M., 2008. Association of low striatal dopamine D2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. *Am. J. Psychiatry* 165, 507–514.
- Ferchmin, P.A., Hao, J., Perez, D., Penzo, M., Maldonado, H.M., Gonzalez, M.T., Rodriguez, A.D., de Vellis, J., 2005. Tobacco cembranoids protect the function of acute hippocampal slices against NMDA by a mechanism mediated by alpha4beta2 nicotinic receptors. *J. Neurosci. Res.* 82, 631–641.
- Ferchmin, P.A., Pagán, O.R., Ulrich, H., Szeto, A.C., Hann, R.M., Eterović, V.A., 2009. Actions of octocoral and tobacco cembranoids on nicotinic receptors. *Toxicol. [Epub ahead of print]*.
- Fergusson, D.M., Woodward, L.J., Horwood, L.J., 1998. Maternal smoking during pregnancy and psychiatric adjustment in late adolescence. *Arch. Gen. Psychiatry* 55, 721–727.
- Finder, V.H., Glockshuber, R., 2007. Amyloid-beta aggregation. *Neurodegener. Dis.* 4, 13–27.
- Fisher, A., 2007. M1 muscarinic agonists target major hallmarks of Alzheimer's disease—an update. *Curr. Alzheimer Res.* 4, 577–580.
- Flomen, R.H., Collier, D.A., Osborne, S., Munro, J., Breen, G., St Clair, D., Makoff, A.J., 2006. Association study of CHRFAM7A copy number and 2 bp deletion polymorphisms with schizophrenia and bipolar affective disorder. *Am. J. Med. Genet. B: Neuropsychiatr. Genet.* 141, 571–575.
- Flomen, R.H., Davies, A.F., Di Forti, M., La Cascia, C., Mackie-Ogilvie, C., Murray, R., Makoff, A.J., 2008. The copy number variant involving part of the alpha7 nicotinic receptor gene contains a polymorphic inversion. *Eur. J. Hum. Genet.* 16, 1364–1371.
- Foddai, M., Dosia, G., Spiga, S., Diana, M., 2004. Acetaldehyde increases dopaminergic neuronal activity in the VTA. *Neuropsychopharmacology* 29, 530–536.
- Font, L., Aragon, C.M., Miquel, M., 2006. Voluntary ethanol consumption decreases after the inactivation of central acetaldehyde by d-penicillamine. *Behav. Brain Res.* 171, 78–86.
- Fornai, F., di Poggio, A.B., Pellegrini, A., Ruggieri, S., Paparelli, A., 2007. Noradrenergic in Parkinson's disease: from disease progression to current therapeutics. *Curr. Med. Chem.* 14, 2330–2334.
- Fowler, J.S., Volkow, N.D., Wang, G.J., Pappas, N., Logan, J., Shea, C., Alexoff, D., MacGregor, R.R., Schlyer, D.J., Zezulkova, I., Wolf, A.P., 1996a. Brain monoamine oxidase A inhibition in cigarette smokers. *Proc. Natl. Acad. Sci. U.S.A.* 93, 14065–14069.
- Fowler, J.S., Volkow, N.D., Wang, G.J., Pappas, N., Logan, J., MacGregor, R., Alexoff, D., Shea, C., Schlyer, D., Wolf, A.P., Warner, D., Zezulkova, I., Cilentio, R., 1996b. Inhibition of monoamine oxidase B in the brains of smokers. *Nature* 379, 733–736.
- Fowler, J.S., Logan, J., Wang, G.J., Volkow, N.D., Telang, F., Zhu, W., Franceschi, D., Shea, C., Garza, V., Xu, Y., Ding, Y.S., Alexoff, D., Warner, D., Netusil, N., Carter, P., Jayne, M., King, P., Vaska, P., 2005. Comparison of monoamine oxidase A in peripheral organs in nonsmokers and smokers. *J. Nucl. Med.* 46, 1414–1420.
- Fowler, C.D., Arends, M.A., Kenny, P.J., 2008. Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. *Behav. Pharmacol.* 19, 461–484.
- Franklin, T.R., Wang, Z., Wang, J., Sciortino, N., Harper, D., Li, Y., Ehrman, R., Kampman, K., O'Brien, C.P., Detre, J.A., Childress, A.R., 2007. Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. *Neuropsychopharmacology* 32, 2301–2309.
- Franklin, T.R., Lohoff, F.W., Wang, Z., Sciortino, N., Harper, D., Li, Y., Jens, W., Cruz, J., Kampman, K., Ehrman, R., Berrettini, W., Detre, J.A., O'Brien, C.P., Childress, A.R., 2009. DAT genotype modulates brain and behavioral responses elicited by cigarette cues. *Neuropsychopharmacology* 34, 717–728.
- Freedman, R., Hall, M., Adler, L.E., Leonard, S., 1995. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. *Biol. Psychiatry* 38, 22–33.
- Freedman, R., Olincy, A., Buchanan, R.W., Harris, J.G., Gold, J.M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M.P., Kutnick, J., Pender, V., Martin, L.F., Stevens, K.E., Wagner, B.D., Zerbe, G.O., Soti, F., Kem, W.R., 2008. Initial phase 2 trial of a nicotinic agonist in schizophrenia. *Am. J. Psychiatry* 165, 1040–1047.
- Frenk, H., Dar, R., 2000. The difficulty of curtailing the smoking habit. In: Myslobodsky, M., Glick, S.D., Kety, S.S., Moscovitch, M., Weinberger, D.R. (Eds.), *A Critique of Nicotine Addiction*. Kluwer Academic Publishers, Boston, pp. 133–150.
- Frishman, W.H., Mitta, W., Kupersmith, A., Ky, T., 2006. Nicotine and non-nicotine smoking cessation pharmacotherapies. *Cardiol. Rev.* 14, 57–73.
- Frölich, L., 2002. The cholinergic pathology in Alzheimer's disease—discrepancies between clinical experience and pathophysiological findings. *J. Neural. Transm.* 109, 1003–1013.
- Fu, Y., Matta, S.G., Gao, W., Sharp, B.M., 2000. Local alpha-bungarotoxin-sensitive nicotinic receptors in the nucleus accumbens modulate nicotine-stimulated dopamine secretion in vivo. *Neuroscience* 101, 369–375.
- Fu, Q., Heath, A.C., Bucholz, K.K., Lyons, M.J., Tsuang, M.T., True, W.R., Eisen, S.A., 2007a. Common genetic risk of major depression and nicotine dependence: the contribution of antisocial traits in a United States veteran male twin cohort. *Twin Res. Hum. Genet.* 10, 470–478.
- Fu, S.S., McFall, M., Saxon, A.J., Beckham, J.C., Carmody, T.P., Baker, D.G., Joseph, A.M., 2007b. Post-traumatic stress disorder and smoking: a systematic review. *Nicotine Tob. Res.* 9, 1071–1084.
- Fucile, S., Sucupane, A., Eusebi, F., 2006. Ca²⁺ permeability through rat cloned alpha9-containing nicotinic acetylcholine receptors. *Cell Calcium* 39, 349–355.
- Fuemmeler, B.F., Kollins, S.H., McClernon, F.J., 2007. Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood. *J. Psychiatr. Psychol.* 32, 1203–1213.
- Fujita, M., Ichise, M., Zoghbi, S.S., Liow, J.S., Ghose, S., Vines, D.C., Sangere, J., Lu, J.Q., Copley, V.L., Iida, H., Kim, K.M., Cohen, M.R., Barajimenez, W., Ravina, B., Innis, R.B., 2006. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. *Ann. Neurol.* 59, 174–177.
- Furey, M.L., Drevets, W.C., 2006. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. *Arch. Gen. Psychiatry* 63, 1121–1129.
- Gahring, L.C., Rogers, S.W., 2006. Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. *AAPS J.* 7, E885–E894.
- Gaimarri, A., Moretti, M., Riganti, L., Zanardi, A., Clementi, F., Gotti, C., 2007. Regulation of neuronal nicotinic receptor traffic and expression. *Brain Res. Rev.* 55, 134–143.
- Galfalvy, H., Oquendo, M.A., Carballo, J.J., Sher, L., Grunebaum, M.F., Burke, A., Mann, J.J., 2006. Clinical predictors of suicidal acts after major depression in bipolar disorder: a prospective study. *Bipolar Disord.* 8, 586–595.
- Galindo-Charles, L., Hernandez-Lopez, S., Galarra, E., Tapia, D., Bargas, J., Garduño, J., Frías-Dominguez, C., Drucker-Colin, R., Mihailescu, S., 2008. Serotonergic dorsal raphe neurons possess functional postsynaptic nicotinic acetylcholine receptors. *Synapse* 62, 601–615.
- Galletly, C., 2009. Recent advances in treating cognitive impairment in schizophrenia. *Psychopharmacology (Berl.)* 202, 259–273.
- Gallinat, J., Meisenzahl, E., Jacobsen, L.K., Kalus, P., Bierbrauer, J., Kienast, T., Witthaus, H., Leopold, K., Seifert, F., Schubert, F., Staedtgen, M., 2006. Smoking and structural brain deficits: a volumetric MR investigation. *Eur. J. Neurosci.* 24, 1744–1750.
- Gallinat, J., Lang, U.E., Jacobsen, L.K., Bajbouj, M., Kalus, P., von Haebler, D., Seifert, F., Schubert, F., 2007. Abnormal hippocampal neurochemistry in smokers: evidence from proton magnetic resonance spectroscopy at 3 T. *J. Clin. Psychopharmacol.* 27, 80–84.
- García-Portilla, M.P., Saiz, P.A., Bascaran, M.T., Martínez, A.S., Benabarre, A., Sierra, P., Torres, P., Montes, J.M., Bousño, M., Bobes, J., on behalf of the General Health

- Status in Bipolar Disorder Collaborative Group, 2009. Cardiovascular risk in patients with bipolar disorder. *J. Affect. Disord.* 115, 302–308.
- García-Rill, E., Biedermann, J.A., Chambers, T., Skinner, R.D., Mrak, R.E., Husain, M., Karson, C.N., 1995. Mesopontine neurons in schizophrenia. *Neuroscience* 66, 321–335.
- Gazdzinski, S., Durazzo, T.C., Studholme, C., Song, E., Banys, P., Meyerhoff, D.J., 2005. Quantitative brain MRI in alcohol dependence: preliminary evidence for effects of concurrent chronic cigarette smoking on regional brain volumes. *Alcohol Clin. Exp. Res.* 29, 1484–1495.
- Gehricke, J.G., Whalen, C.K., Jamner, L.D., Wigal, T.L., Steinhoff, K., 2006. The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: a preliminary examination. *Nicotine Tob. Res.* 8, 37–47.
- Gentry, C.L., Lukas, R.J., 2002. Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. *Curr. Drug Targets CNS Neurol. Disord.* 1, 359–385.
- George, T.P., Weinberger, A.H., 2008. Monoamine oxidase inhibition for tobacco pharmacotherapy. *Clin. Pharmacol. Ther.* 83, 619–621.
- George, O., Ghazizadeh, S., Azar, M.R., Cottone, P., Zorrilla, E.P., Parsons, L.H., O'Dell, L.E., Richardson, H.N., Koob, G.F., 2007. CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. *Proc. Natl. Acad. Sci. U.S.A.* 104, 17198–17203.
- George, T.P., Sacco, K.A., Vessicchio, J.C., Weinberger, A.H., Shytle, R.D., 2008. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. *J. Clin. Psychopharmacol.* 28, 340–344.
- Gershon, A.A., Vishne, T., Grunhaus, L., 2007. Dopamine D2-like receptors and the antidepressant response. *Biol. Psychiatry* 61, 145–153.
- Gershon Grand, R.B., Hwang, S., Han, J., George, T., Brody, A.L., 2007. Short-term naturalistic treatment outcomes in cigarette smokers with substance abuse and/or mental illness. *J. Clin. Psychiatry* 68, 892–898.
- Geula, C., Mesulam, M.M., 1996. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. *Cereb. Cortex* 6, 165–177.
- Ghatan, P.H., Ingvar, M., Eriksson, L., Stone-Elander, S., Serrander, M., Ekberg, K., Wahren, J., 1998. Cerebral effects of nicotine during cognition in smokers and non-smokers. *Psychopharmacology (Berl.)* 136, 179–189.
- Giacobini, E., 2003. Cholinergic function and Alzheimer's disease. *Int. J. Geriatr. Psychiatry* 18 (Suppl. 1), S1–S5.
- Giménez-Llort, L., Blázquez, G., Cañete, T., Johansson, B., Oddo, S., Tobeña, A., LaFerla, F.M., Fernández-Teruel, A., 2007. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. *Neurosci. Biobehav. Rev.* 31, 125–147.
- Giniatullin, R., Nistri, A., Yakel, J.L., 2005. Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. *Trends Neurosci.* 28, 371–378.
- Glantz, M.D., Anthony, J.C., Berglund, P.A., Degenhardt, L., Dierker, L., Kalaydjian, A., Merikangas, K.R., Ruscio, A.M., Swendsen, J., Kessler, R.C., 2009. Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits. *Psychol. Med.* 39, 1365–1377.
- Gleerup, G., Winther, K., 1996. Smoking further increases platelet activity in patients with mild hypertension. *Eur. J. Clin. Invest.* 26, 49–52.
- Glick, S.D., Maisonneuve, I.M., Dickinson, H.A., 2000. 18-MC reduces methamphetamine and nicotine self-administration in rats. *Neuroreport* 11, 2013–2015.
- Glick, S.D., Sell, E.M., Maisonneuve, I.M., 2008. Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration. *Eur. J. Pharmacol.* 599, 91–95.
- Goff, D.C., Sullivan, L.M., McEvoy, J.P., Meyer, J.M., Nasrallah, H.A., Daumit, G.L., Lambert, S., D'Agostino, R.B., Stroup, T.S., Davis, S., Lieberman, J.A., 2005. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophr. Res.* 80, 45–53.
- Goldstein, B.I., Birmaher, B., Axelson, D.A., Goldstein, T.R., Esposito-Smythers, C., Strober, M.A., Hunt, J., Leonard, H., Gill, M.K., Iyengar, S., Grimm, C., Yang, M., Ryan, N.D., Keller, M.B., 2008. Significance of cigarette smoking among youths with bipolar disorder. *Am. J. Addict.* 17, 364–371.
- Gonzalez-Pinto, A., Gutierrez, M., Ezcurra, J., Aizpuru, F., Mosquera, F., Lopez, P., de Leon, J., 1998. Tobacco smoking and bipolar disorder. *J. Clin. Psychiatry* 59, 225–228.
- Goodwin, R.D., Zvolensky, M.J., Keyes, K.M., 2008. Nicotine dependence and mental disorders among adults in the USA: evaluating the role of the mode of administration. *Psychol. Med.* 38, 1277–1286.
- Gordon, S.M., Tulak, F., Troncale, J., 2004. Prevalence and characteristics of adolescent patients with co-occurring ADHD and substance dependence. *J. Addict. Dis.* 23, 31–40.
- Gotti, C., Clementi, F., 2004. Neuronal nicotinic receptors: from structure to pathology. *Prog. Neurobiol.* 74, 363–396.
- Gotti, C., Carbonnelle, E., Moretti, M., Zwart, R., Clementi, F., 2000. Drugs selective for nicotinic receptor subtypes: a real possibility or a dream? *Behav. Brain Res.* 113, 183–192.
- Gotti, C., Moretti, M., Bohr, I., Ziabreva, I., Vailati, S., Longhi, R., Riganti, L., Gaimarri, A., McKeith, I.G., Perry, R.H., Aarsland, D., Larsen, J.P., Sher, E., Beattie, R., Clementi, F., Court, J.A., 2006. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. *Neurobiol. Dis.* 23, 481–489.
- Gotti, C., Riganti, L., Vailati, S., Clementi, F., 2006a. Brain neuronal nicotinic receptors as new targets for drug discovery. *Curr. Pharm. Des.* 12, 407–428.
- Gotti, C., Zoli, M., Clementi, F., 2006b. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. *Trends Pharmacol. Sci.* 27, 482–491.
- Gotti, C., Moretti, M., Gaimarri, A., Zanardi, A., Clementi, F., Zoli, M., 2007. Heterogeneity and complexity of native brain nicotinic receptors. *Biochem. Pharmacol.* 74, 1102–1111.
- Grace, A.A., Floresco, S.B., Goto, Y., Lodge, D.J., 2007. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. *Trends Neurosci.* 30, 220–227.
- Grace, J., Amick, M.M., Friedman, J.H., 2009. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. *J. Neurol. Neurosurg. Psychiatry* 80, 18–23.
- Grandinetti, A., Morens, D.M., Reed, D., MacEachern, D., 1994. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. *Am. J. Epidemiol.* 139, 1129–1138.
- Granon, S., Changeux, J.P., 2006. Attention-deficit/hyperactivity disorder: a plausible mouse model. *Acta Paediatr.* 95, 645–649.
- Grant, B.F., Hasin, D.S., Chou, S.P., Stinson, F.S., Dawson, D.A., 2004. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch. Gen. Psychiatry* 61, 1107–1115.
- Green, M.F., 2007. Stimulating the development of drug treatments to improve cognition in schizophrenia. *Annu. Rev. Clin. Psychol.* 3, 159–180.
- Greenfield, S.A., Day, T., Mann, E.O., Bermudez, I., 2004. A novel peptide modulates alpha7 nicotinic receptor responses: implications for a possible trophic-toxic mechanism within the brain. *J. Neurochem.* 90, 325–331.
- Griesler, P.C., Hu, M.C., Schaffran, C., Kandel, D.B., 2008. Comorbidity of psychiatric disorders and nicotine dependence among adolescents: findings from a prospective, longitudinal study. *J. Am. Acad. Child. Adolesc. Psychiatry* 47, 1340–1350.
- Grilli, M., Parodi, M., Raiteri, M., Marchi, M., 2005. Chronic nicotine differentially affects the function of nicotinic receptor subtypes regulating neurotransmitter release. *J. Neurochem.* 93, 1353–1360.
- Grinevich, V.P., Papke, R.L., Lippio, P.M., Bencherif, M., 2009. Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. *Neuropharmacology* [Epub ahead of print].
- Grunblatt, E., Mandel, S., Youdim, M.B., 2000. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. *J. Neurol.* 247 (Suppl. 2), II95–II102.
- Guan, Z.Z., Zhang, X., Blennow, K., Nordberg, A., 1999. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. *Neuroreport* 10, 1779–1782.
- Guan, Z.Z., Zhang, X., Ravid, R., Nordberg, A., 2000. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. *J. Neurochem.* 74, 237–243.
- Guan, Z.Z., Nordberg, A., Mousavi, M., Rinne, J.O., Hellstrom-Lindahl, E., 2002. Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. *Brain Res.* 956, 358–366.
- Guillemin, K., Vouillac, C., Azar, M.R., Parsons, L.H., Koob, G.F., Cador, M., Stinus, L., 2005. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. *J. Neurosci.* 25, 8593–8600.
- Guillon, O., Abi-Dargham, A., Laruelle, M., 2007. Neurobiology of dopamine in schizophrenia. *Int. Rev. Neurobiol.* 78, 1–39.
- Gujar, S.K., Maheshwari, S., Bjorkman-Burtscher, I., Sundgren, P.C., 2005. Magnetic resonance spectroscopy. *J. Neuropharmacol.* 25, 217–226.
- Gurpegui, M., Martinez-Ortega, J.M., Aguilar, M.C., Diaz, F.J., Quintana, H.M., de Leon, J., 2005. Smoking initiation and schizophrenia: a replication study in a Spanish sample. *Schizophr. Res.* 76, 113–118.
- Gurpegui, M., Martinez-Ortega, J.M., Jurado, D., Aguilar, M.C., Diaz, F.J., de Leon, J., 2007. Subjective effects and the main reason for smoking in outpatients with schizophrenia: a case-control study. *Compr. Psychiatry* 48, 186–191.
- Hahn, B., Stolerman, I.P., 2005. Modulation of nicotine-induced attentional enhancement in rats by adrenoceptor antagonists. *Psychopharmacology (Berl.)* 177, 438–447.
- Hahn, B., Ross, T.J., Yang, Y., Kim, I., Huestis, M.A., Stein, E.A., 2007. Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. *J. Neurosci.* 27, 3477–3489.
- Hajek, P., McRobbie, H., Gillison, F., 2007. Dependence potential of nicotine replacement treatments: effects of product type, patient characteristics, and cost to user. *Prev. Med.* 44, 230–234.
- Hall, M.H., Schulze, K., Sham, P., Kalidindi, S., McDonald, C., Bramon, E., Levy, D.L., Murray, R.M., Rijdsdijk, F., 2008. Further evidence for shared genetic effects between psychotic bipolar disorder and P50 suppression: a combined twin and family study. *Am. J. Med. Genet. B: Neuropsychiatr. Genet.* 147B, 619–627.
- Halperin, R.O., Gaziano, J.M., Sesso, H.D., 2008. Smoking and the risk of incident hypertension in middle-aged and older men. *Am. J. Hypertens.* 21, 148–152.
- Hammond, D., Collishaw, N.E., Callard, C., 2006. Secret science: tobacco industry research on smoking behaviour and cigarette toxicity. *Lancet* 367, 781–787.
- Hanagasi, H.A., Lees, A., Johnson, J.O., Singleton, A., Emre, M., 2007. Smoking-responsive juvenile-onset Parkinsonism. *Mov. Disord.* 22, 115–119.
- Hansen, H.H., Timmermann, D.B., Peters, D., Walters, C., Damaj, M.I., Mikkelsen, J.D., 2007. Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics. *J. Neurosci. Res.* 85, 1810–1818.
- Hapke, U., Schumann, A., Rumpf, H.J., John, U., Konerding, U., Meyer, C., 2005. Association of smoking and nicotine dependence with trauma and posttraumatic stress disorder in a general population sample. *J. Nerv. Ment. Dis.* 193, 843–846.

- Harris, J.G., Kongs, S., Allensworth, D., Martin, L., Tregellas, J., Sullivan, B., Zerbe, G., Freedman, R., 2004. Effects of nicotine on cognitive deficits in schizophrenia. *Neuropsychopharmacology* 29, 1378–1385.
- Harro, J., Fischer, K., Vansteelandt, S., Harro, M., 2004. Both low and high activities of platelet monoamine oxidase increase the probability of becoming a smoker. *Eur. Neuropsychopharmacol.* 14, 65–69.
- Hashimoto, K., Ishima, T., Fujita, Y., Matsuo, M., Kobashi, T., Takahagi, M., Tsukada, H., Iyo, M., 2008. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. *Biol. Psychiatry* 63, 92–97.
- Hasler, G., Gergen, P.J., Kleinbaum, D.G., Ajdacic, V., Gamma, A., Eich, D., Rössler, W., Angst, J., 2005. Asthma and panic in young adults: a 20-year prospective community study. *Am. J. Respir. Crit. Care Med.* 171, 1224–1230.
- Hatzinikolaou, D.G., Lagesson, V., Stavridou, A.J., Pouli, A.E., Lagesson-Andrasko, L., Stavrides, J.C., 2006. Analysis of the gas phase of cigarette smoke by gas chromatography coupled with UV-diode array detection. *Anal. Chem.* 78, 4509–4516.
- Hauser, T.A., Kucinski, A., Jordan, K.G., Gatto, G.J., Wersinger, S.R., Hesse, R.A., Stachowiak, E.K., Stachowiak, M.K., Lippello, P.M., Bencherif, M., 2009. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. *Biochem. Pharmacol.* [Epub ahead of print].
- Hayee, A., Haque, A., Anwarullah, A.K., Rabbani, M.G., 2003. Smoking enhances age related brain atrophy—a quantitative study with computed tomography. *Bangladesh Med. Res. Coun. Bull.* 29, 118–124.
- Heath, C.J., Picciotto, M.R., 2009. Nicotine-induced plasticity during development: modulation of the cholinergic system and long-term consequences for circuits involved in attention and sensory processing. *Neuropharmacology* 56 (Suppl. 1), 254–262.
- Hedberg, M.M., Svedberg, M.M., Mustafiz, T., Yu, W.F., Mousavi, M., Guan, Z.Z., Unger, C., Nordberg, A., 2008. Transgenic mice overexpressing human acetylcholinesterase and the Swedish amyloid precursor protein mutation: effect of nicotine treatment. *Neuroscience* 152, 223–233.
- Heffner, J.L., DelBello, M.P., Fleck, D.E., Anthenelli, R.M., Strakowski, S.M., 2008. Cigarette smoking in the early course of bipolar disorder: association with ages-at-onset of alcohol and marijuana use. *Bipolar Disord.* 10, 838–845.
- Hellenbrand, W., Seidler, A., Robra, B.P., Vieregge, P., Oertel, W.H., Joerg, J., Nischan, P., Schneider, E., Ulm, G., 1997. Smoking and Parkinson's disease: a case-control study in Germany. *Int. J. Epidemiol.* 26, 328–339.
- Hellstrom-Lindahl, E., Mousavi, M., Ravid, R., Nordberg, A., 2004. Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients. *Neurobiol. Dis.* 15, 351–360.
- Hellström-Lindahl, E., Moore, H., Nordberg, A., 2000. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. *J. Neurochem.* 74, 777–784.
- Hellström-Lindahl, E., Ravid, R., Nordberg, A., 2008. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. *Neurobiol. Aging* 29, 210–221.
- Hemby, S.E., Ginsberg, S.D., Brunk, B., Arnold, S.E., Trojanowski, J.Q., Eberwine, J.H., 2002. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. *Arch. Gen. Psychiatry* 59, 631–640.
- Hemmingsson, T., Kriebel, D., 2003. Smoking at age 18–20 and suicide during 26 years of follow-up—how can the association be explained? *Int. J. Epidemiol.* 32, 1000–1004.
- Hennekens, C.H., 2007. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. *J. Clin. Psychiatry* 68 (Suppl. 4), 4–7.
- Hennekens, C.H., Hennekens, A.R., Hollar, D., Casey, D.E., 2005. Schizophrenia and increased risks of cardiovascular disease. *Am. Heart J.* 150, 1115–1121.
- Henningfield, J.E., Zeller, M., 2006. Nicotine psychopharmacology research contributions to United States and global tobacco regulation: a look back and a look forward. *Psychopharmacology (Berl.)* 184, 286–291.
- Henningfield, J.E., Cohen, C., Slade, J.D., 1991. Is nicotine more addictive than cocaine? *Br. J. Addict.* 86, 565–569.
- Henningfield, J., Pankow, J., Garrett, B., 2004. Ammonia and other chemical base tobacco additives and cigarette nicotine delivery: issues and research needs. *Nicotine Tob. Res.* 6, 199–205.
- Henningfield, J.E., Fant, R.V., Buchhalter, A.R., Stitzer, M.L., 2005. Pharmacotherapy for nicotine dependence. *CA Cancer J. Clin.* 55, 281–299.
- Hernán, M.A., Alonso, A., Logrosino, G., 2008. Cigarette smoking and dementia: potential selection bias in the elderly. *Epidemiology* 19, 448–450.
- Herraziz, T., Chaparro, C., 2005. Human monoamine oxidase is inhibited by tobacco smoke: β -carboline alkaloids act as potent and reversible inhibitors. *Biochem. Biophys. Res. Commun.* 326, 378–386.
- Hesse, S., Ballaschke, O., Barthel, H., Sabri, O., 2009. Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. *Psychiatry Res.* 171, 120–128.
- Hikosaka, O., Bromberg-Martin, E., Hong, S., Matsumoto, M., 2008. New insights on the subcortical representation of reward. *Curr. Opin. Neurobiol.* 18, 203–208.
- Hilf, R.J., Dutzler, R., 2008. X-ray structure of a prokaryotic pentameric ligand-gated ion channel. *Nature* 452, 375–379.
- Hilf, R.J., Dutzler, R., 2009. Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel. *Nature* 457, 115–118.
- Hitsman, B., Borrelli, B., McChargue, D.E., Spring, B., Niaura, R., 2003. History of depression and smoking cessation outcome: a meta-analysis. *J. Consult. Clin. Psychol.* 71, 657–663.
- Hitsman, B., Spring, B., Borrelli, B., McChargue, D., Niaura, R., 2004. Response to covey. *Nicotine Tob. Res.* 6, 747–749.
- Hnasko, T.S., Sotak, B.N., Palmiter, R.D., 2005. Morphine reward in dopamine-deficient mice. *Nature* 438, 854–857.
- Hoft, N.R., Corley, R.P., McQueen, M.B., Schlaepfer, I.R., Huizinga, D., Ehringer, M.A., 2009. Genetic association of the CHRNA6 and CHRNA3 genes with tobacco dependence in a nationally representative sample. *Neuropsychopharmacology* 34, 698–706.
- Hogg, R.C., Bertrand, D., 2004. Nicotinic acetylcholine receptors as drug targets. *Curr. Drug Targets CNS Neurol. Disord.* 3, 123–130.
- Hogg, R.C., Bertrand, D., 2007. Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. *Biochem. Pharmacol.* 73, 459–468.
- Hogg, R.C., Buisson, B., Bertrand, D., 2005. Allosteric modulation of ligand-gated ion channels. *Biochem. Pharmacol.* 70, 1267–1276.
- Hong, C.J., Lai, I.C., Liou, L.L., Tsai, S.J., 2004. Association study of the human partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant with bipolar disorder. *Neurosci. Lett.* 355, 69–72.
- Hong, L.E., Wonodi, I., Lewis, J., Thaker, G.K., 2008. Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients. *Neuropsychopharmacology* 33, 2167–2174.
- Hong, D.P., Fink, A.L., Uversky, V.N., 2009a. Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? *Biochim. Biophys. Acta* 1794, 282–290.
- Hong, L.E., Gu, H., Yang, Y., Ross, T.J., Salmeron, B.J., Buchholz, B., Thaker, G.K., Stein, E.A., 2009b. Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits. *Arch. Gen. Psychiatry* 66, 431–441.
- Horiuchi, Y., Kimura, R., Kato, N., Fujii, T., Seki, M., Endo, T., Kato, T., Kawashima, K., 2003. Evolutional study on acetylcholine expression. *Life Sci.* 72, 1745–1756.
- Horvitz, J.C., 2000. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. *Neuroscience* 96, 651–656.
- Huang, L.Z., Parameswaran, N., Bordia, T., McIntosh, J.M., Quik, M., 2009. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. *J. Neurochem.* 109, 826–837.
- Hughes, J.R., 2004. Nicotine-related disorders. In: Sadock, B.J., Sadock, V.A. (Eds.), *Kaplan & Sadock's Comprehensive Textbook of Psychiatry*. 8th ed. Lippincott Williams & Wilkins, pp. 1257–1264.
- Hughes, J.R., 2006. Should criteria for drug dependence differ across drugs? *Addiction* 101 (Suppl. 1), 134–141.
- Hughes, J.R., 2007. Depression during tobacco abstinence. *Nicotine Tob. Res.* 9, 443–446.
- Hughes, J.R., 2008a. Significance of off-label use of NRT. *Addiction* 103, 1704–1705.
- Hughes, J.R., 2008b. Smoking and suicide: a brief overview. *Drug Alcohol Depend.* 98, 169–178.
- Hughes, J.R., Hatsukami, D.K., Mitchell, J.E., Dahlgren, L.A., 1986. Prevalence of smoking among psychiatric outpatients. *Am. J. Psychiatry* 143, 993–997.
- Hughes, J.R., Keely, J., Naud, S., 2004. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction* 99, 29–38.
- Hughes, J.R., Helzer, J.E., Lindberg, S.A., 2006. Prevalence of DSM/ICD-defined nicotine dependence. *Drug Alcohol Depend.* 85, 91–102.
- Huizink, A.C., van Lier, P.A., Crijnen, A.A., 2009. Attention deficit hyperactivity disorder symptoms mediate early-onset smoking. *Eur. Addict. Res.* 15, 1–9.
- Hukkanen, J., Jacob, P.3rd., Benowitz, N.L., 2005. Metabolism and disposition kinetics of nicotine. *Pharmacol. Rev.* 57, 79–115.
- Hulihan-Giblin, B.A., Lumpkin, M.D., Kellar, K.J., 1990. Effects of chronic administration of nicotine on prolactin release in the rat: inactivation of prolactin response by repeated injections of nicotine. *J. Pharmacol. Exp. Ther.* 252, 21–25.
- Humfleet, G.L., Prochaska, J.J., Mengis, M., Cullen, J., Munoz, R., Reus, V., Hall, S.M., 2005. Preliminary evidence of the association between the history of childhood attention-deficit/hyperactivity disorder and smoking treatment failure. *Nicotine Tob. Res.* 7, 453–460.
- Hung, R.J., McKay, J.D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., Fabianova, E., Mates, D., Bencko, V., Foretova, L., Janout, V., Chen, C., Goodman, G., Field, J.K., Liloglou, T., Xinarianos, G., Cassidy, A., McLaughlin, J., Liu, G., Narod, S., Krokan, H.E., Skorpene, F., Elvestad, M.B., Hveem, K., Vatten, L., Linseisen, J., Clavel-Chapelon, F., Vineis, P., Bueno-de-Mesquita, H.B., Lund, E., Martinez, C., Bingham, S., Rasmussen, T., Hainaut, P., Riboli, E., Ahrens, W., Benhamou, S., Lagiou, P., Trichopoulos, D., Holcátová, I., Merletti, F., Kjaerheim, K., Agudo, A., Macfarlane, G., Talamini, R., Simonato, L., Lowry, R., Conway, D.I., Znaor, A., Healy, C., Zelenika, D., Boland, A., Delepine, M., Foglio, M., Lechner, D., Matsuda, F., Blanche, H., Gut, I., Heath, S., Lathrop, M., Brennan, P., 2008. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature* 452, 633–637.
- Hung, S.Y., Huang, W.P., Liou, H.C., Fu, W.M., 2009. Autophagy protects neuron from Abeta-induced cytotoxicity. *Autophagy* 5, 502–510.
- Husky, M.M., Mazure, C.M., Paliwal, P., McKee, S.A., 2008. Gender differences in the comorbidity of smoking behavior and major depression. *Drug Alcohol Depend.* 93, 176–179.
- Huss, M., Poustka, F., Lehmkuhl, G., Lehmkuhl, U., 2008. No increase in long-term risk for nicotine use disorders after treatment with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD): evidence from a non-randomised retrospective study. *J. Neural. Transm.* 115, 335–339.
- Hutson, P.H., Barton, C.L., Jay, M., Blurton, P., Burkamp, F., Clarkson, R., Bristow, L.J., 2000. Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT(2C/2B) receptor antagonists: neurochemical and behavioural studies. *Neuropharmacology* 39, 2318–2328.

- Hyman, S.E., Malenka, R.C., Nestler, E.J., 2006. Neural mechanisms of addiction: the role of reward-related learning and memory. *Annu. Rev. Neurosci.* 29, 565–598.
- Iancu, I., Sapir, A.P., Shaked, G., Poreh, A., Dannon, P.N., Chelben, J., Kotler, M., 2006. Increased suicidal risk among smoking schizophrenia patients. *Clin. Neuropharmacol.* 29, 230–237.
- Ikemoto, S., 2004. Unconditional hyperactivity and transient reinforcing effects of NMDA administration into the ventral tegmental area in rats. *Psychopharmacology (Berl.)* 172, 202–210.
- Ikemoto, S., 2007. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. *Brain Res. Rev.* 56, 27–78.
- Ikonomic, M.D., Abrahamson, E.E., Isanski, B.A., Wu, J., Mufson, E.J., DeKosky, S.T., 2007. Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. *Arch. Neurol.* 64, 1312–1317.
- Ikonomic, M.D., Wecker, L., Abrahamson, E.E., Wu, J., Counts, S.E., Ginsberg, S.D., Mufson, E.J., Dekosky, S.T., 2009. Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. *Arch. Neurol.* 66, 646–651.
- Imamura, K., Takeshima, T., Kashiwaya, Y., Nakaso, K., Nakashima, K., 2006. D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease. *J. Neurosci. Res.* 84, 1376–1384.
- Inestrosa, N.C., Dinamarca, M.C., Alvarez, A., 2008. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. *FEBS J.* 275, 625–632.
- Inglis, W.L., Winn, P., 1995. The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation. *Prog. Neurobiol.* 47, 1–29.
- Ishikawa, A., Miyatake, T., 1993. Effects of smoking in patients with early-onset Parkinson's disease. *J. Neurol. Sci.* 117, 28–32.
- Ismail, K., Sloggett, A., De Stavola, B., 2000. Do common mental disorders increase cigarette smoking? Results from five waves of a population-based panel cohort study. *Am. J. Epidemiol.* 152, 651–657.
- Itkin, O., Nemets, B., Einat, H., 2001. Smoking habits in bipolar and schizophrenic outpatients in southern Israel. *J. Clin. Psychiatry* 62, 269–272.
- Itti, E., Villafane, G., Malek, Z., Brugières, P., Capacchione, D., Itti, L., Maison, P., Cesaro, P., Meignan, M., 2009. Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study. *Nucl. Med. Commun.* 30, 513–518.
- Iwasaki, M., Akechi, T., Uchitomi, Y., Tsugane, S., Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Disease (JPHC study) Group, 2005. Cigarette smoking and completed suicide among middle-aged men: a population-based cohort study in Japan. *Ann. Epidemiol.* 15, 286–292.
- Jackson, K.J., Martin, B.R., Changeux, J.P., Damaj, M.I., 2008. Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. *J. Pharmacol. Exp. Ther.* 325, 302–312.
- Jacobsen, L.K., D'Souza, D.C., Mencil, W.E., Pugh, K.R., Skudlarski, P., Krystal, J.H., 2004. Nicotine effects on brain function and functional connectivity in schizophrenia. *Biol. Psychiatry* 55, 850–858.
- Jacobsen, L.K., Picciotto, M.R., Heath, C.J., Frost, S.J., Tsou, K.A., Dwan, R.A., Jackowski, M.P., Constable, R.T., Mencil, W.E., 2007. Prenatal and adolescent exposure to tobacco smoke modulates the development of white matter microstructure. *J. Neurosci.* 27, 13491–13498.
- Janhunen, S., Ahtee, L., 2007. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development. *Neurosci. Biobehav. Rev.* 31, 287–314.
- Janson, A.M., Moller, A., 1993. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitranssection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. *Neuroscience* 57, 931–941.
- Janson, A.M., Hedlund, P.B., Fuxe, K., von Euler, G., 1994. Chronic nicotine treatment counteracts dopamine D2 receptor upregulation induced by a partial mesodiencephalic hemitranssection in the rat. *Brain Res.* 655, 25–32.
- Japuntich, S.J., Smith, S.S., Jorenby, D.E., Piper, M.E., Fiore, M.C., Baker, T.B., 2007. Depression predicts smoking early but not late in a quit attempt. *Nicotine Tob. Res.* 9, 677–686.
- Jellinger, K., 1988. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. *J. Neurol. Neurosurg. Psychiatry* 51, 540–543.
- Jensen, A.A., Frølund, B., Liljefors, T., Krogsgaard-Larsen, P., 2005. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. *J. Med. Chem.* 48, 4705–4745.
- Jha, P., Chaloupka, F.J., Corrao, M., Jacob, B., 2006. Reducing the burden of smoking world-wide: effectiveness of interventions and their coverage. *Drug Alcohol Rev.* 25, 597–609.
- Ji, H., Shepard, P.D., 2007. Lateral habenula stimulation inhibits rat midbrain dopamine neurons through a GABA(A) receptor-mediated mechanism. *J. Neurosci.* 27, 6923–6930.
- John, U., Meyer, C., Rumpf, H.J., Hapke, U., 2004. Smoking, nicotine dependence and psychiatric comorbidity—a population-based study including smoking cessation after three years. *Drug Alcohol Depend.* 76, 287–295.
- Jones, A.K., Brown, L.A., Sattelle, D.B., 2007. Insect nicotinic acetylcholine receptor gene families: from genetic model organism to vector, pest and beneficial species. *Invert. Neurosci.* 7, 67–73.
- Kadir, A., Almkvist, O., Wall, A., Langstrom, B., Nordberg, A., 2006. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. *Psychopharmacology (Berl.)* 188, 509–520.
- Kadir, A., Darreh-Shori, T., Almkvist, O., Wall, A., Langstrom, B., Nordberg, A., 2007. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. *Psychopharmacology (Berl.)* 191, 1005–1014.
- Kadir, A., Darreh-Shori, T., Almkvist, O., Wall, A., Grut, M., Strandberg, B., Ringheim, A., Eriksson, B., Blomquist, G., Långström, B., Nordberg, A., 2008. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. *Neurobiol. Aging* 29, 1204–1217.
- Kalbag, A.S., Levin, F.R., 2005. Adult ADHD and substance abuse: diagnostic and treatment issues. *Subst. Use Misuse* 40, 1955–1981.
- Kalivas, P.W., Volkow, N.D., 2005. The neural basis of addiction: a pathology of motivation and choice. *Am. J. Psychiatry* 162, 1403–1413.
- Kamal, M.A., Klein, P., Luo, W., Li, Y., Holloway, H.W., Tweedie, D., Greig, N.H., 2008. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. *Neurochem. Res.* 33, 745–753.
- Kandinov, B., Giladi, N., Korczyn, A.D., 2007. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. *Parkinsonism Relat. Disord.* 13, 243–245.
- Kar, S., Quirion, R., 2004. Amyloid β peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer's disease pathology. *Prog. Brain Res.* 145, 261–274.
- Karson, C.N., Casanova, M.F., Kleinman, J.E., Griffin, W.S., 1993. Choline acetyltransferase in schizophrenia. *Am. J. Psychiatry* 150, 454–459.
- Kas, A., Bottlaender, M., Gallezot, J.D., Vidailhet, M., Villafane, G., Grégoire, M.C., Coulon, C., Valette, H., Dollé, F., Ribeiro, M.J., Hantraye, P., Remy, P., 2009. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. *J. Cereb. Blood Flow Metab.* [Epub ahead of print].
- Kassiou, M., Eberl, S., Meikle, S.R., Birrell, A., Constable, C., Fulham, M.J., Wong, D.F., Musachio, J.L., 2001. In vivo imaging of nicotinic receptor upregulation following chronic (–)-nicotine treatment in baboon using SPECT. *Nucl. Med. Biol.* 28, 165–175.
- Kato, T., 2007. Molecular genetics of bipolar disorder and depression. *Psychiatry Clin. Neurosci.* 61, 3–19.
- Katon, W., Lozano, P., Russo, J., McCauley, E., Richardson, L., Bush, T., 2007. The prevalence of DSM-IV anxiety and depressive disorders in youth with asthma compared with controls. *J. Adolesc. Health* 41, 455–463.
- Katusic, S.K., Barbaresi, W.J., Colligan, R.C., Weaver, A.L., Leibson, C.L., Jacobsen, S.J., 2005. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. *J. Child. Adolesc. Psychopharmacol.* 15, 764–776.
- Keath, J.R., Iacoviello, M.P., Barrett, L.E., Mansvelter, H.D., McGehee, D.S., 2007. Differential modulation by nicotine of substantia nigra versus ventral tegmental area dopamine neurons. *J. Neurophysiol.* 98, 3388–3396.
- Keithly, L., Ferris Wayne, G., Cullen, D.M., Connolly, G.N., 2005. Industry research on the use and effects of levulinic acid: a case study in cigarette additives. *Nicotine Tob. Res.* 7, 761–771.
- Kelly, C., McCreadie, R.G., 2000. Cigarette smoking and schizophrenia. *Adv. Psych. Treat.* 6, 327–331.
- Kelton, M.C., Kahn, H.J., Conrath, C.L., Newhouse, P.A., 2000. The effects of nicotine on Parkinson's disease. *Brain Cogn.* 43, 274–282.
- Kenny, P.J., Chartoff, E., Roberto, M., Carlezon Jr., W.A., Markou, A., 2009. NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. *Neuropsychopharmacology* 34, 266–281.
- Kessler, R.C., Berglund, P.A., Borges, G., Castilla-Puentes, R.C., Glantz, M.D., Jaeger, S.A., Merikangas, K.R., Nock, M.K., Russo, L.J., Stang, P.E., 2007. Smoking and suicidal behaviors in the National Comorbidity Survey: Replication. *J. Nerv. Ment. Dis.* 195, 369–377.
- Kessler, R.C., Borges, G., Sampson, N., Miller, M., Nock, M.K., 2008. The association between smoking and subsequent suicide-related outcomes in the National Comorbidity Survey panel sample. *Mol. Psychiatry* [Epub ahead of print].
- Khalil, A.A., Davies, B., Castagnoli Jr, N., 2006. Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. *Bioorg. Med. Chem.* 14, 3392–3398.
- Khan, E.M., Lanir, R., Danielson, A.R., Goldkorn, T., 2008. Epidermal growth factor receptor exposed to cigarette smoke is aberrantly activated and undergoes perinuclear trafficking. *FASEB J.* 22, 910–917.
- Killen, J.D., Fortmann, S.P., Schatzberg, A., Hayward, C., Varady, A., 2003. Onset of major depression during treatment for nicotine dependence. *Addict. Behav.* 28, 461–470.
- Kinnunen, T., Korhonen, T., Garvey, A.J., 2008. Role of nicotine gum and pretreatment depressive symptoms in smoking cessation: twelve-month results of a randomized placebo controlled trial. *Int. J. Psychiatry Med.* 38, 373–389.
- Klungsoyr, O., Nygård, J.F., Sørensen, T., Sandanger, I., 2006. Cigarette smoking and incidence of first depressive episode: an 11-year, population-based follow-up study. *Am. J. Epidemiol.* 163, 421–432.
- Knaapen, A.M., Curfs, D.M., Pachen, D.M., Gottschalk, R.W., de Winther, M.P., Dae-men, M.J., Van Schooten, F.J., 2007. The environmental carcinogen benzo[a]pyrene induces expression of monocyte-chemoattractant protein-1 in vascular tissue: a possible role in atherogenesis. *Mutat. Res.* 621, 31–41.
- Knott, V., McIntosh, J., Millar, A., Fisher, D., Villeneuve, C., Ilivitsky, V., Horn, E., 2006. Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist. *Pharmacol. Biochem. Behav.* 85, 228–242.
- Kollins, S.H., McClernon, F.J., Fuemmeler, B.F., 2005. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. *Arch. Gen. Psychiatry* 62, 1142–1147.

- Kollins, S.H., Garrett, M.E., McClernon, F.J., Lachiewicz, A.M., Morrissey-Kane, E., FitzGerald, D., Collins, A.L., Anastopoulos, A.D., Ashley-Koch, A.E., 2009. Effects of postnatal parental smoking on parent and teacher ratings of ADHD and oppositional symptoms. *J. Nerv. Ment. Dis.* 197, 442–449.
- Koob, G.F., Le Moal, M., 2006. Nicotine. In: Koob, G.F., Le Moal, M. (Eds.), *Neurobiology of Addiction*. Academic Press, London, UK, pp. 243–287.
- Korhonen, T., Broms, U., Varjonen, K., Romanov, K., Koskenvuo, M., Kinnunen, T., Kaprio, J., 2007. Smoking behaviour as a predictor of depression among Finnish men and women: a prospective cohort study of adult twins. *Psychol. Med.* 37, 705–715.
- Koylu, E., Demirgören, S., London, E.D., Pöğün, S., 1997. Sex difference in up-regulation of nicotinic acetylcholine receptors in rat brain. *Life Sci.* 61, PL185–PL190.
- Krause, J., 2008. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. *Expert Rev. Neurother.* 8, 611–625.
- Krause, K.H., Dresel, S.H., Krause, J., la Fougere, C., Ackenheil, M., 2003. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. *Neurosci. Biobehav. Rev.* 27, 605–613.
- Krause, J., Krause, K.H., Dresel, S.H., la Fougere, C., Ackenheil, M., 2006. ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine. *Dialogues Clin. Neurosci.* 8, 29–36.
- Kubota, K., Yamaguchi, T., Abe, Y., Fujiwara, T., Hatazawa, J., Matsuzawa, T., 1983. Effects of smoking on regional cerebral blood flow in neurologically normal subjects. *Stroke* 14, 720–724.
- Kubota, K., Matsuzawa, T., Fujiwara, T., Yamaguchi, T., Ito, K., Watanabe, H., Ono, S., 1987. Age-related brain atrophy enhanced by smoking: a quantitative study with computed tomography. *Tohoku J. Exp. Med.* 153, 303–311.
- Kulak, J.M., Carroll, F.L., Schneider, J.S., 2006. [125I]iodomethyllycaconitine binds to alpha7 nicotinic acetylcholine receptors in monkey brain. *Eur. J. Neurosci.* 23, 2604–2610.
- Kumari, V., Postma, P., 2005. Nicotine use in schizophrenia: the self medication hypotheses. *Neurosci. Biobehav. Rev.* 29, 1021–1034.
- Kuryatov, A., Luo, J., Cooper, J., Lindstrom, J., 2005. Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors. *Mol. Pharmacol.* 68, 1839–1851.
- Kuryatov, A., Onksen, J., Lindstrom, J., 2008. Roles of accessory subunits in alpha4-beta2(*) nicotinic receptors. *Mol. Pharmacol.* 74, 132–143.
- Ladner, C.J., Lee, J.M., 1998. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. *J. Neuropathol. Exp. Neurol.* 57, 719–731.
- Lanari, A., Amenta, F., Silvestrelli, G., Tomassoni, D., Parnetti, L., 2006. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. *Mech. Ageing Dev.* 127, 158–165.
- Lane, R.M., Kivipelto, M., Greig, N.H., 2004. Acetylcholinesterase and its inhibition in Alzheimer disease. *Clin. Neuropharmacol.* 27, 141–149.
- Lane, R.M., Potkin, S.G., Enz, A., 2006. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. *Int. J. Neuropsychopharmacol.* 9, 101–124.
- Langley, K., Rice, F., van den Bree, M.B., Thapar, A., 2005. Maternal smoking during pregnancy as an environmental risk factor for attention deficit hyperactivity disorder behaviour. A review. *Minerva Pediatr.* 57, 359–371.
- Lanteri, C., Salomon, L., Torrens, Y., Glowinski, J., Tassin, J.P., 2008. Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism. *Neuropsychopharmacology* 33, 1724–1734.
- Lanteri, C., Hernández Vallejo, S.J., Salomon, L., Doucet, E.L., Godeheu, G., Torrens, Y., Houades, V., Tassin, J.P., 2009. Inhibition of monoamine oxidases desensitizes 5-HT1A autoreceptors and allows nicotine to induce a neurochemical and behavioral sensitization. *J. Neurosci.* 29, 987–997.
- Lasser, K., Boyd, J.W., Woolhandler, S., Himmelstein, D.U., McCormick, D., Bor, D.H., 2000. Smoking and mental illness: a population-based prevalence study. *JAMA* 284, 2606–2610.
- Lau, P.P., Li, L., Merched, A.J., Zhang, A.L., Ko, K.W., Chan, L., 2006. Nicotine induces proinflammatory responses in macrophages and the aorta leading to acceleration of atherosclerosis in low-density lipoprotein receptor(–/–) mice. *Arterioscler. Thromb. Vasc. Biol.* 26, 143–149.
- Laucht, M., Hohm, E., Esser, G., Schmidt, M.H., Becker, K., 2007. Association between ADHD and smoking in adolescence: shared genetic, environmental and psychopathological factors. *J. Neural. Transm.* 114, 1097–1104.
- Laviolette, S.R., van der Kooy, D., 2003a. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. *Mol. Psychiatry* 8, 50–59.
- Laviolette, S.R., van der Kooy, D., 2003b. The motivational valence of nicotine in the rat ventral tegmental area is switched from rewarding to aversive following blockade of the alpha7-subunit-containing nicotinic acetylcholine receptor. *Psychopharmacology (Berl.)* 166, 306–313.
- Laviolette, S.R., van der Kooy, D., 2004. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. *Nat. Rev. Neurosci.* 5, 55–65.
- Law, C.W., Soczynska, J.K., Woldeyohannes, H.O., Miranda, A., Brooks 3rd, J.O., McIntyre, R.S., 2009. Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder. *Pharmacol. Biochem. Behav.* 92, 12–16.
- Le Foll, B., Goldberg, S.R., 2005. Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. *Trends Pharmacol. Sci.* 26, 287–293.
- Le Foll, B., Chefer, S.I., Kimes, A.S., Shumway, D., Stein, E.A., Mukhin, A.G., Goldberg, S.R., 2009. Baseline expression of alpha4beta2* nicotinic acetylcholine receptors predicts motivation to self-administer nicotine. *Biol. Psychiatry* 65, 714–716.
- Le Houezec, J., 2003. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. *Int. J. Tuberc. Lung Dis.* 7, 811–819.
- Lecourtier, L., Kelly, P.H., 2007. A conductor hidden in the orchestra? Role of the habenular complex in monoamine transmission and cognition. *Neurosci. Biobehav. Rev.* 31, 658–672.
- Lecourtier, L., DeFrancesco, A., Moghaddam, B., 2008. Differential tonic influence of lateral habenula on prefrontal cortex and nucleus accumbens dopamine release. *Eur. J. Neurosci.* 27, 1755–1762.
- Lee, M.J., Breese, C.R., Strook, M.L., Leonard, S., 2001. The effect of nicotine and haloperidol co-treatment on nicotinic receptor levels in the rat brain. *Brain Res. Mol. Brain Res.* 86, 115–124.
- Lee, J.H., Lim, Y., Wiederhold, B.K., Graham, S.J., 2005. A functional magnetic resonance imaging (fMRI) study of cue-induced smoking craving in virtual environments. *Appl. Psychophysiol. Biofeedback* 30, 195–204.
- Lemay, S., Chouinard, S., Blanchet, P., Masson, H., Soland, V., Beuter, A., Bedard, M.A., 2004. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 28, 31–39.
- Léna, C., Changeux, J.P., 1998. Allosteric nicotinic receptors, human pathologies. *J. Physiol. Paris* 92, 63–74.
- Lencer, R., Sprenger, A., Harris, M.S., Reilly, J.L., Keshavan, M.S., Sweeney, J.A., 2008. Effects of second-generation antipsychotics medication on smooth pursuit performance in antipsychotic-naïve schizophrenia. *Arch. Gen. Psychiatry* 65, 1146–1154.
- Lendvai, B., Vizi, E.S., 2008. Nonsynaptic chemical transmission through nicotinic acetylcholine receptors. *Physiol. Rev.* 88, 333–349.
- Leonard, S., Gault, J., Adams, C., Breese, C.R., Rollins, Y., Adler, L.E., Olincy, A., Freedman, R., 1998. Nicotinic receptors, smoking and schizophrenia. *Restor. Neurol. Neurosci.* 12, 195–201.
- Lerman, C., Audrain, J., Tercyak, K., Hawk Jr., L.W., Bush, A., Crystal-Mansour, S., Rose, C., Niaura, R., Epstein, L.H., 2001. Attention-deficit hyperactivity disorder (ADHD) symptoms and smoking patterns among participants in a smoking-cessation program. *Nicotine Tob. Res.* 3, 353–359.
- Leroy, C., Brugalat, V., Berlin, I., Grégoire, M.C., Bottlaender, M., Roumenov, D., Dollé, F., Bourgeois, S., Penttilä, J., Artiges, E., Martinot, J.L., Trichard, C., 2009. Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]belfoxatone. *J. Clin. Psychopharmacol.* 29, 86–88.
- Lessov-Schlaggar, C.N., Pergadia, M.L., Khroyan, T.V., Swan, G.E., 2008. Genetics of nicotine dependence and pharmacotherapy. *Biochem. Pharmacol.* 75, 178–195.
- Leventhal, A.M., Francione Witt, C., Zimmerman, M., 2008. Associations between depression subtypes and substance use disorders. *Psychiatry Res.* 161, 43–50.
- Leventhal, A.M., Kahler, C.W., Ray, L.A., Zimmerman, M., 2009. Refining the depression-nicotine dependence link: patterns of depressive symptoms in psychiatric outpatients with current, past, and no history of nicotine dependence. *Addict. Behav.* 34, 297–303.
- Levin, E.D., Rezvani, A.H., 2006. Nicotinic-antipsychotic drug interactions and cognitive function. *EXS* 98, 185–205.
- Levin, E.D., Rezvani, A.H., 2007. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. *Biochem. Pharmacol.* 74, 1182–1191.
- Levin, E.D., McClernon, F.J., Rezvani, A.H., 2006. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. *Psychopharmacology (Berl.)* 184, 523–539.
- Levy, G., Tang, M.X., Cote, L.J., Louis, E.D., Alfaro, B., Mejia, H., Stern, Y., Marder, K., 2002. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. *Mov. Disord.* 17, 250–257.
- Lewis, D.A., Gonzalez-Burgos, G., 2006. Pathophysiologically based treatment interventions in schizophrenia. *Nat. Med.* 12, 1016–1022.
- Lewis, A., Miller, J.H., Lea, R.A., 2007. Monoamine oxidase and tobacco dependence. *Neurotoxicology* 28, 182–195.
- Li, Z., DiFranza, J.R., Wellman, R.J., Kulkarni, P., King, J.A., 2008. Imaging brain activation in nicotine-sensitized rats. *Brain Res.* 1199, 91–99.
- Liechti, M.E., Markou, A., 2008. Role of the glutamatergic system in nicotine dependence: implications for the discovery and development of new pharmacological smoking cessation therapies. *CNS Drugs* 22, 705–724.
- Limosin, F., Loze, J.Y., Philippe, A., Casadebaig, F., Rouillon, F., 2007. Ten-year prospective follow-up study of the mortality by suicide in schizophrenic patients. *Schizophr. Res.* 94, 23–28.
- Lindstrom, J.M., 2003. Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. *Ann. N.Y. Acad. Sci.* 998, 41–52.
- Linnet, K.M., Wisborg, K., Obel, C., Secher, N.J., Thomsen, P.H., Agerbo, E., Henriksen, T.B., 2005. Smoking during pregnancy and the risk for hyperkinetic disorder in offspring. *Pediatrics* 116, 462–467.
- Liou, H.H., Tsai, M.C., Chen, C.J., Jeng, J.S., Chang, Y.C., Chen, S.Y., Chen, R.C., 1997. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. *Neurology* 48, 1583–1588.
- Lips, K.S., Brüggmann, D., Pfeil, U., Vollerthun, R., Grando, S.A., Kummer, W., 2005. Nicotinic acetylcholine receptors in rat and human placenta. *Placenta* 26, 735–746.
- Littleton, J., Barron, S., Prendergast, M., Nixon, S.J., 2007. Smoking kills (alcoholics)! shouldn't we do something about it? *Alcohol Alcohol* 42, 167–173.
- Liu, L., Murphy, R.M., 2006. Kinetics of inhibition of beta-amyloid aggregation by transthyretin. *Biochemistry* 45, 15702–15709.

- Liu, Q., Wu, J., 2006. Neuronal nicotinic acetylcholine receptors serve as sensitive targets that mediate beta-amyloid neurotoxicity. *Acta Pharmacol. Sin.* 27, 1277–1286.
- Liu, Q., Huang, Y., Xue, F., Simard, A., DeChon, J., Li, G., Zhang, J., Lucero, L., Wang, M., Sierks, M., Hu, G., Chang, Y., Lukas, R.J., Wu, J., 2009. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. *J. Neurosci.* 29, 918–929.
- Lloyd, G.K., Williams, M., 2000. Neuronal nicotinic acetylcholine receptors as novel drug targets. *J. Pharmacol. Exp. Ther.* 292, 461–467.
- Lockman, P.R., McAfee, G., Geldenhuys, W.J., Van der Schyf, C.J., Abbruscato, T.J., Allen, D.D., 2005. Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. *J. Pharmacol. Exp. Ther.* 314, 636–642.
- Lodge, N.J., Li, Y.W., 2008. Ion channels as potential targets for the treatment of depression. *Curr. Opin. Drug Discov. Devel.* 11, 633–641.
- Lohoff, F.W., Ferraro, T.N., McNabb, L., Schwebel, C., Dahl, J.P., Doyle, G.A., Buono, R.J., Berrettini, W.H., 2005. No association between common variations in the neuronal nicotinic acetylcholine receptor alpha2 subunit gene (CHRNA2) and bipolar I disorder. *Psychiatry Res.* 135, 171–177.
- Longstreth Jr., W.T., Diehr, P., Manolio, T.A., Beauchamp, N.J., Jungreis, C.A., Lefkowitz, D., 2001. Cluster analysis and patterns of findings on cranial magnetic resonance imaging of the elderly: the Cardiovascular Health Study. *Arch. Neurol.* 58, 635–640.
- López-León, S., Janssens, A.C., González-Zuloeta Ladd, A.M., Del-Favero, J., Claes, S.J., Oostra, B.A., van Duijn, C.M., 2008. Meta-analyses of genetic studies on major depressive disorder. *Mol. Psychiatry* 13, 772–785.
- Lou, X.Y., Ma, J.Z., Payne, T.J., Beuten, J., Crew, K.M., Li, M.D., 2006. Gene-based analysis suggests association of the nicotinic acetylcholine receptor beta1 subunit (CHRN1) and M1 muscarinic acetylcholine receptor (CHRM1) with vulnerability for nicotine dependence. *Hum. Genet.* 120, 381–389.
- Loughead, J., Wileyto, E.P., Valdez, J.N., Sanborn, P., Tang, K., Strasser, A.A., Ruparel, K., Ray, R., Gur, R.C., Lerman, C., 2008. Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. *Mol. Psychiatry* [Epub ahead of print].
- Luebke, A.E., Maroni, P.D., Guth, S.M., Lysakowski, A., 2005. Alpha-9 nicotinic acetylcholine receptor immunoreactivity in the rodent vestibular labyrinth. *J. Comp. Neurol.* 492, 323–333.
- Lyness, S.A., Zarow, C., Chui, H.C., 2003. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. *Neurobiol. Aging* 24, 1–23.
- Lyons, M.J., Bar, J.L., Kremen, W.S., Toomey, R., Eisen, S.A., Goldberg, J., Faraone, S.V., Tsuang, M., 2002. Nicotine and familial vulnerability to schizophrenia: a discordant twin study. *J. Abnorm. Psychol.* 111, 687–693.
- Lyons, M., Hitsman, B., Xian, H., Panizzon, M.S., Jerskey, B.A., Santangelo, S., Grant, M.D., Rende, R., Eisen, S., Eaves, L., Tsuang, M.T., 2008. A twin study of smoking, nicotine dependence, and major depression in men. *Nicotine Tob. Res.* 10, 97–108.
- Madras, B.K., Miller, G.M., Fischman, A.J., 2005. The dopamine transporter and attention-deficit/hyperactivity disorder. *Biol. Psychiatry* 57, 1397–1409.
- Malone, K.M., Waternaux, C., Haas, G.L., Cooper, T.B., Li, S., Mann, J.J., 2003. Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. *Am. J. Psychiatry* 160, 773–779.
- Malpass, D., Higgs, S., 2007. Acute psychomotor, subjective and physiological responses to smoking in depressed outpatient smokers and matched controls. *Psychopharmacology (Berl.)* 190, 363–372.
- Mamede, M., Ishizu, K., Ueda, M., Mukai, T., Iida, Y., Kawashima, H., Fukuyama, H., Togashi, K., Saji, H., 2007. Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. *J. Nucl. Med.* 48, 1829–1835.
- Mameli-Engvall, M., Evrard, A., Pons, S., Maskos, U., Svensson, T.H., Changeux, J.P., Faure, P., 2006. Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors. *Neuron* 50, 911–921.
- Mannino, D.M., Buist, A.S., 2007. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet* 370, 765–773.
- Mannino, D.M., Kiriz, V.A., 2006. Changing the burden of COPD mortality. *Int. J. Chron. Obstruct. Pulmon. Dis.* 1, 219–233.
- Mansvelder, H.D., De Rover, M., McGee, D.S., Brussaard, A.B., 2003. Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. *Eur. J. Pharmacol.* 480, 117–123.
- Mansvelder, H.D., van Aerde, K.I., Couey, J.J., Brussaard, A.B., 2006. Nicotinic modulation of neuronal networks: from receptors to cognition. *Psychopharmacology (Berl.)* 184, 292–305.
- Mao, D., Perry, D.C., Yasuda, R.P., Wolfe, B.B., Kellar, K.J., 2008. The alpha4beta2alpha5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. *J. Neurochem.* 104, 446–456.
- Marangell, L.B., Bauer, M.S., Dennehy, E.B., Wisniewski, S.R., Allen, M.H., Miklowitz, D.J., Oquendo, M.A., Frank, E., Perlis, R.H., Martinez, J.M., Fagioli, A., Otto, M.W., Chessick, C.A., Zboyan, H.A., Miyahara, S., Sachs, G., Thase, M.E., 2006. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. *Bipolar Disord.* 8, 566–575.
- Margutti, P., Delunardo, F., Ortona, E., 2006. Autoantibodies associated with psychiatric disorders. *Curr. Neurovasc. Res.* 3, 149–157.
- Markou, A., 2007. Metabotropic glutamate receptor antagonists: novel therapeutics for nicotine dependence and depression? *Biol. Psychiatry* 61, 17–22.
- Markou, A., 2008. Review. Neurobiology of nicotine dependence. *Philos. Trans. R. Soc. Lond. B: Biol. Sci.* 363, 3159–3168.
- Martin, L.F., Freedman, R., 2007. Schizophrenia and the alpha7 Nicotinic Acetylcholine Receptor. *Int. Rev. Neurobiol.* 78, 225–246.
- Martin, L.F., Kem, W.R., Freedman, R., 2004. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. *Psychopharmacology (Berl.)* 174, 54–64.
- Martin-Ruiz, C.M., Court, J.A., Molnar, E., Lee, M., Gotti, C., Mamalaki, A., Tsouloufis, T., Tzartos, S., Ballard, C., Perry, R.H., Perry, E.K., 1999. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. *J. Neurochem.* 73, 1635–1640.
- Martin-Ruiz, C.M., Piggott, M., Gotti, C., Lindstrom, J., Mendelow, A.D., Siddique, M.S., Perry, R.H., Perry, R.K., Court, J.A., 2000. Alpha and beta nicotinic acetylcholine receptors subunits and synaptophysin in putamen from Parkinson's disease. *Neuropharmacology* 39, 2830–2839.
- Martin-Ruiz, C.M., Haroutunian, V.H., Long, P., Young, A.H., Davis, K.L., Perry, E.K., Court, J.A., 2003. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. *Biol. Psychiatry* 54, 1222–1233.
- Martin-Soelch, C., 2009. Is depression associated with dysfunction of the central reward system? *Biochem. Soc. Trans.* 37 (Pt 1), 313–317.
- Marubio, L.M., del Mar Arroyo-Jimenez, M., Cordero-Erausquin, M., Léna, C., Le Novère, N., de Kerchove d'Exaerde, A., Huchet, M., Damaj, M.I., Changeux, J.P., 1999. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. *Nature* 398, 805–810.
- Marutle, A., Zhang, X., Court, J., Piggott, M., Johnson, M., Perry, R., Perry, E., Nordberg, A., 2001. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. *J. Chem. Neuroanat.* 22, 115–126.
- Maskos, U., 2008. The cholinergic mesopontine tegmentum is a relatively neglected nicotinic master modulator of the dopaminergic system: relevance to drugs of abuse and pathology. *Br. J. Pharmacol.* 153 (SI), S438–S445.
- Maskos, U., Molles, B.E., Pons, S., Besson, M., Guirard, B.P., Guilloux, J.P., Evrard, A., Cazala, P., Cormier, A., Mameli-Engvall, M., Dufour, N., Cloëz-Tayarani, I., Bemelmans, A.P., Mallet, J., Gardier, A.M., David, V., Faure, P., Granon, S., Changeux, J.P., 2005. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. *Nature* 436, 103–107.
- Mathew, S.V., Law, A.J., Lipska, B.K., Davila-Garcia, M.I., Zamora, E.D., Mitkus, S.N., Vakkalanka, R., Straub, R.E., Weinberger, D.R., Kleinman, J.E., Hyde, T.M., 2007. Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. *Hum. Mol. Genet.* 16, 2921–2932.
- Matsubayashi, H., Inoue, A., Amano, T., Seki, T., Nakata, Y., Sasa, M., Sakai, N., 2004. Involvement of $\alpha 7$ - and $\alpha 4\beta 2$ -type postsynaptic nicotinic acetylcholine receptors in nicotine-induced excitation of dopaminergic neurons in the substantia nigra: a patch clamp and single-cell PCR study using acutely dissociated nigral neurons. *Brain Res. Mol. Brain Res.* 129, 1–7.
- Matsuzawa, S., Suzuki, T., Misawa, M., 2000. Involvement of mu-opioid receptor in the salinolol-associated place preference in rats exposed to conditioned fear stress. *Alcohol Clin. Exp. Res.* 24, 366–372.
- Matta, S.G., Balfour, D.J., Benowitz, N.L., Boyd, R.T., Buccafusco, J.J., Caggiula, A.R., Craig, C.R., Collins, A.C., Damaj, M.I., Donny, E.C., Gardiner, P.S., Grady, S.R., Heberlein, U., Leonard, S.S., Levin, E.D., Lukas, R.J., Markou, A., Marks, M.J., McCallum, S.E., Parameswaran, N., Perkins, K.A., Picciotto, M.R., Quik, M., Rose, J.E., Rothenfluh, A., Schafer, W.R., Stolerman, I.P., Tyndale, R.F., Wehner, J.M., Zirger, J.M., 2007. Guidelines on nicotine dose selection for in vivo research. *Psychopharmacology (Berl.)* 190, 269–319.
- McCaffery, J.M., Papandonatos, G.D., Stanton, C., Lloyd-Richardson, E.E., Niaura, R., 2008. Depressive symptoms and cigarette smoking in twins from the National Longitudinal Study of Adolescent Health. *Health Psychol.* 27, S207–S215.
- McCallum, S.E., Parameswaran, N., Bordia, T., McIntosh, J.M., Grady, S.R., Quik, M., 2005. Decrease in $\alpha 3^*/\alpha 6^*$ nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage. *Mol. Pharmacol.* 68, 737–746.
- McCallum, S.E., Parameswaran, N., Bordia, T., Fan, H., McIntosh, J.M., Quik, M., 2006. Differential regulation of mesolimbic alpha 3/alpha 6 beta 2 and alpha 4 beta 2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys. *J. Pharmacol. Exp. Ther.* 318, 381–388.
- McCann, S.J., LeCouteur, D.G., Green, A.C., Brayne, C., Johnson, A.G., Chan, D., McManus, M.E., Pond, S.M., 1998. The epidemiology of Parkinson's disease in an Australian population. *Neuroepidemiology* 17, 310–317.
- McClave, A.K., Dube, S.R., Strine, T.W., Kroenke, K., Caraballo, R.S., Mokdad, A.H., 2009. Associations between smoking cessation and anxiety and depression among U.S. adults. *Addict. Behav.* 34, 491–497.
- McClernon, F.J., Gilbert, D.G., 2004. Human functional neuroimaging in nicotine and tobacco research: basics, background, and beyond. *Nicotine Tob. Res.* 6, 941–959.
- McClernon, F.J., Kollins, S.H., 2008. ADHD and smoking: from genes to brain to behavior. *Ann. N.Y. Acad. Sci.* 1141, 131–147.
- McClernon, F.J., Hiott, F.B., Westman, E.C., Rose, J.E., Levin, E.D., 2006. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. *Psychopharmacology (Berl.)* 189, 125–133.
- McClernon, F.J., Kozink, R.V., Rose, J.E., 2008a. Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues. *Neuropsychopharmacology* 33, 2148–2157.
- McClernon, F.J., Kollins, S.H., Lutz, A.M., Fitzgerald, D.P., Murray, D.W., Redman, C., Rose, J.E., 2008b. Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study. *Psychopharmacology (Berl.)* 197, 95–105.
- McClernon, F.J., Kozink, R.V., Lutz, A.M., Rose, J.E., 2009. 24-hsmoking abstinence potentiates fMRI-BOLD activation to smoking cues in cerebral cortex and dorsal striatum. *Psychopharmacology (Berl.)* 204, 25–35.

- McGee, R., Williams, S., Nada-Raja, S., 2005. Is cigarette smoking associated with suicidal ideation among young people? *Am. J. Psychiatry* 162, 619–620.
- McGough, J.J., Smalley, S.L., McCracken, J.T., Yang, M., Del'Homme, M., Lynn, D.E., Loo, S., 2005. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. *Am. J. Psychiatry* 162, 1621–1627.
- McIntyre, R.S., 2008. Varenicline and suicidality: a new era in medication safety surveillance. *Expert Opin. Drug Saf.* 7, 511–514.
- Mehler-Wex, C., Riederer, P., Gerlach, M., 2006. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. *Neurotox. Res.* 10, 167–179.
- Melis, M., Spiga, S., Diana, M., 2005. The dopamine hypothesis of drug addiction: hypodopaminergic state. *Int. Rev. Neurobiol.* 63, 101–154.
- Melis, M., Enrico, P., Peana, A.T., Diana, M., 2007. Acetaldehyde mediates alcohol activation of the mesolimbic dopamine system. *Eur. J. Neurosci.* 26, 2824–2833.
- Mellick, G.D., Gartner, C.E., Silburn, P.A., Battistutta, D., 2006. Passive smoking and Parkinson disease. *Neurology* 67, 179–180.
- Mendelson, J.H., Goletiani, N., Sholar, M.B., Siegel, A.J., Mello, N.K., 2008. Effects of smoking successive low- and high-nicotine cigarettes on hypothalamic–pituitary–adrenal axis hormones and mood in men. *Neuropsychopharmacology* 33, 749–760.
- Merritt, L.L., Martin, B.R., Walters, C., Lichtman, A.H., Damaj, M.I., 2008. The endogenous cannabinoid system modulates nicotine reward and dependence. *J. Pharmacol. Exp. Ther.* 326, 483–492.
- Mesulam, M., Shaw, P., Mash, D., Weintraub, S., 2004. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. *Ann. Neurol.* 55, 815–828.
- Metz, C.N., Gregersen, P.K., Malhotra, A.K., 2004. Metabolism and biochemical effects of nicotine for primary care providers. *Med. Clin. N. Am.* 88, 1399–1413.
- Miksyt, S., Tyndale, R.F., 2006. Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. *J. Neural. Transm. Suppl.* 70, 177–180.
- Milberger, S., Biederman, J., Faraone, S.V., Chen, L., Jones, J., 1997. ADHD is associated with early initiation of cigarette smoking in children and adolescents. *J. Am. Acad. Child Adolesc. Psychiatry* 36, 37–44.
- Millan, M.J., 2006. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. *Pharmacol. Ther.* 110, 135–370.
- Millar, N.S., 2008. RIC-3: a nicotinic acetylcholine receptor chaperone. *Br. J. Pharmacol.* 153 (Suppl 1), S177–S183.
- Millar, N.S., Gotti, C., 2009. Diversity of vertebrate nicotinic acetylcholine receptors. *Neuropharmacology* 56, 237–246.
- Millar, N.S., Harkness, P.C., 2008. Assembly and trafficking of nicotinic acetylcholine receptors (Review). *Mol. Membr. Biol.* 25, 279–292.
- Miller, M., Hemenway, D., Rimm, E., 2000a. Cigarettes and suicide: a prospective study of 50,000 men. *Am. J. Public Health* 90, 768–773.
- Miller, M., Hemenway, D., Bell, N.S., Yore, M.M., Amoroso, P.J., 2000b. Cigarette smoking and suicide: a prospective study of 300,000 male active-duty Army soldiers. *Am. J. Epidemiol.* 151, 1060–1063.
- Min, J.Y., Min, K.B., Paek, D., Sakong, J., Cho, S.I., 2007. The association between neurobehavioral performance and lung function. *Neurotoxicology* 28, 441–444.
- Mineur, Y.S., Picciotto, M.R., 2008. Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction. *Biochem. Pharmacol.* 75, 323–333.
- Mineur, Y.S., Sonnenzi, O., Picciotto, M.R., 2007. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. *Neuropharmacology* 52, 1256–1262.
- Mitrouska, I., Bouloukaki, I., Siafakas, N.M., 2007. Pharmacological approaches to smoking cessation. *Pulm. Pharmacol. Ther.* 20, 220–232.
- Mitsis, E.M., Cosgrove, K.P., Staley, J.K., Bois, F., Frohlich, E.B., Tamagnan, G.D., Estok, K.M., Seibyl, J.P., van Dyck, C.H., 2008. Age-related decline in nicotinic receptor availability with [¹²³I]5-IA-85380 SPECT. *Neurobiol. Aging* [Epub ahead of print].
- Miwa, J.M., Stevens, T.R., King, S.L., Caldarone, B.J., Ibanez-Tallon, I., Xiao, C., Fitzsimonds, R.M., Pavlides, C., Lester, H.A., Picciotto, M.R., Heintz, N., 2006. The protoxin lynx1 acts on nicotinic acetylcholine receptors to balance neuronal activity and survival in vivo. *Neuron* 51, 587–600.
- Mobbs, D., Greicius, M.D., Abdel-Azim, E., Menon, V., Reiss, A.L., 2003. Humor modulates the mesolimbic reward centers. *Neuron* 40, 1041–1048.
- Molina, B.S., Pelham Jr., W.E., 2003. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. *J. Abnorm. Psychol.* 112, 497–507.
- Montgomery, A.J., Lingford-Hughes, A.R., Egerton, A., Nutt, D.J., Grasby, P.M., 2007. The effect of nicotine on striatal dopamine release in man: A [¹¹C]raclopride PET study. *Synapse* 61, 637–645.
- Monuteaux, M.C., Spencer, T.J., Faraone, S.V., Wilson, A.M., Biederman, J., 2007. A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. *J. Clin. Psychiatry* 68, 1094–1101.
- Morioka, C., Kondo, H., Akashi, K., Matsumura, K., Ochi, N., Makinaga, G., Furukawa, T., 1997. The continuous and simultaneous blood flow velocity measurement of four cerebral vessels and a peripheral vessel during cigarette smoking. *Psychopharmacology (Berl.)* 131, 220–229.
- Moriya, F., Hashimoto, Y., Furumiyama, J., 2007. Nicotine and cotinine levels in body fluids of smokers who committed suicide. *Forensic Sci. Int.* 168, 102–105.
- Moroni, M., Bermudez, I., 2006. Stoichiometry and pharmacology of two human alpha4beta2 nicotinic receptor types. *J. Mol. Neurosci.* 30, 95–96.
- Morra, J.T., 2007. The neural substrate of disappointment revealed? *J. Neurosci.* 27, 10647–10648.
- Mousavi, M., Hellström-Lindahl, E., 2009. Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. *Neurochem. Int.* 54, 237–244.
- Mousavi, M., Nordberg, A., 2006. Expression of the alpha7, alpha4 and alpha3 nicotinic receptor subtype in the brain and adrenal medulla of transgenic mice carrying genes coding for human AChE and beta-amyloid. *Int. J. Dev. Neurosci.* 24, 269–273.
- Mousavi, M., Hellström-Lindahl, E., Guan, Z.Z., Shan, K.R., Ravid, R., Nordberg, A., 2003. Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease. *Neuroscience* 122, 515–520.
- Mravec, B., 2006. Salsolinol, a derivative of dopamine, is a possible modulator of catecholaminergic transmission: a review of recent developments. *Physiol. Res.* 55, 353–364.
- Mudo, G., Belluardo, N., Fuxe, K., 2007. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. *J. Neural. Transm.* 114, 135–147.
- Mufson, E.J., Counts, S.E., Perez, S.E., Ginsberg, S.D., 2008. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. *Expert Rev. Neurother.* 8, 1703–1718.
- Mukhin, A.G., Kimes, A.S., Chefer, S.I., Matochik, J.A., Contoreggi, C.S., Horti, A.G., Vaupel, D.B., Pavlova, O., Stein, E.A., 2008. Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. *J. Nucl. Med.* 49, 1628–1635.
- Munafò, M.R., Hitsman, B., Rende, R., Metcalfe, C., Niaura, R., 2008. Effects of progression to cigarette smoking on depressed mood in adolescents: evidence from the National Longitudinal Study of Adolescent Health. *Addiction* 103, 162–171.
- Musiak, A., Bajda, M., Malawska, B., 2007. Recent developments in cholinesterase inhibitors for Alzheimer's disease treatment. *Curr. Med. Chem.* 14, 2654–2679.
- Musso, F., Bettermann, F., Vucurevic, G., Stoeter, P., Konrad, A., Winterer, G., 2007. Smoking impacts on prefrontal attentional network function in young adult brains. *Psychopharmacology (Berl.)* 191, 159–169.
- Mykletun, A., Overland, S., Aarø, L.E., Liabø, H.M., Stewart, R., 2008. Smoking in relation to anxiety and depression: evidence from a large population survey: the HUNT study. *Eur. Psychiatry* 23, 77–84.
- Nagata, K., Shinohara, T., Kanno, I., Hatazawa, J., Domino, E., 1995. Effects of tobacco cigarette smoking on cerebral blood flow in normal adults. In: Domino, E.F. (Ed.), *Brain Imaging of Nicotine and Tobacco Smoking*. NPP Books, Ann Arbor, pp. 95–107.
- Nandi, D., Aziz, T.Z., Giladi, N., Winter, J.F., 2002. Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus. *Brain* 125, 2418–2430.
- Naqvi, N.H., Bechara, A., 2009. The hidden island of addiction: the insula. *Trends Neurosci.* 32, 56–67.
- Naqvi, N.H., Rudrauf, D., Damasio, H., Bechara, A., 2007. Damage to the insula disrupts addiction to cigarette smoking. *Science* 315, 531–534.
- Nelson, P.T., Braak, H., Markesbery, W.R., 2009. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. *J. Neuropathol. Exp. Neurol.* 68, 1–14.
- Nestler, E.J., Carlezon Jr., W.A., 2006. The mesolimbic dopamine reward circuit in depression. *Biol. Psychiatry* 59, 1151–1159.
- Neves, F.S., Malloy-Diniz, L.F., Corrêa, H., 2009. Suicidal behavior in bipolar disorder: what is the influence of psychiatric comorbidities? *J. Clin. Psychiatry* 70, 13–18.
- Newberg, A., Lerman, C., Wintering, N., Ploessl, K., Mozley, P.D., 2007. Dopamine transporter binding in smokers and nonsmokers. *Clin. Nucl. Med.* 32, 452–455.
- Newhouse, P.A., Potter, A., Kelton, M., Corwin, J., 2001. Nicotinic treatment of Alzheimer's disease. *Biol. Psychiatry* 49, 268–278.
- Newhouse, P., Singh, A., Potter, A., 2004a. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. *Curr. Top. Med. Chem.* 4, 267–282.
- Newhouse, P.A., Potter, A., Singh, A., 2004b. Effects of nicotinic stimulation on cognitive performance. *Curr. Opin. Pharmacol.* 4, 36–46.
- Nisell, M., Nomikos, G.G., Hertel, P., Panagis, G., Svensson, T.H., 1996. Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. *Synapse* 22, 369–381.
- Nordberg, A., 2001. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. *Biol. Psychiatry* 49, 200–210.
- Nordberg, A., 2006a. Emerging biology of the cholinergic system across the spectrum of Alzheimer's disease. *Int. Psychogeriatr.* 18 (S1), S3–S16.
- Nordberg, A., 2006b. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. *Alzheimer Dis. Assoc. Disord.* 20, S12–S18.
- Nordberg, A., Lundqvist, H., Hartvig, P., Lilja, A., Långström, B., 1995. Kinetic analysis of regional (S)(–)[¹¹C]-nicotine binding in normal and Alzheimer brains—in vivo assessment using positron emission tomography. *Alzheimer Dis. Assoc. Disord.* 9, 21–27.
- Nuutinen, S., Ahtee, L., Tuominen, R.K., 2005. Time and brain region specific up-regulation of low affinity neuronal nicotinic receptors during chronic nicotine administration in mice. *Eur. J. Pharmacol.* 515, 83–89.
- Nuutinen, S., Ekokoski, E., Lahdensuo, E., Tuominen, R.K., 2006. Nicotine-induced upregulation of human neuronal nicotinic alpha7-receptors is potentiated by modulation of cAMP and PKC in SH-EP1-halpha7 cells. *Eur. J. Pharmacol.* 544, 21–30.
- O'Brien, J.T., Colloby, S.J., Pakrasi, S., Perry, E.K., Pimlott, S.L., Wyper, D.J., McKeith, I.G., Williams, E.D., 2007. Alpha4beta2 nicotinic receptor status in Alzheimer's

- disease using 123I-5IA-85380 single-photon-emission computed tomography. *J. Neurol. Neurosurg. Psychiatry* 78, 356–362.
- O'Leary, K., Parameswaran, N., McIntosh, J.M., Quirk, M., 2008. Cotinine selectively activates a subpopulation of $\alpha 6 \beta 2$ nicotinic receptors in monkey striatum. *J. Pharmacol. Exp. Ther.* 325, 646–654.
- Obel, C., Linnet, K.M., Henriksen, T.B., Rodriguez, A., Järvelin, M.R., Kotimaa, A., Moilanen, I., Ebeling, H., Bilenberg, N., Taanila, A., Ye, G., Olsen, J., 2009. Smoking during pregnancy and hyperactivity-inattention in the offspring—comparing results from three Nordic cohorts. *Int. J. Epidemiol.* 38, 698–705.
- Ochoa, E.L., Lasalde-Dominicci, J., 2007. Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. *Cell. Mol. Neurobiol.* 27, 609–639.
- Oddo, S., LaFerla, F.M., 2006. The role of nicotinic acetylcholine receptors in Alzheimer's disease. *J. Physiol. Paris* 99, 172–179.
- Oddo, S., Caccamo, A., Green, K.N., Liang, K., Tran, L., Chen, Y., Leslie, F.M., LaFerla, F.M., 2005. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. *Proc. Natl. Acad. Sci. U.S.A.* 102, 3046–3051.
- Oerlemans, M.E., van den Akker, M., Schuurman, A.G., Kellen, E., Buntinx, F., 2007. A meta-analysis on depression and subsequent cancer risk. *Clin. Pract. Epidemiol. Ment. Health* 3, 29.
- Oertel, W., Poewe, W., Wolters, E., De Deyn, P.P., Emre, M., Kirsch, C., Hsu, C., Tekin, S., Lane, R., 2008. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. *Drug Saf.* 31, 79–94.
- Oishi, N., Hashikawa, K., Yoshida, H., Ishizu, K., Ueda, M., Kawashima, H., Saji, H., Fukuyama, H., 2007. Quantification of nicotinic acetylcholine receptors in Parkinson's disease with (123I)-5IA SPECT. *J. Neurol. Sci.* 256, 52–60.
- Okuda, T., Haga, T., Kanai, Y., Endou, H., Ishihara, T., Katsura, I., 2000. Identification and characterization of the high-affinity choline transporter. *Nat. Neurosci.* 3, 120–125.
- Olinicy, A., Martin, L., 2005. Diminished suppression of the P50 auditory evoked potential in bipolar disorder subjects with a history of psychosis. *Am. J. Psychiatry* 162, 43–49.
- Olinicy, A., Stevens, K.E., 2007. Treating schizophrenia symptoms with an $\alpha 7$ nicotinic agonist, from mice to men. *Biochem. Pharmacol.* 74, 1192–1201.
- Olinicy, A., Harris, J.G., Johnson, L.L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G.O., Leonard, S., Stevens, K.E., Stevens, J.O., Martin, L., Adler, L.E., Soti, F., Kem, W.R., Freedman, R., 2006. Proof-of-concept trial of an $\alpha 7$ nicotinic agonist in schizophrenia. *Arch. Gen. Psychiatry* 63, 630–638.
- Oquendo, M.A., Galfalvy, H., Russo, S., Ellis, S.P., Grunebaum, M.F., Burke, A., Mann, J.J., 2004. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. *Am. J. Psychiatry* 161, 1433–1441.
- Ostacher, M.J., Nierenberg, A.A., Perlis, R.H., Eidelman, P., Borrelli, D.J., Tran, T.B., Marzilli Ericson, G., Weiss, R.D., Sachs, G.S., 2006. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. *J. Clin. Psychiatry* 67, 1907–1911.
- Pacher, P., Kecskeneti, V., 2004. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? *Curr. Med. Chem.* 11, 925–943.
- Pahapill, P.A., Lozano, A.M., 2000. The pedunculopontine nucleus and Parkinson's disease. *Brain* 123, 1767–1783.
- Papapetropoulos, S., Singer, C., Villar, J.M., Gonzalez, J., Mash, D.C., 2005. Does cigarette smoking provide clinically significant neuroprotection among patients diagnosed with Parkinson's disease? *Mov. Disord.* 20, 641–642.
- Papke, R.L., Sanberg, P.R., Shytle, R.D., 2001. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. *J. Pharmacol. Exp. Ther.* 297, 646–656.
- Park, H.J., Lee, P.H., Ahn, Y.W., Choi, Y.J., Lee, G., Lee, D.Y., Chung, E.S., Jin, B.K., 2007. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. *Eur. J. Neurosci.* 26, 79–89.
- Parkinson Study Group, 2006. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. *Neurology* 66, 408–410.
- Parrott, A.C., 2006. Nicotine psychobiology: how chronic-dose prospective studies can illuminate some of the theoretical issues from acute-dose research. *Psychopharmacology (Berl.)* 184, 567–576.
- Pasco, J.A., Williams, L.J., Jacka, F.N., Ng, F., Henry, M.J., Nicholson, G.C., Kotowicz, M.A., Berk, M., 2008. Tobacco smoking as a risk factor for major depressive disorder: population-based study. *Br. J. Psychiatry* 193, 322–326.
- Pasumarthi, R.K., Fadel, J., 2008. Activation of orexin/hypocretin projections to basal forebrain and paraventricular thalamus by acute nicotine. *Brain Res. Bull.* 77, 367–373.
- Patkar, A.A., Mannelli, P., Peindl, K., Murray, H.W., Meier, B., Leone, F.T., 2006. Changes in tobacco smoking following treatment for cocaine dependence. *Am. J. Drug Alcohol Abuse* 32, 135–148.
- Patterson, F., Jepson, C., Strasser, A.A., Loughead, J., Perkins, K.A., Gur, R.C., Frey, J.M., Siegel, S., Lerman, C., 2009. Varenicline improves mood and cognition during smoking abstinence. *Biol. Psychiatry* 65, 144–149.
- Paul, R.H., Grieve, S.M., Niaura, R., David, S.P., Laidlaw, D.H., Cohen, R., Sweet, L., Taylor, G., Clark, R.C., Pogun, S., Gordon, E., 2008. Chronic cigarette smoking and the microstructural integrity of white matter in healthy adults: a diffusion tensor imaging study. *Nicotine Tob. Res.* 10, 137–147.
- Pauly, J.R., 2008. Gender differences in tobacco smoking dynamics and the neuropharmacological actions of nicotine. *Front. Biosci.* 13, 505–516.
- Paz, R., Barsness, B., Martenson, T., Tanner, D., Allan, A.M., 2007. Behavioral teratogenicity induced by nonforced maternal nicotine consumption. *Neuropsychopharmacology* 32, 693–699.
- Pedersen, W., von Soest, T., 2009. Smoking, nicotine dependence and mental health among young adults: a 13-year population-based longitudinal study. *Addiction* 104, 129–137.
- Peng, X., Gerzanich, V., Anand, R., Whiting, P.J., Lindstrom, J., 1994. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. *Mol. Pharmacol.* 46, 523–530.
- Perez, G.H., Nicolau, J.C., Romano, B.W., Laranjeira, R., 2008a. Depression: a predictor of smoking relapse in a 6-month follow-up after hospitalization for acute coronary syndrome. *Eur. J. Cardiovasc. Prev. Rehabil.* 15, 89–94.
- Perez, X.A., Bordia, T., McIntosh, J.M., Grady, S.R., Quirk, M., 2008b. Long-term nicotine treatment differentially regulates striatal $\alpha 6 \beta 2$ and $\alpha 6$ (non $\alpha 4$) $\beta 2$ nAChR expression and function. *Mol. Pharmacol.* 74, 844–853.
- Perez, X., O'Leary, K., Parameswaran, N., McIntosh, J.M., Quirk, M., 2009. Prominent role of $\alpha 3 \beta 2$ nAChRs in regulating evoked dopamine release in primate putamen; effect of long-term nicotine treatment. *Mol. Pharmacol.* 75, 938–946.
- Perkins, K.A., Lerman, C., Grottenthaler, A., Ciccocioppo, M.M., Milanak, M., Conklin, C.A., Bergen, A.W., Benowitz, N.L., 2008. Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. *Behav. Pharmacol.* 19, 641–649.
- Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H., Perry, R.H., 1978. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. *Br. Med. J.* 2, 1457–1459.
- Perry, E., Martin-Ruiz, C., Lee, M., Griffiths, M., Johnson, M., Piggott, M., Haroutunian, V., Buxbaum, J.D., Nasland, J., Davis, K., Gotti, C., Clementi, F., Tzartos, S., Cohen, O., Soreq, H., Jaros, E., Perry, R., Ballard, C., McKeith, I., Court, J., 2000. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. *Eur. J. Pharmacol.* 393, 215–222.
- Perry, C., Sklan, E.H., Soreq, H., 2004. CREB regulates AChE-R-induced proliferation of human glioblastoma cells. *Neoplasia* 6, 279–286.
- Peters, R., Poulter, R., Warner, J., Beckett, N., Burch, L., Bulpitt, C., 2008. Smoking, dementia and cognitive decline in the elderly, a systematic review. *BMC Geriatr.* 8, 36.
- Philip, N.S., Carpenter, L.L., Tyrka, A.R., Whiteley, L.B., Price, L.H., 2009. Varenicline augmentation in depressed smokers: an 8-week, open-label study. *J. Clin. Psychiatry* [Epub ahead of print].
- Phillips, D.E., Hill, L., Weller, P., Willett, M., Bakewell, R., 2003. Tobacco smoke and the upper airway. *Clin. Otolaryngol. Allied Sci.* 28, 492–496.
- Piasecki, T.M., 2006. Relapse to smoking. *Clin. Psychol. Rev.* 26, 196–215.
- Piccardi, M., Congiu, D., Squassina, A., Manconi, F., Putzu, P.F., Mereu, R.M., Chillotti, C., Del Zompo, M., 2007. Alzheimer's disease: case-control association study of polymorphisms in AChE, CHAT, and BChE genes in a Sardinian sample. *Am. J. Med. Genet. B: Neuropsychiatr. Genet.* 144B, 895–899.
- Picciotto, M.R., 2003. Nicotine as a modulator of behavior: beyond the inverted U. *Trends Pharmacol. Sci.* 24, 493–499.
- Picciotto, M.R., Zoli, M., 2008. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. *Front. Biosci.* 13, 492–504.
- Picciotto, M.R., Addy, N.A., Mineur, Y.S., Brunzell, D.H., 2008. It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. *Prog. Neurobiol.* 84, 329–342.
- Pidoplichko, V.I., Noguchi, J., Areola, O.O., Liang, Y., Peterson, J., Zhang, T., Dani, J.A., 2004. Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction. *Learn. Mem.* 11, 60–69.
- Pierce, R.C., Kumaresan, V., 2006. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? *Neurosci. Biobehav. Rev.* 30, 215–238.
- Pietilä, K., Lähde, T., Attila, M., Ahtee, L., Nordberg, A., 1998. Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. *Naunyn-Schmiedeberg Arch. Pharmacol.* 357, 176–182.
- Pimlott, S.L., Piggott, M., Owens, J., Greally, E., Court, J.A., Jaros, E., Perry, R.H., Perry, E.K., Wyper, D., 2004. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[125I]-A-85380. *Neuropsychopharmacology* 29, 108–116.
- Plaha, P., Gill, S.S., 2005. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. *NeuroReport* 16, 1883–1887.
- Plazas, P.V., Katz, E., Gomez-Casati, M.E., Bouzat, C., Elgoyhen, A.B., 2005. Stoichiometry of the $\alpha 9 \beta 10$ nicotinic cholinergic receptor. *J. Neurosci.* 25, 10905–10912.
- Pogocki, R., Duman, T., Danilczuk, M., Danilczuk, M., Celuch, M., Walajtys-Rode, E., 2007. Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders. *Eur. J. Pharmacol.* 563, 18–39.
- Pogun, S., Yararbas, G., 2009. Sex differences in nicotine action. *Handb. Exp. Pharmacol.* 192, 261–291.
- Poltavski, D.V., Petros, T., 2006. Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits. *Physiol. Behav.* 87, 614–624.
- Pomarol-Clotet, E., Honey, G.D., Murray, G.K., Corlett, P.R., Absalom, A.R., Lee, M., McKenna, P.J., Bullmore, E.T., Fletcher, P.C., 2006. Psychological effects of ketamine in healthy volunteers. *Phenomenological study. Br. J. Psychiatry* 189, 173–179.
- Pomerleau, O.F., Downey, K.K., Stelson, F.W., Pomerleau, C.S., 1995. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. *J. Subst. Abuse* 7, 373–378.

- Pompili, M., Rihmer, Z., Innamorati, M., Lester, D., Girardi, P., Tatarelli, R., 2009. Assessment and treatment of suicide risk in bipolar disorders. *Expert Rev. Neurother.* 9, 109–136.
- Pons, S., Fattore, L., Cossu, G., Tolu, S., Porcu, E., McIntosh, J.M., Changeux, J.P., Maskos, U., Fratta, W., 2008. Crucial role of $\alpha 4$ and $\alpha 6$ nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. *J. Neurosci.* 28, 12318–12327.
- Popik, P., Kozela, E., Krawczyk, M., 2003. Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram. *Br. J. Pharmacol.* 139, 1196–1202.
- Popik, P., Krawczyk, M., Kos, T., Nalepa, I., Kowalska, M., Witariski, T., Antkiewicz-Michaluk, L., Vetulani, J., 2005. Nicotine produces antidepressant-like actions: behavioral and neurochemical evidence. *Eur. J. Pharmacol.* 515, 128–133.
- Portugal, G.S., Gould, T.J., 2008. Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. *Behav. Brain Res.* 193, 1–16.
- Potkin, S.G., Alphas, L., Hsu, C., Krishnan, K.R., Anand, R., Young, F.K., Meltzer, H., Green, A., 2003. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. *Biol. Psychiatry* 54, 444–452.
- Potter, A.S., Newhouse, P.A., 2004. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. *Psychopharmacology (Berl.)* 176, 182–194.
- Potter, A.S., Newhouse, P.A., 2008. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. *Pharmacol. Biochem. Behav.* 88, 407–417.
- Potter, A.S., Newhouse, P.A., Bucci, D.J., 2006. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? *Behav. Brain Res.* 175, 201–211.
- Powers, K.M., Kay, D.M., Factor, S.A., Zabetian, C.P., Higgins, D.S., Samii, A., Nutt, J.G., Griffith, A., Leis, B., Roberts, J.W., Martinez, E.D., Montimurro, J.S., Checkoway, H., Payami, H., 2008. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. *Mov. Disord.* 23, 88–95.
- Pozuelo, L., Tesar, G., Zhang, J., Penn, M., Franco, K., Jiang, W., 2009. Depression and heart disease: what do we know, and where are we headed? *Cleve. Clin. J. Med.* 76, 59–70.
- Prasad, C., Ikegami, H., Shimizu, I., Onaivi, E.S., 1994. Chronic nicotine intake decelerates aging of nigrostriatal dopaminergic neurons. *Life Sci.* 54, 1169–1184.
- Prochaska, J.J., Hall, S.M., Bero, L.A., 2008a. Tobacco use among individuals with schizophrenia: what role has the tobacco industry played? *Schizophr. Bull.* 34, 555–567.
- Prochaska, J.J., Hall, S.M., Tsoh, J.Y., Eisendrath, S., Rossi, J.S., Redding, C.A., Rosen, A.B., Meisner, M., Humfleet, G.L., Gorecki, J.A., 2008b. Treating tobacco dependence in clinically depressed smokers: effect of smoking cessation on mental health functioning. *Am. J. Public Health* 98, 446–448.
- Proctor, R.N., 2004. The global smoking epidemic: a history and status report. *Clin. Lung Cancer* 5, 371–376.
- Prus, A.J., Maxwell, A.T., Baker, K.M., Rosecrans, J.A., James, J.R., 2007. Acute behavioral tolerance to nicotine in the conditioned. Taste Aversion Paradigm. *Drug Dev. Res.* 68, 522–528.
- Pryor, W.A., Stone, K., 1993. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. *Ann. N.Y. Acad. Sci.* 686, 12–27.
- Purnell, C., Gao, S., Callahan, C.M., Hendrie, H.C., 2009. Cardiovascular risk factors and incident Alzheimer Disease: a systematic review of the literature. *Alzheimer Dis. Assoc. Disord.* 23, 1–10.
- Quarta, D., Ciruela, F., Patkar, K., Borycz, J., Solinas, M., Lluís, C., Franco, R., Wise, R.A., Goldberg, S.R., Hope, B.T., Woods, A.S., Ferré, S., 2007. Heteromeric nicotinic acetylcholine-dopamine autoreceptor complexes modulate striatal dopamine release. *Neuropsychopharmacology* 32, 35–42.
- Quick, M.W., Lester, R.A., 2002. Desensitization of neuronal nicotinic receptors. *J. Neurobiol.* 53, 457–478.
- Quik, M., 2004. Smoking, nicotine and Parkinson's disease. *Trends Neurosci.* 27, 561–568.
- Quik, M., McIntosh, J.M., 2006. Striatal $\alpha 6^*$ nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy. *J. Pharmacol. Exp. Ther.* 316, 481–489.
- Quik, M., Bordia, T., Forno, L., McIntosh, J.M., 2004. Loss of α -conotoxin MII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum. *J. Neurochem.* 88, 668–679.
- Quik, M., Parameswaran, N., McCallum, S.E., Bordia, T., Bao, S., McCormack, A., Kim, A., Tyndale, R.F., Langston, J.W., Di Monte, D.A., 2006. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. *J. Neurochem.* 98, 1866–1875.
- Quik, M., Bordia, T., O'Leary, K., 2007. Nicotinic receptors as CNS targets for Parkinson's disease. *Biochem. Pharmacol.* 74, 1224–1234.
- Quik, M., O'Leary, K., Tanner, C.M., 2008. Nicotine and Parkinson's disease: implications for therapy. *Mov. Disord.* 23, 1641–1652.
- Rabenstein, R.L., Caldarone, B.J., Picciotto, M.R., 2006. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not $\beta 2$ - or $\alpha 7$ -nicotinic acetylcholine receptor subunit knockout mice. *Psychopharmacology (Berl.)* 189, 395–401.
- Rabinoff, M., Caskey, N., Rissling, A., Park, C., 2007. Pharmacological and chemical effects of cigarette additives. *Am. J. Public Health* 97, 1981–1991.
- Radek, R.J., Miner, H.M., Bratcher, N.A., Decker, M.W., Gopalakrishnan, M., Bitner, R.S., 2006. $\alpha 4\beta 2$ nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating. *Psychopharmacology (Berl.)* 187, 47–55.
- Raghu, P., Sivakumar, B., 2004. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. *Biochim. Biophys. Acta* 1703, 1–9.
- Raiteri, M., 2006. Functional pharmacology in human brain. *Pharmacol. Rev.* 58, 162–193.
- Ramos, K.S., Moorthy, B., 2005. Bioactivation of polycyclic aromatic hydrocarbon carcinogens within the vascular wall: implications for human atherogenesis. *Drug Metab. Rev.* 37, 595–610.
- Ray, R., Loughhead, J., Wang, Z., Detre, J., Yang, E., Gur, R., Lerman, C., 2008. Neuroimaging, genetics and the treatment of nicotine addiction. *Behav. Brain Res.* 193, 159–169.
- Razay, G., Wilcock, G.K., 2008. Galantamine in Alzheimer's disease. *Expert Rev. Neurother.* 8, 9–17.
- Reitz, C., den Heijer, T., van Duijn, C., Hofman, A., Breteler, M.M., 2007. Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. *Neurology* 69, 998–1005.
- Rezvani, K., Teng, Y., Shim, D., De Biasi, M., 2007. Nicotine regulates multiple synaptic proteins by inhibiting proteasomal activity. *J. Neurosci.* 27, 10508–10519.
- Riala, K., Alaräisänen, A., Taanila, A., Hakko, H., Timonen, M., Räsänen, P., 2007a. Regular daily smoking among 14-year-old adolescents increases the subsequent risk for suicide: the Northern Finland 1966 Birth Cohort Study. *J. Clin. Psychiatry* 68, 775–780.
- Riala, K., Viilo, K., Hakko, H., Räsänen, P., STUDY-Seventy Research Group, 2007b. Heavy daily smoking among under 18-year-old psychiatric inpatients is associated with increased risk for suicide attempts. *Eur. Psychiatry* 22, 219–222.
- Rice, M.E., Cragg, S.J., 2004. Nicotine amplifies reward-related dopamine signals in striatum. *Nat. Neurosci.* 7, 583–584.
- Riegel, A.C., Zapata, A., Shippenberg, T.S., French, E.D., 2007. The abused inhalant toluene increases dopamine release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. *Neuropsychopharmacology* 32, 1558–1569.
- Rihmer, Z., 2007. Suicide risk in mood disorders. *Curr. Opin. Psychiatry* 20, 17–22.
- Rihmer, Z., Angst, J., 2005. Mood disorders: epidemiology. In: Sadock, B.J., Sadock, V.A. (Eds.), *Kaplan & Sadock's Comprehensive Textbook of Psychiatry*. 8th ed. Lippincott Williams & Wilkins, pp. 1576–1582.
- Rihmer, Z., Döme, P., Gonda, X., Kiss, H.G., Kovács, D., Seregi, K., Teleki, Z., 2007. Cigarette smoking and suicide attempts in psychiatric outpatients in Hungary. *Neuropsychopharmacol. Hung.* 9, 63–67.
- Ripoll, N., Brionne, M., Bourin, M., 2004. Nicotinic receptors and schizophrenia. *Curr. Med. Res. Opin.* 20, 1057–1074.
- Ritz, B., Ascherio, A., Checkoway, H., Marder, K.S., Nelson, L.M., Rocca, W.A., Ross, G.W., Strickland, D., Van Den Eeden, S.K., Gorell, J., 2007. Pooled analysis of tobacco use and risk of Parkinson disease. *Arch. Neurol.* 64, 990–997.
- Riveles, K., Huang, L.Z., Quik, M., 2008. Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cells. *Neurotoxicology* 29, 421–427.
- Robinson, S.E., James, J.R., Lapp, L.N., Vann, R.E., Gross, D.F., Philbin, S.D., Rosecrans, J.A., 2006. Evidence of cellular nicotinic receptor desensitization in rats exhibiting nicotine-induced acute tolerance. *Psychopharmacology (Berl.)* 184, 306–313.
- Roche, M., Harkin, A., Kelly, J.P., 2007. Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat. *Neuropsychopharmacology* 32, 1312–1320.
- Rodd, Z.A., Oster, S.M., Ding, Z.M., Toalston, J.E., Deehan, G., Bell, R.L., Li, T.K., McBride, W.J., 2008. The reinforcing properties of salsolinol in the ventral tegmental area: evidence for regional heterogeneity and the involvement of serotonin and dopamine. *Alcohol Clin. Exp. Res.* 32, 230–239.
- Rodriguez, D., Tercyak, K.P., Audrain-McGovern, J., 2008. Effects of inattention and hyperactivity/impulsivity symptoms on development of nicotine dependence from mid adolescence to young adulthood. *J. Pediatr. Psychol.* 33, 563–575.
- Rogers, R.L., Meyer, J.S., Shaw, T.G., Mortel, K.F., Hardenberg, J.P., Zaid, R.R., 1983. Cigarette smoking decreases cerebral blood flow suggesting increased risk for stroke. *JAMA* 250, 2796–2800.
- Rogers, R.L., Meyer, J.S., Judd, B.W., Mortel, K.F., 1985. Abstinence from cigarette smoking improves cerebral perfusion among elderly chronic smokers. *JAMA* 253, 2970–2974.
- Roitman, M.F., Wheeler, R.A., Wightman, R.M., Carelli, R.M., 2008. Real-time chemical responses in the nucleus accumbens differentiate rewarding and aversive stimuli. *Nat. Neurosci.* 11, 1376–1377.
- Rollema, H., Guanowsky, V., Mineur, Y.S., Shrikhande, A., Coe, J.W., Seymour, P.A., Picciotto, M.R., 2009. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. *Eur. J. Pharmacol.* 605, 114–116.
- Rose, J.E., 2006. Nicotine and nonnicotine factors in cigarette addiction. *Psychopharmacology (Berl.)* 184, 274–285.
- Rose, J.E., 2007. Multiple brain pathways and receptors underlying tobacco addiction. *Biochem. Pharmacol.* 74, 1263–1270.
- Rose, J.E., Behm, F.M., Westman, E.C., Johnson, M.P., Bates, J.E., Mathew, R.J., London, E.D., 1998. March. Acute effects of nicotine on regional and global cerebral blood flow. Presented at the Brain Imaging Symposium, annual meeting of the Society for Research on Nicotine and Tobacco, New Orleans.
- Rose, J.E., Behm, F.M., Westman, E.C., Mathew, R.J., London, E.D., Hawk, T.C., Turkington, T.G., Coleman, R.E., 2003. PET studies of the influences of nicotine on neural systems in cigarette smokers. *Am. J. Psychiatry* 160, 323–333.
- Rose, J.E., Behm, F.M., Salley, A.N., Bates, J.E., Coleman, R.E., Hawk, T.C., Turkington, T.G., 2007. Regional brain activity correlates of nicotine dependence. *Neuropsychopharmacology* 32, 2441–2452.

- Roshanaei-Moghaddam, B., Katon, W., 2009. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. *Psychiatr. Serv.* 60, 147–156.
- Rossi, S., Singer, S., Shearman, E., Sershen, H., Lajtha, A., 2005a. Regional heterogeneity of nicotine effects on neurotransmitters in rat brains in vivo at low doses. *Neurochem. Res.* 30, 91–103.
- Rossi, S., Singer, S., Shearman, E., Sershen, H., Lajtha, A., 2005b. The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. *Neurochem. Res.* 30, 541–558.
- Rourke, S.B., Dupont, R.M., Grant, I., Lehr, P.P., Lamoureux, G., Halpern, S., Yeung, D.W., 1997. Reduction in cortical IMP-SPET tracer uptake with recent cigarette consumption in a young group of healthy males. San Diego HIV Neurobehavioral Research Center. *Eur. J. Nucl. Med.* 24, 422–427.
- Rowe, D.L., Hermens, D.F., 2006. Attention-deficit/hyperactivity disorder: neurophysiology, information processing, arousal and drug development. *Expert Rev. Neurother.* 6, 1721–1734.
- Rukstalis, M., Jepson, C., Patterson, F., Lerman, C., 2005. Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. *J. Subst. Abuse Treat.* 28, 297–304.
- Rush, C.R., Higgins, S.T., Vansickel, A.R., Stoops, W.W., Lile, J.A., Glaser, P.E., 2005. Methylphenidate increases cigarette smoking. *Psychopharmacology (Berl.)* 181, 781–789.
- Ryan, R.E., Ross, S.A., Drago, J., Loiacono, R.E., 2001. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. *Br. J. Pharmacol.* 132, 1650–1656.
- Sabatinielli, D., Bradley, M.M., Lang, P.J., Costa, V.D., Versace, F., 2007. Pleasure rather than salience activates human nucleus accumbens and medial prefrontal cortex. *J. Neurophysiol.* 98, 1374–1379.
- Sabbagh, M.N., Tyas, S.L., Emery, S.C., Hansen, L.A., Alford, M.F., Reid, R.T., Tiraboschi, P., Thal, L.J., 2005. Smoking affects the phenotype of Alzheimer disease. *Neurology* 64, 1301–1303.
- Sabbagh, M.N., Shah, F., Reid, R.T., Sue, L., Connor, D.J., Peterson, L.K., Beach, T.G., 2006. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. *Arch. Neurol.* 63, 1771–1776.
- Sabbagh, M.N., Walker, D.G., Reid, R.T., Stadnick, T., Anand, K., Lue, L.F., 2008. Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). *Neurosci. Lett.* 448, 217–220.
- Sabia, S., Marmot, M., Dufouil, C., Singh-Manoux, A., 2008. Smoking history and cognitive function in middle age from the Whitehall II study. *Arch. Intern. Med.* 168, 1165–1173.
- Sabri, O., Kendziorra, K., Wolf, H., Gertz, H.J., Brust, P., 2008. Acetylcholine receptors in dementia and mild cognitive impairment. *Eur. J. Nucl. Med. Mol. Imag.* 35, 530–545.
- Sacco, K.A., Bannon, K.L., George, T.P., 2004. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. *J. Psychopharmacol.* 18, 457–474.
- Sacco, K.A., Termine, A., Seyal, A., Dudas, M.M., Vessicchio, J.C., Krishnan-Sarin, S., Jatlow, P.I., Wexler, B.E., George, T.P., 2005. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. *Arch. Gen. Psychiatry* 62, 649–659.
- Sacco, K.A., Creedon, C., Reutenauer, E.L., George, T.P., 2008. Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. *Schizophr. Res.* 103, 326–327.
- Saha, S., Chant, D., McGrath, J., 2007. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? *Arch. Gen. Psychiatry* 64, 1123–1131.
- Salas, R., Sturm, R., Boulter, J., De Biasi, M., 2009. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. *J. Neurosci.* 29, 3014–3018.
- Sallette, J., Pons, S., Devillers-Thiery, A., Soudant, M., Prado de Carvalho, L., Changeux, J.P., Corringier, P.J., 2005. Nicotine upregulates its own receptors through enhanced intracellular maturation. *Neuron* 46, 595–607.
- Salokangas, R.K., Vilkinen, H., Ilonen, T., Taiminen, T., Bergman, J., Haaparanta, M., Solin, O., Alanen, A., Syvalahti, E., Hietala, J., 2000. High levels of dopamine activity in the basal ganglia of cigarette smokers. *Am. J. Psychiatry* 157, 632–634.
- Salvi, V., Albert, U., Chiarle, A., Soreca, I., Bogetto, F., Maina, G., 2008. Metabolic syndrome in Italian patients with bipolar disorder. *Gen. Hosp. Psychiatry* 30, 318–323.
- Samaha, A.N., Robinson, T.E., 2005. Why does the rapid delivery of drugs to the brain promote addiction? *Trends Pharmacol. Sci.* 26, 82–87.
- Samaha, A.N., Yau, W.Y., Yang, P., Robinson, T.E., 2005. Rapid delivery of nicotine promotes behavioral sensitization and alters its neurobiological impact. *Biol. Psychiatry* 57, 351–360.
- Sánchez-Morla, E.M., García-Jiménez, M.A., Barabash, A., Martínez-Vizcaíno, V., Mena, J., Cabranes-Díaz, J.A., Baca-Baldomero, E., Santos, J.L., 2008. P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia. *Acta Psychiatr. Scand.* 117, 313–318.
- Sarter, M., Gehring, W.J., Kozak, R., 2006. More attention must be paid: the neurobiology of attentional effort. *Brain Res. Rev.* 51, 145–160.
- Schilbach, L., Eickhoff, S.B., Rotarska-Jagiela, A., Fink, G.R., Vogele, K., 2008. Minds at rest? Social cognition as the default mode of cognizing and its putative relationship to the “default system” of the brain. *Conscious. Cogn.* 17, 457–467.
- Schilström, B., Ivanov, V.B., Wiker, C., Svensson, T.H., 2007. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. *Neuropsychopharmacology* 32, 43–53.
- Schliebs, R., Arendt, T., 2006. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. *J. Neural. Transm.* 113, 1625–1644.
- Schmaljohann, J., Gündisch, D., Minnerop, M., Bucerius, J., Joe, A., Reinhardt, M., Guhlke, S., Biersack, H.J., Wüllner, U., 2006. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease. *Nucl. Med. Biol.* 33, 305–309.
- Schneider, B., Schnabel, A., Weber, B., Frolich, L., Maurer, K., Wetterling, T., 2005. Nicotine use in suicides: a case-control study. *Eur. Psychiatry* 20, 129–136.
- Schneider, B., Wetterling, T., Georgi, K., Bartusch, B., Schnabel, A., Blettner, M., 2009. Smoking differently modifies suicide risk of affective disorders, substance use disorders, and social factors. *J. Affect. Disord.* 112, 165–173.
- Schnoll, R.A., Patterson, F., 2009. Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. *Drug Alcohol Depend.* [Epub ahead of print].
- Schuller, H.M., 2007. Nitrosamines as nicotinic receptor ligands. *Life Sci.* 80, 2274–2280.
- Schuller, H.M., 2008. Neurotransmission and cancer: implications for prevention and therapy. *Anticancer Drugs* 19, 655–671.
- Schultz, W., 1997. Dopamine neurons and their role in reward mechanisms. *Curr. Opin. Neurobiol.* 7, 191–197.
- Schultz, W., 2007. Behavioral dopamine signals. *Trends Neurosci.* 30, 203–210.
- Schulze, K.K., Hall, M.H., McDonald, C., Marshall, N., Walshe, M., Murray, R.M., Bramon, E., 2007. P50 auditory evoked potential suppression in bipolar disorder patients with psychotic features and their unaffected relatives. *Biol. Psychiatry* 62, 121–128.
- Scott, W.K., Zhang, F., Stajich, J.M., Scott, B.L., Stacy, M.A., Vance, J.M., 2005. Family-based case-control study of cigarette smoking and Parkinson disease. *Neurology* 64, 442–447.
- Scott, D.J., Domino, E.F., Heitzeg, M.M., Koeppe, R.A., Ni, L., Guthrie, S., Zubieta, J.K., 2007. Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. *Neuropsychopharmacology* 32, 450–457.
- Sellin, A.K., Shad, M., Tamminga, C., 2008. Muscarinic agonists for the treatment of cognition in schizophrenia. *CNS Spectr.* 13, 985–996.
- Sellings, L.H., Baharnouri, G., McQuade, L.E., Clarke, P.B., 2008. Rewarding and aversive effects of nicotine are segregated within the nucleus accumbens. *Eur. J. Neurosci.* 28, 342–352.
- Serretti, A., Mandelli, L., 2008. The genetics of bipolar disorder: genome “hot regions”, genes, new potential candidates and future directions. *Mol. Psychiatry* 13, 742–771.
- Serretti, A., Olgiati, P., De Ronchi, D., 2007. Genetics of Alzheimer's disease. A rapidly evolving field. *J. Alzheimer's Dis.* 12, 73–92.
- Seth, P., Cheeta, S., Tucci, S., File, S.E., 2002. Nicotinic-serotonergic interactions in brain and behaviour. *Pharmacol. Biochem. Behav.* 71, 795–805.
- Shanmugam, G., Bhutani, S., Khan, D.A., Brown, E.S., 2007. Psychiatric considerations in pulmonary disease. *Psychiatr. Clin. N. Am.* 30, 761–780.
- Shepard, P.D., Joy, B., Clerkin, L., Schwarcz, R., 2003. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. *Neuropsychopharmacology* 28, 1454–1462.
- Shi, J., Hattori, E., Zou, H., Badner, J.A., Christian, S.L., Gershon, E.S., Liu, C., 2007. No evidence for association between 19 cholinergic genes and bipolar disorder. *Am. J. Med. Genet. B: Neuropsychiatr. Genet.* 144B, 715–723.
- Shimohara, S., Greenwald, D.L., Shafron, D.H., Akaika, A., Maeda, T., Kaneko, S., Kimura, J., Simpkins, C.E., Day, A.L., Meyer, E.M., 1998. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. *Brain Res.* 779, 359–363.
- Shin, E.J., Chae, J.S., Jung, M.E., Bing, G., Ko, K.H., Kim, W.K., Wie, M.B., Cheon, M.A., Nah, S.Y., Kim, H.C., 2007. Repeated intracerebroventricular infusion of nicotine prevents kainate-induced neurotoxicity by activating the alpha7 nicotinic acetylcholine receptor. *Epilepsy Res.* 73, 292–298.
- Shinohara, T., Nagata, K., Yokoyama, E., Sato, M., Matsuoka, S., Kanno, I., Hatazawa, J., Domino, E.F., 2006. Acute effects of cigarette smoking on global cerebral blood flow in overnight abstinent tobacco smokers. *Nicotine Tob. Res.* 8, 113–121.
- Shinotoh, H., Namba, H., Fukushima, K., Nagatsuka, S., Tanaka, N., Aotsuka, A., Tanada, S., Irie, T., 2000. Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography. *Alzheimer Dis. Assoc. Disord.* 14, S114–S118.
- Shintani, S., Shiigai, T., Arinami, T., 1998. Silent lacunar infarction on magnetic resonance imaging (MRI): risk factors. *J. Neurol. Sci.* 160, 82–86.
- Shoptaw, S., Rotheram-Fuller, E., Yang, X., Frosch, D., Nahom, D., Jarvik, M.E., Rawson, R.A., Ling, W., 2002. Smoking cessation in methadone maintenance. *Addiction* 97, 1317–1328.
- Shytle, R.D., Silver, A.A., Lukas, R.J., Newman, M.B., Sheehan, D.V., Sanberg, P.R., 2002. Nicotinic acetylcholine receptors as targets for antidepressants. *Mol. Psychiatry* 7, 525–535.
- Siennicki-Lantz, A., Reinprecht, F., Wollmer, P., Elmstahl, S., 2008. Smoking-related changes in cerebral perfusion in a population of elderly men. *Neuroepidemiology* 30, 84–92.
- Silvestrelli, G., Lanari, A., Parnetti, L., Tomassoni, D., Amenta, F., 2006. Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology. *Mech. Ageing Dev.* 127, 148–157.
- Silvestri, S., Negrete, J.C., Seaman, M.V., Shamm, C.M., Seeman, P., 2004. Does nicotine affect D2 receptor upregulation? A case-control study. *Acta Psychiatr. Scand.* 109, 313–317.

- Silvestrini, M., Troisi, E., Matteis, M., Cupini, L.M., Bernardi, G., 1996. Effect of smoking on cerebrovascular reactivity. *J. Cereb. Blood Flow Metab.* 16, 746–749.
- Singer, S., Rossi, S., Verzosa, S., Hashim, A., Lonow, R., Cooper, T., Sershen, H., Lajtha, A., 2004. Nicotine-induced changes in neurotransmitter levels in brain areas associated with cognitive function. *Neurochem. Res.* 29, 1779–1792.
- Singhal, S.K., Zhang, L., Morales, M., Oz, M., 2007. Antipsychotic clozapine inhibits the function of alpha7-nicotinic acetylcholine receptors. *Neuropharmacology* 52, 387–394.
- Sivaprakasam, K., 2006. Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation. *Curr. Med. Chem.* 13, 2179–2188.
- Skinhoj, E., Olesen, J., Paulson, O.B., 1973. Influence of smoking and nicotine on cerebral blood flow and metabolic rate of oxygen in man. *J. Appl. Physiol.* 35, 820–822.
- Slotkin, T.A., Seidler, F.J., 2006. Cholinergic receptor subtypes in the olfactory bulbectomy model of depression. *Brain Res. Bull.* 68, 341–345.
- Small, D.H., Maksiel, D., Kerr, M.L., Ng, J., Hou, X., Chu, C., Mehrani, H., Unabia, S., Azari, M.F., Loiacono, R., Aguilar, M.I., Chebib, M., 2007. The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor. *J. Neurochem.* 101, 1527–1538.
- Smith, R.C., Warner-Cohen, J., Matute, M., Butler, E., Kelly, E., Vaidyanathaswamy, S., Khan, A., 2006. Effects of nicotine nasal spray on cognitive function in schizophrenia. *Neuropsychopharmacology* 31, 637–643.
- Smith, M.J., Barch, D.M., Wolf, T.J., Mamah, D., Csernansky, J.G., 2008. Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophrenia. *Schizophr. Res.* 106, 294–299.
- Söderman, A., Thomsen, M.S., Hansen, H.H., Nielsen, E.O., Jensen, M.S., West, M.J., Mikkelsen, J.D., 2008. The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta1-42. *Brain Res.* 1227, 240–247.
- Solkhah, R., Wilens, T.E., Daly, J., Prince, J.B., Van Patten, S.L., Biederman, J., 2005. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. *J. Child Adolesc. Psychopharmacol.* 15, 777–786.
- Son, J.H., Winzer-Serhan, U.H., 2008. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs in rat hippocampal GABAergic interneurons. *J. Comp. Neurol.* 511, 286–299.
- Sousa, J.C., Cardoso, I., Marques, F., Saraiva, M.J., Palha, J.A., 2007. Transthyretin and Alzheimer's disease: where in the brain? *Neurobiol. Aging* 28, 713–718.
- Spina, L., Fenu, S., Longoni, R., Rivas, E., Di Chiara, G., 2006. Nicotine-conditioned single-trial place preference: selective role of nucleus accumbens shell dopamine D1 receptors in acquisition. *Psychopharmacology (Berl.)* 184, 447–455.
- Spring, B., Pingitore, R., McChargue, D.E., 2003. Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed, and nonpatient smokers. *Am. J. Psychiatry* 160, 316–322.
- Spring, B., Hitsman, B., Pingitore, R., McChargue, D.E., Gunnarsdottir, D., Corsica, J., Pergadia, M., Doran, N., Crayton, J.W., Baruah, S., Hedeker, D., 2007. Effect of tryptophan depletion on smokers and nonsmokers with and without history of major depression. *Biol. Psychiatry* 61, 70–77.
- Staley, J.K., Krishnan-Sarin, S., Zoghbi, S., Tamagnan, G., Fujita, M., Seibyl, J.P., Maciejewski, P.K., O'Malley, S., Innis, R.B., 2001. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. *Synapse* 41, 275–284.
- Staley, J.K., Krishnan-Sarin, S., Cosgrove, K.P., Krantzler, E., Frohlich, E., Perry, E., Dubin, J.A., Estok, K., Brenner, E., Baldwin, R.M., Tamagnan, G.D., Seibyl, J.P., Jatlow, P., Picciotto, M.R., London, E.D., O'Malley, S., van Dyck, C.H., 2006. Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. *J. Neurosci.* 26, 8707–8714.
- Stapleton, J.M., Gilson, S.F., Wong, D.F., Villemagne, V.L., Dannals, R.F., Grayson, R.F., Henningfield, J.E., London, E.D., 2003. Intravenous nicotine reduces cerebral glucose metabolism: a preliminary study. *Neuropsychopharmacology* 28, 765–772.
- Stephens, S.H., Logel, J., Barton, A., Franks, A., Schultz, J., Short, M., Dickenson, J., James, B., Fingerlin, T.E., Wagner, B., Hodgkinson, C., Graw, S., Ross, R.G., Freedman, R., Leonard, S., 2009. Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. *Schizophr. Res.* 109, 102–112.
- Steptoe, A., Ussher, M., 2006. Smoking, cortisol and nicotine. *Int. J. Psychophysiol.* 59, 228–235.
- Steuber, T.L., Danner, F., 2006. Adolescent smoking and depression: which comes first? *Addict. Behav.* 31, 133–136.
- Stip, E., Sepehry, A.A., Chouinard, S., 2007. Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review. Part 2. *Clin. Neuropharmacol.* 30, 218–229.
- Strand, J.E., Nyback, H., 2005. Tobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls. *Eur. Psychiatry* 20, 50–54.
- Strong, D.R., Kahler, C.W., Ramsey, S.E., Abrantes, A., Brown, R.A., 2004. Nicotine withdrawal among adolescents with acute psychopathology: an item response analysis. *Nicotine Tob. Res.* 6, 547–557.
- Subramanian, J., Govindan, R., 2007. Lung cancer in never smokers: a review. *J. Clin. Oncol.* 25, 561–570.
- Surtees, P.G., Wainwright, N.W., Luben, R.N., Wareham, N.J., Bingham, S.A., Khaw, K.T., 2008. Depression and ischemic heart disease mortality: evidence from the EPIC-Norfolk United Kingdom prospective cohort study. *Am. J. Psychiatry* 165, 515–523.
- Swan, G.E., Lessov-Schlaggar, C.N., 2007. The effects of tobacco smoke and nicotine on cognition and the brain. *Neuropsychol. Rev.* 17, 259–273.
- Swan, G.E., DeCarli, C., Miller, B.L., Reed, T., Wolf, P.A., Carmelli, D., 2000. Biobehavioral characteristics of nondemented older adults with subclinical brain atrophy. *Neurology* 54, 2108–2114.
- Takahashi, H., Fujimura, Y., Hayashi, M., Takano, H., Kato, M., Okubo, Y., Kanno, I., Ito, H., Suhara, T., 2008. Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. *Int. J. Neuropsychopharmacol.* 11, 413–417.
- Talhout, R., Opperhuizen, A., van Amsterdam, J.G., 2006. Sugars as tobacco ingredient: effects on mainstream smoke composition. *Food Chem. Toxicol.* 44, 1789–1798.
- Talhout, R., Opperhuizen, A., van Amsterdam, J.G., 2007. Role of acetaldehyde in tobacco smoke addiction. *Eur. Neuropsychopharmacol.* 17, 627–636.
- Taly, A., Corringer, P.J., Grutter, T., Prado de Carvalho, L., Karplus, M., Changeux, J.P., 2006. Implications of the quaternary twist allosteric model for the physiology and pathology of nicotinic acetylcholine receptors. *Proc. Natl. Acad. Sci. U.S.A.* 103, 16965–16970.
- Tan, H., Bishop, S.F., Lauzon, N.M., Sun, N., Laviolette, S.R., 2009. Chronic nicotine exposure switches the functional role of mesolimbic dopamine transmission in the processing of nicotine's rewarding and aversive effects. *Neuropharmacology* 56, 741–751.
- Tanabe, J., Tregellas, J.R., Martin, L.F., Freedman, R., 2006. Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia. *Biol. Psychiatry* 59, 754–761.
- Tanabe, J., Crowley, T., Hutchison, K., Miller, D., Johnson, G., Du, Y.P., Zerbe, G., Freedman, R., 2008. Ventral striatal blood flow is altered by acute nicotine but not withdrawal from nicotine. *Neuropsychopharmacology* 33, 627–633.
- Tanner, C.M., Goldman, S.M., Aston, D.A., Ottman, R., Ellenberg, J., Mayeux, R., Langston, J.W., 2002. Smoking and Parkinson's disease in twins. *Neurology* 58, 581–588.
- Tanskanen, A., Viinamäki, H., Hintikka, J., Koivumäe-Honkanen, H.T., Lehtonen, J., 1998. Smoking and suicidality among psychiatric patients. *Am. J. Psychiatry* 155, 129–130.
- Tanskanen, A., Tuomilehto, J., Viinamäki, H., Vartiainen, E., Lehtonen, J., Puska, P., 2000. Smoking and the risk of suicide. *Acta Psychiatr. Scand.* 101, 243–245.
- Tapia, L., Kuryatov, A., Lindstrom, J., 2007. Ca²⁺ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors. *Mol. Pharmacol.* 71, 769–776.
- Tapper, A.R., McKinney, S.L., Nashmi, R., Schwarz, J., Deshpande, P., Labarca, C., Whiteaker, P., Marks, M.J., Collins, A.C., Lester, H.A., 2004. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. *Science* 306, 1029–1032.
- Tasneem, A., Iyer, L.M., Jakobsson, E., Aravind, L., 2005. Identification of the prokaryotic ligand-gated ion channels and their implications for the mechanisms and origins of animal Cys-loop ion channels. *Genome Biol.* 6 (1), R4.
- Teaktong, T., Graham, A.J., Johnson, M., Court, J.A., Perry, E.K., 2004. Selective changes in nicotinic acetylcholine receptor subtypes related to tobacco smoking: an immunohistochemical study. *Neuropathol. Appl. Neurobiol.* 30, 243–254.
- Terborg, C., Birkner, T., Schack, B., Witte, O.W., 2002. Acute effects of cigarette smoking on cerebral oxygenation and hemodynamics: a combined study with near-infrared spectroscopy and transcranial Doppler sonography. *J. Neurol. Sci.* 205, 71–75.
- Tercyak, K.P., Lerman, C., Audrain, J., 2002. Association of attention-deficit/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. *J. Am. Acad. Child Adolesc. Psychiatry* 41, 799–805.
- Terrière, E., Dempsey, M.F., Herrmann, L.L., Tierney, K.M., Lonie, J.A., O'Carroll, R.E., Pimlott, S., Wyper, D.J., Herholz, K., Ebmeier, K.P., 2008. 5-(123I)-A-85380 binding to the alpha4beta2-nicotinic receptor in mild cognitive impairment. *Neurobiol. Aging* [Epub ahead of print].
- Terry Jr., A.V., Gearhart, D.A., 2007. Time dependent decreases in central alpha7 nicotinic acetylcholine receptors associated with haloperidol and risperidone treatment in rats. *Eur. J. Pharmacol.* 571, 29–32.
- Terry Jr., A.V., Mahadik, S.P., 2007. Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. *J. Pharmacol. Exp. Ther.* 320, 961–968.
- Terry Jr., A.V., Hill, W.D., Parikh, V., Evans, D.R., Waller, J.L., Mahadik, S.P., 2002. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. *Psychopharmacology (Berl.)* 164, 360–368.
- Terry Jr., A.V., Hill, W.D., Parikh, V., Waller, J.L., Evans, D.R., Mahadik, S.P., 2003. Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. *Neuropsychopharmacology* 28, 300–309.
- Terry Jr., A.V., Hernandez, C.M., Hohnadel, E.J., Bouchard, K.P., Buccafusco, J.J., 2005a. Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. *CNS Drug Rev.* 11, 229–252.
- Terry Jr., A.V., Gearhart, D.A., Mahadik, S.P., Warsi, S., Davis, L.W., Waller, J.L., 2005b. Chronic exposure to typical or atypical antipsychotics in rodents: temporal effects on central alpha7 nicotinic acetylcholine receptors. *Neuroscience* 136, 519–529.
- Terry Jr., A.V., Gearhart, D.A., Mahadik, S.P., Warsi, S., Waller, J.L., 2006. Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain. *Neuroscience* 140, 1277–1287.

- Thaker, G.K., 2007. Schizophrenia endophenotypes as treatment targets. *Expert Opin. Ther. Targets* 11, 1189–1206.
- Thapar, A., Fowler, T., Rice, F., Scourfield, J., van den Bree, M., Thomas, H., Harold, G., Hay, D., 2003. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. *Am. J. Psychiatry* 160, 1985–1989.
- Thapar, A., Rice, F., Hay, D., Boivin, J., Langley, K., van den Bree, M., Rutter, M., Harold, G., 2009. Prenatal smoking might not cause attention-deficit/hyperactivity disorder: evidence from a novel design. *Biol. Psychiatry* [Epub ahead of print].
- Thomsen, M.S., Christensen, D.Z., Hansen, H.H., Redrobe, J.P., Mikkelsen, J.D., 2009. Alpha(7) nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. *Neuropharmacology* 56, 1001–1009.
- Thorgeirsson, T.E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K.P., Manolescu, A., Thorleifsson, G., Stefansson, H., Ingason, A., Stacey, S.N., Bergthorsson, J.T., Thorlacius, S., Gudmundsson, J., Jonsson, T., Jakobsdottir, M., Saeundsdottir, J., Olafsdottir, O., Gudmundsson, L.J., Bjornsdottir, G., Kristjansson, K., Skuladottir, H., Isaksson, H.J., Gudbjartsson, T., Jones, G.T., Mueller, T., Gottsäter, A., Flex, A., Aben, K.K., de Veigt, F., Mulders, P.F., Isla, D., Vidal, M.J., Asin, L., Saez, B., Murillo, L., Blondal, T., Kolbeinsson, H., Stefansson, J.G., Hansdottir, I., Runarsdottir, V., Pola, R., Lindblad, B., van Rij, A.M., Dieplinger, B., Haltmayer, M., Mayordomo, J.I., Kiemeny, L.A., Matthiasson, S.E., Oskarsson, H., Tyrfinsson, T., Gudbjartsson, D.F., Gulcher, J.R., Jonsson, S., Thorsteinsdottir, U., Kong, A., Stefansson, K., 2008. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature* 452, 638–642.
- Thorndike, A.N., Regan, S., McKool, K., Pasternak, R.C., Swartz, S., Torres-Finnerty, N., Rigotti, N.A., 2008. Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease. *Arch. Intern. Med.* 168, 186–191.
- Tidey, J.W., Rohsenow, D.J., Kaplan, G.B., Swift, R.M., 2005. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. *Drug Alcohol Depend.* 80, 259–265.
- Tizabi, Y., Rezvani, A.H., Russell, L.T., Tyler, K.V., Overstreet, D.H., 2000. Depressive characteristics of FSL rats: involvement of central nicotinic receptors. *Pharmacol. Biochem. Behav.* 66, 73–77.
- Tizabi, Y., Getachew, B., Rezvani, A.H., Hauser, S.R., Overstreet, D.H., 2009. Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the Fawn-Hooded rat, an animal model of co-morbid depression and alcoholism. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 33, 398–402.
- Tochigi, M., Suzuki, K., Kato, C., Otowa, T., Hibino, H., Umekage, T., Kato, N., Sasaki, T., 2007. Association study of monoamine oxidase and catechol O-methyltransferase genes with smoking behavior. *Pharmacogenet. Genomics* 17, 867–872.
- Tonstad, S., Andrew Johnston, J., 2006. Cardiovascular risks associated with smoking: a review for clinicians. *Eur. J. Cardiovasc. Prev. Rehabil.* 13, 507–514.
- Touiki, K., Rat, P., Molimard, R., Chait, A., de Beaupaire, R., 2007. Effects of tobacco and cigarette smoke extracts on serotonergic raphe neurons in the rat. *Neuroreport* 18, 925–929.
- Touiki, K., Rat, P., Arib, O., Molimard, R., Chait, A., de Beaupaire, R., 2008. Chronic intermittent nicotine treatment dose-dependently alters serotonergic neurons response to citalopram in the rat. *Pharmacol. Biochem. Behav.* 89, 338–344.
- Tregellas, J.R., Shatti, S., Tanabe, J.L., Martin, L.F., Gibson, L., Wylie, K., Rojas, D.C., 2007. Gray matter volume differences and the effects of smoking on gray matter in schizophrenia. *Schizophr. Res.* 97, 242–249.
- Tseng, K.Y., Mallet, N., Toreson, K.L., Le Moine, C., Gonon, F., O'Donnell, P., 2006. Excitatory response of prefrontal cortical fast-spiking interneurons to ventral tegmental area stimulation in vivo. *Synapse* 59, 412–417.
- Tsukada, H., Miyasato, K., Nishiyama, S., Fukumoto, D., Kakiuchi, T., Domino, E.F., 2005. Nicotine normalizes increased prefrontal cortical dopamine D1 receptor binding and decreased working memory performance produced by repeated pretreatment with MK-801: a PET study in conscious monkeys. *Neuropsychopharmacology* 30, 2144–2153.
- Turetsky, B.I., Calkins, M.E., Light, G.A., Olincy, A., Radant, A.D., Swerdlow, N.R., 2007. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. *Schizophr. Bull.* 33, 69–94.
- Tyas, S.L., White, L.R., Petrovitch, H., Webster Ross, G., Foley, D.J., Heimovitz, H.K., Launer, L.J., 2003. Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. *Neurobiol. Aging* 24, 589–596.
- Tzavara, E.T., Bymaster, F.P., Overshiner, C.D., Davis, R.J., Perry, K.W., Wolff, M., McKinzie, D.L., Witkin, J.M., Nomikos, G.G., 2006. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. *Mol. Psychiatry* 11, 187–195.
- Uçok, A., Polat, A., Bozkurt, O., Meteris, H., 2004. Cigarette smoking among patients with schizophrenia and bipolar disorders. *Psychiatry Clin. Neurosci.* 58, 434–437.
- Ulrich, J., Johannsson-Locher, G., Seiler, W.O., Stahelin, H.B., 1997. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. *Acta Neuropathol.* 94, 450–454.
- Unger, C., Svedberg, M.M., Yu, W.F., Hedberg, M.M., Nordberg, A., 2006. Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APP^{sw}) transgenic mice. *J. Pharmacol. Exp. Ther.* 317, 30–36.
- Ungless, M.A., 2004. Dopamine: the salient issue. *Trends Neurosci.* 27, 702–706.
- Upadhyaya, H.P., 2006. Do patients with ADHD have a harder time quitting cigarettes? *J. Am. Acad. Child Adolesc. Psychiatry* 45, 891.
- Upadhyaya, H.P., Rose, K., Wang, W., O'Rourke, K., Sullivan, B., Deas, D., Brady, K.T., 2005. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. *J. Child Adolesc. Psychopharmacol.* 15, 799–809.
- Vallejo, Y.F., Buisson, B., Bertrand, D., Green, W.N., 2005. Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism. *J. Neurosci.* 25, 5563–5572.
- Valtonen, H.M., Suominen, K., Mantere, O., Leppämäki, S., Arvilommi, P., Isometsä, E.T., 2006. Prospective study of risk factors for attempted suicide among patients with bipolar disorder. *Bipolar Disord.* 8, 576–585.
- van Amsterdam, J., Talhout, R., Vleeming, W., Opperhuizen, A., 2006. Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction. *Life Sci.* 79, 1969–1973.
- Van den Buuse, M., Garner, B., Koch, M., 2003. Neurodevelopmental animal models of schizophrenia: effects on prepulse inhibition. *Curr. Mol. Med.* 3, 459–471.
- van Dijk, E.J., Prins, N.D., Vrooman, H.A., Hofman, A., Koudstaal, P.J., Breteler, M.M., 2008. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. *Stroke* 39, 2712–2719.
- Vanable, P.A., Carey, M.P., Carey, K.B., Maisto, S.A., 2003. Smoking among psychiatric outpatients: relationship to substance use, diagnosis, and illness severity. *Psychol. Addict. Behav.* 17, 259–265.
- Vann, R.E., James, J.R., Rosecrans, J.A., Robinson, S.E., 2006. Nicotinic receptor inactivation after acute and repeated in vivo nicotine exposures in rats. *Brain Res.* 1086, 98–103.
- Vasto, S., Candore, G., Duro, G., Lio, D., Grimaldi, M.P., Caruso, C., 2007. Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. *Pharmacogenomics* 8, 1735–1745.
- Vázquez-Palacios, G., Bonilla-Jaime, H., Velázquez-Moctezuma, J., 2004. Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine. *Pharmacol. Biochem. Behav.* 78, 165–169.
- Venn, A., Britton, J., 2007. Exposure to secondhand smoke and biomarkers of cardiovascular disease risk in never-smoking adults. *Circulation* 115, 990–995.
- Verbitsky, M., Rothlin, C.V., Katz, E., Elgoyhen, A.B., 2000. Mixed nicotinic-muscarinic properties of the alpha9 nicotinic cholinergic receptor. *Neuropharmacology* 39, 2515–2524.
- Vieregge, A., Sieberer, M., Jacobs, H., Hagenah, J.M., Vieregge, P., 2001. Transdermal nicotine in PD. A randomized, double-blind, placebo controlled study. *Neurology* 57, 1032–1035.
- Villafane, G., Cesaro, P., Rialland, A., Baloul, S., Azimi, S., Bourdet, C., Le Houezec, J., Macquin-Mavier, I., Maison, P., 2007. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. *Eur. J. Neurol.* 14, 1313–1316.
- Villarroya, M., Garcia, A.G., Marco-Contelles, J., Lopez, M.G., 2007. An update on the pharmacology of galantamine. *Expert Opin. Investig. Drugs* 16, 1987–1998.
- Villegier, A.S., Lotfipour, S., Belluzzi, J.D., Leslie, F.M., 2007a. Involvement of alpha1-adrenergic receptors in transylcypromine enhancement of nicotine self-administration in rat. *Psychopharmacology (Berl.)* 193, 457–465.
- Villegier, A.S., Lotfipour, S., McQuown, S.C., Belluzzi, J.D., Leslie, F.M., 2007b. Transylcypromine enhancement of nicotine self-administration. *Neuropharmacology* 52, 1415–1425.
- Villegier, A.S., Blanc, G., Glowinski, J., Tassin, J.P., 2003. Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidase inhibitors. *Pharmacol. Biochem. Behav.* 76, 267–274.
- Vizi, E.S., Mike, A., 2006. Nonsynaptic receptors for GABA and glutamate. *Curr. Top. Med. Chem.* 6, 941–948.
- Vizi, E.S., Kiss, J.P., Lendvai, B., 2004a. Nonsynaptic communication in the central nervous system. *Neurochem. Int.* 45, 443–451.
- Vizi, E.S., Rózsa, B., Mayer, A., Kiss, J.P., Zelles, T., Lendvai, B., 2004b. Further evidence for the functional role of nonsynaptic nicotinic acetylcholine receptors. *Eur. J. Pharmacol.* 500, 499–508.
- Voineskos, S., De Luca, V., Mensah, A., Vincent, J.B., Potapova, N., Kennedy, J.L., 2007. Association of alpha4beta2 nicotinic receptor and heavy smoking in schizophrenia. *J. Psychiatry Neurosci.* 32, 412–416.
- Volkow, N., Rutter, J., Pollock, J.D., Shurtleff, D., Baler, R., 2008. One SNP linked to two diseases—addiction and cancer: A Double Whammy?: Nicotine addiction and lung cancer susceptibility. *Mol. Psychiatry* 13, 990–992.
- Volkow, N.D., Fowler, J.S., Wang, G.J., Baler, R., Telang, F., 2009. Imaging dopamine's role in drug abuse and addiction. *Neuropharmacology* 56 (Suppl 1), 3–8.
- Wagena, E.J., van Amelsvoort, L.G., Kant, I., Wouters, E.F., 2005. Chronic bronchitis, cigarette smoking, and the subsequent onset of depression and anxiety: results from a prospective population-based cohort study. *Psychosom. Med.* 67, 656–660.
- Waldman, I.D., Gizer, I.R., 2006. The genetics of attention deficit hyperactivity disorder. *Clin. Psychol. Rev.* 26, 396–432.
- Wallis, D., Russell, H.F., Muenke, M., 2008. Review: genetics of attention deficit/hyperactivity disorder. *J. Pediatr. Psychol.* 33, 1085–1099.
- Walsh, H., Govind, A.P., Mastro, R., Hoda, J.C., Bertrand, D., Vallejo, Y., Green, W.N., 2008. Up-regulation of nicotinic receptors by nicotine varies with receptor subtype. *J. Biol. Chem.* 283, 6022–6032.
- Walters, C.L., Brown, S., Changeux, J.P., Martin, B., Damaj, M.I., 2006. The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice. *Psychopharmacology (Berl.)* 184, 339–344.
- Wang, H., Sun, X., 2005. Desensitized nicotinic receptors in brain. *Brain Res. Brain Res. Rev.* 48, 420–437.
- Wang, H.Y., Li, W., Benedetti, N.J., Lee, D.H., 2003. Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. *J. Biol. Chem.* 278, 31547–31553.
- Wang, J.S., Markowitz, J.S., Donovan, J.L., Devane, C.L., 2005. P-glycoprotein does not actively transport nicotine and cotinine. *Addict. Biol.* 10, 127–129.

- Wang, F., Chen, H., Steketee, J.D., Sharp, B.M., 2007a. Upregulation of ionotropic glutamate receptor subunits within specific mesocorticolimbic regions during chronic nicotine self-administration. *Neuropsychopharmacology* 32, 103–109.
- Wang, Z., Faith, M., Patterson, F., Tang, K., Kerrin, K., Wileyto, E.P., Detre, J.A., Lerman, C., 2007b. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. *J. Neurosci.* 27, 14035–14040.
- Wang, Z., Ray, R., Faith, M., Tang, K., Wileyto, E.P., Detre, J.A., Lerman, C., 2008. Nicotine abstinence-induced cerebral blood flow changes by genotype. *Neurosci. Lett.* 438, 275–280.
- Ward, R.J., Lallemand, F., de Witte, P., Dexter, D.T., 2008. Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents. *Prog. Neurobiol.* 85, 135–147.
- Waxmonsky, J.A., Thomas, M.R., Miklowitz, D.J., Allen, M.H., Wisniewski, S.R., Zhang, H., Ostacher, M.J., Fossey, M.D., 2005. Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the Systematic Treatment Enhancement Program. *Gen. Hosp. Psychiatry* 27, 321–328.
- Weinberger, A.H., Sacco, K.A., Creedon, C.L., Vessicchio, J.C., Jatlow, P.I., George, T.P., 2007. Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. *Schizophr. Res.* 91, 217–225.
- Weinberger, A.H., Maciejewski, P.K., McKee, S.A., Reutenauer, E.L., Mazure, C.M., 2009. Gender differences in associations between lifetime alcohol, depression, panic disorder, and posttraumatic stress disorder and tobacco withdrawal. *Am. J. Addict.* 18, 140–147.
- Weiser, M., Reichenberg, A., Grotto, I., Yasvitzky, R., Rabinowitz, J., Lubin, G., Nahon, D., Knobler, H.Y., Davidson, M., 2004. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. *Am. J. Psychiatry* 161, 1219–1223.
- Weisskopf, M.G., Grodstein, F., Ascherio, A., 2007. Smoking and cognitive function in Parkinson's disease. *Mov. Disord.* 22, 660–665.
- Wells, G.B., 2008. Structural answers and persistent questions about how nicotinic receptors work. *Front. Biosci.* 13, 5479–5510.
- Wennmalm, A., 1982. Effect of cigarette smoking on basal and carbon dioxide stimulated cerebral blood flow in man. *Clin. Physiol.* 2, 529–535.
- West, R., Hajek, P., Foulds, J., Nilsson, F., May, S., Meadows, A., 2000. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. *Psychopharmacology (Berl.)* 149, 198–202.
- Whalen, C.K., Jamner, L.D., Henker, B., Gehricker, J.G., King, P.S., 2003. Is there a link between adolescent cigarette smoking and pharmacotherapy for ADHD? *Psychol. Addict. Behav.* 17, 332–335.
- White, R., Malpass, J.R., Handa, S., Richard Baker, S., Broad, L.M., Folly, L., Mogg, A., 2006. Epibatidine isomers and analogues: structure–activity relationships. *Bioorg. Med. Chem. Lett.* 16, 5493–5497.
- Wilens, T.E., 2004. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. *Psychiatr. Clin. N. Am.* 27, 283–301.
- Wilens, T.E., 2006. Attention deficit hyperactivity disorder and substance use disorders. *Am. J. Psychiatry* 163, 2059–2063.
- Wilens, T.E., Decker, M.W., 2007. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. *Biochem. Pharmacol.* 74, 1212–1223.
- Wilens, T.E., Biederman, J., Milberger, S., Hahesy, A.L., Goldman, S., Wozniak, J., Spencer, T.J., 2000. Is bipolar disorder a risk for cigarette smoking in ADHD youth? *The Am. J. Addict.* 9, 187–195.
- Wilens, T.E., Faraone, S.V., Biederman, J., Gunawardene, S., 2003. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. *Pediatrics* 111, 179–185.
- Wilens, T.E., Waxmonsky, J., Scott, M., Swezey, A., Kwon, A., Spencer, T.J., Biederman, J., 2005a. An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder. *J. Child Adolesc. Psychopharmacol.* 15, 947–955.
- Wilens, T.E., Haight, B.R., Horrigan, J.P., Hudziak, J.J., Rosenthal, N.E., Connor, D.F., Hampton, K.D., Richard, K.E., Modell, J.G., 2005b. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. *Biol. Psychiatry* 57, 793–801.
- Wilens, T.E., Adamson, J., Monuteaux, M.C., Faraone, S.V., Schilling, M., Westberg, D., Biederman, J., 2008a. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. *Arch. Pediatr. Adolesc. Med.* 162, 916–921.
- Wilens, T.E., Vitulano, M., Upadhyaya, H., Adamson, J., Sawtelle, R., Utzinger, L., Biederman, J., 2008b. Cigarette smoking associated with attention deficit hyperactivity disorder. *J. Pediatr.* 153, 414–419.
- Wiles, N.J., Zammit, S., Bebbington, P., Singleton, N., Meltzer, H., Lewis, G., 2006. Self-reported psychotic symptoms in the general population: results from the longitudinal study of the British National Psychiatric Morbidity Survey. *Br. J. Psychiatry* 188, 519–526.
- Williams, J.M., Ziedonis, D.M., Abanyie, F., Steinberg, M.L., Foulds, J., Benowitz, N.L., 2005. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. *Schizophr. Res.* 79, 323–335.
- Wilson, J.J., 2007. ADHD and substance use disorders: developmental aspects and the impact of stimulant treatment. *Am. J. Addict.* 16 (Suppl 1), 5–11.
- Wilson, J.J., Levin, F.R., 2005. Attention-deficit/hyperactivity disorder and early-onset substance use disorders. *J. Child Adolesc. Psychopharmacol.* 15, 751–763.
- Winn, P., 2008. Experimental studies of pedunculopontine functions: are they motor, sensory or integrative? *Parkinsonism Relat. Disord.* 14, S194–S198.
- Wirdefeldt, K., Gatz, M., Pawitan, Y., Pedersen, N.L., 2005. Risk and protective factors for Parkinson's disease: a study in Swedish twins. *Ann. Neurol.* 57, 27–33.
- Wong, H.P., Yu, L., Lam, E.K., Tai, E.K., Wu, W.K., Cho, C.H., 2007. Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. *Toxicol. Appl. Pharmacol.* 221, 261–267.
- Wonnacott, S., 2008. Gates and filters: unveiling the physiological roles of nicotinic acetylcholine receptors in dopaminergic transmission. *Br. J. Pharmacol.* 153, S2–4.
- Wonnacott, S., Sidhpura, N., Balfour, D.J., 2005. Nicotine: from molecular mechanisms to behaviour. *Curr. Opin. Pharm.* 5, 53–59.
- Wooltorton, J.R., Pidoplichko, V.I., Broide, R.S., Dani, J.A., 2003. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. *J. Neurosci.* 23, 3176–3185.
- Wooters, T.E., Bardo, M.T., 2007. The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. *Behav. Pharmacol.* 18, 601–608.
- Wu, P., Duarte, C.S., Mandell, D.J., Fan, B., Liu, X., Fuller, C.J., Musa, G., Cohen, M., Cohen, P., Hoven, C.W., 2006. Exposure to the World Trade Center attack and the use of cigarettes and alcohol among New York City public high-school students. *Am. J. Public Health* 96, 804–807.
- Wullner, U., Gundisch, D., Herzog, H., Minnerop, M., Joe, A., Warnecke, M., Jessen, F., Schutz, C., Reinhardt, M., Eschner, W., Klockgether, T., Schmaljohann, J., 2008. Smoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain. *Neurosci. Lett.* 430, 34–37.
- Xie, Y.X., Bezard, E., Zhao, B.L., 2005. Investigating the receptor-independent neuroprotective mechanisms of nicotine in mitochondria. *J. Biol. Chem.* 280, 32405–32412.
- Xu, Y., Barrantes, F.J., Shen, J., Luo, X., Zhu, W., Chen, K., Jiang, H., 2006. Blocking of the nicotinic acetylcholine receptor ion channel by chlorpromazine, a non-competitive inhibitor: a molecular dynamics simulation study. *J. Phys. Chem. B* 110, 20640–20648.
- Xu, J., Mendrek, A., Cohen, M.S., Monterosso, J., Simon, S., Jarvik, M., Olmstead, R., Brody, A.L., Ernst, M., London, E.D., 2007. Effect of cigarette smoking on prefrontal cortical function in nondeprived smokers performing the Stroop Task. *Neuropsychopharmacology* 32, 1421–1428.
- Xue, Y., Domino, E.F., 2008. Tobacco/nicotine and endogenous brain opioids. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 32, 1131–1138.
- Yamamoto, Y., Nishiyama, Y., Monden, T., Satoh, K., Ohkawa, M., 2003. A study of the acute effect of smoking on cerebral blood flow using 99mTc-ECD SPET. *Eur. J. Nucl. Med. Mol. Imag.* 30, 612–614.
- Yamashita, K., Kobayashi, S., Yamaguchi, S., Koide, H., 1996. Cigarette smoking and silent brain infarction in normal adults. *Intern. Med.* 35, 704–706.
- Yamashita, K., Kobayashi, S., Yamaguchi, S., 2000. Cerebral blood flow and cessation of cigarette smoking in healthy volunteers. *Intern. Med.* 39, 891–893.
- Yang, Y.K., Yao, W.J., McEvoy, J.P., Chu, C.L., Lee, I.H., Chen, P.S., Yeh, T.L., Chiu, N.T., 2006. Striatal dopamine D2/D3 receptor availability in male smokers. *Psychiatry Res.* 146, 87–90.
- Yang, Y.K., Yao, W.J., Yeh, T.L., Lee, I.H., Chen, P.S., Lu, R.B., Chiu, N.T., 2008. Decreased dopamine transporter availability in male smokers—a dual isotope SPECT study. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 32, 274–279.
- Yasuno, F., Ota, M., Ando, K., Ando, T., Maeda, J., Ichimiya, T., Takano, A., Doronbekov, T.K., Fujimura, Y., Nozaki, S., Suhara, T., 2007. Role of ventral striatal dopamine D1 receptor in cigarette craving. *Biol. Psychiatry* 61, 1252–1259.
- Yildiz, D., 2004. Nicotine, its metabolism and an overview of its biological effects. *Toxicol.* 43, 619–632.
- Yogeeswari, P., Sriram, D., Ratan Bal, T., Thirumurugan, R., 2006. Epibatidine and its analogues as nicotinic acetylcholine receptor agonist: an update. *Nat. Prod. Res.* 20, 497–505.
- Yoo, J.H., Valdivinos, M.G., Williams, D.C., 2007. Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature. *J. Autism. Dev. Disord.* 37, 1883–1901.
- You, Z.B., Wang, B., Zitzman, D., Wise, R.A., 2008. Acetylcholine release in the mesocorticolimbic dopamine system during cocaine seeking: conditioned and unconditioned contributions to reward and motivation. *J. Neurosci.* 28, 9021–9029.
- Yu, W.F., Guan, Z.Z., Bogdanovic, N., Nordberg, A., 2005. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. *Exp. Neurol.* 192, 215–225.
- Zafir, A., Ara, A., Banu, N., 2009. In vivo antioxidant status: a putative target of antidepressant action. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 33, 220–228.
- Zammit, S., Allebeck, P., Dalman, C., Lundberg, I., Hemmingsson, T., Lewis, G., 2003. Investigating the association between cigarette smoking and schizophrenia in a cohort study. *Am. J. Psychiatry* 160, 2216–2221.
- Zammit, S., Spurlock, G., Williams, H., Norton, N., Williams, N., O'Donovan, M.C., Owen, M.J., 2007. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. *Br. J. Psychiatry* 191, 402–407.
- Zanardi, A., Ferrari, R., Leo, G., Maskos, U., Changeux, J.P., Zoli, M., 2007. Loss of high-affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment. *FASEB J.* 21, 4028–4037.
- Zanelli, J., Simon, H., Rabe-Hesketh, S., Walshe, M., McDonald, C., Murray, R.M., Maccabe, J.H., 2005. Eye tracking in schizophrenia: does the antisaccade task

- measure anything that the smooth pursuit task does not? *Psychiatry Res.* 136, 181–188.
- Zarow, C., Lyness, S.A., Mortimer, J.A., Chui, H.C., 2003. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. *Arch. Neurol.* 60, 337–341.
- Zevin, S., Benowitz, N.L., 1999. Drug interactions with tobacco smoking. *Clin. Pharmacokinet.* 36, 425–438.
- Zhang, H., Sulzer, D., 2004. Frequency-dependent modulation of dopamine release by nicotine. *Nat. Neurosci.* 7, 581–582.
- Zhang, T., Zhang, L., Liang, Y., Siapas, A.G., Zhou, F.M., Dani, J.A., 2009. Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. *J. Neurosci.* 29, 4035–4043.
- Ziedonis, D., Hitsman, B., Beckham, J.C., Zvolensky, M., Adler, L.E., Audrain-McGovern, J., Breslau, N., Brown, R.A., George, T.P., Williams, J., Calhoun, P.S., Riley, W.T., 2008. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. *Nicotine Tob. Res.* 10, 1691–1715.
- Zouridakis, M., Zisimopoulou, P., Poulas, K., Tzartos, S.J., 2009. Recent advances in understanding the structure of nicotinic acetylcholine receptors. *IUBMB Life* 61, 407–423.
- Zubieta, J.K., Heitzeg, M.M., Xu, Y., Koeppe, R.A., Ni, L., Guthrie, S., Domino, E.F., 2005. Regional cerebral blood flow responses to smoking in tobacco smokers after overnight abstinence. *Am. J. Psychiatry* 162, 567–577.
- Zvolensky, M.J., Bernstein, A., 2005. Cigarette smoking and panic psychopathology. *Curr. Dir. Psychol. Sci.* 14, 301–305.